U.S. patent number RE46,631 [Application Number 13/896,384] was granted by the patent office on 2017-12-12 for dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4.
This patent grant is currently assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services. The grantee listed for this patent is The United States of America, as represented by the Secretary, Department of Health & Human Services, The United States of America, as represented by the Secretary, Department of Health & Human Services. Invention is credited to Joseph E. Blaney, Barry Falgout, Kathryn A. Hanley, Ching-Juh Lai, Lewis Markoff, Brian R. Murphy, Stephen S. Whitehead.
United States Patent |
RE46,631 |
Whitehead , et al. |
December 12, 2017 |
Dengue tetravalent vaccine containing a common 30 nucleotide
deletion in the 3'-UTR of dengue types 1,2,3, and 4, or antigenic
chimeric dengue viruses 1,2,3, and 4
Abstract
The invention relates to a dengue virus tetravalent vaccine
containing a common 30 nucleotide deletion (.DELTA.30) in the
3'-untranslated region of the genome of dengue virus serotypes 1,
2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1,
2, 3, and 4.
Inventors: |
Whitehead; Stephen S.
(Montgomery Village, MD), Murphy; Brian R. (Bethesda,
MD), Markoff; Lewis (Bethesda, MD), Falgout; Barry
(Rockville, MD), Blaney; Joseph E. (Gettysburg, PA),
Hanley; Kathryn A. (Las Cruces, NM), Lai; Ching-Juh
(Bethesda, MD) |
Applicant: |
Name |
City |
State |
Country |
Type |
The United States of America, as represented by the Secretary,
Department of Health & Human Services |
Washington |
DC |
US |
|
|
Assignee: |
The United States of America, as
represented by the Secretary, Department of Health and Human
Services (Washington, DC)
|
Family
ID: |
29406814 |
Appl.
No.: |
13/896,384 |
Filed: |
May 17, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
PCT/US03/13279 |
Apr 25, 2003 |
|
|
|
|
60377860 |
May 3, 2002 |
|
|
|
|
60436500 |
Dec 23, 2002 |
|
|
|
Reissue of: |
10970640 |
Oct 21, 2004 |
7517531 |
Apr 14, 2009 |
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C12N
7/00 (20130101); A61K 39/12 (20130101); A61P
37/04 (20180101); A61P 31/14 (20180101); C12N
7/00 (20130101); A61K 39/12 (20130101); A61K
2039/5256 (20130101); A61K 2039/5254 (20130101); C12N
2770/24134 (20130101); A61K 2039/5256 (20130101); A61K
2039/5254 (20130101); C12N 2770/24161 (20130101); Y02A
50/30 (20180101); C12N 2770/24134 (20130101); A61K
2039/70 (20130101); C12N 2770/24161 (20130101); A61K
2039/70 (20130101) |
Current International
Class: |
C12N
7/00 (20060101); A61K 39/12 (20060101); A61K
39/00 (20060101) |
Field of
Search: |
;424/202.1,199.1,205.1,218.1 ;435/235.1,236,320.1 |
References Cited
[Referenced By]
U.S. Patent Documents
|
|
|
7226602 |
June 2007 |
Whitehead et al. |
7560118 |
July 2009 |
Whitehead et al. |
8039003 |
October 2011 |
Whitehead et al. |
8075903 |
December 2011 |
Whitehead et al. |
|
Foreign Patent Documents
Other References
Durbin et al (American Journal of Tropical Medicine and Hygeine
65:405-413, 2001. cited by examiner .
Lai et al (Clinical and Diagnostic Virology 10:173-179, 1998).
cited by examiner .
Olsthoorn et al (RNA 7:1370-1377, 2001). cited by examiner .
Blaney et al (Journal of Virology 79:5516-5528, 2005, not prior
art). cited by examiner .
Proutski et al (Virus Research 64:107-123, 1999). cited by examiner
.
An, J. et al., 1999 "Develpment of a novel mouse model for dengue
virus infection." Virology 263:70-77. cited by applicant .
Barrett, A.D.T. 1997 "Yellow fever vaccines" Biologicals 25:17-25.
cited by applicant .
Blackwell, J.L. et al. 1997 "Translation elongation factor-1 alpha
interacts with the 3' stem-loop region of West Nile virus genomic
RNA" J. Virol. 71:6433-44. cited by applicant .
Blaney, J.E. Jr. et al. 2001 "Chemical mutagenesis of dengue virus
type 4 yield mutant viruses which are temperature sensitive in vero
cells or human liver cells and attenuated in mice" J. Virol.
75:9731-40. cited by applicant .
Blaney, J.E. Jr. et al. 2002 "Genetic basis of attenuation of
dengue virus type 4 small plaque mutants with restricted
replication in suckling mice and in SCID mice transplanted with
human liver cells." Virology 300:125-139. cited by applicant .
Blaney, J.E. Jr. et al. 2003 "Mutations which enhance the
replication of dengue virus type 4 and antigenic chimeric dengue
virus type 2/4 vaccine candidate in Vero cells" Vaccine 21:4317-27.
cited by applicant .
Blaney, J.E. Jr. et al. 2004 "Genetically modified, live attenuated
dengue virus type 3 vaccine candidates." Am. J. Trop. Med. Hyg.
71:811-821. cited by applicant .
Blaney, J.E. Jr. et al. 2004 "Vaccine candidates derived from a
novel infectious cDNA clone of an American genotype dengue virus
type 2." BMC Infect. Dis. 4:39 (10 pages). cited by applicant .
Blok, J. et al. 1992 "Comparison of a dengue-2 virus and its
candidate vaccine derivative: sequence relationships with the
flaviviruses and other viruses" Virology 187:573-90. cited by
applicant .
Bray, M. et al. 1991 "Construction of intertypic chimeric dengue
viruses by substitution of structural protein genes" PNAS USA
88:10342-6. cited by applicant .
Bray, M. et al. 1996 "Monkeys immunized with intertypic chimeric
dengue viruses are protected against wild-type virus challenge" J.
Virol. 70:4162-6. cited by applicant .
Bray, M. et al. 1998 "Genetic determinants responsible for
acquisition of dengue type 2 virus mouse nuerovirulence" J. Virol.
72:1647-51. cited by applicant .
Brinton, M.A. et al. 1986 "The 3'-nucleotides of flavivirus genomic
RNA form a conserved secondary structure," Virology 153:113-121.
cited by applicant .
Burke, D.S. et al. 1998 "A prospective study of dengue infections
in Bankok" Am. J. Trop. Med. Hyg. 38:172-80. cited by applicant
.
Butrapet, S. et al. 2000 "Attenuation markers of a candidate dengue
type 2 vaccine virus, strain 16681 (PDK-53), are define by
mutations in the 5' noncoding region and nonstructure proteins 1
and 3." J. Virol. 74:3011-3019. cited by applicant .
Chambers, T.J. et al. 2003 "Yellow fever virus/dengue-2 virus and
yellow fever virus/dengue-4 virus chimeras: biological
characterication, immunogenicity, and protection against dengue
encephalitis in the mouse model" J. Virol. 77:3655-68. cited by
applicant .
Chen, W. et al. 1995 "Construction of intertypic chimeric dengue
viruses exhibition type 3 antigenicity and neurovirulence for mice"
J. Virol. 69:5186-5190. cited by applicant .
Durbin, A.P. et al. 2001 "Attenuation and immunogenicity in humans
of a live dengue virus type-4 vaccine candidate with a 30
nucleotide deletion in its 3'-unsaturated region." Am. J. Trop.
Med. Hyg. 65:405-413. cited by applicant .
Gubler, D.J. et al. 1999 "Impact of dengue/dengue hemorrhagic fever
on the developing world." Adv. Virus Res. 53:35-70. cited by
applicant .
Guillot, S. et al. 2000 "Natural genetic exchanges between vaccine
and wild poliovirus strains in humans." J. Virol. 74:8434-8443.
cited by applicant .
Guirakhoo, F. et al. 2001 "Construction, safety, and immunogenicity
in nonhuman primates of a chimeric yellow fever-dengue virus
tetravalent vaccine." J. Virol. 74:7290-7304. cited by applicant
.
Guirakhoo, F. et al. 2002 "Viremia and immunogenicity in nonhuman
primates of a tetravalent yellow fever-dengue chimeric vaccine:
genetic reconstructions, dose adjustment, and antibody responses
against wild-type dengue virus isolates" Virology 298:146-59. cited
by applicant .
Hahn, C.S. et al. 1987 "Conserved elements in the 3' untranslated
region of flavivirus RNAs and potential cyclization sequences." J.
Mol. Biol. 198:33-41. cited by applicant .
Hanley, K.A. et al. 2004 "Introduction of mutations into the
non-structural genes or 3' untranslated region of an attenuated
dengue virus type 4 vaccine candidate further decreases replication
in rheses monkeys while retaining protective immunity." Vaccine
22:3440-3448. cited by applicant .
Huang, C.Y.-H. et al. 2000 "Chimeric dengue type 2 (vaccine strain
PDK-53)/dengie type 1 virus as a potential candidate dengue type 1
virus vaccine." J. Virol. 74:3020-3028. cited by applicant .
Kew, O. et al. 2002 "Outbreak of poliomyelitis in Hispaniola
associated with circulating type 1 vaccine-derived poliovirus"
Science 296-356-9. cited by applicant .
Khromykh, A.A. et al. 1996 "RNA binding properties of core protein
of the flavivirus Kunjin" Arch. Virol. 141:685-99. cited by
applicant .
Lai, C.J. et al. 1991 "Infectious RNA transcribed from stably
cloned full-length cDNA of dengue type 4 virus" PNAS USA
88:5139-43. cited by applicant .
Markoff, L. et al. 1997 "A conserved internal hydrophobic domain
mediates the stable membrane integration of the dengue virus capsid
protein" Virology 233:105-17. cited by applicant .
Markoff, L. et al. 2002 "Derivation and characterizarion of a
dengue type 1 host range-restricted mutant virus that is attenuated
and highly immunogenic in monkeys." J. Virol. 76:3318-3328. cited
by applicant .
Mathew, A. et al. 1998 "Predominance of HLA-restricted cytotoxic
T-lymphocyte responses to serotype-cross-reactive epitopes on
nonstructural proteins following natural secondary dengue virus
infection." J. Virol. 72:3999-4004. cited by applicant .
Men, R. et al. 1996 "Dengue type 4 virus mutants containing
deletions in the 3' noncoding region of the RNA genome: analysis of
growth restriction in cell culture and altered viremia pattern and
immunogenicity in rhesus monkeys." J. Virol. 70:3930-3937. cited by
applicant .
Pletnev, A.G. et al. 1992 "Construction and characterication of
chimeric tick-borne encepalitis/dengue type 4 viruses" PNAS USA
89:10532-6. cited by applicant .
Pletnev, A.G. et al. 1993 "Chimeric tick-borne encephalitis and
dengue type 4 viruses: effects of mutations on neurovirulence in
mice" J. Virol. 67:4956-63. cited by applicant .
Pletnev, A.G. et al. 1998 "Attenuation of the Langat tick-borne
flavivirus by chimerization with mosquito-borne flavivirus dengue
type 4" PNAS USA 95:1746-51. cited by applicant .
Pletnev, A.G. et al. 2002 "West Nile virus/dengue type 4 virus
chimeras that are reduced in neurovirulence and peripheral
virulence without loss of immunogenicity or protective efficacy"
PNAS USA 99:3036-41. cited by applicant .
Polo, S. et al. 1997 "Infectious RNA transcripts from full-length
dengue virus type 2cDNA clones made in yeast." J. Virol.
71:5366-5374. cited by applicant .
Proutski, V. et al. 1997 "Secondary srtucture of the 3'
untranslated region of flaviviruses: similarities and differences."
Nucleic Acids Res. 25:1194-1202. cited by applicant .
Puri, B. et al. 1997 "Molecular analysis of dengue virus
attenuation after serial passage in primary dog kidney cells." J.
Gen. Virol. 78:2287-2291. cited by applicant .
Puri, B. et al. 2000 "Construction of a full length infectious
clone for dengue-1 virus Western Pacific, 74 strain." Virus Genes
20:57-63. cited by applicant .
Rauscher, S. et al. 1997 "Secondary structure of the 3'-noncoding
region of flavivirus genomes: comparative analysis of base pairing
probabilities." RNA 3:779-791. cited by applicant .
Rice, C.M. et al. 1985 "Nucleotide sequence of yellow fever virus:
implications for flavivirus gene expression and evolution" Science
229:726-33. cited by applicant .
Rosen, L. et al. 1985 "Comparative susceptibility of mosquito
species and strains to oral and parental infection with dengue and
Japanese encephalitis viruses." Am. J. Trop. Med. Hyg. 34:603-615.
cited by applicant .
Rosen, L. et al. 1985 "Comparative susceptibility of five species
of Toxrhynchites mosquitoes to parential infection with dengue and
other flaviviruses." Am. J. Trop. Med. Hyg. 34:805-809. cited by
applicant .
Ta, M. et al. 2000 "Mov34 protein from mouse brain interacts with
the 3' noncoding region of Japanese encephalitis virus" J. Virol.
74:5108-15. cited by applicant .
Thein, S. et al. 1997 "Risk factors in dengue shock syndrome" Am.
J. Trop. Med. Hyg. 56:566-72. cited by applicant .
Troyer, J.M. et al. 2001 "A live attenuated recombinant dengue-4
virus vaccine candidate with restricted capacity for dissemination
in mosquitoes and lack of transmission from vaccines to
mosquitoes." Am. J. Trop. Med. Hyg. 65:414-419. cited by applicant
.
Whitehead, S.S. et al. 2003 "A live, attenuated dengue virus type 1
vaccine candidate with a 30-nucleotide deletion in the 3'
untranslated region is highly attenuated and immunogenic in
monkeys" J. Virol. 77:1653-1657. cited by applicant .
Whitehead, S.S. et al. 2003 "Substitution of the structural genes
of dengue virus type 4 with those of type 2 results in chimeric
vaccine candidates which are attenuated for mosquitoes, mice, and
rhesus monkeys." Vaccine 21:4307-4316. cited by applicant .
Worobey, M. et al. "Widespread intra-serotype recombinant in
natural populations of dengue virus." PNAS USA 96:7352-7357. cited
by applicant .
Zeng, L. et al. 1998 "Identification of specific nucleotide
sequence within the conserved 3'-SL in the dengue type 2 virus
genome required for replication." J. Virol. 72:7510-7522. cited by
applicant .
Bhamarapravati, N. et al., 2000, "Live attenuated tetravalent
dengue vaccine," Vaccine 18: 44-47. cited by applicant .
Blaney, Jr. J.E. et al., 2006, "Development of a Live Attenuated
Dengue Virus Vaccine Using Reverse Genetics," Viral Immunol. 19:
10-32. cited by applicant .
Durbin, A.P. et al. 2003, "The Recombinant Live Attenuated Dengue 4
Candidate Vaccine rDEN4delta30 is Safe, Immunogenic, and Highly
Infectious in Healthy Adults," Am. J. Trop. Med. Hyg. p. 361,
Abstract 379. cited by applicant .
Hanley, K.A. et al., 2002, "Paired Charge-to-Alanine Mutagenesis of
Dengue Virus Type 4 NS5 Generated Mutants with
Temperature-Sensitive, Host Range, and Mouse Attenuation
Phenotypes," J. Virol. 76: 525-531. cited by applicant .
Kanesa-Thasan, N. et al., 2001, "Safety and immunogenicity of
attenuated dengue virus vaccines (Aventis Pastuer) in human
volunteers," Vaccine 19: 3179-3188. cited by applicant.
|
Primary Examiner: Ponnaluri; Shri
Attorney, Agent or Firm: Klarquist Sparkman, LLP
Parent Case Text
RELATED APPLICATIONS
This application is a continuation and claims the benefit of
priority of International Application No. PCT/US03/13279 filed Apr.
25, 2003, designating the United States of America and published in
English on Nov. 13, 2003, as WO 03/092592, which claims the benefit
of priority of U.S. Provisional Application No. 60/377,860 filed
May 3, 2002 and U.S. Provisional Application No. 60/436,500 filed
Dec. 23, 2002, all of which are hereby expressly incorporated by
reference in their entireties.
Claims
What is claimed is:
1. A tetravalent immunogenic composition comprising a) a first
attenuated virus that is immunogenic against dengue serotype 1, b)
a second attenuated virus that is immunogenic against dengue
serotype 2, c) a third attenuated virus that is immunogenic against
dengue serotype 3, and d) a fourth attenuated virus that is
immunogenic against dengue serotype 4, wherein each of a), b), c)
and d) comprises a nucleic acid comprising i) a first nucleotide
sequence encoding at least one structural protein from a first
dengue virus, ii) a second nucleotide sequence encoding
nonstructural proteins from the first dengue virus or a second
dengue virus, and iii) a 3' untranslated region, wherein the 3'
untranslated region contains a deletion of about 30 nucleotides
corresponding to the TL2 stem-loop structure, and wherein both the
3' untranslated region and the second nucleotide sequence encoding
nonstructural proteins are from either the first dengue virus or
the second dengue virus; wherein the tetravalent immunogenic
composition is not rDEN1/4.DELTA.30, rDEN2/4.DELTA.30,
rDEN3/4.DELTA.30, rDEN4.DELTA.30.
2. The tetravalent immunogenic composition of claim 1, wherein the
nucleic acid of at least one of a), b), c) or d) further comprises
a mutation that confers a phenotype wherein the phenotype is
temperature sensitivity in Vero cells or the human liver cell line
HuH-7, host-cell restriction in mosquito cells or the human liver
cell line HuH-7, host-cell adaptation for improved replication in
Vero cells, or attenuation in mice or monkeys.
3. The composition of claim 1, wherein the first nucleotide
sequence encoding at least one structural protein and the second
nucleotide sequence encoding nonstructural proteins of at least one
of a), b), c) and d) are from the first dengue virus.
4. The composition of claim 3, wherein the deletion of a) is a
deletion of about 30 nucleotides from the 3' untranslated region of
the dengue type 1 genome corresponding to the TL2 stem-loop
structure between about nucleotides 10562-10591.
5. The composition of claim 3, wherein the deletion of b) is a
deletion of about 30 nucleotides from the 3' untranslated region of
the dengue type 2 genome corresponding to the TL2 stem-loop
structure between about nucleotides 10541-10570.
6. The composition of claim 3, wherein the deletion of c) is by a
deletion of about 30 nucleotides from the 3' untranslated region of
the dengue type 3 genome corresponding to the TL2 stem-loop
structure between about nucleotides 10535-10565.
7. The composition of claim 3, herein the deletion of d) is a
deletion of about 30 nucleotides from the 3' untranslated region of
the dengue type 4 genome corresponding to the TL2 stem-loop
structure between about nucleotides 10478-10507.
8. The composition of claim 1, wherein the first nucleotide
sequence encoding at least one structural protein of at least one
of a), b), c), and d) is from the first dengue virus and the second
nucleotide sequence encoding nonstructural proteins of at least one
of a), b), c), and d) is from the second dengue virus, wherein the
serotype of the first dengue virus and the second dengue virus are
different.
9. The composition of claim 8, wherein the serotype of the second
dengue virus having the deletion is type 1.
10. The composition of claim 9, wherein the serotype of the first
dengue virus of b) is type 2.
11. The composition of claim 9, wherein the serotype of the first
dengue virus of c) is type 3.
12. The composition of claim 9, wherein the serotype of the first
dengue virus of d) is type 4.
13. The composition of claim 9, wherein the first nucleotide
sequence encodes at least two structural proteins of the first
dengue virus.
14. The composition of claim 13, wherein the structural proteins
are prM and E proteins.
15. The composition of claim 9, wherein the deletion of a) is a
deletion of about 30 nucleotides from the 3' untranslated region of
the dengue type 1 genome corresponding to the TL2 stem-loop
structure between about nucleotides 10562 and 10591.
16. The composition of claim 8, wherein the serotype of the second
dengue virus having the deletion is type 2.
17. The composition of claim 16, wherein the serotype of the first
dengue virus of a) is type 1.
18. The composition of claim 16, wherein the serotype of the first
dengue virus of c) is type 3.
19. The composition of claim 16, wherein the serotype of the first
dengue of d) virus is type 4.
20. The composition of claim 16, wherein the first nucleotide
sequence encodes at least two structural proteins of the first
dengue virus.
21. The composition of claim 20, wherein the structural proteins
are prM and E proteins.
22. The composition of claim 16, wherein the deletion is a deletion
of about 30 nucleotides from the 3' untranslated region of the
dengue type 2 genome corresponding to the TL2 stem-loop structure
between about nucleotides 10541 and 10570.
23. The composition of claim 8, wherein the serotype of the second
dengue virus having the deletion is type 3.
24. The composition of claim 23, wherein the serotype of the first
dengue virus of a) is type 1.
25. The composition of claim 23, wherein the serotype of the first
dengue virus of b) is type 2.
26. The composition of claim 23, wherein the serotype of the first
dengue virus of d) is type 4.
27. The composition of claim 23, wherein the first nucleotide
sequence encodes at least two structural proteins of the first
dengue virus.
28. The composition of claim 27, wherein the structural proteins
are prM and E proteins.
29. The composition of claim 23, wherein the deletion is a deletion
of about 30 nucleotides from the 3' untranslated region of the
dengue type 3 genome corresponding to the TL2 stem-loop structure
between about nucleotides 10535 and 10565.
30. The composition of claim 8, wherein the serotype of the second
dengue virus having the deletion is type 4.
31. The composition of claim 30, wherein the serotype of the first
dengue virus of a) is type 1.
32. The composition of claim 30, wherein the serotype of the first
dengue virus of b) is type 2.
33. The composition of claim 30, wherein the serotype of the first
dengue virus of c) is type 3.
34. The composition of claim 30, wherein the first nucleotide
sequence encodes at least two structural proteins of the first
dengue virus.
35. The composition of claim 34, wherein the structural proteins
are prM and E proteins.
36. The composition of claim 30, wherein the deletion is a deletion
of about 30 nucleotides from the 3' untranslated region of the
dengue type 4 genome corresponding to the TL2 stem-loop structure
between about nucleotides 10478 and 10507.
37. A method of inducing an immune response in a subject comprising
administering an effective amount of the composition of claim 1 to
the subject.
38. The method of claim 37 wherein the subject is a human.
39. A tetravalent vaccine comprising the composition of claim
1.
40. A method of preventing disease caused by dengue virus in a
subject comprising administering an effective amount of the vaccine
of claim 39 to the subject.
41. The method of claim 40 wherein the subject is a human.
42. The tetravalent immunogenic composition defined in claim 1,
selected from the group consisting of: (1) rDEN1.DELTA.30,
rDEN2.DELTA.30, rDEN3.DELTA.30, rDEN4.DELTA.30, (2) rDEN1.DELTA.30,
rDEN2.DELTA.30, rDEN3.DELTA.30, rDEN4/1.DELTA.30, (3)
rDEN1.DELTA.30, rDEN2.DELTA.30, rDEN3.DELTA.30, rDEN4/2.DELTA.30,
(4) rDEN1.DELTA.30, rDEN2.DELTA.30, rDEN3.DELTA.30,
rDEN4/3.DELTA.30, (5) rDEN1.DELTA.30, rDEN2.DELTA.30,
rDEN3/1.DELTA.30, rDEN4.DELTA.30, (6) rDEN1.DELTA.30,
rDEN2.DELTA.30, rDEN3/1.DELTA.30, rDEN4/1.DELTA.30, (7)
rDEN1.DELTA.30, rDEN2.DELTA.30, rDEN3/1.DELTA.30, rDEN4/2.DELTA.30,
(8) rDEN1.DELTA.30, rDEN2.DELTA.30, rDEN3/1.DELTA.30,
rDEN4/3.DELTA.30, (9) rDEN1.DELTA.30, rDEN2.DELTA.30,
rDEN3/2.DELTA.30, rDEN4.DELTA.30, (10) rDEN1.DELTA.30,
rDEN2.DELTA.30, rDEN3/2.DELTA.30, rDEN4/1.DELTA.30, (11)
rDEN1.DELTA.30, rDEN2.DELTA.30, rDEN3/2.DELTA.30, rDEN4/2.DELTA.30,
(12) rDEN1.DELTA.30, rDEN2.DELTA.30, rDEN3/2.DELTA.30,
rDEN4/3.DELTA.30, (13) rDEN1.DELTA.30, rDEN2.DELTA.30,
rDEN3/4.DELTA.30, rDEN4.DELTA.30, (14) rDEN1.DELTA.30,
rDEN2.DELTA.30, rDEN3/4.DELTA.30, rDEN4/1.DELTA.30, (15)
rDEN1.DELTA.30, rDEN2.DELTA.30, rDEN3/4.DELTA.30, rDEN4/2.DELTA.30,
(16) rDEN1.DELTA.30, rDEN2.DELTA.30, rDEN3/4.DELTA.30,
rDEN4/3.DELTA.30, (17) rDEN1.DELTA.30, rDEN2/1.DELTA.30,
rDEN3.DELTA.30, rDEN4.DELTA.30, (18) rDEN1.DELTA.30,
rDEN2/1.DELTA.30, rDEN3.DELTA.30, rDEN4/1.DELTA.30, (19)
rDEN1.DELTA.30, rDEN2/1.DELTA.30, rDEN3.DELTA.30, rDEN4/2.DELTA.30,
(20) rDEN1.DELTA.30, rDEN2/1.DELTA.30, rDEN3.DELTA.30,
rDEN4/3.DELTA.30, (21) rDEN1.DELTA.30, rDEN2/1.DELTA.30,
rDEN3/1.DELTA.30, rDEN4.DELTA.30, (22) rDEN1.DELTA.30,
rDEN2/1.DELTA.30, rDEN3/1.DELTA.30, rDEN4/1.DELTA.30, (23)
rDEN1.DELTA.30, rDEN2/1.DELTA.30, rDEN3/1.DELTA.30,
rDEN4/2.DELTA.30, (24) rDEN1.DELTA.30, rDEN2/1.DELTA.30,
rDEN3/1.DELTA.30, rDEN4/3.DELTA.30, (25) rDEN1.DELTA.30,
rDEN2/1.DELTA.30, rDEN3/2.DELTA.30, rDEN4.DELTA.30, (26)
rDEN1.DELTA.30, rDEN2/1.DELTA.30, rDEN3/2.DELTA.30,
rDEN4/1.DELTA.30, (27) rDEN1.DELTA.30, rDEN2/1.DELTA.30,
rDEN3/2.DELTA.30, rDEN4/2.DELTA.30, (28) rDEN1.DELTA.30,
rDEN2/1.DELTA.30, rDEN3/2.DELTA.30, rDEN4/3.DELTA.30, (29)
rDEN1.DELTA.30, rDEN2/1.DELTA.30, rDEN3/4.DELTA.30, rDEN4.DELTA.30,
(30) rDEN1.DELTA.30, rDEN2/1.DELTA.30, rDEN3/4.DELTA.30,
rDEN4/1.DELTA.30, (31) rDEN1.DELTA.30, rDEN2/1.DELTA.30,
rDEN3/4.DELTA.30, rDEN4/2.DELTA.30, (32) rDEN1.DELTA.30,
rDEN2/1.DELTA.30, rDEN3/4.DELTA.30, rDEN4/3.DELTA.30, (33)
rDEN1.DELTA.30, rDEN2/3.DELTA.30, rDEN3.DELTA.30, rDEN4.DELTA.30,
(34) rDEN1.DELTA.30, rDEN2/3.DELTA.30, rDEN3.DELTA.30,
rDEN4/1.DELTA.30, (35) rDEN1.DELTA.30, rDEN2/3.DELTA.30,
rDEN3.DELTA.30, rDEN4/2.DELTA.30, (36) rDEN1.DELTA.30,
rDEN2/3.DELTA.30, rDEN3.DELTA.30, rDEN4/3.DELTA.30, (37)
rDEN1.DELTA.30, rDEN2/3.DELTA.30, rDEN3/1.DELTA.30, rDEN4.DELTA.30,
(38) rDEN1.DELTA.30, rDEN2/3.DELTA.30, rDEN3/1.DELTA.30,
rDEN4/1.DELTA.30, (39) rDEN1.DELTA.30, rDEN2/3.DELTA.30,
rDEN3/1.DELTA.30, rDEN4/2.DELTA.30, (40) rDEN1.DELTA.30,
rDEN2/3.DELTA.30, rDEN3/1.DELTA.30, rDEN4/3.DELTA.30, (41)
rDEN1.DELTA.30, rDEN2/3.DELTA.30, rDEN3/2.DELTA.30, rDEN4.DELTA.30,
(42) rDEN1.DELTA.30, rDEN2/3.DELTA.30, rDEN3/2.DELTA.30,
rDEN4/1.DELTA.30, (43) rDEN1.DELTA.30, rDEN2/3.DELTA.30,
rDEN3/2.DELTA.30, rDEN4/2.DELTA.30, (44) rDEN1.DELTA.30,
rDEN2/3.DELTA.30, rDEN3/2.DELTA.30, rDEN4/3.DELTA.30, (45)
rDEN1.DELTA.30, rDEN2/3.DELTA.30, rDEN3/4.DELTA.30, rDEN4.DELTA.30,
(46) rDEN1.DELTA.30, rDEN2/3.DELTA.30, rDEN3/4.DELTA.30,
rDEN4/1.DELTA.30, (47) rDEN1.DELTA.30, rDEN2/3.DELTA.30,
rDEN3/4.DELTA.30, rDEN4/2.DELTA.30, (48) rDEN1.DELTA.30,
rDEN2/3.DELTA.30, rDEN3/4.DELTA.30, rDEN4/3.DELTA.30, (49)
rDEN1.DELTA.30, rDEN2/4.DELTA.30, rDEN3.DELTA.30, rDEN4.DELTA.30,
(50) rDEN1.DELTA.30, rDEN2/4.DELTA.30, rDEN3.DELTA.30,
rDEN4/1.DELTA.30, (51) rDEN1.DELTA.30, rDEN2/4.DELTA.30,
rDEN3.DELTA.30, rDEN4/2.DELTA.30, (52) rDEN1.DELTA.30,
rDEN2/4.DELTA.30, rDEN3.DELTA.30, rDEN4/3.DELTA.30, (53)
rDEN1.DELTA.30, rDEN2/4.DELTA.30, rDEN3/1.DELTA.30, rDEN4.DELTA.30,
(54) rDEN1.DELTA.30, rDEN2/4.DELTA.30, rDEN3/1.DELTA.30,
rDEN4/1.DELTA.30, (55) rDEN1.DELTA.30, rDEN2/4.DELTA.30,
rDEN3/1.DELTA.30, rDEN4/2.DELTA.30, (56) rDEN1.DELTA.30,
rDEN2/4.DELTA.30, rDEN3/1.DELTA.30, rDEN4/3.DELTA.30, (57)
rDEN1.DELTA.30, rDEN2/4.DELTA.30, rDEN3/2.DELTA.30, rDEN4.DELTA.30,
(58) rDEN1.DELTA.30, rDEN2/4.DELTA.30, rDEN3/2.DELTA.30,
rDEN4/1.DELTA.30, (59) rDEN1.DELTA.30, rDEN2/4.DELTA.30,
rDEN3/2.DELTA.30, rDEN4/2.DELTA.30, (60) rDEN1.DELTA.30,
rDEN2/4.DELTA.30, rDEN3/2.DELTA.30, rDEN4/3.DELTA.30, (61)
rDEN1.DELTA.30, rDEN2/4.DELTA.30, rDEN3/4.DELTA.30, rDEN4.DELTA.30,
(62) rDEN1.DELTA.30, rDEN2/4.DELTA.30, rDEN3/4.DELTA.30,
rDEN4/1.DELTA.30, (63) rDEN1.DELTA.30, rDEN2/4.DELTA.30,
rDEN3/4.DELTA.30, rDEN4/2.DELTA.30, (64) rDEN1.DELTA.30,
rDEN2/4.DELTA.30, rDEN3/4.DELTA.30, rDEN4/3.DELTA.30, (65)
rDEN1/2.DELTA.30, rDEN2.DELTA.30, rDEN3.DELTA.30, rDEN4.DELTA.30,
(66) rDEN1/2.DELTA.30, rDEN2.DELTA.30, rDEN3.DELTA.30,
rDEN4/1.DELTA.30, (67) rDEN1/2.DELTA.30, rDEN2.DELTA.30,
rDEN3.DELTA.30, rDEN4/2.DELTA.30, (68) rDEN1/2.DELTA.30,
rDEN2.DELTA.30, rDEN3.DELTA.30, rDEN4/3.DELTA.30, (69)
rDEN1/2.DELTA.30, rDEN2.DELTA.30, rDEN3/1.DELTA.30, rDEN4.DELTA.30,
(70) rDEN1/2.DELTA.30, rDEN2.DELTA.30, rDEN3/1.DELTA.30,
rDEN4/1.DELTA.30, (71) rDEN1/2.DELTA.30, rDEN2.DELTA.30,
rDEN3/1.DELTA.30, rDEN4/2.DELTA.30, (72) rDEN1/2.DELTA.30,
rDEN2.DELTA.30, rDEN3/1.DELTA.30, rDEN4/3.DELTA.30, (73)
rDEN1/2.DELTA.30, rDEN2.DELTA.30, rDEN3/2.DELTA.30, rDEN4.DELTA.30,
(74) rDEN1/2.DELTA.30, rDEN2.DELTA.30, rDEN3/2.DELTA.30,
rDEN4/1.DELTA.30, (75) rDEN1/2.DELTA.30, rDEN2.DELTA.30,
rDEN3/2.DELTA.30, rDEN4/2.DELTA.30, (76) rDEN1/2.DELTA.30,
rDEN2.DELTA.30, rDEN3/2.DELTA.30, rDEN4/3.DELTA.30, (77)
rDEN1/2.DELTA.30, rDEN2.DELTA.30, rDEN3/4.DELTA.30, rDEN4.DELTA.30,
(78) rDEN1/2.DELTA.30, rDEN2.DELTA.30, rDEN3/4.DELTA.30,
rDEN4/1.DELTA.30, (79) rDEN1/2.DELTA.30, rDEN2.DELTA.30,
rDEN3/4.DELTA.30, rDEN4/2.DELTA.30, (80) rDEN1/2.DELTA.30,
rDEN2.DELTA.30, rDEN3/4.DELTA.30, rDEN4/3.DELTA.30, (81)
rDEN1/2.DELTA.30, rDEN2/1.DELTA.30, rDEN3.DELTA.30, rDEN4.DELTA.30,
(82) rDEN1/2.DELTA.30, rDEN2/1.DELTA.30, rDEN3.DELTA.30,
rDEN4/1.DELTA.30, (83) rDEN1/2.DELTA.30, rDEN2/1.DELTA.30,
rDEN3.DELTA.30, rDEN4/2.DELTA.30, (84) rDEN1/2.DELTA.30,
rDEN2/1.DELTA.30, rDEN3.DELTA.30, rDEN4/3.DELTA.30, (85)
rDEN1/2.DELTA.30, rDEN2/1.DELTA.30, rDEN3/1.DELTA.30,
rDEN4.DELTA.30, (86) rDEN1/2.DELTA.30, rDEN2/1.DELTA.30,
rDEN3/1.DELTA.30, rDEN4/1.DELTA.30, (87) rDEN1/2.DELTA.30,
rDEN2/1.DELTA.30, rDEN3/1.DELTA.30, rDEN4/2.DELTA.30, (88)
rDEN1/2.DELTA.30, rDEN2/1.DELTA.30, rDEN3/1.DELTA.30,
rDEN4/3.DELTA.30, (89) rDEN1/2.DELTA.30, rDEN2/1.DELTA.30,
rDEN3/2.DELTA.30, rDEN4.DELTA.30, (90) rDEN1/2.DELTA.30,
rDEN2/1.DELTA.30, rDEN3/2.DELTA.30, rDEN4/1.DELTA.30, (91)
rDEN1/2.DELTA.30, rDEN2/1.DELTA.30, rDEN3/2.DELTA.30,
rDEN4/2.DELTA.30, (92) rDEN1/2.DELTA.30, rDEN2/1.DELTA.30,
rDEN3/2.DELTA.30, rDEN4/3.DELTA.30, (93) rDEN1/2.DELTA.30,
rDEN2/1.DELTA.30, rDEN3/4.DELTA.30, rDEN4.DELTA.30, (94)
rDEN1/2.DELTA.30, rDEN2/1.DELTA.30, rDEN3/4.DELTA.30,
rDEN4/1.DELTA.30, (95) rDEN1/2.DELTA.30, rDEN2/1.DELTA.30,
rDEN3/4.DELTA.30, rDEN4/2.DELTA.30, (96) rDEN1/2.DELTA.30,
rDEN2/1.DELTA.30, rDEN3/4.DELTA.30, rDEN4/3.DELTA.30, (97)
rDEN1/2.DELTA.30, rDEN2/3.DELTA.30, rDEN3.DELTA.30, rDEN4.DELTA.30,
(98) rDEN1/2.DELTA.30, rDEN2/3.DELTA.30, rDEN3.DELTA.30,
rDEN4/1.DELTA.30, (99) rDEN1/2.DELTA.30, rDEN2/3.DELTA.30,
rDEN3.DELTA.30, rDEN4/2.DELTA.30, (100) rDEN1/2.DELTA.30,
rDEN2/3.DELTA.30, rDEN3.DELTA.30, rDEN4/3.DELTA.30, (101)
rDEN1/2.DELTA.30, rDEN2/3.DELTA.30, rDEN3/1.DELTA.30,
rDEN4.DELTA.30, (102) rDEN1/2.DELTA.30, rDEN2/3.DELTA.30,
rDEN3/1.DELTA.30, rDEN4/1.DELTA.30, (103) rDEN1/2.DELTA.30,
rDEN2/3.DELTA.30, rDEN3/1.DELTA.30, rDEN4/2.DELTA.30, (104)
rDEN1/2.DELTA.30, rDEN2/3.DELTA.30, rDEN3/1.DELTA.30,
rDEN4/3.DELTA.30, (105) rDEN1/2.DELTA.30, rDEN2/3.DELTA.30,
rDEN3/2.DELTA.30, rDEN4.DELTA.30, (106) rDEN1/2.DELTA.30,
rDEN2/3.DELTA.30, rDEN3/2.DELTA.30, rDEN4/1.DELTA.30, (107)
rDEN1/2.DELTA.30, rDEN2/3.DELTA.30, rDEN3/2.DELTA.30,
rDEN4/2.DELTA.30, (108) rDEN1/2.DELTA.30, rDEN2/3.DELTA.30,
rDEN3/2.DELTA.30, rDEN4/3.DELTA.30, (109) rDEN1/2.DELTA.30,
rDEN2/3.DELTA.30, rDEN3/4.DELTA.30, rDEN4.DELTA.30, (110)
rDEN1/2.DELTA.30, rDEN2/3.DELTA.30, rDEN3/4.DELTA.30,
rDEN4/1.DELTA.30, (111) rDEN1/2.DELTA.30, rDEN2/3.DELTA.30,
rDEN3/4.DELTA.30, rDEN4/2.DELTA.30, (112) rDEN1/2.DELTA.30,
rDEN2/3.DELTA.30, rDEN3/4.DELTA.30, rDEN4/3.DELTA.30, (113)
rDEN1/2.DELTA.30, rDEN2/4.DELTA.30, rDEN3.DELTA.30, rDEN4.DELTA.30,
(114) rDEN1/2.DELTA.30, rDEN2/4.DELTA.30, rDEN3.DELTA.30,
rDEN4/1.DELTA.30, (115) rDEN1/2.DELTA.30, rDEN2/4.DELTA.30,
rDEN3.DELTA.30, rDEN4/2.DELTA.30, (116) rDEN1/2.DELTA.30,
rDEN2/4.DELTA.30, rDEN3.DELTA.30, rDEN4/3.DELTA.30, (117)
rDEN1/2.DELTA.30, rDEN2/4.DELTA.30, rDEN3/1.DELTA.30,
rDEN4.DELTA.30, (118) rDEN1/2.DELTA.30, rDEN2/4.DELTA.30,
rDEN3/1.DELTA.30, rDEN4/1.DELTA.30, (119) rDEN1/2.DELTA.30,
rDEN2/4.DELTA.30, rDEN3/1.DELTA.30, rDEN4/2.DELTA.30, (120)
rDEN1/2.DELTA.30, rDEN2/4.DELTA.30, rDEN3/1.DELTA.30,
rDEN4/3.DELTA.30, (121) rDEN1/2.DELTA.30, rDEN2/4.DELTA.30,
rDEN3/2.DELTA.30, rDEN4.DELTA.30, (122) rDEN1/2.DELTA.30,
rDEN2/4.DELTA.30, rDEN3/2.DELTA.30, rDEN4/1.DELTA.30, (123)
rDEN1/2.DELTA.30, rDEN2/4.DELTA.30, rDEN3/2.DELTA.30,
rDEN4/2.DELTA.30, (124) rDEN1/2.DELTA.30, rDEN2/4.DELTA.30,
rDEN3/2.DELTA.30, rDEN4/3.DELTA.30, (125) rDEN1/2.DELTA.30,
rDEN2/4.DELTA.30, rDEN3/4.DELTA.30, rDEN4.DELTA.30, (126)
rDEN1/2.DELTA.30, rDEN2/4.DELTA.30, rDEN3/4.DELTA.30,
rDEN4/1.DELTA.30, (127) rDEN1/2.DELTA.30, rDEN2/4.DELTA.30,
rDEN3/4.DELTA.30, rDEN4/2.DELTA.30, (128) rDEN1/2.DELTA.30,
rDEN2/4.DELTA.30, rDEN3/4.DELTA.30, rDEN4/3.DELTA.30, (129)
rDEN1/3.DELTA.30, rDEN2.DELTA.30, rDEN3.DELTA.30, rDEN4.DELTA.30,
(130) rDEN1/3.DELTA.30, rDEN2.DELTA.30, rDEN3.DELTA.30,
rDEN4/1.DELTA.30, (131) rDEN1/3.DELTA.30, rDEN2.DELTA.30,
rDEN3.DELTA.30, rDEN4/2.DELTA.30, (132) rDEN1/3.DELTA.30,
rDEN2.DELTA.30, rDEN3.DELTA.30, rDEN4/3.DELTA.30, (133)
rDEN1/3.DELTA.30, rDEN2.DELTA.30, rDEN3/1.DELTA.30, rDEN4.DELTA.30,
(134) rDEN1/3.DELTA.30, rDEN2.DELTA.30, rDEN3/1.DELTA.30,
rDEN4/1.DELTA.30, (135) rDEN1/3.DELTA.30, rDEN2.DELTA.30,
rDEN3/1.DELTA.30, rDEN4/2.DELTA.30, (136) rDEN1/3.DELTA.30,
rDEN2.DELTA.30, rDEN3/1.DELTA.30, rDEN4/3.DELTA.30, (137)
rDEN1/3.DELTA.30, rDEN2.DELTA.30, rDEN3/2.DELTA.30, rDEN4.DELTA.30,
(138) rDEN1/3.DELTA.30, rDEN2.DELTA.30, rDEN3/2.DELTA.30,
rDEN4/1.DELTA.30, (139) rDEN1/3.DELTA.30, rDEN2.DELTA.30,
rDEN3/2.DELTA.30, rDEN4/2.DELTA.30, (140) rDEN1/3.DELTA.30,
rDEN2.DELTA.30, rDEN3/2.DELTA.30, rDEN4/3.DELTA.30, (141)
rDEN1/3.DELTA.30, rDEN2.DELTA.30, rDEN3/4.DELTA.30, rDEN4.DELTA.30,
(142) rDEN1/3.DELTA.30, rDEN2.DELTA.30, rDEN3/4.DELTA.30,
rDEN4/1.DELTA.30, (143) rDEN1/3.DELTA.30, rDEN2.DELTA.30,
rDEN3/4.DELTA.30, rDEN4/2.DELTA.30, (144) rDEN1/3.DELTA.30,
rDEN2.DELTA.30, rDEN3/4.DELTA.30, rDEN4/3.DELTA.30, (145)
rDEN1/3.DELTA.30, rDEN2/1.DELTA.30, rDEN3.DELTA.30, rDEN4.DELTA.30,
(146) rDEN1/3.DELTA.30, rDEN2/1.DELTA.30, rDEN3.DELTA.30,
rDEN4/1.DELTA.30, (147) rDEN1/3.DELTA.30, rDEN2/1.DELTA.30,
rDEN3.DELTA.30, rDEN4/2.DELTA.30, (148) rDEN1/3.DELTA.30,
rDEN2/1.DELTA.30, rDEN3.DELTA.30, rDEN4/3.DELTA.30, (149)
rDEN1/3.DELTA.30, rDEN2/1.DELTA.30, rDEN3/1.DELTA.30,
rDEN4.DELTA.30, (150) rDEN1/3.DELTA.30, rDEN2/1.DELTA.30,
rDEN3/1.DELTA.30, rDEN4/1.DELTA.30, (151) rDEN1/3.DELTA.30,
rDEN2/1.DELTA.30, rDEN3/1.DELTA.30, rDEN4/2.DELTA.30, (152)
rDEN1/3.DELTA.30, rDEN2/1.DELTA.30, rDEN3/1.DELTA.30,
rDEN4/3.DELTA.30, (153) rDEN1/3.DELTA.30, rDEN2/1.DELTA.30,
rDEN3/2.DELTA.30, rDEN4.DELTA.30, (154) rDEN1/3.DELTA.30,
rDEN2/1.DELTA.30, rDEN3/2.DELTA.30, rDEN4/1.DELTA.30, (155)
rDEN1/3.DELTA.30, rDEN2/1.DELTA.30, rDEN3/2.DELTA.30,
rDEN4/2.DELTA.30, (156) rDEN1/3.DELTA.30, rDEN2/1.DELTA.30,
rDEN3/2.DELTA.30, rDEN4/3.DELTA.30, (157) rDEN1/3.DELTA.30,
rDEN2/1.DELTA.30, rDEN3/4.DELTA.30, rDEN4.DELTA.30, (158)
rDEN1/3.DELTA.30, rDEN2/1.DELTA.30, rDEN3/4.DELTA.30,
rDEN4/1.DELTA.30, (159) rDEN1/3.DELTA.30, rDEN2/1.DELTA.30,
rDEN3/4.DELTA.30, rDEN4/2.DELTA.30, (160) rDEN1/3.DELTA.30,
rDEN2/1.DELTA.30, rDEN3/4.DELTA.30, rDEN4/3.DELTA.30, (161)
rDEN1/3.DELTA.30, rDEN2/3.DELTA.30, rDEN3.DELTA.30, rDEN4.DELTA.30,
(162) rDEN1/3.DELTA.30, rDEN2/3.DELTA.30, rDEN3.DELTA.30,
rDEN4/1.DELTA.30, (163) rDEN1/3.DELTA.30, rDEN2/3.DELTA.30,
rDEN3.DELTA.30, rDEN4/2.DELTA.30, (164) rDEN1/3.DELTA.30,
rDEN2/3.DELTA.30, rDEN3.DELTA.30, rDEN4/3.DELTA.30, (165)
rDEN1/3.DELTA.30, rDEN2/3.DELTA.30, rDEN3/1.DELTA.30,
rDEN4.DELTA.30, (166) rDEN1/3.DELTA.30, rDEN2/3.DELTA.30,
rDEN3/1.DELTA.30, rDEN4/1.DELTA.30, (167) rDEN1/3.DELTA.30,
rDEN2/3.DELTA.30, rDEN3/1.DELTA.30, rDEN4/2.DELTA.30, (168)
rDEN1/3.DELTA.30, rDEN2/3.DELTA.30, rDEN3/1.DELTA.30,
rDEN4/3.DELTA.30, (169) rDEN1/3.DELTA.30, rDEN2/3.DELTA.30,
rDEN3/2.DELTA.30, rDEN4.DELTA.30, (170) rDEN1/3.DELTA.30,
rDEN2/3.DELTA.30, rDEN3/2.DELTA.30, rDEN4/1.DELTA.30, (171)
rDEN1/3.DELTA.30, rDEN2/3.DELTA.30, rDEN3/2.DELTA.30,
rDEN4/2.DELTA.30, (172) rDEN1/3.DELTA.30, rDEN2/3.DELTA.30,
rDEN3/2.DELTA.30, rDEN4/3.DELTA.30, (173) rDEN1/3.DELTA.30,
rDEN2/3.DELTA.30, rDEN3/4.DELTA.30, rDEN4.DELTA.30, (174)
rDEN1/3.DELTA.30, rDEN2/3.DELTA.30, rDEN3/4.DELTA.30,
rDEN4/1.DELTA.30, (175) rDEN1/3.DELTA.30, rDEN2/3.DELTA.30,
rDEN3/4.DELTA.30, rDEN4/2.DELTA.30, (176) rDEN1/3.DELTA.30,
rDEN2/3.DELTA.30, rDEN3/4.DELTA.30, rDEN4/3.DELTA.30, (177)
rDEN1/3.DELTA.30, rDEN2/4.DELTA.30, rDEN3.DELTA.30, rDEN4.DELTA.30,
(178) rDEN1/3.DELTA.30, rDEN2/4.DELTA.30, rDEN3.DELTA.30,
rDEN4/1.DELTA.30, (179) rDEN1/3.DELTA.30, rDEN2/4.DELTA.30,
rDEN3.DELTA.30, rDEN4/2.DELTA.30, (180) rDEN1/3.DELTA.30,
rDEN2/4.DELTA.30, rDEN3.DELTA.30, rDEN4/3.DELTA.30, (181)
rDEN1/3.DELTA.30, rDEN2/4.DELTA.30, rDEN3/1.DELTA.30,
rDEN4.DELTA.30, (182) rDEN1/3.DELTA.30, rDEN2/4.DELTA.30,
rDEN3/1.DELTA.30, rDEN4/1.DELTA.30, (183) rDEN1/3.DELTA.30,
rDEN2/4.DELTA.30, rDEN3/1.DELTA.30, rDEN4/2.DELTA.30, (184)
rDEN1/3.DELTA.30, rDEN2/4.DELTA.30, rDEN3/1.DELTA.30,
rDEN4/3.DELTA.30, (185) rDEN1/3.DELTA.30, rDEN2/4.DELTA.30,
rDEN3/2.DELTA.30, rDEN4.DELTA.30, (186) rDEN1/3.DELTA.30,
rDEN2/4.DELTA.30, rDEN3/2.DELTA.30, rDEN4/1.DELTA.30, (187)
rDEN1/3.DELTA.30, rDEN2/4.DELTA.30, rDEN3/2.DELTA.30,
rDEN4/2.DELTA.30, (188) rDEN1/3.DELTA.30, rDEN2/4.DELTA.30,
rDEN3/2.DELTA.30, rDEN4/3.DELTA.30, (189) rDEN1/3.DELTA.30,
rDEN2/4.DELTA.30, rDEN3/4.DELTA.30, rDEN4.DELTA.30, (190)
rDEN1/3.DELTA.30, rDEN2/4.DELTA.30, rDEN3/4.DELTA.30,
rDEN4/1.DELTA.30, (191) rDEN1/3.DELTA.30, rDEN2/4.DELTA.30,
rDEN3/4.DELTA.30, rDEN4/2.DELTA.30, (192) rDEN1/3.DELTA.30,
rDEN2/4.DELTA.30, rDEN3/4.DELTA.30, rDEN4/3.DELTA.30, (193)
rDEN1/4.DELTA.30, rDEN2.DELTA.30, rDEN3.DELTA.30, rDEN4.DELTA.30,
(194) rDEN1/4.DELTA.30, rDEN2.DELTA.30, rDEN3.DELTA.30,
rDEN4/1.DELTA.30, (195) rDEN1/4.DELTA.30, rDEN2.DELTA.30,
rDEN3.DELTA.30, rDEN4/2.DELTA.30, (196) rDEN1/4.DELTA.30,
rDEN2.DELTA.30, rDEN3.DELTA.30, rDEN4/3.DELTA.30, (197)
rDEN1/4.DELTA.30, rDEN2.DELTA.30, rDEN3/1.DELTA.30, rDEN4.DELTA.30,
(198) rDEN1/4.DELTA.30, rDEN2.DELTA.30, rDEN3/1.DELTA.30,
rDEN4/1.DELTA.30, (199) rDEN1/4.DELTA.30, rDEN2.DELTA.30,
rDEN3/1.DELTA.30, rDEN4/2.DELTA.30, (200) rDEN1/4.DELTA.30,
rDEN2.DELTA.30, rDEN3/1.DELTA.30, rDEN4/3.DELTA.30, (201)
rDEN1/4.DELTA.30, rDEN2.DELTA.30, rDEN3/2.DELTA.30, rDEN4.DELTA.30,
(202) rDEN1/4.DELTA.30, rDEN2.DELTA.30, rDEN3/2.DELTA.30,
rDEN4/1.DELTA.30, (203) rDEN1/4.DELTA.30, rDEN2.DELTA.30,
rDEN3/2.DELTA.30, rDEN4/2.DELTA.30, (204) rDEN1/4.DELTA.30,
rDEN2.DELTA.30, rDEN3/2.DELTA.30, rDEN4/3.DELTA.30, (205)
rDEN1/4.DELTA.30, rDEN2.DELTA.30, rDEN3/4.DELTA.30, rDEN4.DELTA.30,
(206) rDEN1/4.DELTA.30, rDEN2.DELTA.30, rDEN3/4.DELTA.30,
rDEN4/1.DELTA.30, (207) rDEN1/4.DELTA.30, rDEN2.DELTA.30,
rDEN3/4.DELTA.30, rDEN4/2.DELTA.30, (208) rDEN1/4.DELTA.30,
rDEN2.DELTA.30, rDEN3/4.DELTA.30, rDEN4/3.DELTA.30, (209)
rDEN1/4.DELTA.30, rDEN2/1.DELTA.30, rDEN3.DELTA.30, rDEN4.DELTA.30,
(210) rDEN1/4.DELTA.30, rDEN2/1.DELTA.30, rDEN3.DELTA.30,
rDEN4/1.DELTA.30, (211) rDEN1/4.DELTA.30, rDEN2/1.DELTA.30,
rDEN3.DELTA.30, rDEN4/2.DELTA.30, (212) rDEN1/4.DELTA.30,
rDEN2/1.DELTA.30, rDEN3.DELTA.30, rDEN4/3.DELTA.30, (213)
rDEN1/4.DELTA.30, rDEN2/1.DELTA.30,
rDEN3/1.DELTA.30, rDEN4.DELTA.30, (214) rDEN1/4.DELTA.30,
rDEN2/1.DELTA.30, rDEN3/1.DELTA.30, rDEN4/1.DELTA.30, (215)
rDEN1/4.DELTA.30, rDEN2/1.DELTA.30, rDEN3/1.DELTA.30,
rDEN4/2.DELTA.30, (216) rDEN1/4.DELTA.30, rDEN2/1.DELTA.30,
rDEN3/1.DELTA.30, rDEN4/3.DELTA.30, (217) rDEN1/4.DELTA.30,
rDEN2/1.DELTA.30, rDEN3/2.DELTA.30, rDEN4.DELTA.30, (218)
rDEN1/4.DELTA.30, rDEN2/1.DELTA.30, rDEN3/2.DELTA.30,
rDEN4/1.DELTA.30, (219) rDEN1/4.DELTA.30, rDEN2/1.DELTA.30,
rDEN3/2.DELTA.30, rDEN4/2.DELTA.30, (220) rDEN1/4.DELTA.30,
rDEN2/1.DELTA.30, rDEN3/2.DELTA.30, rDEN4/3.DELTA.30, (221)
rDEN1/4.DELTA.30, rDEN2/1.DELTA.30, rDEN3/4.DELTA.30,
rDEN4.DELTA.30, (222) rDEN1/4.DELTA.30, rDEN2/1.DELTA.30,
rDEN3/4.DELTA.30, rDEN4/1.DELTA.30, (223) rDEN1/4.DELTA.30,
rDEN2/1.DELTA.30, rDEN3/4.DELTA.30, rDEN4/2.DELTA.30, (224)
rDEN1/4.DELTA.30, rDEN2/1.DELTA.30, rDEN3/4.DELTA.30,
rDEN4/3.DELTA.30, (225) rDEN1/4.DELTA.30, rDEN2/3.DELTA.30,
rDEN3.DELTA.30, rDEN4.DELTA.30, (226) rDEN1/4.DELTA.30,
rDEN2/3.DELTA.30, rDEN3.DELTA.30, rDEN4/1.DELTA.30, (227)
rDEN1/4.DELTA.30, rDEN2/3.DELTA.30, rDEN3.DELTA.30,
rDEN4/2.DELTA.30, (228) rDEN1/4.DELTA.30, rDEN2/3.DELTA.30,
rDEN3.DELTA.30, rDEN4/3.DELTA.30, (229) rDEN1/4.DELTA.30,
rDEN2/3.DELTA.30, rDEN3/1.DELTA.30, rDEN4.DELTA.30, (230)
rDEN1/4.DELTA.30, rDEN2/3.DELTA.30, rDEN3/1.DELTA.30,
rDEN4/1.DELTA.30, (231) rDEN1/4.DELTA.30, rDEN2/3.DELTA.30,
rDEN3/1.DELTA.30, rDEN4/2.DELTA.30, (232) rDEN1/4.DELTA.30,
rDEN2/3.DELTA.30, rDEN3/1.DELTA.30, rDEN4/3.DELTA.30, (233)
rDEN1/4.DELTA.30, rDEN2/3.DELTA.30, rDEN3/2.DELTA.30,
rDEN4.DELTA.30, (234) rDEN1/4.DELTA.30, rDEN2/3.DELTA.30,
rDEN3/2.DELTA.30, rDEN4/1.DELTA.30, (235) rDEN1/4.DELTA.30,
rDEN2/3.DELTA.30, rDEN3/2.DELTA.30, rDEN4/2.DELTA.30, (236)
rDEN1/4.DELTA.30, rDEN2/3.DELTA.30, rDEN3/2.DELTA.30,
rDEN4/3.DELTA.30, (237) rDEN1/4.DELTA.30, rDEN2/3.DELTA.30,
rDEN3/4.DELTA.30, rDEN4.DELTA.30, (238) rDEN1/4.DELTA.30,
rDEN2/3.DELTA.30, rDEN3/4.DELTA.30, rDEN4/1.DELTA.30, (239)
rDEN1/4.DELTA.30, rDEN2/3.DELTA.30, rDEN3/4.DELTA.30,
rDEN4/2.DELTA.30, (240) rDEN1/4.DELTA.30, rDEN2/3.DELTA.30,
rDEN3/4.DELTA.30, rDEN4/3.DELTA.30, (241) rDEN1/4.DELTA.30,
rDEN2/4.DELTA.30, rDEN3.DELTA.30, rDEN4.DELTA.30, (242)
rDEN1/4.DELTA.30, rDEN2/4.DELTA.30, rDEN3.DELTA.30,
rDEN4/1.DELTA.30, (243) rDEN1/4.DELTA.30, rDEN2/4.DELTA.30,
rDEN3.DELTA.30, rDEN4/2.DELTA.30, (244) rDEN1/4.DELTA.30,
rDEN2/4.DELTA.30, rDEN3.DELTA.30, rDEN4/3.DELTA.30, (245)
rDEN1/4.DELTA.30, rDEN2/4.DELTA.30, rDEN3/1.DELTA.30,
rDEN4.DELTA.30, (246) rDEN1/4.DELTA.30, rDEN2/4.DELTA.30,
rDEN3/1.DELTA.30, rDEN4/1.DELTA.30, (247) rDEN1/4.DELTA.30,
rDEN2/4.DELTA.30, rDEN3/1.DELTA.30, rDEN4/2.DELTA.30, (248)
rDEN1/4.DELTA.30, rDEN2/4.DELTA.30, rDEN3/1.DELTA.30,
rDEN4/3.DELTA.30, (249) rDEN1/4.DELTA.30, rDEN2/4.DELTA.30,
rDEN3/2.DELTA.30, rDEN4.DELTA.30, (250) rDEN1/4.DELTA.30,
rDEN2/4.DELTA.30, rDEN3/2.DELTA.30, rDEN4/1.DELTA.30, (251)
rDEN1/4.DELTA.30, rDEN2/4.DELTA.30, rDEN3/2.DELTA.30,
rDEN4/2.DELTA.30, (252) rDEN1/4.DELTA.30, rDEN2/4.DELTA.30,
rDEN3/2.DELTA.30, rDEN4/3.DELTA.30, (254) rDEN1/4.DELTA.30,
rDEN2/4.DELTA.30, rDEN3/4.DELTA.30, rDEN4/1.DELTA.30, (255)
rDEN1/4.DELTA.30, rDEN2/4.DELTA.30, rDEN3/4.DELTA.30,
rDEN4/2.DELTA.30, and (256) rDEN1/4.DELTA.30, rDEN2/4.DELTA.30,
rDEN3/4.DELTA.30, rDEN4/3.DELTA.30.
Description
FIELD OF THE INVENTION
The invention relates to a dengue virus tetravalent vaccine
containing a common 30 nucleotide deletion (.DELTA.30) in the
3'-untranslated region of the genome of dengue virus serotypes 1,
2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1,
2, 3, and 4.
BACKGROUND OF THE INVENTION
Dengue virus is a positive-sense RNA virus belonging to the
Flavivirus genus of the family Flaviviridae. Dengue virus is widely
distributed throughout the tropical and semitropical regions of the
world and is transmitted to humans by mosquito vectors. Dengue
virus is a leading cause of hospitalization and death in children
in at least eight tropical Asian countries (WHO 1997 Dengue
Haemorrhagic Fever: Diagnosis, Treatment, Prevention, and Control
2nd Edition, Geneva). There are four serotypes of dengue virus
(DEN1, DEN2, DEN3, and DEN4) that annually cause an estimated
50-100 million cases of dengue fever and 500,000 cases of the more
severe form of dengue virus infection known as dengue hemorrhagic
fever/dengue shock syndrome (DHF/DSS) (Gubler, D. J. and Meltzer,
M. 1999 Adv Virus Res 53:35-70). This latter disease is seen
predominantly in children and adults experiencing a second dengue
virus infection with a serotype different than that of their first
dengue virus infection and in primary infection of infants who
still have circulating dengue-specific maternal antibody (Burke, D.
S. et al. 1988 Am J Trop Med Hyg 38:172-180; Halstead, S. B. et al.
1969 Am J Trop Med Hyg 18:997-1021; Thein, S. et al. 1997 Am J Trop
Med Hyg 56:566-575). A dengue vaccine is needed to lessen disease
burden caused by dengue virus, but none is licensed. Because of the
association of more severe disease with secondary dengue virus
infection, a successful vaccine must simultaneously induce immunity
to all four serotypes. Immunity is primarily mediated by
neutralizing antibody directed against the envelope (E)
glycoprotein, a virion structural protein. Infection with one
serotype induces long-lived homotypic immunity and a short-lived
heterotypic immunity (Sabin, A. 1955 Am J Trop Med Hyg 4:198-207).
Therefore, the goal of immunization is to induce a long-lived
neutralizing antibody response against DEN1, DEN2, DEN3, and DEN4,
which can best be achieved economically using live attenuated virus
vaccines. This is a reasonable goal since a live attenuated vaccine
has already been developed for the related yellow fever virus,
another mosquito-borne flavivirus present in tropical and
semitropical regions of the world (Monath, T. P. and Heinz, F. X.
1996 in: Fields Virology, Fields, D. M et al. eds. Philadelphia:
Lippincott-Raven Publishers, pp. 961-1034).
Several live attenuated dengue vaccine candidates have been
developed and evaluated in humans and non-human primates. The first
live attenuated dengue vaccine candidates were host range mutants
developed by serial passage of wild-type dengue viruses in the
brains of mice and selection of mutants attenuated for humans
(Kimura, R. and Hotta, S. 1944 Jpn J Bacteriol 1:96-99; Sabin, A.
B. and Schlesinger, R. W. 1945 Science 101:640; Wisserman, C. L. et
al. 1963 Am J Trop Med Hyg 12:620-623). Although these candidate
vaccine viruses were immunogenic in humans, their poor growth in
cell culture discouraged further development. Additional live
attenuated DEN1, DEN2, DEN3, and DEN4 vaccine candidates have been
developed by serial passage in non-human tissue culture
(Angsubhakorn, S. et al. 1994 Southeast Asian J Trop Med Public
Health 25:554-559; Bancroft, W. H. et al. 1981 Infect Immun
31:698-703; Bhamarapravati, N. et al. 1987 Bull World Health Organ
65:189-195; Eckels, K. H. et al. 1984 Am J Trop Med Hyg 33:684-698;
Hoke, C. H. Jr. et al. 1990 Am J Trop Med Hyg 43:219-226;
Kanesa-Thasan, N. et al. 2001 Vaccine 19:3179-3188) or by chemical
mutagenesis (McKee, K. T. et al. 1987 Am J Trop Med Hyg
36:435-442). It has proven very difficult to achieve a satisfactory
balance between attenuation and immunogenicity for each of the four
serotypes of dengue virus using these approaches and to formulate a
tetravalent vaccine that is safe and satisfactorily immunogenic
against each of the four dengue viruses (Kanesa-Thasan, N. et al.
2001 Vaccine 19:3179-3188; Bhamarapravati, N. and Sutee, Y. 2000
Vaccine 18:44-47).
Two major advances using recombinant DNA technology have recently
made it possible to develop additional promising live attenuated
dengue virus vaccine candidates. First, methods have been developed
to recover infectious dengue virus from cells transfected with RNA
transcripts derived from a full-length cDNA clone of the dengue
virus genome, thus making it possible to derive infectious viruses
bearing attenuating mutations that have been introduced into the
cDNA clone by site-directed mutagenesis (Lai, C. J. et al. 1991
PNAS USA 88:5139-5143). Second, it is possible to produce antigenic
chimeric viruses in which the structural protein coding region of
the full-length cDNA clone of dengue virus is replaced by that of a
different dengue virus serotype or from a more divergent flavivirus
(Bray, M. and Lai, C. J. 1991 PNAS USA 88:10342-10346; Chen, W. et
al. 1995 J Virol 69:5186-5190; Huang, C. Y. et al. 2000 J Virol
74:3020-3028; Pletnev, A. G. and Men, R. 1998 PNAS USA
95:1746-1751). These techniques have been used to construct
intertypic chimeric dengue viruses that have been shown to be
effective in protecting monkeys against homologous dengue virus
challenge (Bray, M. et al. 1996 J Virol 70:4162-4166). A similar
strategy is also being used to develop attenuated antigenic
chimeric dengue virus vaccines based on the attenuation of the
yellow fever vaccine virus or the attenuation of the cell-culture
passaged dengue viruses (Monath, T. P. et al. 1999 Vaccine
17:1869-1882; Huang, C. Y. et al. 2000 J Virol 74:3020-3028).
Another study examined the level of attenuation for humans of a
DEN4 mutant bearing a 30-nucleotide deletion (.DELTA.30) introduced
into its 3'-untranslated region by site-directed mutagenesis and
that was found previously to be attenuated for rhesus monkeys (Men,
R. et al. 1996 J Virol 70:3930-3937). Additional studies were
carried out to examine whether this .DELTA.30 mutation present in
the DEN4 vaccine candidate was the major determinant of its
attenuation for monkeys. It was found that the .DELTA.30 mutation
was indeed the major determinant of attenuation for monkeys, and
that it specified a satisfactory balance between attenuation and
immunogenicity for humans (Durbin, A. P. et al. 2001 Am J Trop Med
Hyg 65:405-13).
SUMMARY OF THE INVENTION
The previously identified .DELTA.30 attenuating mutation, created
in dengue virus type 4 (DEN4) by the removal of 30 nucleotides from
the 3'-UTR, is also capable of attenuating a wild-type strain of
dengue virus type 1 (DEN1). Removal of 30 nucleotides from the DEN1
3'-UTR in a highly conserved region homologous to the DEN4 region
encompassing the .DELTA.30 mutation yielded a recombinant virus
attenuated in rhesus monkeys to a level similar to recombinant
virus DEN4.DELTA.30. This establishes the transportability of the
.DELTA.30 mutation and its attenuation phenotype to a dengue virus
type other than DEN4. The effective transferability of the
.DELTA.30 mutation, described by this work, establishes the
usefulness of the .DELTA.30 mutation to attenuate and improve the
safety of commercializable dengue virus vaccines of any serotype.
We envision a tetravalent dengue virus vaccine containing dengue
virus types 1, 2, 3, and 4 each attenuated by the .DELTA.30
mutation. We also envision a tetravalent dengue virus vaccine
containing recombinant antigenic chimeric viruses in which the
structural genes of dengue virus types 1, 2, and 3 replace those of
DEN4.DELTA.30; 1, 2, and 4 replace those of DEN3.DELTA.30; 1, 3,
and 4 replace those of DEN2.DELTA.30; and 2, 3, and 4 replace those
of DEN1.DELTA.30. In some instances, such chimeric dengue viruses
are attenuated not only by the .DELTA.30 mutation, but also by
their chimeric nature. The presence of the .DELTA.30 attenuating
mutation in each virus component precludes the reversion to a
wild-type virus by intertypic recombination. In addition, because
of the inherent genetic stability of deletion mutations, the
.DELTA.30 mutation represents an excellent alternative for use as a
common mutation shared among each component of a tetravalent
vaccine.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1. The live attenuated tetravalent dengue virus vaccine
contains dengue viruses representing each of the 4 serotypes, with
each serotype containing its full set of unaltered wild-type
structural and non-structural proteins and a shared .DELTA.30
attenuating mutation. The relative location of the .DELTA.30
mutation in the 3' untranslated region (UTR) of each component is
indicated by an arrow.
FIG. 2. A. The .DELTA.30 mutation removes 30 contiguous nucleotides
(shaded) from the 3' UTR of DEN4. Nucleotides are numbered from the
3' terminus. B. Nucleotide sequence alignment of the TL2 region of
DEN1, DEN2, DEN3, and DEN4 and their .DELTA.30 derivatives. Also
shown is the corresponding region for each of the four DEN
serotypes. Upper case letters indicate sequence homology among all
4 serotypes, underlining indicates nucleotide pairing to form the
stem structure. C. Predicted secondary structure of the TL2 region
of each DEN serotype. Nucleotides that are removed by the .DELTA.30
mutation are boxed (DEN1--between nts 10562-10591, DEN2
Tonga/74--between nts 10541-10570, DEN3 Sleman/78--between nts
10535-10565, and DEN4--between nts 10478-10507).
FIG. 3. Viremia levels in rhesus monkeys inoculated with rDEN4
vaccine candidates bearing 5-FU derived mutations. Groups of four
or two (rDEN4 and rDEN4.DELTA.30) monkeys were inoculated with 5.0
log.sub.10PFU virus subcutaneously. Serum was collected daily and
virus titers were determined by plaque assay in Vero cells. The
limit of virus detection was 0.7 log.sub.10PFU/ml. Mean virus
titers are indicated for each group.
FIG. 4. Viremia levels in rhesus monkeys inoculated with rDEN4
vaccine candidates bearing pairs of charge-to-alanine mutations in
NS5. Groups of four or two (rDEN4 and rDEN4.DELTA.30) monkeys were
inoculated with 5.0 log.sub.10PFU virus subcutaneously. Serum was
collected daily and virus titers were determined by plaque assay in
Vero cells. The limit of virus detection was 1.0 log.sub.10PFU/ml.
Mean virus titers are indicated for each group. Viremia was not
detected in any monkey after day 4.
FIG. 5. The .DELTA.30 mutation attenuates both DEN1 and DEN4 for
rhesus monkeys. Groups of 4 monkeys were immunized subcutaneously
with 5.0 log.sub.10PFU of the indicated virus. Serum was collected
each day following immunization and virus titers were determined
and are shown as mean log.sub.10PFU/ml.
FIG. 6. A. Diagram of the p2 (Tonga/74) full-length cDNA plasmid.
Regions subcloned are indicated above the plasmid. Numbering begins
at the 5' end of the viral sequence. B. The .DELTA.30 mutation
removes the indicated 30 nucleotides from the 3' UTR sequence to
create p2.DELTA.30.
FIG. 7. Viremia levels in rhesus monkeys inoculated with DEN2
(Tonga/74), rDEN2, and rDEN2.DELTA.30 vaccine candidate. Groups of
four monkeys were inoculated with 5.0 log.sub.10PFU virus
subcutaneously. Serum was collected daily and virus titers were
determined by plaque assay in Vero cells. The limit of virus
detection was 0.7 log.sub.10PFU/ml. Mean virus titers are indicated
for each group. Viremia was not detected in any monkey after day
8.
FIG. 8. A. Diagram of the p3 (Sleman/78) full-length cDNA plasmid.
Regions subcloned are indicated above the plasmid. Numbering begins
at the 5' end of the viral sequence. The sequence and insertion
location of the SpeI linker is shown. B. The .DELTA.30 mutation
removes the indicated 31 nucleotides from the 3' UTR sequence to
create p3.DELTA.30.
FIG. 9. A. Recombinant chimeric dengue viruses were constructed by
introducing either the CME or the ME regions of DEN2 (Tonga/74)
into the DEN4 genetic background. The relative location of the
.DELTA.30 mutation in the 3' UTR is indicated by an arrow and
intertypic junctions 1, 2, and 3 are indicated. B. Nucleotide and
amino acid sequence of the intertypic junction regions. Restriction
enzyme recognition sites used in assembly of each chimeric cDNA are
indicated.
FIG. 10. Growth kinetics in Vero cells of chimeric rDEN2/4.DELTA.30
viruses encoding single or combined Vero cell adaptation mutations.
Vero cells were infected with the indicated viruses at an MOI of
0.01. At the indicated time points post-infection, 1 ml samples of
tissue culture medium were removed, clarified by centrifugation,
and frozen at -80.degree. C. The level of virus replication was
assayed by plaque titration in C6/36 cells. Lower limit of
detection was 0.7 log.sub.10PFU/ml. Replication levels on day 4
post-infection are indicated by the dashed line.
FIG. 11. A. Recombinant chimeric dengue viruses were constructed by
introducing either the CME or the ME regions of DEN3 (Sleman/78)
into the DEN4 genetic background. The relative location of the
.DELTA.30 mutation in the 3' UTR is indicated by an arrow and
intertypic junctions 1, 2, and 3 are indicated. Restriction enzyme
recognition sites used in assembly of each chimeric cDNA are
indicated. B. Nucleotide and amino acid sequence of the intertypic
junction regions. Restriction enzyme recognition sites used in
assembly of each chimeric cDNA are indicated.
FIG. 12. A. Recombinant chimeric dengue viruses were constructed by
introducing either the CME or the ME regions of DEN1 (Puerto
Rico/94) into the DEN4 genetic background. The relative location of
the .DELTA.30 mutation in the 3' UTR is indicated by an arrow and
intertypic junctions 1, 2, and 3 are indicated. Restriction enzyme
recognition sites used in assembly of each chimeric cDNA are
indicated. B. Nucleotide and amino acid sequence of the intertypic
junction regions. Restriction enzyme recognition sites used in
assembly of each chimeric cDNA are indicated.
TABLE-US-00001 Brief Description of the Sequences GenBank Accession
Serotype No. or description DEN1 U88535 DEN2 Tonga/74 DEN3
Sleman/78 DEN4 AF326825
TABLE-US-00002 Brief Description of the SEQ ID NOs Figure, Table,
or SEQ Identification Appendix ID NO. TL2 region of DEN1 FIG. 2C 1
TL2 region of DEN2 FIG. 2C 2 TL2 region of DEN3 FIG. 2C 3 TL2
region of DEN4 FIG. 2C 4 TL2 region of DEN1.DELTA.30 FIG. 2B 5 TL2
region of DEN2.DELTA.30 FIG. 2B 6 TL2 region of DEN3.DELTA.30 FIG.
2B 7 TL2 region of DEN4.DELTA.30 FIG. 2B 8 TL2 region of p2 FIG. 6B
9 TL2 region of p2.DELTA.30 FIG. 6B 10 TL2 region of p3 FIG. 8B 11
TL2 region of p3.DELTA.30 FIG. 8B 12 Spel linker in p3 FIG. 8A 13
rDEN2/4 junction 1 FIG. 9B 14-nt, 15-aa rDEN2/4 junction 2 FIG. 9B
16-nt, 17-aa rDEN2/4 junction 3 FIG. 9B 18-nt, 19-aa rDEN3/4
junction 1 FIG. 11B 20-nt, 21-aa rDEN3/4 junction 2 FIG. 11B 22-nt,
23-aa rDEN3/4 junction 3 FIG. 11B 24-nt, 25-aa rDEN1/4 junction 1
FIG. 12B 26-nt, 27-aa rDEN1/4 junction 2 FIG. 12B 28-nt, 29-aa
rDEN1/4 junction 3 FIG. 12B 30-nt, 31-aa D4 selected NS4B region
Table 15 32-nt, 33-aa D1 selected NS4B region Table 15 34-nt, 35-aa
D2 selected NS4B region Table 15 36-nt, 37-aa D3 selected NS4B
region Table 15 38-nt, 39-aa CCACGGGCGCCGT Table 26 40 AAGGCCTGGA
Table 26 41 TATCCCCGGGAC Table 26 42 AGAGCTCTCTC Table 26 43
GAATCTCCACCCGGA Table 26 44 CTGTCGAATC Table 26 45 DEN2 (Tonga/74)
Appendix 1 46-nt, 47-aa cDNA plasmid p2 DEN3 (Sleman/78) Appendix 2
48-nt, 49-aa cDNA plasmid p3 DEN1 (Puerto Rico/94) CME Appendix 3
50-nt, 51-aa chimeric region DEN1 (Puerto Rico/94) ME Appendix 4
52-nt, 53-aa chimeric region
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
Introduction
A molecular approach is herewith used to develop a genetically
stable live attenuated tetravalent dengue virus vaccine. Each
component of the tetravalent vaccine, namely, DEN1, DEN2, DEN3, and
DEN4, must be attenuated, genetically stable, and immunogenic. A
tetravalent vaccine is needed to ensure simultaneous protection
against each of the four dengue viruses, thereby precluding the
possibility of developing the more serious illnesses dengue
hemorrhagic fever/dengue shock syndrome (DHF/DSS), which occur in
humans during secondary infection with a heterotypic wild-type
dengue virus. Since dengue viruses can undergo genetic
recombination in nature (Worobey, M. et al. 1999 PNAS USA
96:7352-7), the tetravalent vaccine should be genetically incapable
of undergoing a recombination event between its four virus
components that could lead to the generation of viruses lacking
attenuating mutations. Previous approaches to develop a tetravalent
dengue virus vaccine have been based on independently deriving each
of the four virus components through separate mutagenic procedures,
such as passage in tissue culture cells derived from a heterologous
host. This strategy has yielded attenuated vaccine candidates
(Bhamarapravati, N. and Sutee, Y. 2000 Vaccine 18:44-7). However,
it is possible that gene exchanges among the four components of
these independently derived tetravalent vaccines could occur in
vaccinees, possibly creating a virulent recombinant virus. Virulent
polioviruses derived from recombination have been generated in
vaccinees following administration of a trivalent poliovirus
vaccine (Guillot, S. et al. 2000 J Virol 74:8434-43).
The present invention describes: (1) improvements to the previously
described rDEN4.DELTA.30 vaccine candidate, 2) attenuated
rDEN1.DELTA.30, rDEN2.DELTA.30, and rDEN3.DELTA.30 recombinant
viruses containing a 30 nucleotide deletion (.DELTA.30) in a
section of the 3' untranslated region (UTR) that is homologous to
that in the rDEN4.DELTA.30 recombinant virus, (3) a method to
generate a tetravalent dengue virus vaccine composed of
rDEN1.DELTA.30, rDEN2.DELTA.30, rDEN3.DELTA.30, and rDEN4.DELTA.30,
4) attenuated antigenic chimeric viruses, rDEN1/4.DELTA.30,
rDEN2/4.DELTA.30, and rDEN3/4.DELTA.30, for which the CME, ME, or E
gene regions of rDEN4.DELTA.30 have been replaced with those
derived from DEN1, DEN2, or DEN3; alternatively rDEN1/3.DELTA.30,
rDEN2/3.DELTA.30, and rDEN4/3.DELTA.30 for which CME, ME, or E gene
regions of rDEN3.DELTA.30 have been replaced with those derived
from DEN1, 2, or 4; alternatively rDEN1/2.DELTA.30,
rDEN3/2.DELTA.30, and rDEN4/2.DELTA.30 for which CME, ME, or E gene
regions of rDEN2.DELTA.30 have been replaced with those derived
from DEN1, 3, or, 4; and alternatively rDEN2/1.DELTA.30,
rDEN3/1.DELTA.30, and rDEN4/1.DELTA.30 for which CME, ME, or E gene
regions of rDEN1.DELTA.30 have been replaced with those derived
from DEN2, 3, or 4, and 5) a method to generate a tetravalent
dengue virus vaccine composed of rDEN1/4.DELTA.30,
rDEN2/4.DELTA.30, rDEN3/4.DELTA.30, and rDEN4.DELTA.30,
alternatively rDEN1/3.DELTA.30, rDEN2/3.DELTA.30, rDEN4/3.DELTA.30,
and rDEN3.DELTA.30, alternatively rDEN1/2.DELTA.30,
rDEN3/2.DELTA.30, rDEN4/2.DELTA.30, and rDEN2.DELTA.30, and
alternatively rDEN2/1.DELTA.30, rDEN3/1.DELTA.30, rDEN4/1.DELTA.30,
and rDEN1.DELTA.30. These tetravalent vaccines are unique since
they contain a common shared attenuating mutation which eliminates
the possibility of generating a virulent wild-type virus in a
vaccinee since each component of the vaccine possesses the same
.DELTA.30 attenuating deletion mutation. In addition, the
rDEN1.DELTA.30, rDEN2.DELTA.30, rDEN3.DELTA.30, rDEN4.DELTA.30
tetravalent vaccine is the first to combine the stability of the
.DELTA.30 mutation with broad antigenicity. Since the .DELTA.30
deletion mutation is in the 3' UTR of each virus, all of the
proteins of the four component viruses are available to induce a
protective immune response. Thus, the method provides a mechanism
of attenuation that maintains each of the proteins of DEN1, DEN2,
DEN3, and DEN4 viruses in a state that preserves the full
capability of each of the proteins of the four viruses to induce
humoral and cellular immune responses against all of the structural
and non-structural proteins present in each dengue virus
serotype.
As previously described, the DEN4 recombinant virus, rDEN4.DELTA.30
(previously referred to as 2A.DELTA.30), was engineered to contain
a 30 nucleotide deletion in the 3'UTR of the viral genome (Durbin,
A. P. et al. 2001 Am J Trop Med Hyg 65:405-13; Men, R. et al. 1996
J Virol 70:3930-7). Evaluation in rhesus monkeys showed the virus
to be significantly attenuated relative to wild-type parental
virus, yet highly immunogenic and completely protective. Also, a
phase I clinical trial with adult human volunteers showed the
rDEN4.DELTA.30 recombinant virus to be safe and satisfactorily
immunogenic (Durbin, A. P. et al. 2001 Am J Trop Med Hyg
65:405-13). To develop a tetravalent vaccine bearing a shared
attenuating mutation in a untranslated region, we selected the
.DELTA.30 mutation to attenuate wild-type dengue viruses of
serotypes 1, 2, and 3 since it attenuated wild-type DEN4 virus for
rhesus monkeys and was safe in humans (FIG. 1).
The .DELTA.30 mutation was first described and characterized in the
DEN4 virus (Men, R. et al. 1996 J Virol 70:3930-7). In DEN4, the
mutation consists of the removal of 30 contiguous nucleotides
comprising nucleotides 10478-10507 of the 3' UTR (FIG. 2A) which
form a putative stem-loop structure referred to as TL2 (Proutski,
V. et al. 1997 Nucleic Acids Res 25:1194-202). Among the
flaviviruses, large portions of the UTR form highly conserved
secondary structures (Hahn, C. S. et al. 1987 J Mol Biol 198:33-41;
Proutski, V. et al. 1997 Nucleic Acids Res 25:1194-202). Although
the individual nucleotides are not necessarily conserved in these
regions, appropriate base pairing preserves the stem-loop structure
in each serotype, a fact that is not readily apparent when only
considering the primary sequence (FIG. 2B, C).
Immunogenic Dengue Chimeras and Methods for their Preparation
Immunogenic dengue chimeras and methods for preparing the dengue
chimeras are provided herein. The immunogenic dengue chimeras are
useful, alone or in combination, in a pharmaceutically acceptable
carrier as immunogenic compositions to minimize, inhibit, or
immunize individuals and animals against infection by dengue
virus.
Chimeras of the present invention comprise nucleotide sequences
encoding the immunogenicity of a dengue virus of one serotype and
further nucleotide sequences selected from the backbone of a dengue
virus of a different serotype. These chimeras can be used to induce
an immunogenic response against dengue virus.
In another embodiment, the preferred chimera is a nucleic acid
chimera comprising a first nucleotide sequence encoding at least
one structural protein from a dengue virus of a first serotype, and
a second nucleotide sequence encoding non-structural proteins from
a dengue virus of a second serotype different from the first. In
another embodiment the dengue virus of the second serotype is DEN4.
In another embodiment, the structural protein can be the C protein
of a dengue virus of the first serotype, the prM protein of a
dengue virus of the first serotype, the E protein of a dengue virus
of the first serotype, or any combination thereof.
The term "residue" is used herein to refer to an amino acid (D or
L) or an amino acid mimetic that is incorporated into a peptide by
an amide bond. As such, the amino acid may be a naturally occurring
amino acid or, unless otherwise limited, may encompass known
analogs of natural amino acids that function in a manner similar to
the naturally occurring amino acids (i.e., amino acid mimetics).
Moreover, an amide bond mimetic includes peptide backbone
modifications well known to those skilled in the art.
Furthermore, one of skill in the art will recognize that individual
substitutions, deletions or additions in the amino acid sequence,
or in the nucleotide sequence encoding for the amino acids, which
alter, add or delete a single amino acid or a small percentage of
amino acids (typically less than 5%, more typically less than 1%)
in an encoded sequence are conservatively modified variations,
wherein the alterations result in the substitution of an amino acid
with a chemically similar amino acid. Conservative substitution
tables providing functionally similar amino acids are well known in
the art. The following six groups each contain amino acids that are
conservative substitutions for one another: 1) Alanine (A), Serine
(S), Threonine (T); 2) Aspartic acid (D), Glutamic acid (E); 3)
Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5)
Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and 6)
Phenylalanine (F), Tyrosine (Y), Tryptophan (W).
As used herein, the terms "virus chimera," "chimeric virus,"
"dengue chimera" and "chimeric dengue virus" means an infectious
construct of the invention comprising nucleotide sequences encoding
the immunogenicity of a dengue virus of one serotype and further
nucleotide sequences derived from the backbone of a dengue virus of
a different serotype.
As used herein, "infectious construct" indicates a virus, a viral
construct, a viral chimera, a nucleic acid derived from a virus or
any portion thereof, which may be used to infect a cell.
As used herein, "nucleic acid chimera" means a construct of the
invention comprising nucleic acid comprising nucleotide sequences
encoding the immunogenicity of a dengue virus of one serotype and
further nucleotide sequences derived from the backbone of a dengue
virus of a different serotype. Correspondingly, any chimeric virus
or virus chimera of the invention is to be recognized as an example
of a nucleic acid chimera.
The structural and nonstructural proteins of the invention are to
be understood to include any protein comprising or any gene
encoding the sequence of the complete protein, an epitope of the
protein, or any fragment comprising, for example, three or more
amino acid residues thereof.
Dengue Chimeras
Dengue virus is a mosquito-borne flavivirus pathogen. The dengue
virus genome contains a 5' untranslated region (5' UTR), followed
by a capsid protein (C) encoding region, followed by a
premembrane/membrane protein (prM) encoding region, followed by an
envelope protein (E) encoding region, followed by the region
encoding the nonstructural proteins
(NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5) and finally a 3' untranslated
region (3' UTR). The viral structural proteins are C, prM and E,
and the nonstructural proteins are NS1-NS5. The structural and
nonstructural proteins are translated as a single polyprotein and
processed by cellular and viral proteases.
The dengue chimeras of the invention are constructs formed by
fusing structural protein genes from a dengue virus of one
serotype, e.g. DEN1, DEN2, DEN3, or DEN4, with non-structural
protein genes from a dengue virus of a different serotype, e.g.,
DEN1, DEN2, DEN3, or DEN4.
The attenuated, immunogenic dengue chimeras provided herein contain
one or more of the structural protein genes, or antigenic portions
thereof, of the dengue virus of one serotype against which
immunogenicity is to be conferred, and the nonstructural protein
genes of a dengue virus of a different serotype.
The chimera of the invention contains a dengue virus genome of one
serotype as the backbone, in which the structural protein gene(s)
encoding C, prM, or E protein(s) of the dengue genome, or
combinations thereof, are replaced with the corresponding
structural protein gene(s) from a dengue virus of a different
serotype that is to be protected against. The resulting viral
chimera has the properties, by virtue of being chimerized with a
dengue virus of another serotype, of attenuation and is therefore
reduced in virulence, but expresses antigenic epitopes of the
structural gene products and is therefore immunogenic.
The genome of any dengue virus can be used as the backbone in the
attenuated chimeras described herein. The backbone can contain
mutations that contribute to the attenuation phenotype of the
dengue virus or that facilitate replication in the cell substrate
used for manufacture, e.g., Vero cells. The mutations can be in the
nucleotide sequence encoding non-structural proteins, the 5'
untranslated region or the 3' untranslated region. The backbone can
also contain further mutations to maintain the stability of the
attenuation phenotype and to reduce the possibility that the
attenuated virus or chimera might revert back to the virulent
wild-type virus. For example, a first mutation in the 3'
untranslated region and a second mutation in the 5' untranslated
region will provide additional attenuation phenotype stability, if
desired. In particular, a mutation that is a deletion of 30 nts
from the 3' untranslated region of the DEN4 genome between nts
10478-10507 results in attenuation of the DEN4 virus (Men et al.
1996 J. Virology 70:3930-3933; Durbin et al. 2001 Am J Trop Med
65:405-413, 2001). Therefore, the genome of any dengue type 4 virus
containing such a mutation at this locus can be used as the
backbone in the attenuated chimeras described herein. Furthermore,
other dengue virus genomes containing an analogous deletion
mutation in the 3' untranslated region of the genomes of other
dengue virus serotypes may also be used as the backbone structure
of this invention.
Such mutations may be achieved by site-directed mutagenesis using
techniques known to those skilled in the art. It will be understood
by those skilled in the art that the virulence screening assays, as
described herein and as are well known in the art, can be used to
distinguish between virulent and attenuated backbone
structures.
Construction of Dengue Chimeras
The dengue virus chimeras described herein can be produced by
substituting at least one of the structural protein genes of the
dengue virus of one serotype against which immunity is desired into
a dengue virus genome backbone of a different serotype, using
recombinant engineering techniques well known to those skilled in
the art, namely, removing a designated dengue virus gene of one
serotype and replacing it with the desired corresponding gene of
dengue virus of a different serotype. Alternatively, using the
sequences provided in GenBank, the nucleic acid molecules encoding
the dengue proteins may be synthesized using known nucleic acid
synthesis techniques and inserted into an appropriate vector.
Attenuated, immunogenic virus is therefore produced using
recombinant engineering techniques known to those skilled in the
art.
As mentioned above, the gene to be inserted into the backbone
encodes a dengue structural protein of one serotype. Preferably the
dengue gene of a different serotype to be inserted is a gene
encoding a C protein, a prM protein and/or an E protein. The
sequence inserted into the dengue virus backbone can encode both
the prM and E structural proteins of the other serotype. The
sequence inserted into the dengue virus backbone can encode the C,
prM and E structural proteins of the other serotype. The dengue
virus backbone is the DEN1, DEN2, DEN3, or DEN4 virus genome, or an
attenuated dengue virus genome of any of these serotypes, and
includes the substituted gene(s) that encode the C, prM and/or E
structural protein(s) of a dengue virus of a different serotype, or
the substituted gene(s) that encode the prM and/or E structural
protein(s) of a dengue virus of a different serotype.
Suitable chimeric viruses or nucleic acid chimeras containing
nucleotide sequences encoding structural proteins of dengue virus
of any of the serotypes can be evaluated for usefulness as vaccines
by screening them for phenotypic markers of attenuation that
indicate reduction in virulence with retention of immunogenicity.
Antigenicity and immunogenicity can be evaluated using in vitro or
in vivo reactivity with dengue antibodies or immunoreactive serum
using routine screening procedures known to those skilled in the
art.
Dengue Vaccines
The preferred chimeric viruses and nucleic acid chimeras provide
live, attenuated viruses useful as immunogens or vaccines. In a
preferred embodiment, the chimeras exhibit high immunogenicity
while at the same time not producing dangerous pathogenic or lethal
effects.
The chimeric viruses or nucleic acid chimeras of this invention can
comprise the structural genes of a dengue virus of one serotype in
a wild-type or an attenuated dengue virus backbone of a different
serotype. For example, the chimera may express the structural
protein genes of a dengue virus of one serotype in either of a
dengue virus or an attenuated dengue virus background of a
different serotype.
The strategy described herein of using a genetic background that
contains nonstructural regions of a dengue virus genome of one
serotype, and, by chimerization, the properties of attenuation, to
express the structural protein genes of a dengue virus of a
different serotype has lead to the development of live, attenuated
dengue vaccine candidates that express structural protein genes of
desired immunogenicity. Thus, vaccine candidates for control of
dengue pathogens can be designed.
Viruses used in the chimeras described herein are typically grown
using techniques known in the art. Virus plaque or focus forming
unit (FFU) titrations are then performed and plaques or FFU are
counted in order to assess the viability, titer and phenotypic
characteristics of the virus grown in cell culture. Wild type
viruses are mutagenized to derive attenuated candidate starting
materials.
Chimeric infectious clones are constructed from various dengue
serotypes. The cloning of virus-specific cDNA fragments can also be
accomplished, if desired. The cDNA fragments containing the
structural protein or nonstructural protein genes are amplified by
reverse transcriptase-polymerase chain reaction (RT-PCR) from
dengue RNA with various primers. Amplified fragments are cloned
into the cleavage sites of other intermediate clones. Intermediate,
chimeric dengue clones are then sequenced to verify the sequence of
the inserted dengue-specific cDNA.
Full genome-length chimeric plasmids constructed by inserting the
structural or nonstructural protein gene region of dengue viruses
into vectors are obtainable using recombinant techniques well known
to those skilled in the art.
Methods of Administration
The viral chimeras described herein are individually or jointly
combined with a pharmaceutically acceptable carrier or vehicle for
administration as an immunogen or vaccine to humans or animals. The
terms "pharmaceutically acceptable carrier" or "pharmaceutically
acceptable vehicle" are used herein to mean any composition or
compound including, but not limited to, water or saline, a gel,
salve, solvent, diluent, fluid ointment base, liposome, micelle,
giant micelle, and the like, which is suitable for use in contact
with living animal or human tissue without causing adverse
physiological responses, and which does not interact with the other
components of the composition in a deleterious manner.
The immunogenic or vaccine formulations may be conveniently
presented in viral plaque forming unit (PFU) unit or focus forming
unit (FFU) dosage form and prepared by using conventional
pharmaceutical techniques. Such techniques include the step of
bringing into association the active ingredient and the
pharmaceutical carrier(s) or excipient(s). In general, the
formulations are prepared by uniformly and intimately bringing into
association the active ingredient with liquid carriers.
Formulations suitable for parenteral administration include aqueous
and non-aqueous sterile injection solutions which may contain
anti-oxidants, buffers, bacteriostats and solutes which render the
formulation isotonic with the blood of the intended recipient, and
aqueous and non-aqueous sterile suspensions which may include
suspending agents and thickening agents. The formulations may be
presented in unit-dose or multi-dose containers, for example,
sealed ampoules and vials, and may be stored in a freeze-dried
(lyophilized) condition requiring only the addition of the sterile
liquid carrier, for example, water for injections, immediately
prior to use. Extemporaneous injection solutions and suspensions
may be prepared from sterile powders, granules and tablets commonly
used by one of ordinary skill in the art.
Preferred unit dosage formulations are those containing a dose or
unit, or an appropriate fraction thereof, of the administered
ingredient. It should be understood that in addition to the
ingredients particularly mentioned above, the formulations of the
present invention may include other agents commonly used by one of
ordinary skill in the art.
The immunogenic or vaccine composition may be administered through
different routes, such as oral or parenteral, including, but not
limited to, buccal and sublingual, rectal, aerosol, nasal,
intramuscular, subcutaneous, intradermal, and topical. The
composition may be administered in different forms, including, but
not limited to, solutions, emulsions and suspensions, microspheres,
particles, microparticles, nano-particles and liposomes. It is
expected that from about 1 to about 5 doses may be required per
immunization schedule. Initial doses may range from about 100 to
about 100,000 PFU or FFU, with a preferred dosage range of about
500 to about 20,000 PFU or FFU, a more preferred dosage range of
from about 1000 to about 12,000 PFU or FFU and a most preferred
dosage range of about 1000 to about 4000 PFU or FFU. Booster
injections may range in dosage from about 100 to about 20,000 PFU
or FFU, with a preferred dosage range of about 500 to about 15,000,
a more preferred dosage range of about 500 to about 10,000 PFU or
FFU, and a most preferred dosage range of about 1000 to about 5000
PFU or FFU. For example, the volume of administration will vary
depending on the route of administration. Intramuscular injections
may range in volume from about 0.1 ml to 1.0 ml.
The composition may be stored at temperatures of from about
-100.degree. C. to about 4.degree. C. The composition may also be
stored in a lyophilized state at different temperatures including
room temperature. The composition may be sterilized through
conventional means known to one of ordinary skill in the art. Such
means include, but are not limited to, filtration. The composition
may also be combined with bacteriostatic agents to inhibit
bacterial growth.
Administration Schedule
The immunogenic or vaccine composition described herein may be
administered to humans, especially individuals travelling to
regions where dengue virus infection is present, and also to
inhabitants of those regions. The optimal time for administration
of the composition is about one to three months before the initial
exposure to the dengue virus. However, the composition may also be
administered after initial infection to ameliorate disease
progression, or after initial infection to treat the disease.
Adjuvants
A variety of adjuvants known to one of ordinary skill in the art
may be administered in conjunction with the chimeric virus in the
immunogen or vaccine composition of this invention. Such adjuvants
include, but are not limited to, the following: polymers,
co-polymers such as polyoxyethylene-polyoxypropylene copolymers,
including block co-polymers, polymer p 1005, Freund's complete
adjuvant (for animals), Freund's incomplete adjuvant; sorbitan
monooleate, squalene, CRL-8300 adjuvant, alum, QS 21, muramyl
dipeptide, CpG oligonucleotide motifs and combinations of CpG
oligonucleotide motifs, trehalose, bacterial extracts, including
mycobacterial extracts, detoxified endotoxins, membrane lipids, or
combinations thereof.
Nucleic Acid Sequences
Nucleic acid sequences of dengue virus of one serotype and dengue
virus of a different serotype are useful for designing nucleic acid
probes and primers for the detection of dengue virus chimeras in a
sample or specimen with high sensitivity and specificity. Probes or
primers corresponding to dengue virus can be used to detect the
presence of a vaccine virus. The nucleic acid and corresponding
amino acid sequences are useful as laboratory tools to study the
organisms and diseases and to develop therapies and treatments for
the diseases.
Nucleic acid probes and primers selectively hybridize with nucleic
acid molecules encoding dengue virus or complementary sequences
thereof. By "selective" or "selectively" is meant a sequence which
does not hybridize with other nucleic acids to prevent adequate
detection of the dengue virus sequence. Therefore, in the design of
hybridizing nucleic acids, selectivity will depend upon the other
components present in the sample. The hybridizing nucleic acid
should have at least 70% complementarity with the segment of the
nucleic acid to which it hybridizes. As used herein to describe
nucleic acids, the term "selectively hybridizes" excludes the
occasional randomly hybridizing nucleic acids, and thus has the
same meaning as "specifically hybridizing." The selectively
hybridizing nucleic acid probes and primers of this invention can
have at least 70%, 80%, 85%, 90%, 95%, 97%, 98% and 99%
complementarity with the segment of the sequence to which it
hybridizes, preferably 85% or more.
The present invention also contemplates sequences, probes and
primers that selectively hybridize to the encoding nucleic acid or
the complementary, or opposite, strand of the nucleic acid.
Specific hybridization with nucleic acid can occur with minor
modifications or substitutions in the nucleic acid, so long as
functional species-species hybridization capability is maintained.
By "probe" or "primer" is meant nucleic acid sequences that can be
used as probes or primers for selective hybridization with
complementary nucleic acid sequences for their detection or
amplification, which probes or primers can vary in length from
about 5 to 100 nucleotides, or preferably from about 10 to 50
nucleotides, or most preferably about 18-24 nucleotides. Isolated
nucleic acids are provided herein that selectively hybridize with
the species-specific nucleic acids under stringent conditions and
should have at least five nucleotides complementary to the sequence
of interest as described in Molecular Cloning: A Laboratory Manual,
2nd ed., Sambrook, Fritsch and Maniatis, Cold Spring Harbor
Laboratory, Cold Spring Harbor, N.Y., 1989.
If used as primers, the composition preferably includes at least
two nucleic acid molecules which hybridize to different regions of
the target molecule so as to amplify a desired region. Depending on
the length of the probe or primer, the target region can range
between 70% complementary bases and full complementarity and still
hybridize under stringent conditions. For example, for the purpose
of detecting the presence of dengue virus, the degree of
complementarity between the hybridizing nucleic acid (probe or
primer) and the sequence to which it hybridizes is at least enough
to distinguish hybridization with a nucleic acid from other
organisms.
The nucleic acid sequences encoding dengue virus can be inserted
into a vector, such as a plasmid, and recombinantly expressed in a
living organism to produce recombinant dengue virus peptide and/or
polypeptides.
The nucleic acid sequences of the invention include a diagnostic
probe that serves to report the detection of a cDNA amplicon
amplified from the viral genomic RNA template by using a
reverse-transcription/polymerase chain reaction (RT/PCR), as well
as forward and reverse amplimers that are designed to amplify the
cDNA amplicon. In certain instances, one of the amplimers is
designed to contain a vaccine virus-specific mutation at the
3'-terminal end of the amplimer, which effectively makes the test
even more specific for the vaccine strain because extension of the
primer at the target site, and consequently amplification, will
occur only if the viral RNA template contains that specific
mutation.
Automated PCR-based nucleic acid sequence detection systems have
been recently developed. TaqMan assay (Applied Biosystems) is
widely used. A more recently developed strategy for diagnostic
genetic testing makes use of molecular beacons (Tyagi and Kramer,
1996 Nature Biotechnology 14:303-308). Molecular beacon assays
employ quencher and reporter dyes that differ from those used in
the TaqMan assay. These and other detection systems may used by one
skilled in is the art.
EXAMPLE 1
Improvement of Dengue Virus Vaccine Candidate rDEN4.DELTA.30
The safety of recombinant live-attenuated dengue-4 vaccine
candidate rDEN4.DELTA.30 was evaluated in twenty human volunteers
who received a dose of 5.0 log.sub.10plaque forming units (PFU)
(Durbin A. P. et al. 2001 Am J Trop Med Hyg 65:405-413). The
vaccine candidate was found to be safe, well-tolerated and
immunogenic in all of the vaccinees. However, five of the vaccinees
experienced a transient elevation in alanine aminotransferase
levels, three experienced neutropenia and ten vaccinees developed
an asymptomatic macular rash, suggesting that it may be necessary
to further attenuate this vaccine candidate.
Currently, a randomized, double-blind, placebo-controlled, dose
de-escalation study is being conducted to determine the human
infectious dose 50 (HID.sub.50) of rDEN4.DELTA.30. Each dose cohort
consists of approximately twenty vaccinees and four placebo
recipients. To date, complete data for doses of 3.0 log.sub.10PFU
and 2.0 log.sub.10PFU has been collected. rDEN4.DELTA.30 infected
100% of vaccinees when 3.0 log.sub.10PFU was administered and 95%
of vaccinees when 2.0 log.sub.10PFU was administered (Table 1). The
vaccine candidate caused no symptomatic illness at either dose
(Table 1). One vaccinee who received 3.0 log.sub.10PFU experienced
a transient elevation in alanine aminotransferase levels and
approximately one fourth of the vaccinees experienced neutropenia
at both doses (Table 1). Neutropenia was transient and mild. More
than half of the vaccinees developed a macular rash at both doses;
the occurrence of rash was not correlated with vaccination dose or
with viremia (Table 1 and Table 2). Neither peak titer nor onset of
viremia differed between the 3.0 log.sub.10PFU and 2.0
log.sub.10PFU doses, though both measures of viremia were
significantly lower for these doses than for a dose of 5.0
log.sub.10PFU (Table 3). The vaccine candidate was immunogenic in
95% of vaccinees at both doses and neutralizing antibody did not
decline between days 28 and 42 post-vaccination (Table 4). Although
the HID.sub.50 has not been determined yet, it is clearly less than
2.0 log.sub.10PFU. Interestingly, decreases in the dose of vaccine
have had no consistent effect on immunogenicity, viremia, benign
neutropenia or the occurrence of rash. Thus will not necessarily be
possible to further attenuate rDEN4.DELTA.30 by decreasing the dose
of virus administered, and other approaches must be developed.
TABLE-US-00003 TABLE 1 rDEN4.DELTA.30 clinical summary No. No. Mean
No. volunteers with: No. of in- with peak Neutro- subjects
Dose.sup.a fected viremia titer.sup.b Fever Rash penia.sup.c .upa-
rw.ALT 20 5.0 20 14 1.2 (0.2) 1.sup.d 10 3 5 20 3.0 20 7 0.4 (0.0)
0 11 5 1.sup.e 20 2.0 19 11 0.6 (0.1) 1.sup.d 16 4 0 8 0 0 0 0 0 0
0 0 .sup.aLog.sub.10 pfu .sup.bLog.sub.10 pfu/mL .sup.cNeutropenia
defined as ANC < 1500/dl .sup.dT Max in volunteer =
100.4.degree. F. .sup.eALT day 0 = 78, ALT max = 91 (day 14)
TABLE-US-00004 TABLE 2 Pattern of rash in vaccinees No. No. Mean
with with Viremia Viremia Mean day of duration Dose.sup.a viremia
rash & rash no rash onset .+-. SD (days .+-. SD) 5 14/20 10/20
9/20 5/20 .sub. 8.1 .+-. 1.3 [A].sup.a 3.6 .+-. 2.0 [A] 3 7/20
11/20 6/20 1/20 12.2 .+-. 1.4 [B] 5.0 .+-. 2.1 [A] 2 11/20 16/20
9/20 2/20 11.2 .+-. 1.4 [B] 6.9 .+-. 1.7 [B] .sup.alog.sub.10 pfu
.sup.bMeans in each column with different letters are significantly
different (.alpha. = 0.05)
TABLE-US-00005 TABLE 3 rDEN4.DELTA.30 viremia summary Mean onset of
Mean duration # with Mean peak titer viremia of viremia Dose.sup.a
viremia (log.sub.10 pfu/mL) (day .+-. SD) (day .+-. SD) 5 14 1.2
.+-. 0.2 [A] 5.8 .+-. 2.4 [A].sup.b 4.4 .+-. 2.4 [A] 3 7 0.4 .+-.
0.0 [B] 9.1 .+-. 2.5 [B] 1.6 .+-. 1.0 [B] 2 11 0.6 .+-. 0.1 [B] 8.7
.+-. 2.4 [B] 2.6 .+-. 2.0 [A] .sup.alog.sub.10 pfu .sup.bMeans in
each column with different letters are significantly different
(.alpha. = 0.05)
TABLE-US-00006 TABLE 4 Immunogenicity of rDEN4.DELTA.30 Geometric
mean serum neutralizing % No. of Dose No. antibody titer (range)
serocon- subjects (log.sub.10) infected Day 28 Day 42 version 20
5.0 20 567 (72-2455) 399 (45-1230) 100 20 3.0 20 156 (5-2365) 158
(25-1222) 95 20 2.0 19 163 (5-943) 165 (5-764) 95 8 0 0 0 0 0
Two approaches have been taken to further attenuate rDEN4.DELTA.30.
This first is the generation and characterization of attenuating
point mutations in rDEN4 using 5' fluorouracil mutagenesis (Blaney,
J. E. Jr. et al. 2002 Virology 300: 125-139; Blaney, J. E. Jr. et
al. 2001 J. Virol. 75: 9731-9740). This approach has identified a
panel of point mutations that confer a range of temperature
sensitivity (ts) and small plaque (sp) phenotypes in Vero and HuH-7
cells and attenuation (att) phenotypes in suckling mouse brain and
SCID mice engrafted with HuH-7 cells (SCID-HuH-7 mice). In this
example, a subset of these mutations has been introduced to
rDEN4.DELTA.30 and the phenotypes of the resulting viruses
evaluated.
A second approach was to create a series of paired
charge-to-alanine mutations in contiguous pairs of charged amino
acid residues in the rDEN4 NS5 gene. As demonstrated previously,
mutation of 32 individual contiguous pairs of charged amino acid
residues in rDEN4 NS5 conferred a range of ts phenotypes in Vero
and HuH-7 cells and a range of att phenotypes in suckling mouse
brain (Hanley, K. H. et al. 2002 J. Virol. 76 525-531). As
demonstrated below, these mutations also confer an att phenotype in
SCID-HuH-7 mice. These mutations have been introduced, either as
single pairs or sets of two pairs, into rDEN4.DELTA.30 to determine
whether they are compatible with the .DELTA.30 mutation and whether
they enhance the att phenotypes of rDEN4.DELTA.30.
A panel of rDEN4 viruses bearing individual point mutations have
been characterized which possess temperature sensitive and/or small
plaque phenotypes in tissue culture and varying levels of
attenuated replication in suckling mouse brain when compared to
wild type rDEN4 virus (Blaney, J. E. et al. 2002 Virology
300:125-139; Blaney, J. E. et al. 2001 J Virol. 75:9731-9740).
Three mutations have been selected to combine with the .DELTA.30
deletion mutation to evaluate their ability to further restrict
replication of rDEN4.DELTA.30 in rhesus monkeys. First, the
missense mutation in NS3 at nucleotide 4995 (Ser>Pro) which
confers temperature sensitivity in Vero and HuH-7 cells and
restricted replication in suckling mouse brain was previously
combined with the .DELTA.30 mutation (Blaney, J. E. et al. 2001 J
Virol. 75:9731-9740). The resulting virus, rDEN4.DELTA.30-4995, was
found to be more restricted (1,000-fold) in mouse brain replication
than rDEN4.DELTA.30 virus (<5-fold) when compared to wild type
rDEN4 virus. Second, a missense mutation at nucleotide 8092
(Glu>Gly) which also confers temperature sensitivity in Vero and
HuH-7 cells and 10,000-fold restricted replication in suckling
mouse brain was combined with the .DELTA.30 mutation here. Third, a
substitution in the 3' UTR at nucleotide 10634 which confers
temperature sensitivity in Vero and HuH-7 cells, small plaque size
in HuH-7 cells, and approximately 1,000-fold restricted replication
in suckling mouse brain and SCID mice transplanted with HuH-7 cells
was combined with the .DELTA.30 mutation here (Blaney, J. E. et al.
2002 Virology 300:125-139).
For the present investigation, subcloned fragments of p4 (Durbin,
A. P. et al. 2001 Am J Trop Med Hyg 65:405-13) containing the above
mutations were introduced into the p4.DELTA.30 cDNA clone. For
transcription and recovery of virus, cDNA was linearized with
Acc65I (isoschizomer of KpnI which cleaves leaving only a single 3'
nucleotide) and used as template for transcription by SP6 RNA
polymerase as previously described (Blaney, J. E. et al. 2002
Virology 300:125-139). C6/36 mosquito cells were transfected using
liposome-mediated transfection and cell culture supernatants were
harvested between days five and seven. Recovered virus was
terminally diluted twice in Vero cells and passaged two
(rDEN4.DELTA.30-4995) or three (rDEN4.DELTA.30-8092 and
rDEN4.DELTA.30-10634) times in Vero cells.
The complete genomic sequences of rDEN4.DELTA.30-4995,
rDEN4.DELTA.30-8092, and rDEN4.DELTA.30-10634 viruses were
determined as previously described (Durbin et al. 2001 Am. J. Trop.
Med. Hyg. 65:405-413). As expected, each rDEN4.DELTA.30 virus
derivative contained the .DELTA.30 mutation. Unexpectedly, in
rDEN4.DELTA.30-4995 virus, the nucleotide changes in the codon
containing nucleotide 4995, resulted in a Ser>Leu amino acid
change rather than a Ser>Pro change since the p4.DELTA.30-4995
cDNA was designed to introduce the Ser>Pro change (Table 5). The
p4.DELTA.30-4995 cDNA clone was indeed found to encode a Ser>Pro
change at nucleotide 4995, so it is unclear how the virus
population acquired the Ser>Leu mutation. Nevertheless, this
virus was evaluated to assess the phenotype specified by this
missense mutation. rDEN4.DELTA.30-4995 virus was also found to
contain an incidental mutation at nucleotides 4725-6 which resulted
in a single amino acid change (Ser>Asp). The rDEN4.DELTA.30-8092
and rDEN4.DELTA.30-10634 viruses contained the appropriate
nucleotide substitutions as well as additional incidental mutations
in E, NS4B and NS4B, respectively (Table 5).
TABLE-US-00007 TABLE 5 Missense and UTR mutations present in
rDEN4.DELTA.30 virus derivatives bearing introduced point
mutations. Amino Amino Nucleotide Nucleotide acid acid Virus Gene
position substitution position.sup.a change rDEN4.DELTA.30- NS3
4725 U > G 1542 Ser > Asp 4995 NS3 4726 C > A 1542 Ser
> Asp NS3 4995.sup.b U > C 1632 Ser > Leu rDEN4.DELTA.30-
E 1612 A > C 504 Asp > Ala 8092 NS4B 7131 A > G 2344 Thr
> Ala NS5 8092.sup.b A > G 2664 Glu > Gly rDEN4.DELTA.30-
NS4B 6969 A > U 2290 Met > Leu 10634 NS4B 7182 G > C 2361
Gly > Arg 3' UTR 10634.sup.b U > C none none .sup.aAmino acid
position in DEN4 polyprotein beginning with the methionine residue
of the C protein (nucleotides 102-104) as position 1.
.sup.bMutation restricts replication in mouse models of DEN4
infection which were introduced by Kunkel mutagenesis.
Replication of the three modified rDEN4.DELTA.30 viruses were
compared to rDEN4.DELTA.30 and wild type rDEN4 virus in the
suckling mouse brain model and SCID mice transplanted with HuH-7
cells (SCID-HuH-7 mice). Experiments were conducted as previously
described (Blaney, J. E. et al. 2002 Virology 300:125-139; Blaney,
J. E. et al. 2001 J Virol. 75:9731-9740). Briefly, for infection of
suckling mouse brain, groups of six seven-day-old mice were
inoculated intracerebrally with 4.0 log.sub.10PFU of virus and the
brain of each mouse was removed five days later. Clarified
supernatants of 10% brain suspensions were then frozen at
-70.degree. C., and the virus titer was determined by plaque assay
in Vero cells. For analysis of DEN4 virus replication in SCID-HuH-7
mice, four to six week-old SCID mice were injected
intraperitoneally with 10.sup.7 HuH-7 cells. Five to six weeks
after transplantation, mice were infected by direct inoculation
into the tumor with 4.0 log.sub.10PFU of virus, and serum for virus
titration was obtained by tail-nicking on day 7. The virus titer
was determined by plaque assay in Vero cells.
Wild type rDEN4 virus replicated to 6.0 log.sub.10PFU/g in suckling
mouse brain, and rDEN4.DELTA.30 was restricted in replication by
0.7 log.sub.10PFU/g, which is similar to previous observations
(Table 6) (Blaney, J. E. et al. 2001 J Virol. 75:9731-9740).
rDEN4.DELTA.30-4995, rDEN4.DELTA.30-8092, and rDEN4.DELTA.30-10634
viruses were found to have restricted replication in suckling mouse
brain when compared to rDEN4 virus of 3.3, 2.8, and 2.4
log.sub.10PFU/g, respectively. These results indicate that the
additional attenuating mutations serve to further restrict
replication of the rDEN4.DELTA.30 virus in mouse brain ranging from
50-fold (rDEN4.DELTA.30-10634) to 400-fold (rDEN4.DELTA.30-4995).
In SCID-HuH-7 mice, virus titer of rDEN4.DELTA.30 virus was 0.4
log.sub.10PFU/ml lower than rDEN4 virus, which is also similar to
previous studies (Blaney, J. E. et al. 2002 Virology 300:125-139).
Each modified rDEN4.DELTA.30 virus was found to be further
restricted in replication in SCID-HuH-7 mice (Table 6).
rDEN4.DELTA.30-4995, rDEN4.DELTA.30-8092, and rDEN4.DELTA.30-10634
viruses had restricted replication in SCID-HuH-7 mice when compared
to rDEN4 virus of 2.9, 1.1, and 2.3 log.sub.10PFU/g below the level
of wild type rDEN4 virus, respectively. Two important observations
were made: (1) The 4995, 8092 and 10634 mutations were compatible
for viability with the .DELTA.30 mutation, and (2) These three
modified rDEN4.DELTA.30 viruses had between a 10 and 1,000-fold
reduction in replication in comparison to rDEN4 wild-type virus,
which allows viruses with a wide range of attenuation in this model
to be further evaluated in monkeys or humans.
TABLE-US-00008 TABLE 6 Addition of point mutations in NS3, NS5, or
the 3' UTR to rDEN4.DELTA.30 virus further attenuates the virus for
suckling mouse brain and SCID-HuH-7 mice. Replication in suckling
Replication in mouse brain.sup.a SCID-HuH-7 mice.sup.c Virus Mean
Virus Mean titer .+-. SE log.sub.10-unit titer .+-. SE
log.sub.10-unit No. of log.sub.10 PFU/g reduction No. of log.sub.10
PFU/ml reduction Virus mice brain from wt.sup.b mice serum from
wt.sup.b rDEN4 12 6.0 .+-. 0.1 -- 13 6.4 .+-. 0.2 -- rDEN4.DELTA.30
12 5.3 .+-. 0.1 0.7 20 6.0 .+-. 0.2 0.4 rDEN4.DELTA.30-4995 6 2.7
.+-. 0.4 3.3 5 3.5 .+-. 0.3 2.9 rDEN4.DELTA.30-8092 6 3.2 .+-. 0.2
2.8 7 5.0 .+-. 0.4 1.1 rDEN4.DELTA.30-10634 12 3.6 .+-. 0.1 2.4 5
4.4 .+-. 0.3 2.3 .sup.aGroups of 6 suckling mice were inoculated
i.c. with 10.sup.4 PFU of virus. Brains were removed 5 days later,
homogenized, and titered in Vero cells. .sup.bComparison of mean
virus titers of mice inoculated with mutant virus and concurrent
rDEN4 wt control. .sup.cGroups of HuH-7-SCID mice were inoculated
directly into the tumor with 10.sup.4 PFU virus. Serum was
collected on day 6 and 7 and titered in Vero cells.
Based on the findings in the two mouse models of DEN4 virus
infection, each of the rDEN4.DELTA.30-4995, rDEN4.DELTA.30-8092,
and rDEN4.DELTA.30-10634 viruses was evaluated in the rhesus
macaque model of DEN4 infection which has been previously described
(Durbin et al. 2001 Am. J. Trop. Med. Hyg. 65:405-413). Briefly,
groups of four (rDEN4.DELTA.30-4995, rDEN4.DELTA.30-8092, and
rDEN4.DELTA.30-10634) or two (rDEN4, rDEN4.DELTA.30, mock) monkeys
were inoculated with 5.0 log.sub.10PFU virus subcutaneously.
Monkeys were observed daily and serum was collected on days 0 to 6,
8, 10, and 12, and virus titers were determined by plaque assay in
Vero cells for measurement of viremia. On day 28, serum was drawn
and the level of neutralizing antibodies was tested by plaque
reduction assay in Vero cells as previously described (Durbin et
al. 2001 Am. J. Trop. Med. Hyg. 65:405-413).
Viremia was detected beginning on day 1 post-infection and ended by
day 4 in all monkeys (Table 7, FIG. 3). Viremia was present in each
monkey infected with rDEN4, rDEN4.DELTA.30, or rDEN4.DELTA.30-10634
virus, but only 2 out of 4 monkeys infected with
rDEN4.DELTA.30-4995 or rDEN4.DELTA.30-8092 virus had detectable
viremia. As expected, infection with rDEN4 virus resulted in the
highest mean number of viremic days per monkey (3.0 days) as well
as mean peak virus titer (2.2 log.sub.10PFU/ml). Monkeys infected
with rDEN4.DELTA.30 virus had both a lower mean number of viremic
days per monkey (2.0 days) and mean peak virus titer (1.1
log.sub.10PFU/ml) compared to rDEN4 virus. Groups of monkeys
infected with each of the modified rDEN4.DELTA.30 viruses had a
further restricted mean number of viremic days with those
inoculated with rDEN4.DELTA.30-8092 virus having the lowest value,
0.5 days, a 4-fold reduction compared to rDEN4.DELTA.30 virus. The
mean peak virus titer of monkeys infected with rDEN4.DELTA.30-4995
(0.9 log.sub.10PFU/ml) or rDEN4.DELTA.30-8092 (0.7
log.sub.10PFU/ml) was also lower than those infected with
rDEN4.DELTA.30 virus. However, the mean peak virus titer of monkeys
infected with rDEN4.DELTA.30-10634 (1.3 log.sub.10PFU/ml) was
slightly higher than those infected with rDEN4.DELTA.30
particularly on day 2 (FIG. 3).
TABLE-US-00009 TABLE 7 Addition of point mutations to
rDEN4.DELTA.30 further attenuates the virus for rhesus monkeys.
Geometric mean No. of Mean no. serum neutralizing monkeys of
viremic Mean peak antibody titer No. of with days per virus titer
(reciprocal dilution) Virus.sup.a monkeys viremia monkey.sup.b
(log.sub.10 PFU/ml .+-. SE) Day 0 Day 28 mock 2 0 0 <0.7 <10
<10 rDEN4 2 2 3.0 2.2 .+-. 0.6 <10 398 rDEN4.DELTA.30 2 2 2.0
1.1 .+-. 0.4 <10 181 rDEN4.DELTA.30-4995 4 2 0.8 0.9 .+-. 0.2
<10 78 rDEN4.DELTA.30-8092 4 2 0.5 0.7 .+-. 0.1 <10 61
rDEN4.DELTA.30-10634 4 4 1.3 1.3 .+-. 0.2 <10 107 .sup.aGroups
of rhesus monkeys were inoculated subcutaneously with 10.sup.5 PFU
of the indicated virus in a 1 ml dose. Serum was collected on days
0 to 6, 8, 10, 12, and 28. Virus titer was determined by plaque
assay in Vero cells. .sup.bViremia was not detected in any monkey
after day 4.
Serum collected on day 0 and 28 was tested for the level of
neutralizing antibodies against rDEN4. No detectable neutralizing
antibodies were found against DEN4 on day 0, as expected, since the
monkeys were pre-screened to be negative for neutralizing
antibodies against flaviviruses (Table 7). On day 28, monkeys
infected with rDEN4 had a mean serum neutralizing antibody titer
(reciprocal dilution) of 398 which was approximately two-fold
higher than monkeys infected with rDEN4.DELTA.30 virus (1:181).
This result and the two-fold higher level of viremia in rDEN4
virus-infected monkeys are similar to results obtained previously
(Durbin et al. 2001 Am. J. Trop. Med. Hyg. 65:405-413). Monkeys
infected with rDEN4.DELTA.30-4995 (1:78), rDEN4.DELTA.30-8092
(1:61), and rDEN4.DELTA.30-10634 (1:107) viruses each had a reduced
mean serum neutralizing antibody titer compared to monkeys infected
with rDEN4.DELTA.30 virus. The four monkeys which had no detectable
viremia did have serum neutralizing antibody titers indicating that
they were indeed infected. Despite the slight increase in mean peak
virus titer of rDEN4.DELTA.30-10634 virus compared with
rDEN4.DELTA.30 virus, rDEN4.DELTA.30-10634 virus had a lower mean
serum neutralizing antibody titer compared to monkeys infected with
rDEN4.DELTA.30 virus. This and the lower mean number of viremic
days per monkey suggests that the 10634 mutation can attenuate the
replication of rDEN4.DELTA.30 virus in monkeys.
On day 28 after inoculation, all monkeys were challenged with 5.0
log.sub.10PFU wild type rDEN4 virus subcutaneously. Monkeys were
observed daily and serum was collected on days 28 to 34, 36, and
38, and virus titers were determined by plaque assay in Vero cells
for measurement of viremia after challenge. Twenty eight days after
rDEN4 virus challenge, serum was drawn and the level of
neutralizing antibodies was tested by plaque reduction assay in
Vero cells. Mock-inoculated monkeys had a mean peak virus titer of
2.3 log.sub.10PFU/ml after challenge with a mean number of viremic
days of 3.5 (Table 8). However, monkeys inoculated with rDEN4,
rDEN4.DELTA.30, or each of the modified rDEN4.DELTA.30 viruses had
no detectable viremia, indicating that despite the decreased
replication and immunogenicity of rDEN4.DELTA.30-4995,
rDEN4.DELTA.30-8092, and rDEN4.DELTA.30-10634 viruses, each was
sufficiently immunogenic to induce protection against wild type
rDEN4. Increases in mean neutralizing antibody titer were minimal
(<3-fold) following challenge in all inoculation groups except
mock-infected providing further evidence that the monkeys were
protected from the challenge.
TABLE-US-00010 TABLE 8 rDEN4.DELTA.30 containing additional point
mutations protects rhesus monkeys from wt DEN4 virus challenge Mean
no. of Geometric mean serum viremic days per neutralizing antibody
monkey after Mean peak titer (reciprocal No. of rDEN4 virus titer
dilution) Virus.sup.a monkeys challenge (log.sub.10 PFU/ml .+-. SE)
Day 28 Day 56 Mock 2 3.5 2.3 .+-. 0.1 <10 358 rDEN4 2 0.0
<0.7 398 753 rDEN4.DELTA.30 2 0.0 <0.7 181 202
rDEN4.DELTA.30-4995 4 0.0 <0.7 78 170 rDEN4.DELTA.30-8092 4 0.0
<0.7 61 131 rDEN4.DELTA.30-10634 4 0.0 <0.7 107 177 .sup.a28
days after primary inoculation with the indicated viruses, rhesus
monkeys were challenged subcutaneously with 10.sup.5 PFU rDEN4
virus in a 1 ml dose. Serum was collected on days 28 to 34, 36, 38,
and 56. Virus titer was determined by plaque assay in Vero
cells.
Taken together, these results indicate that the three point
mutations, 4995, 8092, and 10634) described above do further
attenuate the rDEN4.DELTA.30 vaccine candidate in suckling mouse
brain, SCID-HuH-7 mice, and rhesus monkeys. Because of additional
incidental mutations (Table 4) present in each modified
rDEN4.DELTA.30 virus, the phenotypes cannot be directly attributed
to the individual 4995, 8092, and 10634 point mutations. However,
the presence of similar mouse-attenuation phenotypes in other rDEN4
viruses bearing one of these three mutations supports the
contention that the 4995, 8092, and 10634 point mutations are
responsible for the att phenotypes of the modified rDEN4.DELTA.30
viruses. Since rDEN4.DELTA.30-4995, rDEN4.DELTA.30-8092, and
rDEN4.DELTA.30-10634 virus demonstrated decreased replication in
rhesus monkeys while retaining sufficient immunogenicity to confer
protective immunity, these viruses are contemplated as dengue
vaccines for humans.
DEN4 viruses carrying both .DELTA.30 and charge-to-alanine
mutations were next generated. A subset of seven groups of
charge-to-alanine mutations described above were identified that
conferred between a 10-fold and 1,000-fold decrease in replication
in SCID-HuH-7 mice and whose unmutated sequence was well-conserved
across the four dengue serotypes. These mutations were introduced
as single pairs and as two sets of pairs to rDEN4.DELTA.30 using
conventional cloning techniques. Transcription and recovery of
virus and terminal dilution of viruses were conducted as described
above. Assay of the level of temperature sensitivity of the
charge-cluster-to-alanine mutant viruses in Vero and HuH-7 cells,
level of replication in the brain of suckling mice and level of
replication in SCID-HuH-7 mice was conducted as described
above.
Introduction of one pair of charge-to-alanine mutations to rDEN4
produced recoverable virus in all cases (Table 9). Introduction of
two pairs of charge-to-alanine mutations produced recoverable virus
in two out of three cases (rDEN4.DELTA.30-436-437-808-809 was not
recoverable).
rDEN4.DELTA.30 is not ts in Vero or HuH-7 cells. In contrast, seven
of the seven sets of charge-to-alanine mutations used in this
example conferred a ts phenotype in HuH-7 cells and five also
conferred a ts phenotype in Vero cells. All six viruses carrying
both .DELTA.30 and charge-to-alanine mutations showed a ts
phenotype in both Vero and HuH-7 cells (Table 9). rDEN4.DELTA.30 is
not attenuated in suckling mouse brain, whereas five of the seven
sets of charge-to-alanine mutations conferred an att phenotype in
suckling mouse brain (Table 10). Four of the viruses carrying both
.DELTA.30 and charge-to-alanine mutations were attenuated in
suckling mouse brain (Table 10). In one case
(rDEN4.DELTA.30-23-24-396-397) combination of two mutations that
did not attenuate alone resulted in an attenuated virus. Generally,
viruses carrying both .DELTA.30 and charge-to-alanine mutations
showed levels of replication in the suckling mouse brain more
similar to their charge-to-alanine mutant parent virus than to
rDEN4.DELTA.30.
rDEN4.DELTA.30 is attenuated in SCID-HuH-7 mice, as are six of the
seven charge-to-alanine mutant viruses used in this example.
Viruses carrying both .DELTA.30 and charge-to-alanine mutations
tended to show similar or slightly lower levels of replication in
SCID-HuH-7 mice compared to their charge-to-alanine mutant parent
virus (Table 10). In three cases, viruses carrying both .DELTA.30
and charge-to-alanine mutations showed at least a fivefold greater
reduction in SCID-HuH-7 mice than rDEN4.DELTA.30.
The complete genomic sequence of five viruses (rDEN4-200-201,
rDEN4.DELTA.30-200-201, rDEN4-436-437 [clone 1],
rDEN4.DELTA.30-436-437, and rDEN4-23-24-200-201) that replicated to
>10.sup.5 PFU/ml in Vero cells at 35.degree. C. and that showed
a hundredfold or greater reduction in replication in SCID-HuH-7
mice was determined (Table 11). Each of the five contained one or
more incidental mutations. In one virus, rDEN4.DELTA.30-436-437,
the one additional mutation has been previously associated with
Vero cell adaptation (Blaney, J. E. Jr. et al. 2002 Virology
300:125-139). Each of the remaining viruses contained at least one
incidental mutation whose phenotypic effect is unknown.
Consequently, the phenotypes described cannot be directly
attributed to the charge-to-alanine mutations. However, the fact
that rDEN4 and rDEN4.DELTA.30 viruses carrying the same
charge-to-alanine mutations shared similar phenotypes provides
strong support for the ability of charge-to-alanine mutations to
enhance the attenuation of rDEN4.DELTA.30. Because rDEN4-436-437
[clone 1] contained 4 incidental mutations, a second clone of this
virus was prepared. rDEN4-436-437 [clone2] contained only one
incidental mutation (Table 11), and showed the same phenotypes as
rDEN4-436-437 in cell culture and SCID-HuH-7 mice. rDEN4-436-437
[clone 2] was used in the rhesus monkey study described below.
TABLE-US-00011 TABLE 9 Addition of charge-to-alanine mutations to
rDEN4.DELTA.30 confers a ts phenotype in both Vero and HuH-7 cells.
Mean virus titer (log.sub.10 PFU/ml) at indicated temperature
(.degree. C.).sup.a AA No. nt Vero HuH-7 Virus changed.sup.b
changed 35 37 38 39 .DELTA..sup.c 35 37 38 39 .DELTA. rDEN4 none 0
7.4 7.1 7.7 7.2 0.2 7.7 7.5 7.5 7.4 0.3 rDEN4.DELTA.30 none 30 6.6
6.6 6.5 6.5 0.1 7.4 6.9 7.0 6.4 1.0 rDEN4-23-24 KE 3 6.7 6.6 6.0
6.5 0.2 7.1 7.3 5.6 <1.7 >5.4 rDEN4.DELTA.30-23-24 6.1 5.5
4.9 <1.7 4.4 6.5 5.9 4.7 <1.7 >4.2- rDEN4-200-201 KH 4 5.3
4.8 4.8 4.3 1.0 5.7 5.4 2.7 <1.7 >4.0 rDEN4.DELTA.30-200-201
6.0 5.3 5.6 <1.7 >4.3 5.8 5.0 5.9 <1.7 &- gt;4.1
rDEN4-436-437 DK 4 5.2 4.2 3.4 1.9 3.3 5.9 4.9 3.2 <1.7 >4.2
rDEN4.DELTA.30-436-437 6.3 5.7 5.5 <1.7 >4.6 6.5 5.7 5.1
<1.7 &- gt;4.8 [clone1] rDEN4-808-809 ED 3 4.6 4.1 <1.7
<1.7 >2.9 5.2 <1.7 <1.7 <- ;1.7 >3.5
rDEN4.DELTA.30-808-809 5.6 4.9 4.9 <1.7 >3.9 5.9 4.8 5.1
<1.7 &- gt;4.2 rDEN4-23-24-200-201 KE, KH 7 6.0 5.2 4.2
<1.7 >4.3 6.9 6.3 <1.7 <1.7 >5.2
rDEN4.DELTA.30-23-24-200-201 4.5 4.2 4.8 <1.7 >2.8 4.9 4.5
2.9 <- ;1.7 >3.2 rDEN4-23-24-396-397 KE, RE 7 6.5 5.8 5.5
<1.7 >4.8 7.1 5.9 5.4 <1.7 >5.4
rDEN4.DELTA.30-23-24-396-397 6.1 5.2 4.8 <1.7 >4.4 6.9 5.4
4.9 <- ;1.7 >5.2 rDEN-436-437-808-809 DK, ED 7 4.9 4.9 5.1
<1.7 >3.2 5.5 3.2 <1.7 <1.7 >3.8 .sup.aUnderlined
values indicate a 2.5 or 3.5 log.sub.10 PFU/ml reduction in titer
in Vero or HuH-7 cells, respectively, at the indicated temperature
when compared to the permissive temperature (35.degree. C.).
.sup.bAmino acid pair(s) changed to pair of Ala residues.
.sup.cReduction in titer (log.sub.10 pfu/ml) compared to the
permissive temperature (35.degree. C.).
TABLE-US-00012 TABLE 10 Addition of charge-to-alanine mutations
attenuates rDEN4.DELTA.30 in suckling mouse brain and enhances
attenuation in SCID-HuH-7 mice. Replication in suckling mice.sup.a
Replication in SCID-HuH-7 mice.sup.b Mean log Mean log Mean virus
titer .+-. SE reduction from Mean virus titer .+-. SE reduction
from Virus n (log.sub.10 PFU/g brain) wt.sup.b n (log.sub.10 PFU/ml
serum) wt.sup.d rDEN4 18 6.2 .+-. 0.4 -- 33 5.4 .+-. 0.3 --
rDEN4.DELTA.30 12 5.9 .+-. 0.8 0.2 8 3.4 .+-. 0.3 2.3 rDEN4-23-24
18 4.7 .+-. 0.1 1.6 19 4.7 .+-. 0.5 1.3 rDEN4.DELTA.30-23-24 6 5.6
.+-. 0.3 0.7 7 4.6 .+-. 0.4 1.5 rDEN4-200-201 12 5.5 .+-. 0.5 0.6
12 3.7 .+-. 0.2 2.6 rDEN4.DELTA.30-200-201 6 5.5 .+-. 0.6 0.1 4 3.3
.+-. 0.6 1.8 rDEN4-436-437 18 2.7 .+-. 0.4 3.5 10 2.9 .+-. 0.7 2.5
rDEN4.DELTA.30-436-437 [clone 1] 6 2.9 .+-. 0.3 3.4 4 2.3 .+-. 0.4
2.8 rDEN4-808-809 6 1.8 .+-. 0.1 3.1 8 3.2 .+-. 0.4 3.0
rDEN4.DELTA.30-808-809 12 3.9 .+-. 0.7 2.1 4 3.7 .+-. 0.6 2.4
rDEN4-23-24-200-201 12 5.3 .+-. 0.5 0.7 13 3.4 .+-. 0.1 2.9
rDEN4.DELTA.30-23-24-200-201 6 3.0 .+-. 0.2 2.6 5 1.8 .+-. 0.1 3.3
rDEN4-23-24-396-397 12 4.6 .+-. 0.9 1.5 8 3.6 .+-. 0.3 2.3
rDEN4.DELTA.30-23-24-396-397 6 3.0 .+-. 0.2 2.6 5 2.2 .+-. 0.3 2.9
rDEN-436-437-808-809 6 <1.7 .+-. 0.0 3.6 8 2.1 .+-. 0.3 2.4
.sup.aGroups of six suckling mice were inoculated i.c. with
10.sup.4 PFU virus in a 30 .mu.l inoculum. The brain was removed 5
days later, homogenized, and virus was quantitated by titration in
Vero cells. .sup.bDetermined by comparing the mean viral titers in
mice inoculated with sample virus and concurrent wt controls (n =
6). The attenuation (att) phenotype is defined as a reduction of
.gtoreq.1.5 log.sub.10 PFU/g compared to wt virus; reductions of
1.5 are listed in boldface. .sup.cGroups of SCID-HuH-7 mice were
inoculated directly into the tumor with 10.sup.4 PFU virus.
.sup.dDetermined by comparing mean viral titers in mice inoculated
with sample virus and concurrent wt controls.
The attenuation phenotype is defined as a reduction of .gtoreq.1.5
log.sub.10PFU/g compared to wt virus; reductions of .gtoreq.1.5 are
listed in boldface.
TABLE-US-00013 TABLE 11 Missense and UTR mutations present in rDEN4
virus derivatives bearing charge-to-alanine and the .DELTA.30
mutation. Nucleotide Nucleotide Amino acid Virus Gene.sup.a,b
position substitution position.sup.c Amino acid change.sup.b
rDEN4-200-201 prM 626 A > T 61 Glu > Asp NS4A 6659 C > T
93 Leu > Phe NS5 8160-8165 AAACA > GCAGC 200-201 LysHis >
AlaAla rDEN4.DELTA.30-200-201 NS3 4830 G > A 102 Gly > Arg
NS5 8106 G > A 181 Val > Ile NS5 8160-8165 AAACA > GCAGC
200-201 LysHis > AlaAla 3' UTR 10478-10507 .DELTA.30 deletion
None None rDEN4-436-437 [clone 1] E 2331 T > G 464 Trp > Gly
NS1 2845 C > T 140 Ser > Phe NS3* 4891 T > C 122 Ile >
Thr NS5 8869-8873 GACAA > GCAGC 436-437 AspLys > AlaAla NS5
9659 A > G 699 Lys > Arg rDEN4-436-437 [clone 2] NS4B 7153 T
> C 108 Val > Ala NS5 8869-8873 GACAA > GCAGC 436-437
AspLys > AlaAla rDEN4.DELTA.30-436-437 NS4B* 7163 A > C 111
Leu > Phe NS5 8869-73 GACAA > GCAGC 436-437 AspLys >
AlaAla 3' UTR 10478-10507 .DELTA.30 deletion None None
rDEN4-23-24-200-201 NS3 6751 A > C 124 Lys > Thr NS5
7629-7633 AAAGA > GCAGC 23-24 LysGlu > AlaAla NS5 8160-8165
AAACA > GCAGC 200-201 LysHis > AlaAla .sup.aAsterisk
indicates previously identified Vero cell adaptation mutation.
.sup.bBold values indicate mutations designed to occur in the
designated virus. .sup.cAmino acid position in the protein product
of the designated DEN4 gene; numbering starts with the amino
terminus of the protein.
Based on the attenuation in the SCID-HuH7 mouse model, four of the
charge-to-alanine mutant viruses (rDEN4-200-201,
rDEN4.DELTA.30-200-201, rDEN4-436-437 [clone 2],
rDEN4.DELTA.30-436-437) were evaluated in rhesus macaques as
described above. As with the study of viruses carrying attenuating
point mutations, viremia was detected on day 1 post-infection and
ended by day 4 in all monkeys (FIG. 4, Table 12). Viremia was
detected in most of the monkeys infected; only one of the four
monkeys infected with rDEN4.DELTA.30-200-201 and one of the four
monkeys infected with rDEN4.DELTA.30-436-437 showed no detectable
viremia. Monkeys infected with rDEN4 showed the highest mean peak
virus titer; and in each case viruses carrying the .DELTA.30
mutation showed an approximately 0.5 log decrease in mean peak
virus titer relative to their parental viruses and a 0.5 to 2 day
decrease in mean number of viremic days per monkey. Monkeys
infected with viruses carrying both the .DELTA.30 and
charge-to-alanine mutations showed a two-fold reduction in mean
peak viremia relative to those infected with rDEN4.DELTA.30. This
suggests that addition of the charge-to-alanine mutations further
attenuates rDEN4.DELTA.30 for rhesus macaques.
As expected, none of the monkeys in this study showed detectable
levels of neutralizing antibody on day 0. On day 28, every monkey
infected with a virus showed a detectable levels of neutralizing
antibody, indicating that all of the monkeys, even those that
showed no detectable viremia, had indeed been infected. As in the
study of attenuating point mutations, monkeys infected with rDEN4
had a mean serum neutralizing antibody titer (reciprocal dilution)
which was approximately twice that of monkeys that had been
infected with rDEN4.DELTA.30. Monkeys infected with rDEN4-200-201
and rDEN4-436-437 [clone 2] had similar mean neutralizing antibody
titers to rDEN4, and those infected with rDEN4.DELTA.30-200-201 and
rDEN4.DELTA.30-436-437 had similar mean neutralizing antibody
titers to rDEN4. In each case the addition of the .DELTA.30
mutation to a virus resulted in a two-fold decrease in neutralizing
antibody. Thus, although the addition of charge-to-alanine
mutations to rDEN4.DELTA.30 decreased mean peak viremia below that
of rDEN4.DELTA.30 alone, it did not affect levels of neutralizing
antibody.
TABLE-US-00014 TABLE 12 Addition of paired charge-to-alanine
mutations to rDEN4.DELTA.30 further attenuates the virus for rhesus
monkeys. Geometric mean serum neutralizing No. of Mean no. antibody
titer monkeys of viremic Mean peak (reciprocal No. of with days per
virus titer dilution) Virus.sup.a monkeys viremia monkey.sup.b
(log.sub.10 PFU/ml .+-. SE) Day 0 Day 28 mock 2 0 0 <0.7 <5
<5 rDEN4 2 2 2.5 2.6 .+-. 0.3 <5 276 rDEN4.DELTA.30 2 2 2.0
2.1 .+-. 0.1 <5 131 rDEN4-200, 201 4 4 2.3 1.8 .+-. 0.3 <5
212 rDEN4.DELTA.30-200, 201 4 3 1.5 1.3 .+-. 0.2 <5 139
rDEN4-436, 437 [cl 2) 4 4 3.3 1.8 .+-. 0.2 <5 273
rDEN4.DELTA.30-436, 437 4 3 1.3 1.0 .+-. 0.0 <5 143 .sup.aGroups
of rhesus monkeys were inoculated subcutaneously with 10.sup.5 PFU
of the indicated virus in a 1 ml dose. Serum was collected on days
0 to 6, 8, 10 and 28. Virus titer was determined by plaque assay in
Vero cells. .sup.bViremia was not detected in any monkey after day
4.
After challenge with rDEN4 on day 28, mock-infected monkeys had a
mean peak virus titer of 1.5 log.sub.10PFU/ml and a mean number of
viremic days of 3.0 (Table 13). However, none of the monkeys
previously inoculated with rDEN4, rDEN4.DELTA.30 or the
charge-to-alanine mutant viruses showed detectable viremia.
Additionally, none of the monkeys showed a greater than four-fold
increase in serum neutralizing antibody titer. Together these data
indicate that infection with any of the viruses, including those
carrying both .DELTA.30 and the charge-to-alanine mutations,
protected rhesus macaques from challenge with rDEN4.
TABLE-US-00015 TABLE 13 rDEN4.DELTA.30 containing charge-to-alanine
mutations protects rhesus monkeys from wt DEN4 virus challenge Mean
no. of Geometric mean serum viremic days neutralizing antibody per
monkey Mean peak titer (reciprocal No. of after rDEN4 virus titer
dilution) Virus.sup.a monkeys challenge (log.sub.10 PFU/ml .+-. SE)
Day 28 Day 56 mock 2 3.0 1.5 .+-. 0.7 <5 284 rDEN4 2 0.0 <0.7
276 316 rDEN4.DELTA.30 2 0.0 <0.7 131 96 rDEN4-200, 201 4 0.0
<0.7 212 356 rDEN4.DELTA.30-200, 201 4 0.0 <0.7 139 132
rDEN4-436, 4 0.0 <0.7 273 401 437 [cl 2] rDEN4.DELTA.30-436, 437
4 0.0 <0.7 143 182 .sup.a28 days after primary inoculation with
the indicated viruses, rhesus monkeys were challenged
subcutaneously with 10.sup.5 PFU rDEN4 virus in a 1 ml dose. Serum
was collected on days 28 to 34, 36, 10, and 56. Virus titer was
determined by plaque assay in Vero cells.
Addition of charge-to-alanine mutations to rDEN4.DELTA.30 can
confer a range of is phenotypes in both Vero and HuH-7 cells and
att phenotypes in suckling mouse brain and can either enhance or
leave unchanged attenuation in SCID-HuH-7 mice. Most importantly,
addition of these mutations can decrease the viremia produced by
rDEN4.DELTA.30 in rhesus macaques without decreasing neutralizing
antibody titer or protective efficacy. Thus addition of such
mutations to rDEN4.DELTA.30 is contemplated as enhancing
attenuation in humans. Also, mutations are contemplated as being
added that do not change the overall level of attenuation, but
stabilize the attenuation phenotype because they themselves are
independently attenuating even in the absence of the .DELTA.30
mutation. Charge-to-alanine mutations are particularly useful
because they occur outside of the structural gene regions, and so
can be used to attenuate structural gene chimeric viruses.
Moreover, they involve at least three nucleotide changes, making
them unlikely to revert to wild type sequence.
A series of point mutations that enhance the replication of rDEN4
in Vero cells tissue culture have been identified; these are
primarily located in the NS4B gene (Blaney, J. E. et. al. 2002
Virology 300:125-139; Blaney, J. E. et al. 2001 J Virol
75:9731-9740). Vero cell adaptation mutations confer two desirable
features upon a vaccine candidate. First, they enhance virus yield
in Vero cells, the intended substrate for vaccine production, and
thus render vaccine production more cost-effective. Second,
although each of these Vero adaptation mutations are point
mutations, they are likely to be extremely stable during vaccine
manufacture, because they give a selective advantage in Vero cells.
At least one Vero cell adaptation mutation, at position 7129, was
also shown to decrease mosquito infectivity of rDEN4; poor mosquito
infectivity is another desirable characteristic of a dengue vaccine
candidate. To investigate the generality of this finding, we tested
the effect of the remaining Vero cell adaptation mutations on the
ability of rDEN4 to infect Aedes aegypti mosquitoes fed on an
infectious bloodmeal. Table 14 shows the infectivity of each virus
carrying a single Vero cell adaptation mutation at high titer. Of
these, only one mutation, at position 7182, was associated with a
large decrease in mosquito infectivity. Thus 7182 may be a
particularly valuable mutation to include in an rDEN4 vaccine
candidate, as it has opposite effects on replication in Vero cells
and in mosquitoes.
TABLE-US-00016 TABLE 14 Effect of Vero cell adaptation mutations on
rDEN4 mosquito infectivity Aedes aegypti (oral infection)
Dose.sup.a % infected.sup.b Virus (log.sub.10 pfu) No. tested
Midgut Head rDEN4 4.3 27 70 25 rDEN4-4891 4.4 23 74 13 rDEN4-4995
4.8 20 80 50 rDEN4-7153 4.8 20 80 30 rDEN4-7546 4.6 20 55 10
rDEN4-7162 5.0 20 55 25 rDEN4-7163 4.9 15 73 72 rDEN4-7182 5.0 20
20 0 rDEN4-7630 4.3 10 70 10 .sup.aVirus titer ingested, assuming a
2 i.mu.l bloodmeal. .sup.bPercentage of mosquitoes with IFA
detectable antigen in midgut or head tissue prepared 21 days after
oral infection.
EXAMPLE 2
Generation and Characterization of a Recombinant DEN1 Virus
Containing the .DELTA.30 Mutation
We first sought to determine if the .DELTA.30 mutation was able to
satisfactorily attenuate a wild-type DEN virus other than the DEN4
serotype. To do this, the .DELTA.30 mutation was introduced into
the cDNA for DEN1 (Western Pacific). The pRS424DEN1WP cDNA clone
(Puri, B. et al. 2000 Virus Genes 20:57-63) was digested with BamHI
and used as template in a PCR using Pfu polymerase with forward
primer 30 (DEN1 nt 10515-10561 and 10592-10607) and the M13 reverse
sequencing primer (101 nt beyond the 3' end of DEN1 genome
sequence). The resulting PCR product was 292 bp and contained the
.DELTA.30 mutation. The pRS424DEN1WP cDNA was partially digested
with Apa I, then digested to completion with Sac II and the vector
was gel isolated, mixed with PCR product, and used to transform
yeast strain YPH857 to yield growth on plates lacking tryptophan
(Polo, S. et al. 1997 J Virol 71:5366-74). Positive yeast colonies
were confirmed by PCR and restriction enzyme analysis. DNA isolated
from two independent yeast colonies was used to transform E. coli
strain STBL2. Plasmid DNA suitable for generating RNA transcripts
was prepared and the presence of the .DELTA.30 mutation was
verified by sequence analysis.
For transcription and generation of virus, cDNA (designated
pRS424DEN1.DELTA.30) that was linearized with Sac II was used as
template in a transcription reaction using SP6 RNA polymerase as
described (Polo, S. et al. 1997 J Virol 71:5366-74). Transcription
reactions were electroporated into LLC-MK2 cells and infection was
confirmed by observation of CPE and immunofluorescence and
harvested on day 14. Virus stocks were amplified on C6/36 mosquito
cells and titered on LLC-MK2 cells. The genome of the resulting
virus, rDEN1.DELTA.30, was sequenced to confirm the presence of the
.DELTA.30 mutation. The .DELTA.30 mutation removes nucleotides
10562-10591 of DEN1 (FIG. 2B, C), which corresponds to the TL2 of
DEN1. The virus replicates efficiently in Vero cell culture to
titers of 6.5 log.sub.10PFU/ml, indicating that the .DELTA.30
mutation is compatible with efficient growth of DEN1 in cell
culture, a property essential for manufacture of the vaccine. Using
similar techniques, parent virus rDEN1 was generated. Incidental
mutations arising from virus passage in tissue culture were
identified in both rDEN1 and rDEN1.DELTA.30 using sequence analysis
and are listed in Table 15. An additional rDEN1.DELTA.30 virus was
derived by transfection and amplification in Vero cells. Although
this virus was not evaluated in the studies described below, its
sequence analysis is included in Table 15. The properties of
rDEN1.DELTA.30 as a vaccine in vivo were next examined.
TABLE-US-00017 TABLE 15 Missense mutations present among the
recombinant DEN1 viruses and correlation of NS4B region mutations
with those found in DEN4 Trans- Nucleo- Nucleo- Amino Amino fection
tide tide acid acid Virus cell type Gene position change position
change wt rDEN1 LLC-MK2 prM 816 C > U 241 Ala > Val NS4B
7165.sup.a U > G 2357 Phe > Leu NS4B 7173.sup.b U > C 2360
Val > Ala rDEN1.DELTA.30 LLC-MK2 E 1748 A > U 552 Thr >
Ser rDEN1.DELTA.30 Vero E 1545 A > G 484 Lys > Arg .sup.aSame
nucleotide as 7154 in rDEN4. .sup.bSame nucleotide as 7162 in
rDEN4
* Nucleotide and amino acid comparison of selected NS4B region:
TABLE-US-00018 7 7 7 7 7 7 DEN4 1 1 1 1 1 1 base 3 4 5 6 7 8
Number:
890123456789012345678901234567890123456789012345678901234567 ++ ++
+ +++++ + + + + ++ + ++++++++ ++ ++ ++ ++ D4 7128-
CCAACAACCUUGACAGCAUCCUUAGUCAUGCUUUUAGUCCAUUAUGCAAUAAUAGGCCCA P T T
L T A S L V M L L V H T A I I G P D1 7139-
CCGCUGACGCUGACAGCGGCGGUAUUUAUGCUAGUGGCUCAUUAUGCCAUAAUUGGACCC P L T
L T A A V P M L V A H T A I I G P D2 7135-
CCUAUAACCCUCACAGCGGCUCUUCUUUUAUUGGUAGCACAUUAUGCCAUCAUAGGACCG P I T
L T A A L L L L V A H T A I I G P D3 7130-
CCACUAACUCUCACAGCGGCAGUUCUCCUGCUAGUCACGCAUUAUGCUAUUAUAGGUCCA P L T
L T A A V L L L V T H T A I I G P + + + + + + + + + + + + + D4 =
rDEN4 Dl = rDENl(WP) D2 = rDEN2(Tonga/74) D3 = rDEN3(Sleman/78)
+Homology among all four serotypes Nucleotides are underlined in
even multiples of 10.
Evaluation of the replication, immunogenicity, and protective
efficacy of rDEN1.DELTA.30 and wild-type parental rDEN1 virus
(derived from the pRS424DEN1WP cDNA) in juvenile rhesus monkeys was
performed as follows. Dengue virus-seronegative monkeys were
injected subcutaneously with 5.0 log.sub.10PFU of virus in a 1 ml
dose divided between two injections in each side of the upper
shoulder area. Monkeys were observed daily and blood was collected
on days 0-10 and 28 and serum was stored at -70.degree. C. Titer of
virus in serum samples was determined by plaque assay in Vero cells
as described previously (Durbin, A. P. et al. 2001 Am J Trop Med
Hyg 65:405-13). Plaque reduction neutralization titers were
determined for the day 28 serum samples as previously described
(Durbin, A. P. et al. 2001 Am J Trop Med Hyg 65:405-13). All
monkeys were challenged on day 28 with a single dose of 5.0
log.sub.10PFU of wild-type rDEN1 and blood was collected for 10
days. Virus titer in post-challenge sera was determined by plaque
assay in Vero cells. Monkeys inoculated with full-length wild-type
rDEN1 were viremic for 2-3 days with a mean peak titer of 2.1
log.sub.10PFU/ml (Table 16), and monkeys inoculated with
rDEN1.DELTA.30 were viremic for less than 1 day with a mean peak
titer of 0.8 log.sub.10PFU/ml, indicating that the .DELTA.30
mutation is capable of attenuating DEN1. As expected for an
attenuated virus, the immune response, as measured by neutralizing
antibody titer, was lower following inoculation with rDEN1.DELTA.30
compared to inoculation with wild-type rDEN1 (Table 16), yet
sufficiently high to protect the animals against wild-type DEN1
virus challenge. Wild-type rDEN1 virus was not detected in any
serum sample collected following virus challenge, indicating that
monkeys were completely protected following immunization with
either full-length wild-type rDEN1 or recombinant virus
rDEN1.DELTA.30. The level of attenuation specified by the .DELTA.30
mutation was comparable in both the DEN1 and DEN4 genetic
backgrounds (FIG. 5).
TABLE-US-00019 TABLE 16 The .DELTA.30 mutation attenuates rDEN1 for
rhesus monkeys Mean no. Mean peak Mean Mean peak days with titer
neutralization titer of Virus* n viremia (log.sub.10 pfu/ml) titer
challenge virus rDEN1 4 2.8 2.1 1230 <0.7 rDEN1.DELTA.30 4 0.5
0.8 780 <0.7 *Rhesus monkeys were inoculated subcuateously with
5.0 log.sub.10 PFU of virus. Serum samples were collected daily for
10 days. Serum for neutralization assay was collected on day 28.
All monkeys were challenged on day 28 with 5.0 log.sub.10 PFU of
rDEN1.
As previously reported, rDEN4 virus replicated to greater than 6.0
log.sub.10PFU/ml serum in SCID-HuH-7 mice, while the replication of
rDEN4 virus bearing the .DELTA.30 mutation was reduced by about
10-fold (Blaney, J. E. Jr. et al. 2002 Virology 300:125-139). The
replication of rDEN1.DELTA.30 was compared to that of wt rDEN1 in
SCID-HuH-7 mice (Table 17). rDEN1.DELTA.30 replicated to a level
approximately 100-fold less than its wt rDEN1 parent. This result
further validates the use of the SCID-HuH-7 mouse model for the
evaluation of attenuated strains of DEN virus, with results
correlating closely with those observed in rhesus monkeys.
TABLE-US-00020 TABLE 17 The .DELTA.30 mutation attenuates rDEN1 for
HuH-7-SCID mice No. of Mean peak virus titer.sup.6 Virus Mice.sup.5
(log.sub.10 pfu/ml .+-. SE) wt rDEN1 9 7.3 .+-. 0.2 rDEN1.DELTA.30
8 5.0 .+-. 0.3 .sup.5Groups of HuH-7-SCID mice were inoculated
directly into the tumor with 4.0 log.sub.10 pfu virus. Serum was
collected on day 6 and 7, and virus titer was determined by plaque
assay in Vero cells. .sup.6Significant difference was found between
rDEN1 and rDEN1.DELTA.30 viruses, Tukey-Kramer test (P <
0.005).
Finally, the infectivity of rDEN1 and rDEN1.DELTA.30 for mosquitoes
was assessed, using the methods described in detail in Example 5.
Previously, the .DELTA.30 mutation was shown to decrease the
ability of rDEN4 to cross the mosquito midgut barrier and establish
a salivary gland infection (Troyer, J. M. et al. 2001 Am J Trop Med
Hyg 65:414-419). However neither rDEN1 nor rDEN1.DELTA.30 was able
to infect the midgut of Aedes aegypti mosquitoes efficiently via an
artificial bloodmeal (Table 18), so it was not possible to
determine whether .DELTA.30 might further block salivary gland
infection. A previous study also showed that the .DELTA.30 had no
effect on the infectivity of rDEN4 for Toxorhynchites splendens
mosquitoes infected via intrathoracic inoculation (Troyer, J. M. et
al. 2001 Am J Trop Med Hyg 65:414-419), and a similar pattern was
seen for rDEN1 and rDEN1.DELTA.30 (Table 18). The genetic basis for
the inability of rDEN1 to infect the mosquito midgut has not been
defined at this time. However, this important property of
restricted infectivity for the mosquito midgut is highly desirable
in a vaccine candidate since it would serve to greatly restrict
transmission of the vaccine virus from a vaccinee to a mosquito
vector.
TABLE-US-00021 TABLE 18 DEN1 and DEN1.DELTA.30 viruses are both
highly infectious for Toxorhynchites splendens, but do not infect
Aedes aegypti efficiently. Toxorhynchites splendens (intrathoracic
inoculation) Aedes aegypti (oral infection) Dose.sup.a Dose.sup.c %
infected.sup.d Virus (log.sub.10 pfu) No. tested % infected.sup.b
(log.sub.10 pfu) No. tested Midgut Head rDEN1 3.5 7 100 4.0 26 11 0
2.5 8 75 1.5 7 71 0.5 5 60 MID.sub.50 < 0.5 MID.sub.50 .gtoreq.
4.4 rDEN1 2.7 8 100 3.2 20 10 0 .DELTA.30 1.7 7 100 0.7 6 83
MID.sub.50 < 0.7 MID.sub.50 .gtoreq. 3.6 .sup.aAmount of virus
present in 0.22 .mu.l inoculum. .sup.bPercentage of mosquitoes with
IFA detectable antigen in head tissue prepared 14 days after
inoculation. .sup.cVirus titer ingested, assuming a 2 .mu.l
bloodmeal. .sup.dPercentage of mosquitoes with IFA detectable
antigen in midgut or head tissue prepared 21 days after oral
infection. When virus infection was detected, but did not exceed a
frequency of 50% at the highest dose of virus ingested, the
MID.sub.50 was estimated by assuming that a 10-fold more
concentrated virus dose would infect 100% of the mosquitoes.
Thus, the .DELTA.30 mutation, first described in DEN4, was
successfully transferred to rDEN1. The resulting virus,
rDEN1.DELTA.30, was shown to be attenuated in monkeys and
SCID-HuH-7 mice to levels similar to recombinant virus
rDEN4.DELTA.30, thereby establishing the conservation of the
attenuation phenotype specified by the .DELTA.30 mutation in a
different DEN virus background. Based on the favorable results of
rDEN4.DELTA.30 in recent clinical trials (Durbin, A. P. et al. 2001
Am J Trop Med Hyg 65:405-13), it is predicted that rDEN1.DELTA.30
will be suitably attenuated in humans. To complete the tetravalent
vaccine, attenuated rDEN2 and rDEN3 recombinant viruses bearing the
.DELTA.30 mutation are contemplated as being prepared (See Examples
3 and 4 below). The demonstration that the .DELTA.30 mutation
specifies a phenotype that is transportable to another DEN serotype
has important implications for development of the tetravalent
vaccine. This indicates that the .DELTA.30 mutation is expected to
have a corresponding effect on DEN2 and DEN3 wild-type viruses.
EXAMPLE 3
Generation and Characterization of a Recombinant DEN2 Virus
Containing the .DELTA.30 Mutation
Evaluation of rDEN1.DELTA.30 showed that it was satisfactorily
attenuated. Based on this result, we sought to extend our
technology to the creation of a DEN2 vaccine candidate. To do this,
the .DELTA.30 mutation was introduced into the cDNA of DEN2. A DEN2
virus isolate from a 1974 dengue epidemic in the Kingdom of Tonga
(Tonga/74) (Gubler, D. J. et al. 1978 Am J Trop Med Hyg 27:581-589)
was chosen to represent wt DEN2. The genome of DEN2 (Tonga/74) was
sequenced in its entirety and served as consensus sequence for the
construction of a full-length cDNA clone (Appendix 1). cDNA
fragments of DEN2 (Tonga/74) were generated by
reverse-transcription of the genome as indicated in FIG. 6A. Each
fragment was subcloned into a plasmid vector and sequenced to
verify that it matched the consensus sequence as determined for the
virus. This yielded seven cloned cDNA fragments spanning the
genome. Cloned fragments were modified as follows: Fragment X,
representing the 5' end of the genome was abutted to the SP6
promoter; Fragment L was modified to contain a
translationally-silent SpeI restriction site at genomic nucleotide
2353; Fragment R was modified to contain a translationally-silent
SpeI restriction site also at genomic nucleotide 2353, and to
stabilize the eventual full-length clone, two additional
translationally-silent mutations at nucleotides 2362-2364 and 2397
were created to ensure that translation stop codons were present in
all reading frames other than that used to synthesize the virus
polyprotein; Fragment A was modified at nucleotide 3582 to ablate a
naturally occurring SpeI restriction site and at nucleotide 4497 to
ablate a naturally occurring KpnI restriction site; Fragment C was
modified at nucleotide 9374 to ablate a naturally occurring KpnI
restriction site; and Fragment Y, representing the 3' end of the
genome was abutted to a KpnI restriction site. Each fragment was
added incrementally between the AscI and KpnI restriction sites of
DEN4 cDNA clone p4 (Durbin, A. P. et al. 2001 Am J Trop Med Hyg
65:405-13) to generate a full-length DEN2 cDNA clone (p2) with the
same vector background successfully used to generate rDEN4 and
rDEN4.DELTA.30. cDNA clone p2 was sequenced to confirm that the
virus genome region matched the DEN2 (Tonga/74) consensus sequence,
with the exception of the translationally-silent modifications
noted above. The .DELTA.30 mutation was introduced into Fragment Y
to generate Fragment Y.DELTA.30. To create p2.DELTA.30, the
Fragment Y region of p2 was replaced with Fragment Y.DELTA.30 (FIG.
6A, B).
For transcription and generation of infectious virus, cDNA (p2 and
p2.DELTA.30) was linearized with Acc65I (isoschizomer of KpnI which
cleaves leaving only a single 3' nucleotide) and used as template
in a transcription reaction using SP6 RNA polymerase as previously
described (Blaney, J. E. et. al. 2002 Virology 300:125-139).
Transcripts were introduced into Vero cells or C6/36 mosquito cells
using liposome-mediated transfection and cell culture supernatants
were harvested on day 7.
rDEN2 virus was recovered from the p2 cDNA in both Vero and C6/36
cells, while rDEN2.DELTA.30 was recovered from the p2.DELTA.30 cDNA
clone in only C6/36 cells (Table 19). The level of infectious virus
recovered in C6/36 cells was comparable for the p2 and p2.DELTA.30
cDNA clones when assayed by plaque titration and immunostaining in
Vero or C6/36 cells. As previously observed, the efficiency of
transfection in C6/36 cells was higher than that in Vero cells. Two
rDEN2.DELTA.30 viruses were recovered from independent cDNA clones,
#2 and #10.
TABLE-US-00022 TABLE 19 rDEN2 virus is recovered in Vero and C6/36
cells, but rDEN2.DELTA.30 virus is recovered only in C6/36 cells.
Virus titer of transfection harvest (day 7) determined in the
indicated Transfection cDNA cell type (log.sub.10 PFU/ml) cell type
construct Clone Virus Vero cells C6/36 cells Vero cells p2 #8A
rDEN2 3.1 4.3 p2.DELTA.30 #2 rDEN2.DELTA.30 <0.7 <0.7
p2.DELTA.30 #10 rDEN2.DELTA.30 <0.7 <0.7 C6/36 cells p2 #8A
rDEN2 5.5 7.5 p2.DELTA.30 #2 rDEN2.DELTA.30 4.8 7.6 p2.DELTA.30 #10
rDEN2.DELTA.30 4.6 7.5
To produce working stocks of rDEN2 and rDEN2.DELTA.30 viruses,
transfection harvests were passaged and terminally diluted in Vero
cells, and genomic sequences of the viruses were determined. The
Vero cell transfection harvest of rDEN2 virus was terminally
diluted once in Vero cells, and individual virus clones were
passaged once in Vero cells. To assess whether any homologous Vero
cell adaptation mutations identified in the rDEN4 NS4B 7100-7200
region were present in these virus clones, seven independent
terminally diluted clones were sequenced over this region. Each of
the seven rDEN2 viruses contained a single nucleotide substitution
in this region at nucleotide 7169 (U>C) resulting in a
Val>Ala amino acid change. This nucleotide corresponds to the
7162 mutation identified in rDEN4 (Blaney, J. E. et. al. 2002
Virology 300:125-139), which has a known Vero cell adaptation
phenotype suggesting that this mutation may confer a replication
enhancement phenotype in rDEN2 virus. One rDEN2 virus clone was
completely sequenced and in addition to the 7169 mutation, a
missense mutation (Glu>Ala) was found in NS5 at residue 3051
(Table 20).
TABLE-US-00023 TABLE 20 Missense mutations which accumulate in
rDEN2 and rDEN2.DELTA.30 viruses after transfection or passage in
Vero cells. Nucleotide Nucleotide Amino acid Amino acid Virus Gene
position substitution position.sup.a change rDEN2.sup.b NS4B .sup.
7169.sup.c U > C 2358 Val > Ala (Vero) NS5 9248 A > C 3051
Glu > Ala rDEN2.DELTA.30.sup.d NS3 4946 A > G 1617 Lys >
Arg (Vero) NS4B .sup. 7169.sup.c U > C 2358 Val > Ala
.sup.aAmino acid position in DEN2 polyprotein beginning with the
methionine residue of the C protein (nucleotides 97-99) as position
1. .sup.bVirus was recovered in Vero cells and terminally-diluted
once in Vero cells. Virus stock was prepared in Vero cells.
.sup.cSame nucleotide position as 7162 in rDEN4. .sup.dVirus was
recovered in C6/36 cells and passaged three times in Vero cells.
Virus was then terminally diluted and a stock was prepared in Vero
cells.
Because both rDEN2 and rDEN2.DELTA.30 viruses grown in Vero cells
acquired the same mutation at nucleotide 7169, which corresponds to
the Vero cell adaptation mutation previously identified in rDEN4 at
nucleotide 7162, it was reasoned that this mutation is associated
with growth adaptation of rDEN2 and rDEN2.DELTA.30 in Vero cells.
In anticipation that the 7169 mutation may allow rDEN2.DELTA.30 to
be recovered directly in Vero cells, the mutation was introduced
into the rDEN2.DELTA.30 cDNA plasmid to create p2.DELTA.30-7169.
Transcripts synthesized from p2.DELTA.30-7169, as well as p2 and
p2.DELTA.30 were introduced into Vero cells or C6/36 mosquito cells
using liposome-mediated transfection as described above. Virus
rDEN2.DELTA.30-7169 was recovered from the p2.DELTA.30-7169 cDNA in
both Vero and C6/36 cells, while rDEN2.DELTA.30 was recovered from
the p2.DELTA.30 cDNA clone in only C6/36 cells (Table 21). The 7169
mutation is both necessary and sufficient for the recovery of
rDEN2.DELTA.30 in Vero cells.
TABLE-US-00024 TABLE 21 rDEN2.DELTA.30-7169 virus containing the
7169 Vero cell adaptation mutation is recovered in both Vero and
C6/36 cells Virus titer of trans- fection harvest (day 14)
determined Transfection cDNA in C6/36 cells cell type construct
Clone Virus (log.sub.10 PFU/ml) Vero cells p2 #8A rDEN2 6.8
p2.DELTA.30 #2 rDEN2.DELTA.30 <0.7 p2.DELTA.30-7169.sup.a #37
rDEN2.DELTA.30-7169 5.1 C6/36 cells p2 #8A rDEN2 6.9 p2.DELTA.30 #2
rDEN2.DELTA.30 7.1 p2.DELTA.30-7169 #37 rDEN2.DELTA.30-7169 7.2
.sup.aNucleotide 7169 in rDEN2 corresponds to nucleotide 7162 in
rDEN4 which has been shown to be associated with growth adaptation
in Vero cells.
To initially assess the ability of the .DELTA.30 mutation to
attenuate rDEN2 virus in an animal model, the replication of DEN2
(Tonga/74), rDEN2, and rDEN2.DELTA.30 viruses was evaluated in
SCID-HuH-7 mice. Previously, attenuation of vaccine candidates in
SCID-HuH-7 mice has been demonstrated to be predictive of
attenuation in the rhesus monkey model of infection (Examples 1 and
2). The recombinant viruses tested in this experiment were
recovered in C6/36 cells. The DEN2 Tonga/74 virus isolate, rDEN2,
and two independent rDEN2.DELTA.30 viruses, (clones 20A and 21A)
which were derived from two independent p2.DELTA.30 cDNA clones,
were terminally diluted twice in C6/36 cells prior to production of
a working stock in C6/36 cells. These viruses should not contain
any Vero cell adaptation mutations. DEN2 Tonga/74 virus replicated
to a mean virus titer of 6.2 log.sub.10PFU/ml in the serum of
SCID-HuH-7 mice, and rDEN2 virus replicated to a similar level, 5.6
log.sub.10 PFU/ml (Table 22). Both rDEN2.DELTA.30 viruses were
greater than 100-fold restricted in replication compared to rDEN2
virus. These results indicate that the .DELTA.30 mutation has an
attenuating effect on replication of rDEN2 virus similar to that
observed for rDEN4 and rDEN1 viruses.
TABLE-US-00025 TABLE 22 The .DELTA.30 mutation restricts rDEN2
virus replication in SCID-HuH-7 mice. Mean virus Mean
log.sub.10-unit No. of titer .+-. SE (log.sub.10 reduction from
Virus mice PFU/ml serum).sup.a value for wt.sup.b DEN2 (Tonga/74) 8
6.2 .+-. 0.3 -- rDEN2 9 5.6 .+-. 0.2 -- rDEN2.DELTA.30 (clone 20A)
9 3.1 .+-. 0.2 2.5 rDEN2.DELTA.30 (clone 21A) 9 2.9 .+-. 0.3 2.7
.sup.aGroups of SCID-HuH-7 mice were inoculated directly into the
tumor with 10.sup.4 PFU virus grown in C6/36 cells. Serum was
collected on day 7 and titered in C6/36 cells. .sup.bComparison of
mean virus titers of mice inoculated with mutant virus and
concurrent rDEN2 control.
DEN2 virus replication in SCID-HuH-7 mice was also determined using
DEN2 (Tonga/74), rDEN2, and rDEN2.DELTA.30 which were passaged in
Vero cells (see Table 20, footnotes b and d). Both rDEN2 and
rDEN2.DELTA.30 had acquired a mutation in NS4B, nucleotide 7169,
corresponding to the 7162 mutation identified in rDEN4 as Vero cell
adaptation mutation. In the presence of the 7169 mutation, the
.DELTA.30 mutation reduced replication of rDEN2.DELTA.30 by 1.0
log.sub.10PFU/ml (Table 23). Previously, using virus grown in C6/36
cells and lacking the 7169 mutation, the .DELTA.30 mutation reduced
replication of rDEN2.DELTA.30 by about 2.5 log.sub.10PFU/ml (Table
22). These results indicate that Vero cell growth adaptation in
DEN2 may also confer a slight growth advantage in HuH-7 liver
cells. Nevertheless, the attenuation conferred by the .DELTA.30
mutation is still discernible in these Vero cell growth adapted
viruses.
TABLE-US-00026 TABLE 23 The .DELTA.30 mutation restricts Vero cell
adapted rDEN2 virus replication in SCID-HuH-7 mice. Mean
log.sub.10-unit No. Mean virus titer .+-. SE reduction from Virus
of mice (log.sub.10 PFU/ml serum).sup.a value for wt.sup.b DEN2
(Tonga/74) 6 5.9 .+-. 0.3 -- rDEN2 7 5.9 .+-. 0.2 -- rDEN2.DELTA.30
9 4.9 .+-. 0.3 1.0 .sup.aGroups of SCID-HuH-7 mice were inoculated
directly into the tumor with 10.sup.4 PFU virus. Serum was
collected on day 7 and titered in C6/36 cells. .sup.bComparison of
mean virus titers of mice inoculated with rDEN2.DELTA.30 and rDEN2
control.
Evaluation of the replication, immunogenicity, and protective
efficacy of rDEN2.DELTA.30 and wild-type parental rDEN2 virus in
juvenile rhesus monkeys was performed as follows. Dengue
virus-seronegative monkeys were injected subcutaneously with 5.0
log.sub.10PFU of virus in a 1 ml dose divided between two
injections in each side of the upper shoulder area. Monkeys were
observed daily and blood was collected on days 0-10 and 28 and
serum was stored at -70.degree. C. Viruses used in this experiment
were passaged in Vero cells, and recombinant viruses contained the
mutations shown in Table 20 (See footnotes b and d). Titer of virus
in serum samples was determined by plaque assay in Vero cells as
described previously (Durbin, A. P. et al. 2001 Am J Trop Med Hyg
65:405-13). Plaque reduction neutralization titers were determined
for the day 28 serum samples as previously described (Durbin, A. P.
et al. 2001 Am J Trop Med Hyg 65:405-13). All monkeys were
challenged on day 28 with a single dose of 5.0 log.sub.10PFU of wt
DEN2 (Tonga/74) and blood was collected for 10 days. Virus titer in
post-challenge sera was determined by plaque assay in Vero cells.
Monkeys inoculated with wt DEN2 (Tonga/74) or rDEN2 were viremic
for 4-5 days with a mean peak titer of 2.1 or 1.9 log.sub.10PFU/ml,
respectively.
Monkeys inoculated with rDEN2.DELTA.30 were viremic for 2-3 days
with a mean peak titer of 1.7 log.sub.10PFU/ml (Table 24, FIG. 7),
indicating that the .DELTA.30 mutation is capable of attenuating
DEN2, although not to the same low level observed in rDEN1.DELTA.30
(Table 16). As expected for an attenuated virus, the immune
response, as measured by neutralizing antibody titer, was lower
following inoculation with rDEN2.DELTA.30 compared to inoculation
with wt DEN2 (Tonga/74) or rDEN2 (Table 24), yet sufficiently high
to protect the animals against wt DEN2 virus challenge (Table 25).
Thus, the decreased number of days of viremia for rDEN2.DELTA.30,
the decreased mean peak titer, and the decreased serum antibody
response indicate that the .DELTA.30 mutation attenuates rDEN2 for
rhesus monkeys.
TABLE-US-00027 TABLE 24 rDEN2.DELTA.30 is slightly more attenuated
for rhesus monkeys than rDEN2 Geometric mean serum neutralizing No.
of Mean no. antibody titer monkeys of viremic Mean peak (reciprocal
No. of with days per virus titer dilution) Virus.sup.a monkeys
viremia monkey.sup.b (log.sub.10 PFU/ml .+-. SE) Day 0 Day 28 mock
2 0 0 <0.7 <10 <10 DEN2 (Tonga/74) 4 4 4.5 2.1 .+-. 0.3
<10 311 rDEN2 (Vero) 4 4 4.0 1.9 .+-. 0.1 <10 173
rDEN2.DELTA.30 (Vero) 4 4 2.8 1.7 .+-. 0.2 <10 91 .sup.aGroups
of rhesus monkeys were inoculated subcutaneously with 10.sup.5 PFU
of the indicated virus in a 1 ml dose. Serum was collected on days
0 to 6, 8, 10, 12, and 28. Virus titer was determined by plaque
assay in Vero cells. .sup.bViremia was not detected in any monkey
after day 8.
TABLE-US-00028 TABLE 25 rDEN2.DELTA.30 protects rhesus monkeys from
wt DENT2 virus challenge Geometric mean Mean no. of serum
neutralizing viremic days per Mean peak antibody titer No. of
monkey after virus titer (reciprocal dilution) Virus.sup.a monkeys
DEN2 challenge (log.sub.10 PFU/ml .+-. SE) Day 28 Day 56 Mock 2 4.0
2.1 .+-. 0.1 <10 338 DEN2 (Tonga/74) 4 0 <0.7 311 334 rDEN2
(Vero) 4 0 <0.7 173 318 rDEN2.DELTA.30 (Vero) 4 0 <0.7 91 267
.sup.a28 days after inoculation with the indicated viruses, monkeys
were challenged subcutaneously with 10.sup.5 PFU DEN2 (Tonga/74) in
a 1 ml dose. Serum was collected on days 28 to 34, 36, 38, and 56.
Virus titer was determined by plaque assay in Vero cells.
The infectivity of DEN2 (Tonga/74), rDEN2 and rDEN2.DELTA.30 for
Aedes aegypti mosquitoes via an artificial bloodmeal was evaluated
using the methods described in detail in Example 5. However at
doses of 3.3 to 3.5 log.sub.10pfu ingested, none of these three
viruses infected any mosquitoes, indicating that DEN2 (Tonga/74) is
poorly infectious for Aedes aegypti. As with rDEN1, the genetic
basis for this lack of infectivity remains to be defined. The
important property of restricted infectivity for the mosquito
midgut is highly desirable in a vaccine candidate because it would
serve to greatly restrict transmission of the virus from a vaccinee
to a mosquito vector.
Several missense mutation identified in rDEN4 have been
demonstrated to confer attenuated replication in suckling mouse
brain and/or SCID-HuH-7 mice (Blaney, J. E. et al. 2002 Virology
300:125-139; Blaney, J. E. et al. 2001 J Virol 75:9731-9740). In
addition, missense mutations that enhance replication of rDEN4
virus in Vero cells have been characterized. The significant
sequence conservation among the DEN virus serotypes provides a
strategy by which the mutations identified in rDEN4 viruses are
contemplated as being used to confer similar phenotypes upon rDEN2
virus. Six mutations identified in rDEN4 virus that are at a site
conserved in rDEN2 virus are being introduced into the p2 and
p2.DELTA.30 cDNA clones (Table 26). Specifically, two rDEN4
mutations, NS3 4891 and 4995, which confer Vero cell adaptation
phenotypes and decreased replication in mouse brain, one mutation,
NS4B 7182, which confers a Vero cell adaptation phenotype, and
three mutations, NS1 2650, NS3 5097, and 3' UTR 10634 which confer
decreased replication in mouse brain and SCID-HuH-7 mice are being
evaluated. These mutations have been introduced into sub-cloned
fragments of the p2 and p2.DELTA.30 cDNA clones, and have been used
to generate mutant full-length cDNA clones (Table 26), from which
virus has been recovered in C6/36 cells (Table 27). The evaluation
of these mutant rDEN2 viruses is contemplated as determining that
such point mutations can be transported into a different DEN virus
serotype and confer a similar useful phenotype, as has been
demonstrated for the .DELTA.30 deletion mutation.
TABLE-US-00029 TABLE 26 Introduction of conserved point mutations
characterized in rDEN4 viruses into rDEN2 Tonga/74 virus. Phenotype
in rDEN4 virus Mutation in rDEN4 virus Mutation introduced into
DEN2 virus Vero Mouse SCID- Nucleo- Amino Amino Nucleo- Amino Amino
RE Adap- brain HuH-7 tide acid acid tide acid acid site/mutagenic
tation.sup.a att.sup.b att.sup.c Gene/region position
position.sup.d chang- e position position.sup.d change region.sup.e
+ + - NS3 4891 1597 Ile > Thr 4889 1598 Ile > Thr Nar I
CCAcgGGcGCCGT + + - NS3 4995 1632 Ser > Pro 4993 1633 Ser >
Pro Stu I AAGGccTGGA + - - NS4b 7182 2361 Gly > Ser 7189 2365
Gly > Ser Xma I TAtccCCGGGAC - + + NS1 2650 850 Asn > Ser
2648 851 Asn > Ser Sac I AGAgcTctcTC - + + NS3 5097 1666 Asp
> Asn 5095 1667 Asp > Asn Xma I GaATCTCCACCCgGA - + + 3' UTR
10634 n/a.sup.f n/a 10698 n/a n/a none CTGTcGAATC .sup.aPresence of
the indicated mutation increases plaque size in Vero cells two-fold
or greater than rDEN4 virus. .sup.bPresence of the indicated
mutation restricts replication in 7-day-old mouse brain greater
than 100-fold compared to rDEN4 virus. .sup.cPresence of the
indicated mutation restricts replication in SCID-HuH-7 mice greater
than 100-fold compared to rDEN4 virus. .sup.dAmino acid position in
DEN4 or DEN2 polyprotein beginning with the methionine residue of
the C protein (nucleotides 102-104 or 97-99, respectively) as
position 1. .sup.ePrimers were engineered which introduced
(underline) translationally-silent restriction enzyme (RE) sites.
Lowercase letters indicate nt changes and bold letters indicate the
site of the 5-FU mutation, which in some oligonucleotides differs
from the original nucleotide substitution change in order to create
a unique RE site. The change preserves the codon for the amino acid
substitution. .sup.fNucleotide substitution in the 3' UTR is U >
C in DEN4 and DEN2 virus.
TABLE-US-00030 TABLE 27 rDEN2 viruses containing conserved 5-FU
mutations are recovered in C6/36 cells. Virus Nucleotide Virus
titer of transfection (nucleotide position in harvest (day 7)
determined position in rDEN2) rDEN4 in C6/36 cells (log.sub.10
PFU/ml) rDEN2-4889 4891 7.6 rDEN2-4993 4995 7.2 rDEN2-7189 7182 3.5
rDEN2-2648 2650 --.sup.a rDEN2-5095 5097 --.sup.a rDEN2-10698 10634
7.7 .sup.aTransfection has not yet been attempted.
EXAMPLE 4
Generation and Characterization of a Recombinant DEN3 Virus
Containing the .DELTA.30 Mutation
Because rDEN1.DELTA.30 was satisfactorily attenuated, we sought to
extend our technology to the creation of a DEN3 vaccine candidate.
To do this, the .DELTA.30 mutation was introduced into the cDNA of
DEN3, similar to the method used to create rDEN2.DELTA.30. A DEN3
virus isolate from a 1978 dengue epidemic in rural Sleman, Central
Indonesia (Sleman/78) (Gubler, D. J. et al. 1981 Am J Trop Med Hyg
30:1094-1099) was chosen to represent wt DEN3. The genome of DEN3
(Sleman/78) was sequenced in its entirety and served as consensus
sequence for the construction of a full-length cDNA clone (Appendix
2). cDNA fragments of DEN3 (Sleman/78) were generated by
reverse-transcription of the genome as indicated in FIG. 8A. Each
fragment was subcloned into a plasmid vector and sequenced to
verify that it matched the consensus sequence as determined for the
virus. This yielded six cloned cDNA fragments spanning the genome.
Cloned fragments were modified as follows: Fragment 5, representing
the 5' end of the genome was abutted to the SP6 promoter preceded
by an AscI restriction site; Fragment 1L was modified to contain a
translationally-silent SpeI restriction site at genomic nucleotide
2345; Fragment 1R was modified to contain a translationally-silent
SpeI restriction site also at genomic nucleotide 2345, and to
stabilize the eventual full-length clone, three additional
translationally-silent mutations at nucleotides 2354-2356,
2360-2362, and 2399 were created to ensure that translation stop
codons were present in all reading frames other than that used to
synthesize the virus polyprotein; Fragment 3 was modified at
nucleotide 9007 to ablate a naturally occurring KpnI restriction
site; and Fragment 4, representing the 3' end of the genome was
abutted to a KpnI restriction site. Each fragment was added
incrementally between the AscI and KpnI restriction sites of DEN4
cDNA clone p4 (Durbin, A. P. et al. 2001 Am J Trop Med Hyg
65:405-13) to generate a full-length DEN3 cDNA clone with the same
vector background successfully used to generate rDEN4 and rDEN2.
However, a stable, full-length clone could not be recovered in E.
coli when fragments 1L and 1R were combined into the same cDNA
molecule. To overcome this instability, a synthetic DNA linker
(FIG. 8A) containing redundant termination codons in each of the
forward and reverse open reading frames was introduced into the
SpeI restriction site at the same time that fragment 1L was added
to complete the full-length cDNA construct. The resulting p3 clone
containing the linker sequence was stable in E. coli, indicating
that the linker sequence was sufficient to interrupt whatever
deleterious element exists in this region. cDNA clone p3 was
sequenced and the virus genome was found to match the DEN3
(Sleman/78) consensus sequence, with the exception of the linker
sequence and translationally-silent modifications noted above
(Appendix 2--shown with the linker sequence removed). The .DELTA.30
mutation was introduced into Fragment 4 to generate Fragment
4.DELTA.30. To create p3.DELTA.30, the Fragment 4 region of p3 was
replaced with Fragment 4.DELTA.30 (FIG. 8A, B).
For transcription and generation of infectious virus, cDNA plasmids
p3 and p3.DELTA.30 were digested with SpeI and religated to remove
the linker sequence, linearized with Acc65I (isoschizomer of KpnI
which cleaves leaving only a single 3' nucleotide), and used as
templates in a transcription reaction using SP6 RNA polymerase as
previously described (Blaney, J. E. et. al. 2002 Virology
300:125-139). Transcripts were introduced into Vero cells or C6/36
mosquito cells using liposome-mediated transfection and cell
culture supernatants were harvested on day 14.
rDEN3 virus was recovered from the p3 cDNA in both Vero and C6/36
cells, while rDEN3.DELTA.30 was recovered from the p3.DELTA.30 cDNA
clone in only C6/36 cells (Table 28). The level of infectious virus
recovered in C6/36 cells was comparable for the p3 and p3.DELTA.30
cDNA clones when assayed by plaque titration in Vero or C6/36
cells. As previously observed, the efficiency of transfection in
C6/36 cells was higher than that in Vero cells. Two rDEN3.DELTA.30
viruses were recovered from independent cDNA clones, #22 and
#41.
TABLE-US-00031 TABLE 28 rDEN3 virus is recovered in Vero and C6/36
cells, but rDEN3.DELTA.30 virus is recovered only in C6/36 cells.
Virus titer of transfection harvest (day 14) determined in the
indicated Transfection cDNA cell type (log.sub.10 PFU/ml) cell type
construct Clone Virus Vero cells C6/36 cells Vero cells p3 #50
rDEN3 5.2 6.3 p3.DELTA.30 #22 rDEN3.DELTA.30 <0.7 <0.7
p3.DELTA.30 #41 rDEN3.DELTA.30 <0.7 <0.7 C6/36 cells p3 #50
rDEN3 5.2 6.0 p3.DELTA.30 #22 rDEN3.DELTA.30 5.9 6.9 p3.DELTA.30
#41 rDEN3.DELTA.30 5.1 7.2
To produce working stocks of viruses, transfection harvests will be
passaged and terminally diluted in Vero cells, and genomic
sequences of the viruses will be determined. To improve virus yield
in Vero cells, the Vero cell adaptation mutation previously
identified in rDEN4 at nucleotide 7162 was introduced into the
homologous NS4B region of p3 and p3.DELTA.30 to create p3-7164 and
p3.DELTA.30-7164. This mutation creates a Val to Ala substitution
at amino acid position 2357. As demonstrated for rDEN2.DELTA.30,
this mutation allowed for the direct recovery of virus in Vero
cells (Table 27) and is anticipated to have the same effect for
rDEN3.DELTA.30.
To initially assess the ability of the .DELTA.30 mutation to
attenuate rDEN3 virus in an animal model, the replication of DEN3
(Sleman/78), rDEN3, and rDEN3.DELTA.30 viruses will be evaluated in
SCID-HuH-7 mice and rhesus monkeys. Previously, attenuation of
vaccine candidates in SCID-HuH-7 mice has been demonstrated to be
predictive of attenuation in the rhesus monkey model of infection
(Examples 1 and 2). The evaluation of these mutant rDEN3 viruses is
contemplated as determining that the .DELTA.30 deletion mutations
can be transported into the DEN3 virus serotype and confer a
similar useful phenotype, as has been demonstrated for DEN1, DEN2,
and DEN4.
In summary, the strategy of introducing the .DELTA.30 mutation into
wild-type DEN viruses of each serotype to generate a suitably
attenuated tetravalent vaccine formulation is a unique and
attractive approach for several reasons. First, the mutation
responsible for attenuation is a 30-nucleotide deletion in the 3'
UTR, thus assuring that all of the structural and non-structural
proteins expressed by each of the four components of the
tetravalent vaccine are authentic wild-type proteins. Such
wild-type proteins should elicit an antibody response that is broad
based, rather than based solely on the M and E proteins that are
present in chimeric dengue virus vaccine candidates (Guirakhoo, F.
et al. 2001 J Virol 75:7290-304; Huang, C. Y. et al. 2000 J Virol
74:3020-8). The uniqueness of this approach derives from the fact
that other live attenuated dengue virus vaccines have mutations in
their structural or non-structural proteins (Butrapet, S. et al.
2000 J Virol 74:3011-9; Puri, B. et al. 1997 J Gen Virol
78:2287-91), therefore the immune response induced by these viruses
will be to a mutant protein, rather than a wild-type protein.
Second, deletion mutations are genetically more stable than point
mutations, and reversion of the attenuation phenotype is unlikely.
In humans, DEN4.DELTA.30 present in serum of vaccinees retained its
.DELTA.30 mutation, confirming its genetic stability in vivo
(Durbin, A. P. et al. 2001 Am J Trop Med Hyg 65:405-13). The
attenuating mutations in other existing dengue live attenuated
vaccine candidates are based on less stable point mutations
(Butrapet, S. et al. 2000 J Virol 74:3011-9: Puri, B. et al. 1997 J
Gen Virol 78:2287-91). Third, since the .DELTA.30 mutation is
common to each of the four viruses of the tetravalent vaccine,
recombination between any of the four vaccine serotypes would not
lead to loss of the attenuating mutation or reversion to a
wild-type phenotype. Recombination between components of the
trivalent polio vaccine has been observed (Guillot, S. et al. 2000
J Virol 74:8434-43), and naturally occurring recombinant dengue
viruses have been described (Worobey, M. et al. 1999 PNAS USA
96:7352-7) indicating the ability of this flavivirus to exchange
genetic elements between two different viruses. Clearly, gene
exchange is readily achieved between different DEN virus serotypes
using recombinant cDNA techniques (Bray, M. and Lai, C. J. 1991
PNAS USA 88:10342-6). Fourth, viruses with wild-type structural
proteins appear more infectious than viruses with altered
structural proteins (Huang, C. Y. et al. 2000 J Virol 74:3020-80).
This permits the use of a low quantity of each of the four virus
components in the final vaccine, contributing to the low cost of
manufacture. Low-cost manufacture is an essential element in
defining the ultimate utility of a dengue virus vaccine.
EXAMPLE 5
Generation and Characterization of Intertypic Chimeric DEN2 Viruses
Containing the .DELTA.30 Mutation
The four serotypes of dengue virus are defined by antibody
responses induced by the structural proteins of the virus,
primarily by a neutralizing antibody response to the envelope (E)
protein. These structural proteins include the E glycoprotein, a
membrane protein (M), and a capsid (C) protein. The mature virus
particle consists of a well-organized outer protein shell
surrounding a lipid bilayer membrane and a less-well-defined inner
nucleocapsid core (Kuhn, R. J. et al. 2002 Cell 108:717-25). The E
glycoprotein is the major protective antigen and readily induces
virus neutralizing antibodies that confer protection against dengue
virus infection. An effective dengue vaccine must therefore
minimally contain the E protein of all four serotypes, namely DEN1,
DEN2, DEN3, and DEN4, thereby inducing broad immunity and
precluding the possibility of developing the more serious illnesses
DHF/DSS, which occur in humans during secondary infection with a
heterotypic wild-type dengue virus. Based on a previously reported
strategy (Bray, M. and Lai, C. J. 1991 PNAS USA 88:10342-6), a
recombinant cDNA technology is being used to develop a live
attenuated tetravalent dengue virus vaccine composed of a set of
intertypic chimeric dengue viruses bearing the structural proteins
of each serotype.
Following the identification of a suitably attenuated and
immunogenic DEN4 recombinant virus, namely DEN4.DELTA.30 (Durbin,
A. P et al. 2001 Am J Trop Med Hyg 65:405-13), chimeric viruses
based on the DEN4 cDNA have been generated in which the C-M-E (CME)
or M-E (ME) genes have been replaced with the corresponding genes
derived from the prototypic DEN2 New Guinea C (NGC) strain (FIG.
9A). To create the CME chimeric viruses, the BglII/XhoI region of
the cDNA for either rDEN4 or rDEN4.DELTA.30 was replaced with a
similar region derived from DEN2. Likewise, to create the ME
chimeric viruses, the PstI/XhoI region of the cDNA for either rDEN4
or rDEN4.DELTA.30 was replaced with a homologous region derived
from DEN2. The nucleotide and amino acid sequences of the resulting
junctions are shown in FIG. 9B. The GenBank accession number for
the nucleotide sequence of rDEN4.DELTA.30 is AF326837. The GenBank
accession number for DEN2 NGC is M29095, which represents the mouse
neurovirulent strain of DEN2 NGC and differs from the prototypic
strain used here as previously documented (Bray, M. et al. 1998 J
Virol 72:1647-51).
For transcription and generation of virus, chimeric cDNA clones
were linearized and used as template in a transcription reaction
using SP6 RNA polymerase as described (Durbin, A. P et al. 2001 Am
J Trop Med Hyg 65:405-13). Transcripts were introduced into Vero
cells using liposome-mediated transfection and recombinant dengue
virus was harvested on day 7. The genomes of the resulting viruses
were confirmed by sequence analysis of viral RNA isolated from
recovered virus as previously described (Durbin, A. P et al. 2001
Am J Trop Med Hyg 65:405-13). Incidental mutations arising from
virus passage in tissue culture were identified in all viruses and
are listed in Table 29. Notably, each virus contained a missense
mutation in NS4B corresponding to a previously identified mutation
from rDEN4 and associated with adaptation to replication in Vero
cells (See Table 30 for correlation of nucleotide positions between
rDEN4 and chimeric viruses). All viruses replicated in Vero cells
to titers in excess of 6.0 log.sub.10PFU/ml, indicating that the
chimeric viruses, even those containing the .DELTA.30 mutation,
replicate efficiently in cell culture, a property essential for
manufacture of the vaccine.
TABLE-US-00032 TABLE 29 Missense mutations observed among the Vero
cell-grown chimeric DEN2/4 viruses Amino Amino Nucleotide
Nucleotide acid acid Virus Gene position change position change
rDEN2/4(CME) NS4B 7161.sup.a A > U 2355 Leu > Phe
rDEN2/4.DELTA.30(CME) M 743 G > A 216 Gly > Glu E 1493 C >
U 466 Ser > Phe NS4B 7544.sup.b C > T 2483 Ala > Val
rDEN2/4(ME) E 1065 U > C 322 Phe > Leu NS4B 7163.sup.a A >
U 2354 Leu > Phe rDEN2/4.DELTA.30(ME) NS4B 7163.sup.a A > C
2354 Leu > Phe .sup.aSame nucleotide position as 7163 in rDEN4.
.sup.bSame nucleotide position as 7546 in rDEN4.
TABLE-US-00033 TABLE 30 Nucleotide (nt) length differences for DEN
chimeric viruses compared to rDEN4. rDEN nt difference Amino
chimeric from rDEN4 ORF start acid length virus (following CME
region) (nt position) C M E 1/4 ME 0 102 113 166 495 1/4 CME +3 102
114 166 495 2/4 ME 0 102 113 166 495 2/4 CME -2 97 114 166 495 3/4
ME -6 102 113 166 493 3/4 CME -3 102 114 166 493 rDEN4 -- 102 113
166 495
Results of a safety, immunogenicity, and efficacy study in monkeys
are presented in Table 31. Monkeys inoculated with wild-type DEN2
were viremic for approximately 5 days with a mean peak titer of 2.1
log.sub.10PFU/ml, while monkeys inoculated with any of the chimeric
DEN2 viruses were viremic for 1.2 days or less and had a mean peak
titer of less than 1.0 log.sub.10PFU/ml. This reduction in the
magnitude and duration of viremia clearly indicates that the
chimeric viruses containing either the CME or ME proteins of DEN2
were more attenuated than the parental DEN2 NGC virus. Neither the
animals receiving the wild-type DEN2 nor the DEN2/4 chimeric
viruses were ill. The decreased replication of the attenuated
viruses in monkeys is accompanied by a reduction in the immune
response of inoculated monkeys. This is indicated in Table 31 by
approximately a 5-fold reduction in the level of neutralizing
antibody following inoculation with the chimeric viruses in
comparison to titers achieved in animals inoculated with wild-type
virus. Addition of the .DELTA.30 mutation to the CME chimeric virus
further attenuated the virus, such that rDEN2/4.DELTA.30(CME) did
not replicate in monkeys to a detectable level and did not induce a
detectable immune response. This virus appeared over-attenuated,
and if similar results were seen in humans, this virus would not be
suitable for use as a vaccine. However, addition of the .DELTA.30
mutation to the ME chimeric virus did not further attenuate this
chimeric virus and the resulting rDEN2/4.DELTA.30(ME) virus appears
satisfactorily attenuated and immunogenic for use as a vaccine.
TABLE-US-00034 TABLE 31 Chimerization between dengue virus types 2
and 4 results in recombinant viruses which are attenuated for
rhesus monkeys. Mean peak Geometric mean Mean no. virus titer
neutralizing days with (log.sub.10 antibody titer Group* Virus n
viremia pfu/ml) (reciprocal) 1 rDEN2/4 (CME) 6 1.2 0.9 50 2
rDEN2/4.DELTA.30 (CME) 8 0 <0.7 <5 3 rDEN2/4 (ME) 4 1.0 0.8
76 4 rDEN2/4.DELTA.30 (ME) 4 0.3 0.7 62 5 DEN2 NGC 6 5.5 2.1 312
*Rhesus monkeys were inoculated subcutaneously with 5.0 log.sub.10
PFU of virus. Serum samples were collected daily for 10 days. Serum
for neutralization assay was collected on day 28. Serum samples
obtained before virus inoculation had a neutralizing antibody titer
of <5.
As described in the previous examples, SCID mice transplanted with
the HuH-7 cells are a sensitive model for the evaluation of dengue
virus attenuation. Each chimeric DEN2/4 virus was inoculated into
groups of SCID-HuH-7 mice and levels of virus in the serum were
determined (Table 32). Chimeric viruses replicated to levels
between 20- and 150-fold lower than either of the parental viruses
(rDEN4 and DEN2-NGC). CME chimeric viruses were slightly more
attenuated than the comparable ME chimeric viruses, with the
.DELTA.30 mutation providing a 0.5 log.sub.10 reduction in
replication. This level of attenuation by the .DELTA.30 mutation
was similar to that observed previously for rDEN4.DELTA.30.
TABLE-US-00035 TABLE 32 Chimerization between dengue virus types 2
and 4 results in recombinant viruses which are attenuated for
HuH-7-SCID mice. No. of Mean peak virus titer Statistical
Virus.sup.a mice (log.sub.10 pfu/ml .+-. SE) group.sup.b rDEN4 32
6.3 .+-. 0.2 A DEN2-NGC 9 6.1 .+-. 0.2 A rDEN2/4 (CME) 7 4.4 .+-.
0.3 B rDEN2/4.DELTA.30 (CME) 7 3.9 .+-. 0.3 B rDEN2/4 (ME) 6 4.8
.+-. 0.5 B rDEN2/4.DELTA.30 (ME) 9 4.3 .+-. 0.2 B .sup.aGroups of
HuH-7-SCID mice were inoculated into the tumor with 4.0 log.sub.10
PFU of the indicated virus. Serum was collected on day 7 and virus
titer was determined in Vero cells. .sup.bMean peak titers were
assigned to statistical groups using the Tukey post-hoc test (P
< 0.05). Groups with the same letter designation are not
significantly different.
To evaluate the replication levels of each DEN2/4 chimeric virus in
mosquitoes, two different genera of mosquitoes were experimentally
infected. Aedes aegypti were infected by ingesting a
virus-containing blood meal. By evaluating the presence of virus
antigen in both the midgut and head tissue, infectivity could be
determined for the local tissues (midgut), and the ability of virus
to disseminate and replicate in tissues beyond the midgut barrier
(head) could also be measured. The presence of virus in the head is
limited by the ability of the ingested virus to replicate in the
midgut and then disseminate to the salivary glands in the head, as
well as the innate ability of the virus to replicate in the
salivary glands. Intrathoracic inoculation of virus into
Toxorhynchites splendens bypasses the mosquito midgut barrier.
Parental viruses rDEN4 and DEN2-NGC readily infect Ae. aegypti and
T splendens (Table 33), with DEN2-NGC appearing to be much more
infectious in T. splendens. Each of the rDEN2/4 chimeric viruses
was also tested in both mosquito types. In many cases it was not
possible to inoculate Ae. aegypti with an undiluted virus stock of
sufficient titer to achieve a detectable infection due to the very
low infectivity of several of the viruses. Nevertheless, it is
clear that the rDEN2/4 chimeric viruses are less infectious for the
midgut and head. Parental viruses rDEN4 and DEN2-NGC, administered
at a maximum dose of approximately 4.0 log.sub.10PFU, were
detectable in 74% and 94% of midgut preparations, and 32% and 71%
of head preparations, respectively. Among the chimeric viruses, the
highest level of infectivity, as observed for rDEN2/4.DELTA.30
(CME), resulted in only 26% infected midgut samples and 6% head
samples. In the more permissive T. splendens, the rDEN2/4 chimeric
viruses were generally less infectious than either parental virus,
with CME chimeric viruses being less infectious than ME viruses. It
has previously been reported for DEN4 that the .DELTA.30 mutation
does not have a discernable effect on virus infectivity in T.
splendens similar to that observed here for the rDEN2/4 chimeric
viruses (Troyer, J. M. et al. 2001 Am J Trop Med Hyg
65:414-419).
TABLE-US-00036 TABLE 33 Dengue 2/4 chimeric viruses are less
infectious compared to either parental virus strain in mosquitoes
Toxorhynchites splendens Aedes aegypti (intrathoracic inoculation)
(oral infection) Dose.sup.a No. % Dose.sup.c No. % infected.sup.d
Virus log.sub.10 pfu tested infected.sup.b log.sub.10 pfu tested
Midgut Head rDEN4 3.3 6 83 3.8 38 74 32 2.3 7 57 2.8 15 26 6 1.3 6
0 1.8 20 10 5 MID.sub.50 = 2.2 MID.sub.50 = 3.4 MID.sub.50 .gtoreq.
4.1 DEN2-NGC 2.5 5 100 4.0 17 94 71 1.2 15 93 3.0 25 36 16 0.2 4 75
2.0 30 0 0 0.02 8 38 MID.sub.50 = 3.2 MID.sub.50 = 3.6 MID.sub.50 =
0.5 rDEN2/4 (CME) 3.9 9 11 4.4 11 9 0 2.9 5 0 3.4 10 0 0 MID.sub.50
.gtoreq. 4.3 MID.sub.50 .gtoreq. 4.9 Nc.sup.e rDEN2/4.DELTA.30 3.5
6 17 4.0 15 26 6 (CME) 2.5 6 17 3.0 10 0 0 MID.sub.50 .gtoreq. 3.9
MID.sub.50 .gtoreq. 4.3 MID.sub.50 .gtoreq. 4.5 rDEN2/4 (ME) 3.4 6
100 3.9 23 4 0 2.4 5 20 MID.sub.50 .gtoreq. 4.4 Nc 1.4 5 0
MID.sub.50 = 2.8 rDEN2/4.DELTA.30 2.6 11 9 3.1 30 0 0 (ME)
MID.sub.50 .gtoreq. 3.0 nc Nc .sup.aAmount of virus present in 0.22
.mu.l inoculum. .sup.bPercentage of mosquitoes with IFA detectable
antigen in head tissue prepared 14 days after inoculation.
.sup.cVirus titer ingested, assuming a 2 .mu.l bloodmeal.
.sup.dPercentage of mosquitoes with IFA detectable antigen in
midgut or head tissue prepared 21 days after oral infection. When
virus infection was detected, but did not exceed a frequency of 50%
at the highest dose of virus ingested, the MID.sub.50 was estimated
by assuming that a 10-fold more concentrated virus dose would
infect 100% of the mosquitoes. .sup.enc = not calculated, since
virus antigen was not detected.
Chimerization of the DEN2 structural genes with rDEN4.DELTA.30
virus resulted in a virus, rDEN2/4.DELTA.30(CME), that had
decreased replication in Vero cells compared to either parent
virus. To evaluate Vero cell adaptation mutations (Blaney, J. E. et
al. 2002 Virology 300:125-139) as a means of increasing the virus
yield of a DEN vaccine candidate in Vero cells, selected mutations
were introduced into this chimeric virus. Accordingly,
rDEN2/4.DELTA.30(CME) viruses bearing adaptation mutations were
recovered, terminally diluted, and propagated in C6/36 cells to
determine if the virus yield in Vero cells could be increased.
rDEN2/4.DELTA.30(CME) viruses bearing Vero cell adaptation
mutations were generated as follows. DNA fragments were excised
from rDEN4 cDNA constructs encompassing single or double DEN4 Vero
cell adaptation mutations and introduced into the cDNA clone of
rDEN2/4.DELTA.30(CME). The presence of the Vero cell adaptation
mutation was confirmed by sequence analysis, and RNA transcripts
derived from the mutant cDNA clones were transfected, terminally
diluted, and propagated in C6/36 cells.
For evaluation of growth kinetics, Vero cells were infected with
the indicated viruses at a multiplicity of infection (MOI) of 0.01.
Confluent cell monolayers in duplicate 25-cm.sup.2 tissue culture
flasks were washed and overlaid with a 1 ml inoculum containing the
indicated virus. After a two hour incubation at 37.degree. C.,
cells were washed three times in MEM and 5 ml of MEM supplemented
with 2% FBS was added. A 1 ml aliquot of tissue culture medium was
removed, replaced with fresh medium, and designated the day 0
time-point. At the indicated time points post-infection, 1 ml
samples of tissue culture medium were removed, clarified by
centrifugation, and frozen at -80.degree. C. The level of virus
replication was assayed by plaque titration in C6/36 cells and
visualized by immunoperoxidase staining. The limit of detection was
<0.7 log.sub.10PFU/ml.
The growth properties of rDEN2/4.DELTA.30(CME) viruses bearing
single Vero cell adaptation mutations at NS4B-7153, -7162, -7163,
-7182, NS5-7630 or three combinations of mutations were compared in
Vero cells with rDEN2/4.DELTA.30 (CME) virus (FIG. 10). Without an
introduced Vero cell adaptation mutation, rDEN2/4.DELTA.30(CME)
virus yield peaked at 4.4 log.sub.10PFU/ml. Each individual
adaptation mutation and the combined mutations conferred a
substantial increase in replication. Specifically,
rDEN2/4.DELTA.30(CME)-7182 grew to the highest titer of 7.1
log.sub.10PFU/ml, which was a 500-fold increase in yield.
rDEN2/4.DELTA.30(CME)-7162 had the lowest yield but still was
increased 125-fold over the level of replication by
rDEN2/4.DELTA.30(CME) virus. Introduction of two adaptation
mutations into rDEN2/4.DELTA.30(CME) virus did not significantly
increase virus yield over that of viruses bearing single Vero cell
adaptation mutations. The observed increase of up to 500-fold in
virus yield by the introduction of a Vero cell adaptation mutation
into this chimeric vaccine candidate demonstrates the value of
identifying and characterizing specific replication-promoting
sequences in DEN viruses.
These results have particular significance for the development of a
live attenuated dengue virus vaccine. First, it is clear that
chimerization leads to attenuation of the resulting virus, as
indicated by studies in rhesus monkeys, HuH7-SCID mice and
mosquitoes. Although this conclusion was not made in the previous
study with DEN2/DEN4 or DEN1/DEN4 chimeric viruses (Bray, M. et al.
1996 J Virol 70:4162-6), careful examination of the data would
suggest that the chimeric viruses are more attenuated in monkeys
compared to the wild-type parent viruses. Second, the .DELTA.30
mutation can further augment this attenuation in a
chimeric-dependent manner. Specifically, in this example, chimeric
viruses bearing the CME region of DEN2 were over-attenuated by the
addition of .DELTA.30, whereas the attenuation phenotype of
chimeric viruses bearing just the ME region of DEN2 was unaltered
by the addition of the .DELTA.30 mutation. This unexpected finding
indicates that in a tetravalent vaccine comprised of individual
component viruses bearing a shared attenuating mutation, such as
the .DELTA.30 mutation, only ME chimeric viruses can be utilized
since CME chimeric viruses bearing the .DELTA.30 mutation can be
over-attenuated in rhesus monkeys and might provide only limited
immunogenicity in humans.
EXAMPLE 6
Generation and Characterization of Intertypic Chimeric DEN3 Viruses
Containing the .DELTA.30 Mutation
Chimeric viruses based on the DEN4 cDNA have been generated in
which the CME or ME genes have been replaced with the corresponding
genes derived from DEN3 (Sleman/78), a virus isolate from the 1978
dengue outbreak in the Sleman region of Indonesia (Gubler, D. J. et
al. 1981 Am J Trop Med Hyg 30:1094-1099) (Appendix 2). As described
in Example 5 for the DEN2 chimeric viruses, CME chimeric viruses
for DEN3 were generated by replacing the BglII/XhoI region of the
cDNA for either rDEN4 or rDEN4.DELTA.30 with a similar region
derived from DEN3 (Sleman/78) (FIG. 11A). Likewise, to create the
ME chimeric viruses, the PstI/XhoI region of the cDNA for either
rDEN4 or rDEN4.DELTA.30 was replaced with a similar region derived
from DEN3 (Sleman/78). The nucleotide and amino acid sequences of
the resulting junctions are shown in FIG. 11B. The genomes of the
resulting viruses were confirmed by sequence analysis of viral RNA
isolated from recovered virus as previously described (Durbin, A. P
et al. 2001 Am J Trop Med Hyg 65:405-13). Incidental mutations
arising from virus passage in tissue culture were identified in all
viruses and are listed in Table 34. Notably, each virus contained a
missense mutation in NS4B corresponding to a previously identified
mutation from rDEN4 and associated with adaptation to growth in
Vero cells (See Table 30 for correlation of nucleotide positions
between rDEN4 and chimeric viruses). All viruses replicated in Vero
cells to titers in excess of 5.7 log.sub.10PFU/ml, indicating that
the chimeric viruses, even those containing the .DELTA.30 mutation,
replicate efficiently in cell culture, a property essential for
manufacture of the vaccine.
TABLE-US-00037 TABLE 34 Missense mutations observed among Vero
cell-grown chimeric DEN3/4 viruses Amino Amino Nucleotide
Nucleotide acid acid Virus Gene position change position change
rDEN3/4.DELTA.30 M 825 T > C 242 Phe > Leu (CME) E 1641 C
> T 514 Leu > Phe E 2113 A > G 671 Lys > Arg NS4B
7159.sup.a T > C 2353 Leu > Ser rDEN3/4(ME) M 460 A > G
120 Asp > Gly NS4B 7177.sup.b G > U 2359 Gly > Val NS5
7702 C > U 2534 Ser > Phe rDEN3/4.DELTA.30 E 1432 A > U
444 Gln > Leu (ME) NS4B 7156.sup.a U > C 2352 Leu > Ser
NS5 8692 A > C 2864 Asn > His .sup.aSame nucleotide position
as 7162 in rDEN4. .sup.bSame nucleotide position as 7183 in
rDEN4.
As described in the previous examples, SCID mice transplanted with
HuH-7 cells are a sensitive model for the evaluation of dengue
virus attenuation. Each chimeric DEN3/4 virus was inoculated into
groups of SCID-HuH-7 mice and levels of virus in the serum were
determined (Table 35). While chimeric virus rDEN3/4 (CME) was not
attenuated, the remaining chimeric viruses replicated to levels
between 40- and 400-fold lower than either of the parental viruses
(rDEN4 and DEN3-Sleman/78). In the CME chimeric virus, the
.DELTA.30 mutation providing a remarkable 2.7 log.sub.10 reduction
in replication. This level of attenuation conferred by the
.DELTA.30 mutation in the CME chimeric virus was much greater than
that observed previously for rDEN4.DELTA.30. The rDEN3/4 (ME) virus
was 100-fold reduced in replication compared to either parent virus
indicating that the ME chimerization was attenuating per se.
Addition of the .DELTA.30 mutation to rDEN3/4 (ME) did not result
in additional attenuation.
TABLE-US-00038 TABLE 35 Chimerization between dengue virus types 3
and 4 results in recombinant viruses which are attenuated for
HuH-7-SCID mice. No. of Mean peak virus titer Statistical
Virus.sup.a mice (log.sub.10 pfu/ml .+-. SE) group.sup.b rDEN4 32
6.3 .+-. 0.2 A DEN3-Sleman/78 23 6.4 .+-. 0.2 A rDEN3/4 (CME) 7 6.4
.+-. 0.6 A rDEN3/4.DELTA.30 (CME) 5 3.7 .+-. 0.4 B rDEN3/4 (ME) 6
4.2 .+-. 0.7 B rDEN3/4.DELTA.30 (ME) 7 4.7 .+-. 0.4 A, B
.sup.aGroups of HuH-7-SCID mice were inoculated into the tumor with
4.0 log.sub.10 PFU of the indicated virus. Serum was collected on
day 7 and virus titer was determined in Vero cells. .sup.bMean peak
titers were assigned to statistical groups using the Tukey post-hoc
test (P < 0.05). Groups with the same letter designation are not
significantly different.
Evaluation of the replication and immunogenicity of the DEN3
chimeric recombinant viruses and wild-type DEN3 virus in monkeys
was performed as described in Example 5. Results of this safety and
immunogenicity study in monkeys are presented in Table 36. Monkeys
inoculated with rDEN3/4(CME) and wild-type DEN (Sleman/78) were
viremic for approximately 2 days with a mean peak titer of between
1.6 and 1.8 log.sub.10PFU/ml, respectively, indicating that
chimerization of the CME structural genes of DEN3 did not lead to
attenuation of virus replication, a different pattern than that
observed for DEN2 chimerization (Table 31). However, chimerization
of the ME structural genes resulted in attenuated viruses with
undetectable viremia in monkeys, although all monkeys seroconverted
with a greater than 10-fold increase in serum antibody levels. As
expected for an attenuated virus, the immune response, as measured
by neutralizing antibody titer, was lower following inoculation
with any of the chimeric viruses compared to inoculation with wt
DEN3 (Sleman/78), yet sufficiently high to protect the animals
against wtDEN3 virus challenge (Table 37). It is clear that
addition of the .DELTA.30 mutation to rDEN3/4(CME) was capable of
further attenuating the resulting virus rDEN3/4.DELTA.30(CME).
TABLE-US-00039 TABLE 36 The .DELTA.30 mutation further attenuates
rDEN3/4(CME) for rhesus monkeys Geometric mean Mean peak serum
neutralizing Mean no. virus titer antibody of viremic (log.sub.10
titer (reciprocal No. of days per PFU/ml .+-. dilution) Virus.sup.a
monkeys monkey.sup.b SE) Day 0 Day 28 DEN3 4 2.3 1.8 <5 707
(Sleman/78) rDEN3/4 4 2.0 1.6 <5 211 (CME) rDEN3/4.DELTA.30 4 0
<1.0 <5 53 (CME) rDEN3/4 4 0 <1.0 <5 70 (ME)
rDEN3/4.DELTA.30 4 0 <1.0 <5 58 (ME) .sup.aGroups of rhesus
monkeys were inoculated subcutaneously with 10.sup.5 PFU of the
indicated virus in a 1 ml dose. Serum was collected on days 0 to 6,
8, 10, 12, and 28. Virus titer was determined by plaque assay in
Vero cells. .sup.bViremia was not detected in any monkey after day
4.
TABLE-US-00040 TABLE 37 rDEN3/4 chimeric viruses protect rhesus
monkeys from wt DEN3 virus challenge Geometric mean serum
neutralizing Mean no. of Mean peak antibody titer viremic days
virus titer (reciprocal per monkey (log.sub.10 dilution) No. of
after rDEN3 PFU/ml .+-. Day Day Virus.sup.a monkeys challenge SE)
28 56 Mock 2 5.0 2.5 .+-. 0.4 <5 372 DEN3 (Sleman/78) 4 0
<1.0 707 779 rDEN3/4 (CME) 4 0 <1.0 211 695 rDEN3/4.DELTA.30
(CME) 4 0.8 1.1 .+-. 0.2 53 364 rDEN3/4 (ME) 4 0 <1.0 70 678
rDEN3/4.DELTA.30 (ME) 4 0 <1.0 58 694 .sup.a28 days after
primary inoculation with the indicated viruses, rhesus monkeys were
challenged subcutaneously with 10 PFU DEN3 (Sleman/78) virus in a 1
ml dose. Serum was collected on days 28 to 34, 36, 38, and 56.
Virus titer was determined by plaque assay in Vero cells.
To evaluate the replication levels of each DEN3/4 chimeric virus in
mosquitoes, Aedes aegypti were infected by ingesting a
virus-containing blood meal (Table 38). Parental viruses rDEN4 and
DEN3 (Sleman/78) readily infect Ae. aegypti. Each of the rDEN3/4
chimeric viruses was also tested. In many cases it was not possible
to infect Ae. aegypti with an undiluted virus stock of sufficient
titer to achieve a detectable infection due to the very low
infectivity of several of the viruses. At a dose of approximately
2.8-2.9 log.sub.10PFU, rDEN4, DEN3 (Sleman/78), and rDEN3/4(CME)
were equally infectious and disseminated to the head with equal
efficiency. For the remaining chimeric viruses, infection was not
detectable even at a dose of 3.4 log.sub.10PFU, indicating that
replication of rDEN3/4(ME) and rDEN3/4.DELTA.30(CME) is restricted
in Ae. aegypti. By comparing infectivity of rDEN3/4(CME) and
rDEN3/4.DELTA.30(CME), it is clear that the .DELTA.30 mutation is
capable of further attenuating the chimeric virus for
mosquitoes.
TABLE-US-00041 TABLE 38 Ability of DEN3/4 chimeric viruses to
infect Aedes aegypti fed an infectious bloodmeal. No. Dose Mosqui-
No. (%) No. (%) Ingested toes Midgut Disseminated Virus Tested
(log.sub.10 pfu).sup.a Tested Infections.sup.b,c,d Infections.sup.e
rDEN4 3.8 18 14 (77%) 2 (14%) 2.8 20 7 (34%) 2 (10%) 1.8 18 0 0
MID.sub.50 = 3.4 MID.sub.50 .gtoreq. 4.4 DEN3 2.9 16 3 (18%) 2
(12%) (Sleman) 1.9 10 1 (10%) 0 MID.sub.50 .gtoreq. 3.5
MID.sub.50+0.gtoreq. 3.5 rDEN3/4 3.9 20 6 (30%) 2 (10%) (CME) 2.9
18 4 (22%) 0 1.9 13 1 (7%) 0 MID.sub.50 .gtoreq. 4.2 MID.sub.50
.gtoreq. 4.5 DEN3/4.DELTA.30 3.3 20 0 0 (CME) MID.sub.50 .gtoreq.
4.3 MID.sub.50 .gtoreq. 4.3 DEN3/4 3.4 15 0 0 (ME) MID.sub.50
.gtoreq. 4.4 MID.sub.50 .gtoreq. 4.4 aAmount of virus ingested,
assuming a 2.mu. bloodmeal. .sup.bNumber (percentage) of mosquitoes
with detectable dengue virus in midgut tissue; mosquitoes were
assayed 21 days post feed, and dengue virus antigen was identified
by IFA. .sup.cWhen infection was detected, but did not exceed a
frequency of 50% at the highest dose of virus ingested, the
MID.sub.50 was estimated by assuming that a 10-fold more
concentrated virus dose would infect 100% of the mosquitoes.
.sup.dWhen no infection was detected, the MID.sub.50 was assumed to
be greater than a 10-fold higher dose of virus than the one used.
.sup.eNumber (percentage) of mosquitoes with detectable dengue
virus antigen in both midgut and head tissue.
EXAMPLE 7
Generation and Characterization of Intertypic Chimeric DEN1 Viruses
Containing the .DELTA.30 Mutation
Chimeric viruses based on the DEN4 cDNA have been generated in
which the CME or ME genes have been replaced with the corresponding
genes derived from DEN1 (Puerto Rico/94), a virus isolate from a
1994 dengue outbreak in Puerto Rico (Appendices 3 and 4). As
described in Example 4 for the DEN2 chimeric viruses, CME chimeric
viruses for DEN1 were generated by replacing the BglII/XhoI region
of the cDNA for either rDEN4 or rDEN4.DELTA.30 with a similar
region derived from DEN1 (Puerto Rico/94) (FIG. 12A). Likewise, to
create the ME chimeric viruses, the PstI/XhoI region of the cDNA
for either rDEN4 or rDEN4.DELTA.30 was replaced with a similar
region derived from DEN1 (Puerto Rico/94). The nucleotide and amino
acid sequences of the resulting junctions are shown in FIG.
12B.
For transcription and generation of virus, chimeric cDNA clones
were linearized and used as template in a transcription reaction
using SP6 RNA polymerase as described. Transcripts were introduced
into C6/36 mosquito cells using liposome-mediated transfection and
recombinant dengue virus was harvested between day 7 and 14.
Viruses were subsequently grown in Vero cells and biologically
cloned by terminal dilution in Vero cells. All viruses replicated
in Vero cells to titers in excess of 6.0 log.sub.10PFU/ml,
indicating that the chimeric viruses, even those containing the
.DELTA.30 mutation, replicate efficiently in cell culture. Genomic
sequence analysis is currently underway to identify incidental
mutations arising from virus passage in tissue culture.
To evaluate the replication levels of DEN1/4(CME) and
rDEN1/4.DELTA.30(CME) chimeric virus in mosquitoes, Aedes aegypti
were infected by ingesting a virus-containing blood meal (Table
39). Parental virus rDEN4 infects Ae. aegypti with an MID50 of 4.0
log.sub.10PFU. However, parental virus DEN1(Puerto Rico/94), is
unable to infect Ae. aegypti at a dose of up to 3.4 log.sub.10PFU.
Thus CME chimeric viruses DEN1/4 and rDEN1/4.DELTA.30 share this
inability to infect Ae. aegypti. Therefore, it is unnecessary in
Ae. aegypti to evaluate the effect of the .DELTA.30 mutation on the
infectivity of the DEN1/4 chimeric viruses, in a manner similar to
that used for the DEN2/4 and DEN3/4 chimeric viruses.
TABLE-US-00042 TABLE 39 Inability of DEN1/4 chimeric viruses to
infect Aedes aegypti fed an infectious bloodmeal. No. Dose Mosqui-
No. (%) No. (%) Virus ingested toes Midgut Disseminated tested
(log.sub.10 pfu).sup.a Tested Infections.sup.b,c,d Infections.sup.e
rDEN4 4.3 21 18 (85%) 8 (44%) 3.3 15 3 (20%) 0 2.3 20 0 0
MID.sub.50 = 4.0 MID.sub.50 .gtoreq. 4.3 DEN1 3.4 21 0 0 (Puerto
Rico/94) MID.sub.50 .gtoreq. 4.4 MID.sub.50 .gtoreq. 4.4 rDEN 1/4
3.8 20 0 0 (CME) MID.sub.50 .gtoreq. 4.8 MID.sub.50 .gtoreq. 4.8
rDEN1/4.DELTA.30 2.8 20 0 0 (CME) MID.sub.50 .gtoreq. 3.8
MID.sub.50 .gtoreq. 3.8 .sup.aAmount of virus ingested, assuming a
2.mu. bloodmeal. .sup.bNumber (percentage) of mosquitoes with
detectable dengue virus in midgut tissue; mosquitoes were assayed
21 days post feed, and dengue virus antigen was identified by IFA.
.sup.cWhen infection was detected, but did not exceed a frequency
of 50% at the highest dose of virus ingested, the MID.sub.50 was
estimated by assuming that a 10-fold more concentrated virus dose
would infect 100% of the mosquitoes. .sup.dWhen no infection was
detected, the MID.sub.50 was assumed to be greater than a 10-fold
higher dose of virus than the one used. .sup.eNumber (percentage)
of mosquitoes with detectable dengue virus antigen in both midgut
and head tissue.
As described in the previous examples, SCID mice transplanted with
the HuH-7 cells are a sensitive model for the evaluation of dengue
virus attenuation. Each chimeric DEN1/4 virus was inoculated into
groups of SCID-HuH-7 mice and levels of virus in the serum were
determined (Table 40). Chimeric viruses replicated to levels
between 15- and 250-fold lower than either of the parental viruses,
rDEN4 and DEN1 (Puerto Rico/94). CME chimeric viruses were more
attenuated than the comparable ME chimeric viruses, with the
.DELTA.30 mutation providing a 0.8 log.sub.10 reduction in
replication. This level of attenuation exerted by the .DELTA.30
mutation in the CME chimeric viruses was similar to that observed
previously for rDEN4.DELTA.30. However, the attenuating effect of
the .DELTA.30 mutation in the ME chimeric viruses is
indiscernible.
TABLE-US-00043 TABLE 40 Chimerization between dengue virus types 1
and 4 results in recombinant viruses which are attenuated for
HuH-7-SCID mice. No. of Mean peak virus titer Statistical
Virus.sup.a mice (log.sub.10 pfu/ml .+-. SE) group.sup.b rDEN4 32
6.3 .+-. 0.2 A DEN1 4 6.4 .+-. 0.2 A (Puerto Rico/94) rDEN1/4 (CME)
8 4.7 .+-. 0.2 B, C rDEN1/4.DELTA.30 (CME) 6 3.9 .+-. 0.4 C rDEN1/4
(ME) 6 5.0 .+-. 0.2 B rDEN1/4.DELTA.30 (ME) 6 5.1 .+-. 0.3 B
.sup.aGroups of HuH-7-SCID mice were inoculated into the tumor with
4.0 log.sub.10 PFU of the indicated virus. Serum was collected on
day 7 and virus titer was determined in Vero cells. .sup.bMean peak
titers were assigned to statistical groups using the Tukey post-hoc
test (P < 0.05). Groups with the same letter designation are not
significantly different.
TABLE-US-00044 APPENDIX 1 Nucleotide and amino acid sequence of
DEN2 (Tonga/74) cDNA plasmid p2 10 20 30 40 50 60 70 80 90 100
AGTTGTTAGTCTACGTGGACCGACAAAGACAGATTCTTTGAGGGAGCTAAGCTCAACGTAGTTCTAACTGTTTT-
TTGATTAGAGAGCAGATCTCTGATGA Met> 110 120 130 140 150 160 170 180
190 200
ATAACCAACGGAAAAAGGCGAGAAACACGCCTTTCAATATGCTGAAACGCGAGAGAAACCGCGTGTCAACTGTA-
CAACAGTTGACAAAGAGATTCTCACT
AsnAsnGlnArgLysLysAlaArgAsnThrProPheAsnMetLeuLysArgGluArgAsnArgValSerThrVa-
lGlnGlnLeuThrLysArgPheSerLeu> 210 220 230 240 250 260 270 280
290 300
TGGAATGCTGCAGGGACGAGGACCACTAAAATTGTTCATGGCCCTGGTGGCATTCCTTCGTTTCCTAACAATCC-
CACCAACAGCAGGGATATTAAAAAGA
GlyMetLeuGlnGlyArgGlyProLeuLysLeuPheMetAlaLeuValAlaPheLeuArgPheLeuThrIlePr-
oProThrAlaGlyIleLeuLysArg> 310 320 330 340 350 360 370 380 390
400
TGGGGAACAATTAAAAAATCAAAGGCTATTAATGTTCTGAGAGGCTTCAGGAAGAGATTTGGAAGGATGCTGAA-
TATCTTAAACAGGAGACGTAGAACTG
TrpGlyThrIleLysLysSerLysAlaIleAsnValLeuArgGlyPheArgLysGluIleGlyArgMetLeuAs-
nIleLeuAsnArgARgArgArgThr> 410 420 430 440 450 460 470 480 490
500
TAGGCATGATCATCATGCTGACTCCAACAGTGATGGCGTTTCATCTGACCACACGCAACGGAGAACCACACATG-
ATTGTCAGTAGACAAGAAAAAGGGAA
ValGlyMetIleIleMetLeuThrProThrValMetAlaPheHisLeuThrThrArgAsnGlyGluProHisMe-
tIleValSerArgGlnGluLysGlyLys> 510 520 530 540 550 560 570 580
590 600
AAGCCTTCTGTTCAAGACAAAGGATGGCACGAACATGTGTACCCTCATGGCCATGGACCTTGGTGAGTTGTGTG-
AAGACACAATCACGTATAAATGTCCT
SerLeuLeuPheLysThrLysAspGlyThrAsnMetCysThrLeuMetAlaMetAspLeuGlyGluLeuCysGl-
uAspThrIleThrTyrLysCysPro> 610 620 630 640 650 660 670 680 690
700
TTTCTCAAGCAGAACGAACCAGAAGACATAGATTGTTGGTGCAACTCCACGTCCACATGGGTAACTTATGGGAC-
ATGTACCACCACAGGAGAGCACAGAA
PheLeuLysGlnAsnGluProGluAspIleAspCysTrpCysAsnSerThrSerThrTrpValThrTyrGlyTh-
rCysThrThrThrGlyGluHisArg> 710 720 730 740 750 760 770 780 790
800
GAGAAAAAAGATCAGTGGCGCTTGTTCCACACGTGGGAATGGGATTGGAGACACGAACTGAAACATGGATCTCA-
TCAGAAGGGGCCTGGAAACATGCCCA
ArgGluLysArgSerValAlaLeuValProHisValGlyMetGlyLeuGluThrArgThrGluThrTrpMetSe-
rSerGluGlyAlaTrpLysHisAlaGln> 810 820 830 840 850 860 870 880
890 900
GAGAATTGAAACTTGGATTCTGAGACATCCAGGCTTTACCATAATGGCCGCAATCCTGGCATACACCATAGGGA-
CGACGCATTTCCAAAGAGTCCTGATA
ArgIleGluThrTrpIleLeuArgHisProGlyPheThrIleMetAlaAlaIleLeuAlaTyrThrIleGlyTh-
rThrHisPheGlnArgValLeuIle> 910 920 930 940 950 960 970 980 990
1000
TTCATCCTACTGACAGCCATCGCTCCTTCAATGACAATGCGCTGCATAGGAATATCAAATAGGGACTTTGTGGA-
AGGAGTGTCAGGAGGGAGTTGGGTTG
PheIleLeuLeuThrAlaIleAlaProSerMetThrMetArgCysIleGlyIleSerAsnArgAspPheValGl-
uGlyValSerGlyGlySerTrpVal> 1010 1020 1030 1040 1050 1060 1070
1080 1090 1100
ACATAGTTTTAGAACATGGAAGTTGTGTGACGACGATGGCAAAAAACAAACCAACACTGGACTTTGAACTGATA-
AAAACAGAAGCCAAACAACCTGCCAC
AspIleValLeuGluHisGlySerCysValThrThrMetAlaLysAsnLysProThrLeuAspPheGluLeuIl-
eLysThrGluAlaLysGlnProAlaThr> 1110 1120 1130 1140 1150 1160 1170
1180 1190 1200
CTTAAGGAAGTACTGTATAGAGGCCAAACTGACCAACACGACAACAGACTCGCGCTGCCCAACACAAGGGGAAC-
CCACCCTGAATGAAGAGCAGGACAAA
LeuArgLysTyrCysIleGluAlaLysLeuThrAsnThrThrThrAspSerArgCysProThrGlnGlyGluPr-
oThrLeuAsnGluGluGlnAspLys> 1210 1220 1230 1240 1250 1260 1270
1280 1290 1300
AGGTTTGTCTGCAAACATTCCATGGTAGACAGAGGATGGGGAAATGGATGTGGATTGTTTGGAAAAGGAGGCAT-
CGTGACCTGTGCTATGTTCACATGCA
ArgPheValCysLysHisSerMetValAspArgGlyTrpGlyAsnGlyCysGlyLeuPheGlyLysGlyGlyIl-
eValThrCysAlaMetPheThrCys> 1310 1320 1330 1340 1350 1360 1370
1380 1390 1400
AAAAGAACATGGAAGGAAAAATTGTTCAGCCAGAAAACCTGGAATACACTGTCGTGATAACACCTCATTCAGGG-
GAAGAACATGCAGTGGGAAATGACAC
LysLysAsnMetGluGlyLysIleValGlnProGluAsnLeuGluTyrThrValValIleThrProHisSerGl-
yGluGluHisAlaValGlyAsnAspThr> 1410 1420 1430 1440 1450 1460 1470
1480 1490 1500
AGGAAAACATGGTAAAGAAGTCAAGATAACACCACAGAGCTCCATCACAGAGGCGGAACTGACAGGCTATGGCA-
CTGTTACGATGGAGTGCTCTCCAAGA
GlyLysHisGlyLysGluValLysIleThrProGlnSerSerIleThrGluAlaGluLeuThrGlyTyrGlyTh-
rValThrMetGluCysSerProArg> 1510 1520 1530 1540 1550 1560 1570
1580 1590 1600
ACGGGCCTCGACTTCAATGAGATGGTGTTGCTGCAAATGGAAGACAAAGCCTGGCTGGTGCACAGACAATGGTT-
CCTAGACCTACCGTTGCCATGGCTGC
ThrGlyLeuAspPheAsnGluMetValLeuLeuGlnMetGluAspLysAlaTrpLeuValHisArgGlnTrpPh-
eLeuAspLeuProLeuProTrpLeu> 1610 1620 1630 1640 1650 1660 1670
1680 1690 1700
CCGGAGCAGACACACAAGGATCAAATTGGATACAGAAAGAAACACTGGTCACCTTCAAAAATCCCCATGCGAAA-
AAACAGGATGTTGTTGTCTTAGGATC
ProGlyAlaAspThrGlnGlySerAsnTrplleGlnLysGluThrLeuValThrPheLysAsnProHisAlaLy-
sLysGlnAspValValValLeuGlySer> 1710 1720 1730 1740 1750 1760 1770
1780 1790 1800
CCAAGAGGGGGCCATGCATACAGCACTCACAGGGGCTACGGAAATCCAGATGTCATCAGGAAACCTGCTGTTCA-
CAGGACATCTCAAGTGCAGGCTGAGA
GlnGluGlyAlaMetHisThrAlaLeuThrGlyAlaThrGluIleGlnMetSerSerGlyAsnLeuLeuPheTh-
rGlyHisLeuLysCysArgLeuArg> 1810 1820 1830 1840 1850 1860 1870
1880 1890 1900
ATGGACAAATTACAACTTAAAGGGATGTCATACTCCATGTGCACAGGAAAGTTTAAAATTGTGAAGGAAATAGC-
AGAAACACAACATGGAACAATAGTCA
MetAspLysLeuGlnLeuLysGlyMetSerTyrSerMetCysThrGlyLysPheLysIleValLysGluIleAl-
aGluThrGlnHisGlyThrIleVal> 1910 1920 1930 1940 1950 1960 1970
1980 1990 2000
TTAGAGTACAATATGAAGGAGACGGCTCTCCATGCAAGATCCCCTTTGAGATAATGGATCTGGAAAAAAGACAT-
GTTTTGGGCCGCCTGATCACAGTCAA
IleArgValGlnTyrGluGlyAspGlySerProCysLysIleProPheGluIleMetAspLeuGluLysArgHi-
sValLeuGlyArgLeuIleThrValAsn> 2010 2020 2030 2040 2050 2060 2070
2080 2090 2100
CCCAATTGTAACAGAAAAGGACAGTCCAGTCAACATAGAAGCAGAACCTCCATTCGGAGACAGCTACATCATCA-
TAGGAGTGGAACCAGGACAATTGAAG
ProIleValThrGluLysAspSerProValAsnIleGluAlaGluProProPheGlyAspSerTyrIleIleIl-
eGlyValGluProGlyGlnLeuLys> 2110 2120 2130 2140 2150 2160 2170
2180 2190 2200
CTGGACTGGTTCAAGAAAGGAAGTTCCATCGGCCAAATGTTTGAGACAACAATGAGGGGAGCGAAAAGAATGGC-
CATTTTGGGTGACACAGCCTGGGATT
LeuAspTrpPheLysLysGlySerSerIleGlyGlnMetPheGluThrThrMetArgGlyAlaLysArgMetAl-
aIleLeuGlyAspThrAlaTrpAsp> 2210 2220 2230 2240 2250 2260 2270
2280 2290 2300
TTGGATCTCTGGGAGGAGTGTTCACATCAATAGGAAAGGCTCTCCACCAGGTTTTTGGAGCAATCTACGGGGCT-
GCTTTCAGTGGGGTCTCATGGACTAT
PheGlySerLeuGlyGlyValPheThrSerIleGlyLysAlaLeuHisGlnValPheGlyAlaIleTyrGlyAl-
aAlaPheSerGlyValSerTrpThrMet> 2310 2320 2330 2340 2350 2360 2370
2380 2390 2400
GAAGATCCTCATAGGAGTTATCATCACATGGATAGGAATGAACTCACGTAGCACTAGTCTGAGCGTGTCACTGG-
TGTTAGTGGGAATCGTGACACTTTAC
LysIleLeuIleGlyValIleIleThrTrpIleGlyMetAsnSerArgSerThrSerLeuSerValSerLeuVa-
lLeuValGlyIleValThrLeuTyr> 2410 2420 2430 2440 2450 2460 2470
2480 2490 2500
TTGGGAGTTATGGTGCAGGCCGATAGTGGTTGCGTTGTGAGCTGGAAGAACAAAGAACTAAAATGTGGCAGTGG-
AATATTCGTCACAGATAACGTGCATA
LeuGlyValMetValGlnAlaAspSerGlyCysValValSerTrpLysAsnLysGluLeuLysCysGlySerGl-
yIlePheValThrAspAsnValHis> 2510 2520 2530 2540 2550 2560 2570
2580 2590 2600
CATGGACAGAACAATACAAGTTCCAACCAGAATCCCCTTCAAAACTGGCCTCAGCCATCCAGAAAGCGCATGAA-
GAGGGCATCTGTGGAATCCGCTCAGT
ThrTrpThrGluGlnTyrLysPheGlnProGluSerProSerLysLeuAlaSerAlaIleGlnLysAlaHisGl-
uGluGlyIleCysGlyIleArgSerVal> 2610 2620 2630 2640 2650 2660 2670
2680 2690 2700
AACAAGACTGGAAAATCTTATGTGGAAACAGATAACATCAGAATTGAATCATATTCTATCAGAAAATGAAGTGA-
AACTGACCATCATGACAGGAGACATC
ThrArgLeuGluAsnLeuMetTrpLysGlnIleThrSerGluLeuAsnHisIleLeuSerGluAsnGluValLy-
sLeuThrIleMetThrGlyAspIle> 2710 2720 2730 2740 2750 2760 2770
2780 2790 2800
AAAGGAATCATGCAGGTAGGAAAACGATCTTTGCGGCCTCAACCCACTGAGTTGAGGTATTCATGGAAAACATG-
GGGTAAAGCGAAAATGCTCTCCACAG
LysGlyIleMetGlnValGlyLysArgSerLeuArgProGlnProThrGluLeuArgTyrserTrpLysThrTr-
pGlyLysAlaLysMetLeuSerThr> 2810 2820 2830 2840 2850 2860 2870
2880 2890 2900
AACTCCACAATCAGACCTTCCTCATTGATGGTCCCGAAACAGCAGAATGCCCCAACACAAACAGAGCTTGGAAT-
TCACTGGAAGTTGAGGACTACGGCTT
GluLeuHisAsnGlnThrPheLeuIleAspGlyProGluThrAlaGluCysProAsnThrAsnArgAlaTrpAs-
nSerLeuGluValGluAspTyrGlyPhe> 2910 2920 2930 2940 2950 2960 2970
2980 2990 3000
TGGAGTATTCACTACCAATATATGGCTAAGATTGAGAGAAAAGCAGGATGTATTTTGTGACTCAAACTCATGTG-
CAGCGGCCATAAAGGACAACAGAGCC
GlyValPheThrThrAsnIleTrpLeuArgLeuArgGluLysGlnAspValPheCysAspSerLysLeuMetSr-
eAlaAlaIleLysAspAsnArgAla> 3010 3020 3030 3040 3050 3060 3070
3080 3090 3100
GTCCATGCTGATATGGGTTATTGGATAGAAAGCGCACTCAATGATACATGGAAGATAGAGAAAGCTTCTTTCAT-
TGAAGTCAAAAGTTGCCACTGGCCAA
ValHisAlaAspMetGlyTryTrpIleGluSerAlaLeuAsnAspThrTrpLysIleGluLysAlaSerPheIl-
eGluValLysSerCysHisTrpPro> 3110 3120 3130 3140 3150 3160 3170
3180 3190 3200
AGTCACACACCCTATGGAGTAATGGAGTGCTAGAAAGCGAGATGGTCATTCCAAAGAATTTCGCTGGACCAGTG-
TCACAACATAATAACAGACCAGGCTA
LysSerHisThrLeuTrpSerAsnGlyValLeuGluSerGluMetValIleProLysAsnPheAlaGlyProVa-
lSerGlnHisAsnAsnArgProGlyTyr> 3210 3220 3230 3240 3250 3260 3270
3280 3290 3300
TTACACACAAACAGCAGGACCTTGGCATCTAGGCAAGCTTGAGATGGACTTTGATTTCTGCGAAGGGACTACAG-
TGGTGGTAACCGAGAACTGTGGAAAC
TyrThrGlnThrAlaGlyProTrpHisLeuGlyLysLeuGluMetAspPheAspPheCysGluGlyThrThrVa-
lValValThrGluAsnCysGlyAsn> 3310 3320 3330 3340 3350 3360 3370
3380 3390 3400
AGAGGGCCCTCTTTAAGAACAACCACTGCCTCAGGAAAACTCATAACGGAATGGTGTTGTCGATCTTGCACACT-
ACCACCACTAAGATACAGAGGTGAGG
ArgGlyProSerLeuArgThrThrThrAlaSerGlyLysLeuIleThrGluTrpCysCysArgSerCysThrLe-
uProProLeuArgTyrArgGlyGlu> 3410 3420 3430 3440 3450 3460 3470
3480 3490 3500
ATGGATGTTGGTACGGGATGGAAATCAGACCATTGAAAGAGAAAGAAGAAAATCTGGTCAGTTCTCTGGTTACA-
GCCGGACATGGGCAGATTGACAATTT
AspGlyCysTrpTyrGlyMetGluIleArgProLeuLysGluLysGluGluAsnLeuValSerSerLeuValTh-
rAlaGlyHisGlyGlnIleAspAsnPhe> 3510 3520 3530 3540 3550 3560 3570
3580 3590 3600
CTCATTAGGAATCTTGGGAATGGCACTGTTCCTTGAAGAAATGCTCAGGACTCGAGTAGGAACAAAACATGCAA-
TATTACTCGTCGCAGTTTCTTTCGTG
SerLeuGlyIleLeuGlyMetAlaLeuPheLeuGluGluMetLeuArgThrArgValGlyThrLysHisAlaIl-
eLeuLeuValAlaValSerPheVal> 3610 3620 3630 3640 3650 3660 3670
3680 3690 3700
ACGCTAATCACAGGGAACATGTCTTTTAGAGACCTGGGAAGAGTGATGGTTATGGTGGGTGCCACCATGACAGA-
TGACATAGGCATGGGTGTGACTTATC
ThrLeuIleThrGlyAsnMetSerPheArgAspLeuGlyArgValMetValMetValGlyAlaThrMetThrAs-
pAspIleGlyMetGlyValThrTyr> 3710 3720 3730 3740 3750 3760 3770
3780 3790 3800
TCGCTCTACTAGCAGCTTTTAGAGTCAGACCAACCTTTGCAGCTGGACTGCTCTTGAGAAAACTGACCTCCAAG-
GAATTAATGATGACTACCATAGGAAT
LeuAlaLeuLeuAlaAlaPheArgValArgProThrPheAlaAlaGlyLeuLeuLeuArgLysLeuThrSerLy-
sGluLeuMetMetThrThrIleGlyIle> 3810 3820 3830 3840 3850 3860 3870
3880 3890 3900
CGTTCTTCTCTCCCAGAGTAGCATACCAGAGACCATTCTTGAACTGACCGACGCGTTAGCTCTAGGCATGATGG-
TCCTCAAGATGGTGAGAAACATGGAA
ValLeuLeuSerGlnSerSerIleProGluThrIleLeuGluLeuThrAspAlaLeuAlaLeuGlyMetMetVa-
lLeuLysMetValArgAsnMetGlu> 3910 3920 3930 3940 3950 3960 3970
3980 3990 4000
AAATATCAGCTGGCAGTGACCATCATGGCTATTTTGTGCGTCCCAAATGCTGTGATATTACAGAACGCATGGAA-
AGTGAGTTGCACAATATTGGCAGTGG
LysTyrGlnLeuAlaValThrIleMetAlaIleLeuCysValProAsnAlaValIleLeuGlnAsnAlaTrpLy-
sValSerCysThrIleLeuAlaVal> 4010 4020 4030 4040 4050 4060 4070
4080 4090 4100
TGTCTGTTTCCCCCCTGCTCTTAACATCCTCACAACAGAAAGCGGACTGGATACCATTAGCGTTGACGATCAAA-
GGTCTTAATCCAACAGCCATTTTTCT
ValSerValSerProLeuLeuLeuThrSerSerGlnGlnLysAlaAspTrpIleProLeuAlaLeuThrIleLy-
sGlyLeuAsnProThrAlaIlePheLeu> 4110 4120 4130 4140 4150 4160 4170
4180 4190 4200
AACAACCCTCTCAAGAACCAACAAGAAAAGGAGCTGGCCTTTAAATGAGGCCATCATGGCGGTTGGGATGGTGA-
GTATCTTGGCCAGCTCTCTCTTAAAG
ThrThrLeuSerArgThrAsnLysLysArgSerTrpProLeuAsnGluAlaIleMetAlaValGlyMetValSe-
rIleLeuAlaSerSerLeuLeuLys> 4210 4220 4230 4240 4250 4260 4270
4280 4290 4300
AATGACATCCCCATGACAGGACCATTAGTGGCTGGAGGGCTCCTTACTGTGTGCTACGTGCTAACTGGGCGGTC-
AGCCGATCTGGAATTAGAGAGAGCTA
AsnAspIleProMetThrGlyProLeuValAlaGlyGlyLeuLeuThrValCysTyrValLeuThrGlyArgSe-
rAlaAspLeuGluLeuGluArgAla> 4310 4320 4330 4340 4350 4360 4370
4380 4390 4400
CCGATGTCAAATGGGATGACCAGGCAGAGATATCAGGTAGCAGTCCAATCCTGTCAAGAACAATATCAGAAGAT-
GGCAGCATGTCAATAAAGAATGAAGA
ThrAspValLysTrpAspAspGlnAlaGluIleSerGlySerSerProIleLeuSerIleThrIleSerGluAs-
pGlySerMetSerlleLysAsnGluGlu> 4410 4420 4430 4440 4450 4460 4470
4480 4490 4500
GGAAGAGCAAACACTGACTATACTCATTAGAACAGGATTGCTTGTGATCTCAGGACTCTTTCCGGTATCAATAC-
CAATTACAGCAGCAGCATGGTATCTG
GluGluGlnThrLeuTheIleLeuIleArgThrGlyLeuLeuValIleSerGlyLeuPheProValSerIlePr-
oIleThrAlaAlaAlaTrpTyrLeu> 4510 4520 4530 4540 4550 4560 4570
4580 4590 4600
TGGGAAGTAAAGAAACAACGGGCTGGAGTGCTGTGGGATGTCCCCTCACCACCACCCGTGGGAAAAGCTGAATT-
GGAAGATGGAGCCTACAGAATCAAGC
TrpGluValLysLysGlnArgAlaGlyValLeuTrpAspValProSerProProProValGlyLysAlaGluLe-
uGluAspGlyAlaTyrArgIleLys> 4610 4620 4630 4640 4650 4660 4670
4680 4690 4700
AAAAAGGAATCCTTGGATATTCCCAGATCGGAGCTGGAGTTTACAAAGAAGGAACATTTCACACAATGTGGCAC-
GTCACACGTGGCGCTGTCCTAATGCA
GlnLysGlyIleLeuGlyTyrSerGlnIleGlyAlaGlyValTyrLysGluGlyThrPheHisThrMetTrpHi-
sValThrArgGlyAlaValLeuMetHis> 4710 4720 4730 4740 4750 4760 4770
4780 4790 4800
TAAGGGGAAGAGGATTGAACCATCATGGGCGGACGTCAAGAAAGACTTAATATCATATGGAGGAGGTTGGAAGC-
TAGAAGGAGAATGGAAAGAAGGAGAA
LysGlyLysArgIleGluProSerTrpAlaAspValLysLysAspLeuIleSerTyrGlyGlyGlyTrpLysLe-
uGluGlyGluTrpLysGluGlyGlu> 4810 4820 4830 4840 4850 4860 4870
4880 4890 4900
GAAGTCCAGGTCTTGGCATTGGAGCCAGGGAAAAATCCAAGAGCCGTCCAAACAAAGCCTGGCCTTTTTAGAAC-
CAACACTGGAACCATAGGTGCCGTAT
GluValGlnValLeuAlaLeuGluProGlyLysAsnProArgAlaValGlnThrLysProGlyLeuPheArgTh-
rAsnThrGlyThrIleGlyAlaVal> 4910 4920 4930 4940 4950 4960 4970
4980 4990 5000
CTCTGGACTTTTCCCCTGGGACGTCAGGATCTCCAATCGTCGACAAAAAAGGAAAAGTTGTAGGTCTCTATGGC-
AATGGTGTCGTTACAAGGAGTGGAGC
SerLeuAspPheSerProGlyThrSerGlySerProIleValAspLysLysGlyLysValValGlyLeuTyrGl-
yAsnGlyValValThrArgSerGlyAla> 5010 5020 5030 5040 5050 5060 5070
5080 5090 5100
ATATGTGAGTGCCATAGCTCAGACTGAAAAAAGCATTGAAGACAATCCAGAGATTGAAGATGACATCTTTCGAA-
AGAGAAGATTGACTATCATGGATCTC
TyrValSerAlaIleAlaGlnThrGluLysSerIleGluAspAsnProGluIleGluAspAspIlePheArgLy-
sArgArgLeuThrIleMetAspLeu> 5110 5120 5130 5140 5150 5160 5170
5180 5190 5200
CACCCAGGAGCAGGAAAGACAAAGAGATACCTCCCGGCCATAGTCAGAGAGGCCATAAAAAGAGGCTTGAGAAC-
ACTAATCCTAGCCCCCACTAGAGTCG
HisProGlyAlaGlyLysThrLysArgTyrLeuProAlaIleValArgGluAlaIleLysArgGlyLeuArgTh-
rLeuIleLeuAlaProThrArgVal> 5210 5220 5230 5240 5250 5260 5270
5280 5290 5300
TGGCAGCTGAAATGGAGGAAGCCCTTAGAGGACTTCCAATAAGATACCAAACTCCAGCTATCAGGGCTGAGCAC-
ACCGGGCGGGAGATTGTAGACTTAAT
ValAlaAlaGluMetGluGluAlaLeuArgGlyLeuProIleArgTyrGlnThrProAlaIleArgAlaGluHi-
sThrGlyArgGluIleValAspLeuMet> 5310 5320 5330 5340 5350 5360 5370
5380 5390 5400
GTGTCATGCCACATTTACCATGAGGCTGCTATCACCAATCAGGGTGCCAAATTACAACCTGATCATCATGGACG-
AAGCCCATTTTACAGATCCAGCAAGC
CysHisAlaThrPheThrMetArgLeuLeuSerProIleArgValProAsnTyrAsnLeuIleIleMetAspGl-
uAlaHisPheThrAspProAlaSer> 5410 5420 5430 5440 5450 5460 5470
5480 5490 5500
ATAGCAGCTAGGGGATACATCTCAACTCGAGTGGAGATGGGGGAGGCAGCTGGAATTTTTATGACAGCCACTCC-
TCCGGGTAGTAGAGATCCATTTCCTC
IleAlaAlaArgGlyTyrIleSerThrArgValGluMetGlyGluAlaAlaGlyIlePheMetThrAlaThrPr-
oProGlySerArgAspProPhePro> 5510 5520 5530 5540 5550 5560 5570
5580 5590 5600
AGAGCAATGCACCAATTATGGACGAAGAAAGAGAAATTCCGGAACGTTCATGGAACTCTGGGCACGAGTGGGTC-
ACGGATTTTAAAGGAAAGACTGTCTG
GlnSerAsnAlaProIleMetAspGluGluArgGluIleProGluArgSerTrpAsnSerGlyHisGluTrpVa-
lThrAspPheLysGlyLysThrValTrp> 5610 5620 5630 5640 5650 5660 5670
5680 5690 5700
GTTTGTTCCAAGCATAAAAACCGGAAATGACATAGCAGCCTGCCTGAGAAAGAATGGAAAGAGGGTGATACAAC-
TCAGTAGGAAGACCTTTGATTCTGAA
PheValProSerIleLysThrGlyAsnAspIleAlaAlaCysLeuArgLysAsnGlyLysArgValIleGlnLe-
uSerArgLysThrPheAspSerGlu> 5710 5720 5730 5740 5750 5760 5770
5780 5790 5800
TATGTCAAGACTAGAACCAATGACTGGGATTTCGTGGTTACAACTGACATCTCGGAAATGGGCGCCAACTTTAA-
AGCTGAGAGGGTCATAGACCCCAGAC
TyrValLysThrArgThrAsnAspTrpAspPheValValThrThrAspIleSerGluMetGlyAlaAsnPheLy-
sAlaGluArgValIleAspProArg> 5810 5820 5830 5840 5850 5860 5870
5880 5890 5900
GCTGCATGAAACCAGTTATATTGACAGACGGCGAAGAGCGGGTGATTCTGGCAGGACCCATGCCAGTGACCCAC-
TCTAGTGCAGCACAAAGAAGAGGGAG
ArgCysMetLysProValIleLeuThrAspGlyGluGluArgValIleLeuAlaGluProMetProValThrHi-
sSerSerAlaAlaGlnArgArgGlyArg> 5910 5920 5930 5940 5950 5960 5970
5980 5990 6000
AATAGGAAGGAATCCAAGGAATGAAAATGATCAATATATATATATGGGGGAACCACTGGAAAATGATGAAGACT-
GTGCGCACTGGAAGGAAGCTAAGATG
IleGlyArgAsnProArgAsnGluAsnAspGlnTyrIleTyrMetGlyGluProLeuGluAsnAspGluAspCy-
sAlaHisTrpLysGluAlaLysMet> 6010 6020 6030 6040 6050 6060 6070
6080 6090 6100
CTCCTAGATAATATCAACACACCTGAAGGAATCATTCCCAGCTTGTTCGAGCCAGAGCGTGAAAAGGTGGATGC-
CATTGACGGTGAATATCGCTTGAGAG
LeuLeuAspAsnIleAsnThrProGluGlyIleIleProSerLeuPheGluProGluArgGluLysValAspAl-
aIleAspGlyGluTyrArgLeuArg> 6110 6120 6130 6140 6150 6160 6170
6180 6190 6200
GAGAAGCACGGAAAACTTTTGTGGACCTAATGAGAAGAGGAGACCTACCAGTCTGGTTGGCTTATAAAGTGGCA-
GCTGAAGGTATCAACTACGCAGACAG
GlyGluAlaArgLysThrPheValAspLeuMetArgArgGlyAspLeuProValTrpLeuAlaTyrLysValAl-
aAlaGluGlyIleAsnTyrAlaAspArg> 6210 6220 6230 6240 6250 6260
6270 6280 6290 6300
AAGATGGTGTTTTGACGGAACCAGAAACAATCAAATCTTGGAAGAAAATGTGGAAGTGGAAATCTGGACAAAGG-
AAGGGGAAAGGAAAAAATTGAAACCT
ArgTrpCysPheAspGlyThrArgAsnAsnGlnIleLeuGluGluAsnValGluValGluIleTrpThrLysGl-
uGlyGluArgLysLysLeuLysPro> 6310 6320 6330 6340 6350 6360 6370
6380 6390 6400
AGATGGTTAGATGCTAGGATCTACTCCGACCCACTGGCGCTAAAAGAGTTCAAGGAATTTGCAGCCGGAAGAAA-
GTCCCTAACCCTGAACCTAATTACAG
ArgTrpLeuAspAlaArgIleTyrSerAspProLeuAlaLeuLysGluPheLysGluPheAlaAlaGlyArgLy-
sSerLeuThrLeuAsnLeuIleThr> 6410 6420 6430 6440 6450 6460 6470
6480 6490 6500
AGATGGGCAGACTCCCAACTTTTATGACTCAGAAGGCCAGAGATGCACTAGACAACTTGGCGGTGCTGCACACG-
GCTGAAGCGGGTGGAAAGGCATACAA
GluMetGlyArgLeuProThrPheMetThrGlnLysAlaArgAspAlaLeuAspAsnLeuAlaValLeuHisTh-
rAlaGluAlaGlyGlyLysAlaTyrAsn> 6510 6520 6530 6540 6550 6560 6570
6580 6590 6600
TCATGCTCTCAGTGAATTACCGGAGACCCTGGAGACATTGCTTTTGCTGACACTGTTGGCCACAGTCACGGGAG-
GAATCTTCCTATTCCTGATGAGCGGA
HisAlaLeuSerGluLeuProGluThrLeuGluThrLeuLeuLeuLeuThrLeuLeuAlaThrValThrGlyGl-
yIlePheLeuPheLeuMetSerGly> 6610 6620 6630 6640 6650 6660 6670
6680 6690 6700
AGGGGTATGGGGAAGATGACCCTGGGAATGTGCTGCATAATCACGGCCAGCATCCTCTTATGGTATGCACAAAT-
ACAGCCACATTGGATAGCAGCCTCAA
ArgGlyMetGlyLysMetThrLeuGlyMetCysCysIleIleThrAlaSerIleLeuLeuTryTyrAlaGlnIl-
eGlnProHisTrpIleAlaAlaSer> 6710 6720 6730 6740 6750 6760 6770
6780 6790 6800
TAATATTGGAGTTCTTTCTCATAGTCTTGCTCATTCCAGAACCAGAAAAGCAGAGGACACCTCAGGATAATCAA-
TTGACTTATGTCATCATAGCCATCCT
IleIleLeuGluPhePheLeuIleValLeuLeuIleProGluProGluLysGlnArgThrProGlnAspAsnGl-
nLeuThrTyrVallleIleAlaIleLeu> 6810 6820 6830 6840 6850 6860 6870
6880 6890 6900
CACAGTGGTGGCCGCAACCATGGCAAACGAAATGGGTTTTCTGGAAAAAACAAAGAAAGACCTCGGACTGGGAA-
ACATTGCAACTCAGCAACCTGAGAGC
ThrValValAlaAlaThrMetAlaAsnGluMetGlyPheLeuGluLysThrLysLysAspLeuGlyLeuGlyAs-
nIleAlaThrGlnGlnProGluSer> 6910 6920 6930 6940 6950 6960 6970
6980 6990 7000
AACATTCTGGACATAGATCTACGTCCTGCATCAGCATGGACGTTGTATGCCGTGGCTACAACATTTATCACACC-
AATGTTGAGACATAGCATTGAAAATT
AsnIleLeuAspIleAspLeuArgProAlaSerAlaTrpThrLeuTyrAlaValAlaThrThrPheIleThrPr-
oMetLeuArgHisSerIleGluAsn> 7010 7020 7030 7040 7050 7060 7070
7080 7090 7100
CCTCAGTAAATGTGTCCCTAACAGCCATAGCTAACCAAGCCACAGTGCTAATGGGTCTCGGAAAAGGATGGCCA-
TTGTCAAAGATGGACATTGGAGTTCC
SerSerValAsnValSerLeuThrAlaIleAlaAsnGlnAlaThrValLeuMetGlyLeuGlyLysGlyTrpPr-
oLeuSerLysMetAspIleGlyValPro> 7110 7120 7130 7140 7150 7160 7170
7180 7190 7200
CCTCCTTGCTATTGGGTGTTACTCACAAGTCAACCCTATAACCCTCACAGCGGCTCTTCTTTTATTGGTAGCAC-
ATTATGCCATCATAGGACCGGGACTT
LeuLeuAlaIleGlyCysTyrSerGlnValAsnProIleThrLeuThrAlaAlaLeuLeuLeuLeuValAlaHi-
sTyrAlaIleIleGlyProGlyLeu> 7210 7220 7230 7240 7250 7260 7270
7280 7290 7300
CAAGCCAAAGCAACTAGAGAAGCTCAGAAAAGAGCAGCAGCGGGCATCATGAAAAACCCAACTGTGGATGGAAT-
AACAGTGATAGATCTAGATCCAATAC
GlnAlaLysAlaThrArgGluAlaGlnLysArgAlaAlaAlaGlyIleMetLysAsnProThrValAspGlyIl-
eThrValIleAspLeuAspProIle> 7310 7320 7330 7340 7350 7360 7370
7380 7390 7400
CCTATGATCCAAAGTTTGAAAAGCAGTTGGGACAAGTAATGCTCCTAGTCCTCTGCGTGACCCAAGTGCTGATG-
ATGAGGACTACGTGGGCTTTGTGTGA
ProTyrAspProLysPheGluLysGlnLeuGlyGlnValMetLeuLeuValLeuCysValThrGlnValLeuMe-
tMetArgThrThrTrpAlaLeuCysGlu> 7410 7420 7430 7440 7450 7460 7470
7480 7490 7500
AGCCTTAACTCTAGCAACTGGACCCGTGTCCACATTGTGGGAAGGAAATCCAGGGAGATTCTGGAACACAACCA-
TTGCAGTGTCAATGGCAAACATCTTT
AlaLeuThrLeuAlaThrGlyProValSerThrLeuTrpGluGlyAsnProGlyArgPheTrpAsnThrThrIl-
eAlaValSerMetAlaAsnIlePhe> 7510 7520 7530 7540 7550 7560 7570
7580 7590 7600
AGAGGGAGTTACCTGGCTGGAGCTGGACTTCTCTTTTCTATCATGAAGAACACAACCAGCACGAGAAGAGGAAC-
TGGCAATATAGGAGAAACGTTAGGAG
ArgGlySerTyrLeuAlaGlyAlaGlyLeuLeuPheSerIleMetLysAsnThrThrSerThrArgArgGlyTh-
rGlyAsnIleGlyGluThrLeuGly> 7610 7620 7630 7640 7650 7660 7670
7680 7690 7700
AGAAATGGAAAAGCAGACTGAACGCATTGGGGAAAAGTGAATTCCAGATCTACAAAAAAAGTGGAATTCAAGAA-
GTGGACAGAACCTTAGCAAAAGAAGG
GluLysTrpLysSerArgLeuAsnAlaLeuGlyLysSerGluPheGlnIleTyrLysLysSerGlyIleGlnGl-
uValAspArgThrLeuAlaLysGluGly> 7710 7720 7730 7740 7750 7760 7770
7780 7790 7800
CATTAAAAGAGGAGAAACGGATCATCACGCTGTGTCGCGAGGCTCAGCAAAACTGAGATGGTTCGTTGAAAGGA-
ATTTGGTCACACCAGAAGGGAAAGTA
IleLysArgGlyGluThrAspHisHisAlaValSerArgGlySerAlaLysLeuArgTrpPheValGluArgAs-
nLeuValThrProGluGlyLysVal> 7810 7820 7830 7840 7850 7860 7870
7880 7890 7900
GTGGACCTTGGTTGTGGCAGAGGGGGCTGGTCATACTATTGTGGAGGATTAAAGAATGTAAGAGAAGTTAAAGG-
CTTAACAAAAGGAGGACCAGGACACG
ValAspLeuGlyCysGlyArgGlyGlyTrpSerTyrTyrCysGlyGlyLeuLysAsnValArgGluValLysGl-
yLeuThrLysGlyGlyProGlyHis> 7910 7920 7930 7940 7950 7960 7970
7980 7990 8000
AAGAACCTATCCCTATGTCAACATATGGGTGGAATCTAGTACGCTTACAGAGCGGAGTTGATGTTTTTTTTGTT-
CCACCAGAGAAGTGTGACACATTGTT
GluGluProIleProMetSerThrTyrGlyTrpAsnLeuValArgLeuGlnSerGlyValAspValPhePheVa-
lProProGluLysCysAspThrLeuLeu> 8010 8020 8030 8040 8050 8060 8070
8080 8090 8100
GTGTGACATAGGGGAATCATCACCAAATCCCACGGTAGAAGCGGGACGAACACTCAGAGTCCTCAACCTAGTGG-
AAAATTGGCTGAACAATAACACCCAA
CysAspIleGlyGluSerSerProAsnProThrValGluAlaGlyArgThrLeuArgValLeuAsnLeuValGl-
uAsnTrpLeuAsnAsnAsnThrGln> 8110 8120 8130 8140 8150 8160 8170
8180 8190 8200
TTTTGCGTAAAGGTTCTTAACCCGTACATGCCCTCAGTCATTGAAAGAATGGAAACCTTACAACGGAAATACGG-
AGGAGCCTTGGTGAGAAATCCACTCT
PheCysValLysValLeuAsnProTyrMetProSerValIleGluArgMetGluThrLeuGlnArgLysTyrGl-
yGlyAlaLeuValArgAsnProLeu> 8210 8220 8230 8240 8250 8260 8270
8280 8290 8300
CACGGAATTCCACACATGAGATGTACTGGGTGTCCAATGCTTCCGGGAACATAGTGTCATCAGTGAACATGATT-
TCAAGAATGCTGATCAACAGATTCAC
SerArgAsnSerThrHisGluMetTyrTrpValSerAsnAlaSerGlyAsnIleValSerSerValAsnMetIl-
eSerArgMetLeuIleAsnArgPheThr> 8310 8320 8330 8340 8350 8360 8370
8380 8390 8400
TATGAGACACAAGAAGGCCACCTATGAGCCAGATGTCGACCTCGGAAGCGGAACCCGCAATATTGGAATTGAAA-
GTGAGACACCGAACCTAGACATAATT
MetArgHisLysLysAlaThrTyrGluProAspValAspLeuGlySerGlyThrArgAsnIleGlyIleGluSe-
rGluThrProAsnLeuAspIleIle> 8410 8420 8430 8440 8450 8460 8470
8480 8490 8500
GGGAAAAGAATAGAAAAAATAAAACAAGAGCATGAAACGTCATGGCACTATGATCAAGACCACCCATACAAAAC-
ATGGGCTTACCATGGCAGCTATGAAA
GlyLysArgIleGluLysIleLysGlnGluHisGluThrSerTrpHisTyrAspGlnAspHisProTyrLysTh-
rTrpAlaTyrHisGlySerTyrGlu> 8510 8520 8530 8540 8550 8560 8570
8580 8590 8600
CAAAACAGACTGGATCAGCATCATCCATGGTGAACGGAGTAGTCAGATTGCTGACAAAACCCTGGGACGTTGTT-
CCAATGGTGACACAGATGGCAATGAC
ThrLysGlnThrGlySerAlaSerSerMetValAsnGlyValValArgLeuLeuThrLysProTrpAspValVa-
lProMetValThrGlnMetAlaMetThr> 8610 8620 8630 8640 8650 8660 8670
8680 8690 8700
AGACACAACTCCTTTTGGACAACAGCGCGTCTTCAAAGAGAAGGTGGATACGAGAACCCAAGAACCAAAAGAAG-
GCACAAAAAAACTAATGAAAATCACG
AspThrThrPropheGlyGlnGlnArgValPheLysGluLysValAspThrArgThrGlnGluProLysGluGl-
yThrLysLysLeuMetLysIleThr> 8710 8720 8730 8740 8750 8760 8770
8780 8790 8800
GCAGAGTGGCTCTGGAAAGAACTAGGAAAGAAAAAGACACCTAGAATGTGTACCAGAGAAGAATTCACAAAAAA-
GGTGAGAAGCAATGCAGCCTTGGGGG
AlaGluTrpLeuTrpLysGluLeuGlyLysLysLysThrProArgMetCysThrArgGluGluPheThrLysLy-
sValArgSerAsnAlaAlaLeuGly> 8810 8820 8830 8840 8850 8860 8870
8880 8890 8900
CCATATTCACCGATGAGAACAAGTGGAAATCGGCGCGTGAAGCCGTTGAAGATAGTAGGTTTTGGGAGCTGGTT-
GACAAGGAAAGGAACCTCCATCTTGA
AlaIlePheThrAspGluAsnLysTrpLysSerAlaArgGluAlaValGluAspSerArgPheTrpGluLeuVa-
lAspLySGluArgAsnLeuHisLeuGlu> 8910 8920 8930 8940 8950 8960 8970
8980 8990 9000
AGGGAAATGTGAAACATGTGTATACAACATGATGGGGAAAAGAGAGAAAAAACTAGGAGAGTTTGGTAAAGCAA-
AAGGCAGCAGAGCCATATGGTACATG
GlyLysCysGluThrCysValTyrAsnMetMetGlyLysArgGluLysLysLeuGlyGluPheGlyLysAlaLy-
sGlySerArgAlaIleTrpTyrMet> 9010 9020 9030 9040 9050 9060 9070
9080 9090 9100
TGGCTCGGAGCACGCTTCTTAGAGTTTGAAGCCCTAGGATTTTTGAATGAAGACCATTGGTTCTCCAGAGAGAA-
CTCCCTGAGTGGAGTGGAAGGAGAAG
TrpLeuGlyAlaArgPheLeuGluPheGluAlaLeuGlyPheLeuAsnGluAspHisTrpPheSerArgGluAs-
nSerLeuSerGlyValGluGlyGlu> 9110 9120 9130 9140 9150 9160 9170
9180 9190 9200
GGCTGCATAAGCTAGGTTACATCTTAAGAGAGGTGAGCAAGAAAGAAGGAGGAGCAATGTATGCCGATGACACC-
GCAGGCTGGGACACAAGAATCACAAT
GlyLeuHisLysLeuGlyTyrIleLeuArgGluValSerLysLysGluGlyGlyAlaMetTyrAlaAspAspTh-
rAlaGlyTrpAspThrArgIleThrIle> 9210 9220 9230 9240 9250 9260 9270
9280 9290 9300
AGAGGATTTGAAAAATGAAGAAATGATAACGAACCACATGGCAGGAGAACACAAGAAACTTGCCGAGGCCATTT-
TTAAATTGACGTACCAAAACAAGGTG
GluAspLeuLysAsnGluGluMetIleThrAsnHisMetAlaGlyGluHisLysLysLeuAlaGluAlaIlePh-
eLysLeuThrTyrGlnAsnLysVal> 9310 9320 9330 9340 9350 9360 9370
9380 9390 9400
GTGCGTGTGCAAAGACCAACACCAAGAGGCACAGTAATGGACATCATATCGAGAAGAGACCAAAGGGGTAGTGG-
ACAAGTTGGCACCTATGGCCTCAACA
ValArgValGlnArgProThrProArgGlyThrValMetAspIleIleSerArgArgAspGlnArgGlySerGl-
yGlnValGlyThrTyrGlyLeuAsn> 9410 9420 9430 9440 9450 9460 9470
9480 9490 9500
CTTTCACCAACATGGAAGCACAACTAATTAGGCAAATGGAGGGGGAAGGAATCTTCAAAAGCATCCAGCACTTG-
ACAGCCTCAGAAGAAATCGCTGTGCA
ThrPheThrAsnMetGluAlaGlnLeuIleArgGlnMetGluGlyGluGlyIlePheLysSerIleGlnHisLe-
uThrAlaSerGluGluIleAlaValGln> 9510 9520 9530 9540 9550 9560 9570
9580 9590 9600
AGATTGGCTAGTAAGAGTAGGGCGTGAAAGGTTGTCAAGAATGGCCATCAGTGGAGATGATTGTGTTGTGAAAC-
CTTTAGATGATAGATTTGCAAGAGCT
AspTrpLeuValArgValGlyArgGluArgLeuSerArgMetAlaIleSerGlyAspAspCysValValLysPr-
oLeuAspAspArgPheAlaArgAla> 9610 9620 9630 9640 9650 9660 9670
9680 9690 9700
CTAACAGCTCTAAATGACATGGGAAAGGTTAGGAAGGACATACAGCAATGGGAGCCCTCAAGAGGATGGAACGA-
CTGGACGCAGGTGCCCTTCTGTTCAC
LeuThrAlaLeuAsnAspMetGlyLysValArgLysAspIleGlnGlnTrpGluProSerArgGlyTrpAsnAs-
pTrpThrGlnValProPheCysSer> 9710 9720 9730 9740 9750 9760 9770
9780 9790 9800
ACCATTTTCACGAGTTAATTATGAAAGATGGTCGCACACTCGTAGTTCCATGCAGAAACCAAGATGAATTGATC-
GGCAGAGCCCGAATTTCCCAGGGAGC
HisHisPheHisGluLeuIleMetLysAspGlyArgThrLeuValValProCysArgAsnGlnAspGluLeuIl-
eGlyArgAlaArgIleSerGlnGlyAla> 9810 9820 9830 9840 9850 9860 9870
9880 9890 9900
TGGGTGGTCTTTACGGGAGACGGCCTGTTTGGGGAAGTCTTACGCCCAAATGTGGAGCTTGATGTACTTCCACA-
GACGTGATCTCAGGCTAGCGGCAAAT
GlyTrpSerLeuArgGluThrAlaCysLeuGlyLysSerTyrAlaGlnMetTrpSerLeuMetTyrPheHisAr-
gArgAspLeuArgLeuAlaAlaAsn> 9910 9920 9930 9940 9950 9960 9970
9980 9990 10000
GCCATCTGCTCGGCAGTCCCATCACACTGGATTCCAACAAGCCGGACAACCTGGTCCATACACGCCAGCCATGA-
ATGGATGACGACGGAAGACATGTTGA
AlaIleCysSerAlaValProSerHisTrpIleProThrSerArgThrThrTrpSerIleHisAlaSerHisGl-
uTrpMetThrThrGluAspMetLeu> 10010 10020 10030 10040 10050 10060
10070 10080 10090 10100
CAGTTTGGAACAGAGTGTGGATCCTAGAAAATCCATGGATGGAAGACAAAACTCCAGTGGAATCATGGGAGGAA-
ATCCCATACCTGGGAAAAAGAGAAGA
ThrValTrpAsnArgValTrpIleLeuGluAsnProTrpMetGluAspLysThrProValGluSerTrpGluGl-
uIleProTyrLeuGlyLysArgGluAsp> 10110 10120 10130 10140 10150
10160 10170 10180 10190 10200
CCAATGGTGCGGCTCGCTGATTGGGCTGACAAGCAGAGCCACCTGGGCGAAGAATATCCAGACAGCAATAAACC-
AAGTCAGATCCCTCATTGGCAATGAG
GlnTrpCysGlySerLeuIleGlyLeuThrSerArgAlaThrTrpAlaLysAsnIleGlnThrAlaIleAsnGl-
nValArgSerLeuIleGlyAsnGlu> 10210 10220 10230 10240 10250 10260
10270 10280 10290 10300
GAATACACAGATTACATGCCATCCATGAAAAGATTCAGAAGAGAAGAGGAAGAGGCAGGAGTTTTGTGGTAGAA-
AAACATGAAACAAAACAGAAGTCAGG
GluTyrThrAspTyrMetProSerMetLysArgPheArgArgGluGluGluGluAlaGlyValLeuTrp***&-
gt; 10310 10320 10330 10340 10350 10360 10370 10380 10390 10400
TCGGATTAAGCCATAGTACGGGAAAAACTATGCTACCTGTGAGCCCCGTCCAAGGACGTTAAAAGAAGTCAGGC-
CATTTTGATGCCATAGCTTGAGCAAA 10410 10420 10430 10440 10450 10460
10470 10480 10490 10500
CTGTGCAGCCTGTAGCTCCACCTGAGAAGGTGTAAAAAATCCGGGAGGCCACAAACCATGGAAGCTGTACGCAT-
GGCGTAGTGGACTAGCGGTTAGAGGA 10510 10520 10530 10540 10550 10560
10570 10580 10590 10600
GACCCCTCCCTTACAGATCGCAGCAACAATGGGGGCCCAAGGTGAGATGAAGCTGTAGTCTCACTGGAAGGACT-
AGAGGTTAGAGGAGACCCCCCCAAAA 10610 10620 10630 10640 10650 10660
10670 10680 10690 10700
CAAAAAACAGCATATTGACGCTGGGAAAGACCAGAGATCCTGCTGTCTCCTCAGCATCATTCCAGGCACAGGAC-
GCCAGAAAATGGAATGGTGCTGTTGA 10710 10720 10730 10740 10750 10760
10770 10780 10790 10800
ATCAACAGGTTCTGGTACCGGTAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGT-
TCCCAACGATCAAGGCGAGTTACATG 10810 10820 10830 10840 10850 10860
10870 10880 10890 10900
ATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAG-
TGTTATCACTCATGGTTATGGCAGCA 10910 10920 10930 10940 10950 10960
10970 10980 10990 11000
CTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATT-
CTGAGAATAGTGTATGCGGCGACCGA 11010 11020 11030 11040 11050 11060
11070 11080 11090 11100
GTTGCTCTTGCCCGGCGTCAACACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGA-
AAACGTTCTTCGGGGCGAAAACTCTC 11110 11120 11130 11140 11150 11160
11170 11180 11190 11200
AAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTA-
CTTTCACCAGCGTTTCTGGGTGAGCA 11210 11220 11230 11240 11250 11260
11270 11280 11290 11300
AAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCT-
TTTTCAATATTATTGAAGCATTTATC 11310 11320 11330 11340 11350 11360
11370 11380 11390 11400
AGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACA-
TTTCCCCGAAAAGTGCCACCTGACGT 11410 11420 11430 11440 11450 11460
11470 11480 11490 11500
CTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTCTTCAAGAAT-
TCTCATGTTTGACAGCTTATCATCGA 11510 11520 11530 11540 11550 11560
11570 11580 11590 11600
TAAGCTTTAATGCGGTAGTTTATCACAGTTAAATTGCTAACGCAGTCAGGCACCGTGTATGAAATCTAACAATG-
CGCTCATCGTCATCCTCGGCACCGTC 11610 11620 11630 11640 11650 11660
11670 11680 11690 11700
ACCCTGGATGCTGTAGGCATAGGCTTGGTTATGCCGGTACTGCCGGGCCTCTTGCGGGATATCGTCCATTCCGA-
CAGCATCGCCAGTCACTATGGCGTGC 11710 11720 11730 11740 11750 11760
11770 11780 11790 11800
TGCTGGCGCTATATGCGTTGATGCAATTTCTATGCGCACCCGTTCTCGGAGCACTGTCCGACCGCTTTGGCCGC-
CGCCCAGTCCTGCTCGCTTCGCTACT 11810 11820 11830 11840 11850 11860
11870 11880 11890 11900
TGGAGCCACTATCGACTACGCGATCATGGCGACCACACCCGTCCTGTGGATCCTCTACGCCGGACGCATCGTGG-
CCGGCATCACCGGCGCCACAGGTGCG 11910 11920 11930 11940 11950 11960
11970 11980 11990 12000
GTTGCTGGCGCCTATATCGCCGACATCACCGATGGGGAAGATCGGGCTCGCCACTTCGGGCTCATGAGCGCTTG-
TTTCGGCGTGGGTATGGTGGCAGGCC 12010 12020 12030 12040 12050 12060
12070 12080 12090 12100
CCGTGGCCGGGGGACTGTTGGGCGCCATCTCCTTGCATGCACCATTCCTTGCGGCGGCGGTGCTCAACGGCCTC-
AACCTACTACTGGGCTGCTTCCTAAT 12110 12120 12130 12140 12150 12160
12170 12180 12190 12200
GCAGGAGTCGCATAAGGGAGAGCGTCGACCGATGCCCTTGAGAGCCTTCAACCCAGTCAGCTCCTTCCGGTGGG-
CGCGGGGCATGACTATCGTCGCCGCA 12210 12220 12230 12240 12250 12260
12270 12280 12290 12300
CTTATGACTGTCTTCTTTATCATGCAACTCGTAGGACAGGTGCCGGCAGCGCTCTGGGTCATTTTCGGCGAGGA-
CCGCTTTCGCTGGAGCGCGACGATGA 12310 12320 12330 12340 12350 12360
12370 12380 12390 12400
TCGGCCTGTCGCTTGCGGTATTCGGAATCTTGCACGCCCTCGCTCAAGCCTTCGTCACTGGTCCCGCCACCAAA-
CGTTTCGGCGAGAAGCAGGCCATTAT 12410 12420 12430 12440 12450 12460
12470 12480 12490 12500
CGCCGGCATGGCGGCCGACGCGCTGGGCTACGTCTTGCTGGCGTTCGCGACGCGAGGCTGGATGGCCTTCCCCA-
TTATGATTCTTCTCGCTTCCGGCGGC 12510 12520 12530 12540 12550 12560
12570 12580 12590 12600
ATCGGGATGCCCGCGTTGCAGGCCATGCTGTCCAGGCAGGTAGATGACGACCATCAGGGACAGCTTCAAGGATC-
GCTCGCGGCTCTTACCAGCCTAACTT 12610 12620 12630 12640 12650 12660
12670 12680 12690 12700
CGATCACTGGACCGCTGATCGTCACGGCGATTTATGCCGCCTCGGCGAGCACATGGAACGGGTTGGCATGGATT-
GTAGGCGCCGCCCTATACCTTGTCTG 12710 12720 12730 12740 12750 12760
12770 12780 12790 12800
CCTCCCCGCGTTGCGTCGCGGTGCATGGAGCCGGGCCACCTCGACCTGAATGGAAGCCGGCGGCACCTCGCTAA-
CGGATTCACCACTCCAAGAATTGGAG 12810 12820 12830 12840 12850 12860
12870 12880 12890 12900
CCAATCAATTCTTGCGGAGAACTGTGAATGCGCAAACCAACCCTTGGCAGAACATATCCATCGCGTCCGCCATC-
TCCAGCAGCCGCACGCGGCGCATCTC 12910 12920 12930 12940 12950 12960
12970 12980 12990 13000
GGGCAGCGTTGGGTCCTGGCCACGGGTGCGCATGATCGTGCTCCTGTCGTTGAGGACCCGGCTAGGCTGGCGGG-
GTTGCCTTACTGGTTAGCAGAATGAA 13010 13020 13030 13040 13050 13060
13070 13080 13090 13100
TCACCGATACGCGAGCGAACGTGAAGCGACTGCTGCTGCAAAACGTCTGCGACCTGAGCAACAACATGAATGGT-
CTTCGGTTTCCGTGTTTCGTAAAGTC 13110 13120 13130 13140 13150 13160
13170 13180 13190 13200
TGGAAACGCGGAAGTCAGCGCCCTGCACCATTATGTTCCGGATCTGCATCGCAGGATGCTGCTGGCTACCCTGT-
GGAACACCTACATCTGTATTAACGAA
13210 13220 13230 13240 13250 13260 13270 13280 13290 13300
GCGCTGGCATTGACCCTGAGTGATTTTTCTCTGGTCCCGCCGCATCCATACCGCCAGTTGTTTACCCTCACAAC-
GTTCCAGTAACCGGGCATGTTCATCA 13310 13320 13330 13340 13350 13360
13370 13380 13390 13400
TCAGTAACCCGTATCGTGAGCATCCTCTCTCGTTTCATCGGTATCATTACCCCCATGAACAGAAATCCCCCTTA-
CACGGAGGCATCAGTGACCAAACAGG 13410 13420 13430 13440 13450 13460
13470 13480 13490 13500
AAAAAACCGCCCTTAACATGGCCCGCTTTATCAGAAGCCAGACATTAACGCTTCTGGAGAAACTCAACGAGCTG-
GACGCGGATGAACAGGCAGACATCTG 13510 13520 13530 13540 13550 13560
13570 13580 13590 13600
TGAATCGCTTCACGACCACGCTGATGAGCTTTACCGCAGCTGCCTCGCGCGTTTCGGTGATGACGGTGAAAACC-
TCTGACACATGCAGCTCCCGGAGACG 13610 13620 13630 13640 13650 13660
13670 13680 13690 13700
GTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTG-
TCGGGGCGCAGCCATGACCCAGTCAC 13710 13720 13730 13740 13750 13760
13770 13780 13790 13800
GTAGCGATAGCGGAGTGTATACTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATGC-
GGTGTGAAATACCGCACAGATGCGTA 13810 13820 13830 13840 13850 13860
13870 13880 13890 13900
AGGAGAAAATACCGCATCAGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCG-
GCGAGCGGTATCAGCTCACTCAAAGG 13910 13920 13930 13940 13950 13960
13970 13980 13990 14000
CGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCC-
AGGAACCGTAAAAAGGCCGCGTTGCT 14010 14020 14030 14040 14050 14060
14070 14080 14090 14100
GGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACC-
CGACAGGACTATAAAGATACCAGGCG 14110 14120 14130 14140 14150 14160
14170 14180 14190 14200
TTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCT-
CCCTTCGGGAAGCGTGGCGCTTTCTC 14210 14220 14230 14240 14250 14260
14270 14280 14290 14300
ATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCC-
GTTCAGCCCGACCGCTGCGCCTTATC 14310 14320 14330 14340 14350 14360
14370 14380 14390 14400
CGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGA-
TTAGCAGAGCGAGGTATGTAGGCGGT 14410 14420 14430 14440 14450 14460
14470 14480 14490 14500
GCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCT-
GAATCCAGTTACCTTCGGAAAAAGAG 14510 14520 14530 14540 14550 14560
14570 14580 14590 14600
TTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACG-
CGCAGAAAAAAAGGATCTCAAGAAGA 14610 14620 14630 14640 14650 14660
14670 14680 14690 14700
TCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGAT-
TATCAAAAAGGATCTTCACCTAGATC 14710 14720 14730 14740 14750 14760
14770 14780 14790 14800
CTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATG-
CTTAATCAGTGAGGCACCTATCTCAG 14810 14820 14830 14840 14850 14860
14870 14880 14890 14900
CGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTA-
CCATCTGGCCCCAGTGCTGCAATGAT 14910 14920 14930 14940 14950 14960
14970 14980 14990 15000
ACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAA-
GTGGTCCTGCAACTTTATCCGCCTCC 15010 15020 15030 15040 15050 15060
15070 15080 15090 15100
ATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGC-
CATTGCTGCAAGATCTGGCTAGCGAT 15110 15120 15130 15140 15150
GACCCTGCTGATTGGTTCGCTGACCATTTCCGGGCGCGCCGATTTAGGTGACACTATAG Bases 1
to 10713: DEN2 virus genome cDNA Bases 97 to 10269: DEN2
polyprotein ORF Bases 97 to 438: C protein ORF Bases 439 to 936:
prM protein ORF Bases 937 to 2421: E protein ORF Bases 2422 to
3477: NS1 protein ORF Bases 3478 to 4131: NS2A protein ORF Bases
4132 to 4521: NS2B protein ORF Bases 4522 to 6375: NS3 protein ORF
Bases 6376 to 6756: NS4A protein ORF Bases 6757 to 6825: 2K protein
ORF Bases 6826 to 7569: NS4B protein ORF Bases 7570 to 10269: NS5
protein ORF
TABLE-US-00045 APPENDIX 2 Nucleotide and amino acid sequence of
DEN3 (S1eman/78) cDNA plasmid p3 10 20 30 40 50 60 70 80 90 100
AGTTGTTAGTCTACGTGGACCGACAAGAACAGTTTCGACTCGGAAGCTTGCTTAACGTAGTACTGACAGTTTTT-
TATTAGAGAGCAGATCTCTGATGAACMet Asn> 110 120 130 140 150 160 170
180 190 200
AACCAACGGAAAAAGACGGGAAAACCGTCTATCAATATGCTGAAACGCGTGAGAAACCGTGTGTCAACTGGATC-
ACAGTTGGCGAAGAGATTCTCAAGAG
AsnGlnArgLysLysThrGlyLysProSerIleAsnMetLeuLysArgValArgAsnArgValSerThrGlySe-
rGlnLeuAlaLysArgPheSerArg> 210 220 230 240 250 260 270 280 290
300
GACTGCTGAACGGCCAAGGACCAATGAAATTGGTTATGGCGTTCATAGCTTTCCTCAGATTTCTAGCCATTCCA-
CCGACAGCAGGAGTCTTGGCTAGATG
GlyLeuLeuAsnGlyGlnGlyProMetLysLeuValMetAlaPheIleAlaPheLeuArgPheLeuAlaIlePr-
oProThrAlaGlyValLeuAlaArgTrp> 310 320 330 340 350 360 370 380
390 400
GGGAACCTTTAAGAAGTCGGGGGCTATTAAGGTCCTGAGAGGCTTCAAGAAGGAGATCTCAAACATGCTGAGCA-
TTATCAACAGACGGAAAAAGACATCG
GlyThrPheLysLysSerGlyAlaIleLysValLeuArgGlyPheLysLysGluIleSerAsnMetLeuSerIl-
eIleAsnArgArgLysLysThrSer> 410 420 430 440 450 460 470 480 490
500
CTCTGTCTCATGATGATGTTACCAGCAACACTTGCTTTCCACTTGACTTCACGAGATGGAAGCCGCGCATGATT-
GTGGGGAAGAATGAAAGAGGAAAAT
LeuCysLeuMetMetLeuProAlaThrLeuAlaPheHisLeuThrSerArgAspGlyGluProArgMetIleVa-
lGlyLysAsnGluArgGlyLys> 510 520 530 540 550 560 570 580 590 600
CCCTACTTTTTAAGACAGCCTCTGGAATCAACATGTGCACACTCATAGCCATGGATTTGGGAGAGATGTGTGAT-
GACACGGTCACCTACAAATGCCCCCT
SerLeuLeuPheLysThrAlaSerGlyIleAsnMetCysThrLeuIleAlaMetAspLeuGlyGluMetCysAs-
pAspThrValThrTyrLysCysProLeu> 610 620 630 640 650 660 670 680
690 700
CATTACTGAAGTGGAGCCTGAAGACATTGACTGCTGGTGCAACCTTACATCGACATGGGTGACCTACGGAACGT-
GCAATCAAGCTGGAGAGCACAGACGC
IleThrGluValGluProGluAspIleAspCysTrpCysAsnLeuThrSerThrTrpValThrTyrGlyThrCy-
sAsnGlnAlaGlyGluHisArgArg> 710 720 730 740 750 760 770 780 790
800
GACAAAAGATCGGTGGCGTTAGCTCCCCATGTCGGCATGGGACTGGACACACGCACCCAAACCTGGATGTCGGC-
TGAAGGAGCTTGGAGACAGGTCGAGA
AspLysArgSerValAlaLeuAlaProHisValGlyMetGlyLeuAspThrArgThrGlnThrTrpMetSerAl-
aGluGlyAlaTrpArgGlnValGlu> 810 820 830 840 850 860 870 880 890
900
AGGTAGAGACATGGGCCTTTAGGCACCCAGGGTTCACAATACTAGCCCTATTTCTTGCCCATTACATAGGCACT-
TCCTTGACCCAGAAAGTGGTTATTTT
LysValGluThrTrpAlaPheArgHisProGlyPheThrIleLeuAlaLeuPheLeuAlaHisTyrIleGlyTh-
rSerLeuThrGlnLysValValIlePhe> 910 920 930 940 950 960 970 980
990 1000
CATACTACTAATGCTGGTCACCCCATCCATGACAATGAGATGCGTGGGAGTAGGAAACAGAGATTTTGTGGAAG-
GCCTATCAGGAGCTACGTGGGTTGAC
IleLeuLeuMetLeuValThrProSerMetThrMetArgCysValGlyValGlyAsnArgAspPheValGluGl-
yLeuSerGlyAlaThrTrpValAsp> 1010 1020 1030 1040 1050 1060 1070
1080 1090 1100
GTGGTGCTCGAGCACGGTGGGTGTGTGACTACCATGGCTAAGAACAAGCCCACGCTGGATATAGAGCTCCAGAA-
GACCGAGGCCACCCAACTGGCGACCC
ValValLeuGluHisGlyGlyCysValThrThrMetAlaLysAsnLysProThrLeuAspIleGluLeuGlnLy-
sThrGluAlaThrGlnLeuAlaThr> 1110 1120 1130 1140 1150 1160 1170
1180 1190 1200
TAAGGAAACTATGTATTGAGGGAAAAATTACCAACGTAACAACCGACTCAAGGTGCCCCACCCAAGGGGAAGCG-
ATTTTACCTGAGGAGCAGGACCAGAA
LeuArgLysLeuCysIleGluGlyLysIleThrAsnValThrThrAspSerArgCysProThrGlnGlyGluAl-
aIleLeuProGluGluGlnAspGlnAsn> 1210 1220 1230 1240 1250 1260 1270
1280 1290 1300
CCACGTGTGCAAGCACACATACGTGGACAGAGGCTGGGGAAACGGTTGTGGTTTGTTTGGCAAGGGAAGCCTGG-
TAACATGCGCGAAATTTCAATGTTTG
HisValCysLysHisThrTyrValAspArgGlyTrpGlyAsnGlyCysGlyLeuPheGlyLysGlySerLeuVa-
lThrCysAlaLysPheGlnCysLeu> 1310 1320 1330 1340 1350 1360 1370
1380 1390 1400
GAATCAATAGAGGGAAAAGTGGTGCAGCATGAGAACCTCAAATACACCGTCATCATCACAGTGCACACAGGAGA-
TCAACACCAGGTGGGAAATGAAACGC
GluSerIleGluGlyLysValValGlnHisGluAsnLeuLysTyrThrValIleIleThrValHisThrGlyAs-
pGlnHisGlnValGlyAsnGluThr> 1410 1420 1430 1440 1450 1460 1470
1480 1490 1500
AGGGAGTCACGGCTGAGATAACACCCCAGGCATCAACCGTTGAAGCCATCTTACCTGAATATGGAACCCTTGGG-
CTAGAATGCTCACCACGGACAGGTTT
GlnGlyValThrAlaGluIleThrProGlnAlaSerThrValGluAlaIleLeuProGluTyrGlyThrLeuGl-
yLeuGluCysSerProArgThrGlyLeu> 1510 1520 1530 1540 1550 1560 1570
1580 1590 1600
AGATTTCAATGAAATGATTTTGTTGACAATGAAGAACAAAGCATGGATGGTACATAGACAATGGTTTTTTGACC-
TACCTTTACCATGGACATCAGGAGCT
AspPheAsnGluMetIleLeuLeuThrMetLysAsnLysAlaTrpMetValHisArgGlnTrpPhePheAspLe-
uProLeuProTrpThrSerGlyAla> 1610 1620 1630 1640 1650 1660 1670
1680 1690 1700
ACAACAGAAACACCAACCTGGAATAAGAAAGAGCTTCTTGTGACATTCAAAAACGCACATGCAAAAAAGCAAGA-
AGTAGTAGTCCTTGGATCGCAAGAGG
ThrThrGluThrProThrTrpAsnLysLysGluLeuLeuValThrPheLysAsnAlaHisAlaLysLysGlnGl-
uValValValLeuGlySerGlnGlu> 1710 1720 1730 1740 1750 1760 1770
1780 1790 1800
GAGCAATGCACACAGCACTGACAGGAGCTACAGAGATCCAAACCTCAGGAGGCACAAGTATTTTTGCGGGGCAC-
TTAAAATGTAGACTCAAGATGGACAA
GlyAlaMetHisThrAlaLeuThrGlyAlaThrGluIleGlnThrSerGlyGlyThrSerIlePheAlaGlyHi-
sLeuLysCysArgLeuLysMetAspLys> 1810 1820 1830 1840 1850 1860 1870
1880 1890 1900
ATTGGAACTCAAGGGGATGAGCTATGCAATGTGCTTGAATGCCTTTGTGTTGAAGAAAGAAGTCTCCGAAACGC-
AACATGGGACAATACTCATCAAGGTT
LeuGluLeuLysGlyMetSerTyrAlaMetCysLeuAsnAlaPheValLeuLysLysGluValSerGluThrGl-
nHisGlyThrIleLeuIleLysVal> 1910 1920 1930 1940 1950 1960 1970
1980 1990 2000
GAGTACAAAGGGGAAGATGCACCTTGCAAGATTCCTTTCTCCACGGAGGATGGACAAGGGAAAGCCCACAATGG-
CAGACTGATCACAGCTAACCCAGTGG
GluTyrLysGlyGluAspAlaProCysLysIleProPheSerThrGluAspGlyGlnGlyLysAlaHisAsnGl-
yArgLeuIleThrAlaAsnProVal> 2010 2020 2030 2040 2050 2060 2070
2080 2090 2100
TGACCAAGAAGGAGGAGCCTGTCAATATTGAGGCAGAACCTCCTTTTGGGGAAAGCAATATAGTAATTGGAATT-
GGAGACAAAGCCTTGAAAATCAACTG
ValThrLysLysGluGluProValAsnIleGluAlaGluProProPheGlyGluSerAsnIleValIleGlyIl-
eGlyAspLysAlaLeuLysIleAsnTrp> 2110 2120 2130 2140 2150 2160 2170
2180 2190 2200
GTACAAGAAGGGAAGCTCGATTGGGAAGATGTTCGAGGCCACTGCCAGAGGTGCAAGGCGCATGGCCATCTTGG-
GAGACACAGCCTGGGACTTTGGATCA
TyrLysLysGlySerSerIleGlyLysMetPheGluAlaThrAlaArgGlyAlaArgArgMetAlaIleLeuGl-
yAspThrAlaTrpAspPheGlySer> 2210 2220 2230 2240 2250 2260 2270
2280 2290 2300
GTAGGTGGTGTTTTAAATTCATTAGGAAAAATGGTGCACCAAATATTTGGAAGTGCTTACACAGCCCTATTTAG-
TGGAGTCTCCTGGATAATGAAAATTG
ValGlyGlyValLeuAsnSerLeuGlyLysMetValHisGlnIlePheGlySerAlaTyrThrAlaLeuPheSe-
rGlyValSerTrpIleMetLysIle> 2310 2320 2330 2340 2350 2360 2370
2380 2390 2400
GAATAGGTGTCCTTTTAACCTGGATAGGGTTGAATTCAAAAAACACTAGTATGAGCTTTAGCTGCATTGTGATA-
GGAATCATTACACTCTATCTGGGAGC
GlyIleGlyValLeuLeuThrTrpIleGlyLeuAsnSerLysAsnThrSerMetSerPheSerCysIleValIl-
eGlyIleIleThrLeuTyrLeuGlyAla> 2410 2420 2430 2440 2450 2460 2470
2480 2490 2500
CGTGGTGCAAGCTGACATGGGGTGTGTCATAAACTGGAAAGGCAAAGAACTCAAATGTGGAAGTGGAATTTTCG-
TCACTAATGAGGTCCACACCTGGACA
ValValGlnAlaAspMetGlyCysValIleAsnTrpLysGlyLysGluLeuLysCysGlySerGlyIlePheVa-
lThrAsnGluValHisThrTrpThr> 2510 2520 2530 2540 2550 2560 2570
2580 2590 2600
GAGCAATACAAATTTCAAGCAGACTCCCCCAAAAGACTGGCGACAGCCATTGCAGGCGCTTGGGAGAATGGAGT-
GTGCGGAATCAGGTCGACAACCAGAA
GluGlnTyrLysPheGlnAlaAspSerProLysArgLeuAlaThrAlaIleAlaGlyAlaTrpGluAsnGlyVa-
lCysGlyIleArgSerThrThrArg> 2610 2620 2630 2640 2650 2660 2670
2680 2690 2700
TGGAGAACCTCTTGTGGAAGCAAATAGCCAATGAACTGAACTACATATTATGGGAAAACAACATCAAATTAACG-
GTAGTTGTGGGTGATATAATTGGGGT
MetGluAsnLeuLeuTrpLysGlnIleAlaAsnGluLeuAsnTyrIleLeuTrpGluAsnAsnIleLysLeuTh-
rValValValGlyAspIleIleGlyVal> 2710 2720 2730 2740 2750 2760 2770
2780 2790 2800
CTTAGAGCAAGGGAAAAGAACACTAACACCACAACCCATGGAACTAAAATATTCATGGAAAACATGGGGAAAGG-
CGAAGATAGTGACAGCTGAAACACAA
LeuGluGlnGlyLysArgThrLeuThrProGlnProMetGluLeuLysTyrSerTrpLysThrTrpGlyLysAl-
aLysIleValThrAlaGluThrGln> 2810 2820 2830 2840 2850 2860 2870
2880 2890 2900
AATTCCTCTTTCATAATAGATGGGCCAAACACACCAGAGTGTCCAAGTGCCTCAAGAGCATGGAATGTGTGGGA-
GGTGGAAGATTACGGGTTCGGAGTCT
AsnSerSerPheIleIleAspGlyProAsnThrProGluCysProSerAlaSerArgAlaTrpAsnValTrpGl-
uValGluAspTyrGlyPheGlyVal> 2910 2920 2930 2940 2950 2960 2970
2980 2990 3000
TCACAACTAACATATGGCTGAAACTCCGAGAGATGTACACCCAACTATGTGACCACAGGCTAATGTCGGCAGCC-
GTTAAGGATGAGAGGGCCGTACACGC
PheThrThrAsnIleTrpLeuLysLeuArgGluMetTyrThrGlnLeuCysAspHisArgLeuMetSerAlaAl-
aValLysAspGluArgAlaValHisAla> 3010 3020 3030 3040 3050 3060 3070
3080 3090 3100
CGACATGGGCTATTGGATAGAAAGCCAAAAGAATGGAAGTTGGAAGCTAGAAAAGGCATCCCTCATAGAGGTAA-
AAACCTGCACATGGCCAAAATCACAC
AspMetGlyTyrTrpIleGluSerGlnLysAsnGlySerTrpLysLeuGluLysAlaSerLeuIleGluValLy-
sThrCysThrTrpProLysSerHis> 3110 3120 3130 3140 3150 3160 3170
3180 3190 3200
ACTCTTTGGAGCAATGGTGTGCTAGAGAGTGACATGATCATCCCAAAGAGTCTGGCTGGTCCCATTTCGCAACA-
CAACTACAGGCCCGGATACCACACCC
ThrLeuTrpSerAsnGlyValLeuGluSerAspMetIleIleProLysSerLeuAlaGlyProIleSerGlnHi-
sAsnTyrArgProGlyTyrHisThr> 3210 3220 3230 3240 3250 3260 3270
3280 3290 3300
AAACGGCAGGACCCTGGCACTTAGGAAAATTGGAGCTGGACTTCAACTATTGTGAAGGAACAACAGTTGTCATC-
ACAGAAAATTGTGGGACAAGAGGCCC
GlnThrAlaGlyProTrpHisLeuGlyLysLeuGluLeuAspPheAsnTyrCysGluGlyThrThrValValIl-
eThrGluAsnCysGlyThrArgGlyPro> 3310 3320 3330 3340 3350 3360 3370
3380 3390 3400
ATCACTGAGAACAACAACAGTGTCAGGGAAGTTGATACACGAATGGTGTTGCCGCTCGTGTACACTTCCTCCCC-
TGCGATACATGGGAGAAGACGGCTGC
SerLeuArgThrThrThrValSerGlyLysLeuIleHisGluTrpCysCysArgSerCysThrLeuProProLe-
uArgTyrMetGlyGluAspGlyCys> 3410 3420 3430 3440 3450 3460 3470
3480 3490 3500
TrpTyrGlyMetGluIleArgProIleAsnGluLysGluGluAsnMetValLysSerLeuValSerAlaGlySe-
rGlyLysValAspAsnPheThrMet>
TGGTATGGCATGGAAATTAGACCCATTAATGAGAAAGAAGAGAACATGGTAAAGTCTTTAGTCTCAGCAGGGAG-
TGGAAAGGTGGATAACTTCACAATGG 3510 3520 3530 3540 3550 3560 3570 3580
3590 3600
GTGTCTTGTGTTTGGCAATCCTTTTTGAAGAGGTGATGAGAGGAPAATTTGGGAPAAAGCACATGATTGCAGGG-
GTTCTCTTCACGTTTGTACTCCTCT
GlyValLeuCysLeuAlaIleLeuPheGluGluValMetArgGlyLysPheGlyLysLysHisMetIleAlaGl-
yValLeuPheThrPheValLeuLeuLeu> 3610 3620 3630 3640 3650 3660 3670
3680 3690 3700
CTCAGGGCAAATAACATGGAGAGACATGGCGCACACACTCATAATGATTGGGTCCAACGCCTCTGACAGAATGG-
GAATGGGCGTCACTTACCTAGCATTG
SerGlyGlnIleThrTrpArgAspMetAlaHisThrLeuIleMetIleGlySerAsnAlaSerAspArgMetGl-
yMetGlyValThrTyrLeuAlaLeu> 3710 3720 3730 3740 3750 3760 3770
3780 3790 3800
ATTGCAACATTTAAAATTCAGCCATTTTTGGCTTTGGGATTCTTCCTGAGGAAACTGACATCTAGAGAAAATTT-
ATTGTTGGGAGTTGGGTTGGCCATGG
IleAlaThrPheLysIleGlnProPheLeuAlaLeuGlyPhePheLeuArgLysLeuThrSerArgGluAsnLe-
uLeuLeuGlyValGlyLeuAlaMet> 3810 3820 3830 3840 3850 3860 3870
3880 3890 3900
CAACAACGTTACAACTGCCAGAGGACATTGAACAAATGGCGAATGGAATAGCTTTAGGGCTCATGGCTCTTAAA-
TTAATAACACAATTTGAAACATACCA
AlaThrThrLeuGlnLeuProGluAspIleGluGlnMetAlaAsnGlyIleAlaLeuGlyLeuMetAlaLeuLy-
sLeuIleThrGlnPheGluThrTyrGln> 3910 3920 3930 3940 3950 3960 3970
3980 3990 4000
ACATGGACGGCATTAGTCTCCCTAATGTGTTCAAATACAATTTTCACGTTGACTGTTGCCTGGAGAACAGCCAC-
CCTGATTTTGGCCGGAATTTCTCTT
LeuTrpThrAlaLeuValSerLeuMetCysSerAsnThrIlePheThrLeuThrValAlaTrpArgThrAlaTh-
rLeuIleLeuAlaGlyIleSerLeu> 4010 4020 4030 4040 4050 4060 4070
4080 4090 4100
TTGCCAGTGTGCCAGTCTTCGAGCATGAGGAAAACAGATTGGCTCCCAATGGCTGTGGCAGCTATGGGAGTTCC-
ACCCCTACCACTTTTTATTTTCAGTT
LeuProValCysGlnSerSerSerMetArgLysThrAspTrpLeuProMetAlaValAlaAlaMetGlyValPr-
oProLeuProLeuPheIlePheSer>
4110 4120 4130 4140 4150 4160 4170 4180 4190 4200
TGAAAGATACGCTCAAAAGGAGAAGCTGGCCACTGAATGAGGGGGTGATGGCTGTTGGACTTGTGAGTATTCTA-
GCTAGTTCTCTCCTTAGGAATGACGT
LeuLysAspThrLeuLysArgArgSerTrpProLeuAsnGluGlyValMetAlaValGlyLeuValSerIleLe-
uAlaSerSerLeuLeuArgAsnAspVal> 4210 4220 4230 4240 4250 4260 4270
4280 4290 4300
GCCCATGGCTGGACCATTAGTGGCTGGGGGCTTGCTGATAGCGTGCTACGTCATAACTGGCACGTCAGCAGACC-
TCACTGTAGAAAAAGCAGCAGATGTC
ProMetAlaGlyProLeuValAlaGlyGlyLeuLeuIleAlaCysTyrValIleThrGlyThrSerAlaAspLe-
uThrValGluLysAlaAlaAspVal> 4310 4320 4330 4340 4350 4360 4370
4380 4390 4400
ACATGGGAGGAAGAGGCTGAGCAAACAGGAGTGTCCCACAATTTAATGATCACAGTTGATGACGATGGAACAAT-
GAGAATAAAAGATGATGAGACTGAGA
ThrTrpGluGluGluAlaGluGlnThrGlyValSerHisAsnLeuMetIleThrValAspAspAspGlyThrMe-
tArgIleLysAspAspGluThrGlu> 4410 4420 4430 4440 4450 4460 4470
4480 4490 4500
ACATCTTAACAGTGCTTTTGAAAACAGCATTACTAATAGTGTCAGGCATTTTTCCATACTCCATACCCGCAACA-
CTGTTGGTCTGGCACACTTGGCAAAA
AsnIleLeuThrValLeuLeuLysThrAlaLeuLeuIleValSerGlyIlePheProTyrSerIleProAlaTh-
rLeuLeuValTrpHisThrTrpGlnLys> 4510 4520 4530 4540 4550 4560 4570
4580 4590 4600
GCAAACCCAAAGATCCGGTGTCCTATGGGACGTTCCCAGCCCCCCAGAGACACAGAAAGCAGAACTGGAAGAAG-
GGGTTTATAGGATCAAGCAGCAAGGA
GlnThrGlnArgSerGlyValLeuTrpAspValProSerProProGluThrGlnLysAlaGluLeuGluGluGl-
yValTyrArgIleLysGlnGlnGly> 4610 4620 4630 4640 4650 4660 4670
4680 4690 4700
ATTTTTGGGAAAACCCAAGTGGGGGTTGGAGTACAAAAAGAAGGAGTTTTCCACACCATGTGGCACGTCACAAG-
AGGAGCAGTGTTGACACACAATGGGA
IlePheGlyLysThrGlnValGlyValGlyValGlnLysGluGlyValPheHisThrMetTrpHisValThrAr-
gGlyAlaValLeuThrHisAsnGly> 4710 4720 4730 4740 4750 4760 4770
4780 4790 4800
AAAGACTGGAACCAAACTGGGCTAGCGTGAAAAAAGATCTGATTTCATACGGAGGAGGATGGAAATTGAGTGCA-
CAATGGCAAAAAGGAGAGGAGGTGCA
LysArgLeuGluProAsnTrpAlaSerValLysLysAspLeuIleSerTyrGlyGlyGlyTrpLysLeuSerAl-
aGlnTrpGlnLysGlyGluGluValGln> 4810 4820 4830 4840 4850 4860 4870
4880 4890 4900
GGTTATTGCCGTAGAGCCTGGGAAGAACCCAAAGAACTTTCAAACCATGCCAGGCATTTTCCAGACAACAACAG-
GGGGAGATAGGAGCGATTGCACTGGAC
ValIleAlaValGluProGlyLysAsnProLysAsnPheGlnThrMetProGlyIlePheGlnThrThrThrGl-
yGluIleGlyAlaIleAlaLeuAsp> 4910 4920 4930 4940 4950 4960 4970
4980 4990 5000
TTCAAGCCTGGAACTTCAGGATCTCCCATCATAAACAGAGAGGGAAAGGTACTGGGATTGTATGGCAATGGAGT-
GGTCACAAAGAATGGTGGCTATGTCA
PheLysProGlyThrSerGlySrProIleIleAsnArgGluGlyLysValLeuGlyLeuTyrGlyAsnGlyVal-
ValThrLysAsnGlyGlyTyrVal> 5010 5020 5030 5040 5050 5060 5070
5080 5090 5100
GTGGAATAGCACAAACAAATGCAGAACCAGACGGACCGACACCAGAGTTGGAAGAAGAGATGTTCAAAAAGCGA-
AATCTAACCATAATGGATCTCCATCC
SerGlyIleAlaGlnThrAsnAlaGluProAspGlyProThrProGluLeuGluGluGluMetPheLysLysAr-
gAsnLeuThrIleMetAspLeuHisPro> 5110 5120 5130 5140 5150 5160 5170
5180 5190 5200
CGGGTCAGGAAAGACGCGGAAATATCTTCCAGCTATTGTTAGAGAGGCAATCAAGAGACGCTTAAGGACTCTAA-
TTTTGGCACCAACAAGGGTAGTTGCA
GlySerGlyLysThrArgLysTyrLeuProAlaIleValArgGluAlaIleLysArgArgLeuArgThrLeuIl-
eLeuAlaProThrArgValValAla> 5210 5220 5230 5240 5250 5260 5270
5280 5290 5300
GCTGAGATGGAAGAAGCATTGAAAGGGCTCCCAATAAGGTATCAAACAACTGCAACAAAATCTGAACACACAGG-
GAGAGAGATTGTTGATCTAATGTGCC
AlaGluyMetGluGluAlaLeuLysGlyLeuProIleArgTyrGlnThrThrAlaThrLysSerGluHisThrG-
lyArgGluIleValAspLeuMetCys> 5310 5320 5330 5340 5350 5360 5370
5380 5390 5400
ACGCAACGTTCACAATGCGTTTGCTGTCACCAGTCAGGGTTCCAAACTACAACTTGATAATAATGGATGAGGCT-
CATTTCACAGACCCAGCCAGTATAGC
HisAlaThrPheThrMetArgLeuLeuSerProValArgValProAsnTyrAsnLeuIleIleMetAspGluAl-
aHisPheThrAspProAlaSerIleAla> 5410 5420 5430 5440 5450 5460 5470
5480 5490 5500
GGCTAGAGGGTACATATCAACTCGTGTAGGAATGGGAGAGGCAGCCGCAATTTTCATGACAGCCACACCCCCTG-
GAACAGCTGATGCCTTTCCTCAGAGC
AlaArgGlyTyrIleSerThrArgValGlyMetGlyGluAlaAlaAlaIlePheMetThrAlaThrProProGl-
yThrAlaAspAlaPheProGlnSer> 5510 5520 5530 5540 5550 5560 5570
5580 5590 5600
AACGCTCCAATTCAAGATGAAGAAAGAGACATACCAGAACGCTCATGGAATTCAGGCAATGAATGGATTACCGA-
CTTTGCCGGGAAGACGGTGTGGTTTG
AsnAlaProIleGlnAspGluGluArgAspIleProGluArgSerTrpAsnSerGlyAsnGluTrpIleThrAs-
pPheAlaGlyLysThrValTrpPhe> 5610 5620 5630 5640 5650 5660 5670
5680 5690 5700
TCCCTAGCATCAAAGCTGGAAATGACATAGCAAACTGCTTGCGGAAAAATGGAAAAAAGGTCATTCAACTTAGT-
AGGAAGACTTTTGACACAGAATATCA
ValProSerIleLysAlaGlyAsnAspIleAlaAsnCysLeuArgLysAsnGlyLysLysValIleGlnLeuSe-
rArgLysThrPheAspThrGluTyrGln> 5710 5720 5730 5740 5750 5760 5770
5780 5790 5800
AAAGACTAAACTAAATGATTGGGACTTTGTGGTGACAACAGACATTTCAGAAATGGGAGCCAATTTCAAAGCAG-
ACAGAGTGATCGACCCAAGAAGATGT
LysThrLysLeuAsnAspTrpAspPheValValThrThrAspIleSerGluMetGlyAlaAsnPheLysAlaAs-
pArgValIleAspProArgArgCys> 5810 5820 5830 5840 5850 5860 5870
5880 5890 5900
CTCAAGCCAGTGATTTTGACAGACGGACCCGAGCGCGTGATCCTGGCGGGACCAATGCCAGTCACCGTAGCGAG-
CGCTGCGCAAAGGAGAGGGAGAGTTG
LeuLysProValIleLeuThrAspGlyProGluArgValIleLeuAlaGlyProMetProValThrValAlaSe-
rAlaAlaGlnArgArgGlyArgVal> 5910 5920 5930 5940 5950 5960 5970
5980 5990 6000
GCAGGAACCCACAAAAAGAAAATGACCAATACATATTCATGGGCCAGCCCCTCAATAATGATGAAGACCATGCT-
CACTGGACAGAAGCAAAAATGCTGCT
GlyArgAsnProGlnLysGluAsnAspGlnTyrIlePheMetGlyGlnProLeuAsnAsnAspGluAspHisAl-
aHisTrpThrGluAlaLysMetLeuLeu> 6010 6020 6030 6040 6050 6060 6070
6080 6090 6100
AGACAACATCAACACACCAGAAGGGATCATACCAGCTCTCTTTGAACCAGAAAGGGAGAAGTCAGCCGCCATAG-
ACGGCGAATACCGCCTGAAGGGTGAG
AspAsnIleAsnThrProGluGlyIleIleProAlaLeuPheGluProGluArgGluLysSerAlaAlaIleAs-
pGlyGluTyrArgLeuLysGlyGlu> 6110 6120 6130 6140 6150 6160 6170
6180 6190 6200
TCCAGGAAGACCTTCGTGGAACTCATGAGGAGGGGTGACCTCCCAGTTTGGCTAGCCCATAAAGTAGCATCAGA-
AGGGATCAAATATACAGATAGAAAGT
SerArgLysThrPheValGluLeuMetArgArgGlyAspLeuProValTrpLeuAlaHisLysValAlaSerGl-
uGlyIleLysTyrThrAspArgLys> 6210 6220 6230 6240 6250 6260 6270
6280 6290 6300
GGTGTTTTGATGGAGAACGCAACAATCAAATTTTAGAGGAGAATATGGATGTGGAAATCTGGACAAAGGAAGGA-
GAAAAGAAAAAATTGAGACCTAGGTG
TrpCysPheAspGlyGluArgAsnAsnGlnIleLeuGluGluAsnMetAspValGluIleTrpThrLysGluGl-
yGluLysLysLysLeuArgProArgTrp> 6310 6320 6330 6340 6350 6360 6370
6380 6390 6400
GCTTGATGCCCGCACTTATTCAGATCCCTTAGCGCTCAAGGAATTCAAGGACTTTGCGGCTGGTAGAAAGTCAA-
TTGCCCTTGATCTTGTGACAGAAATA
LeuAspAlaArgThrTyrSerAspProLeuAlaLeuLysGluPheLysAspPheAlaAlaGlyArgLysSerIl-
eAlaLeuAspLeuValThrGluIle> 6410 6420 6430 6440 6450 6460 6470
6480 6490 6500
GGAAGAGTGCCTTCACACTTAGCTCACAGAACGAGAAACGCCCTGGACAATCTGGTGATGTTGCACACGTCAGA-
ACATGGCGGGAGGGCCTACAGGCATG
GlyArgValProSerHisLeuAlaHisArgThrArgAsnAAlaLeuAspAsnLeuValMetLeuHisThrSerG-
LuHisGlyGlyArgAlaTyrArgHis> 6510 6520 6530 6540 6550 6560 6570
6580 6590 6600
CAGTGGAGGAACTACCAGAAACAATGGAAACACTCTTACTCCTGGGACTCATGATCCTGTTAACAGGTGGAGCA-
ATGCTTTTCTTGATATCAGGTAAAGG
AlaValGluGluLeuProGluThrMetGluThrLeuLeuLeuLeuGlyLeuMetIleLeuLeuThrGlyGlyAl-
aMetLeuPheLeuIleSerGlyLysGly> 6610 6620 6630 6640 6650 6660 6670
6680 6690 6700
GATTGGAAAGACTTCAATAGGACTCATTTGTGTAGCTGCTTCCAGCGGTATGTTATGGATGGCTGATGTCCCAC-
TCCAATGGATCGCGTCTGCCATAGTC
IleGlyLysThrSerIleGLyLeuIleCysValAlaAlaSerSerGlyMetLeuTrpMetAlaAspValProLe-
uGlnTrpIleAlaSerAlaIleVal> 6710 6720 6730 6740 6750 6760 6770
6780 6790 6800
CTGGAGTTTTTTATGATGGTGTTACTTATACCAGAACCAGAAAAGCAGAGAACTCCCCAAGACAATCAACTCGC-
ATATGTCGTGATAGGCATACTCACAC
LeuGluPhePheMetMetValLeuLeuIleProGluProGluLysGlnArgThrProGlnAspAsnGlnLeuAl-
aTyrValValIleGlyIleLeuThr> 6810 6820 6830 6840 6850 6860 6870
6880 6890 6900
TGGCTGCAATAGTAGCAGCCAATGAAATGGGACTGTTGGAAACCACAAAGAGAGATTTAGGAATGTCCAAAGAA-
CCAGGTGTTGTTTCTCCAACCAGCTA
LeuAlaAlaIleValAlaAlaAsnGluMetGlyLeuLeuGluThrThrLysArgAspLeuGlyMetSerLysGl-
uProGlyValValSerProThrSerTyr> 6910 6920 6930 6940 6950 6960 6970
6980 6990 7000
TTTGGATGTGGACTTGCACCCAGCATCAGCCTGGACATTGTACGCTGTGGCCACAACAGTAATAACACCAATGT-
TGAGACATACCATAGAGAATTCCACA
LeuAspValAspLeuHisProAlaSerAlaTrpThrLeuTyrAlaValAlaThrThrValIleThrProMetLe-
uArgHisThrIleGluAsnSerThr> 7010 7020 7030 7040 7050 7060 7070
7080 7090 7100
GCAAATGTGTCCCTGGCAGCTATAGCCAACCAGGCAGTGGTCCTGATGGGTTTAGACAAAGGATGGCCGATATC-
GAAAATGGACTTAGGCGTGCCACTAT
AlaAsnValSerLeuAlaAlaIleAlaAsnGlnAlaValValLeuMetGlyLeuAspLysGlyTrpProIleSe-
rLysMetAspLeuGLyValProLeu> 7110 7120 7130 7140 7150 7160 7170
7180 7190 7200
TGGCACTGGGTTGTTATTCACAAGTGAACCCACTAACTCTCACAGCGGCAGTTCTCCTGCTAGTCACGCATTAT-
GCTATTATAGGTCCAGGATTGCAGGC
LeuAlaLeuGlyCysTyrSerGlnValAsnProLeuThrLeuThrAlaAlaValLeuLeuLeuValThrHisTy-
rAlaIleIleGlyProGlyLeuGlnAla> 7210 7220 7230 7240 7250 7260 7270
7280 7290 7300
AAAAGCCACTCGTGAAGCTCAAAAAAGGACAGCTGCTGGAATAATGAAGAATCCAACGGTGGATGGGATAATGA-
CAATAGACCTAGATCCTGTAATATAC
LysAlaThrArgGluAlaGlnLysArgThrAlaAlaGlyIleMetLysAsnProThrValAspGlyIleMetTh-
rIleAspLeuAspProValIleTyr> 7310 7320 7330 7340 7350 7360 7370
7380 7390 7400
GATTCAAAATTTGAAAAGCAACTAGGACAGGTTATGCTCCTGGTTCTGTGTGCAGTTCAACTTTTGTTAATGAG-
AACATCATGGGCTTTTTGTGAAGCTC
AspSerLysPheGluLysGlnLeuGlyGlnValMetLeuLeuValLeuCysAlaValGlnLeuLeuLeuMetAr-
gThrSerTrpAlaPheCysGluAla> 7410 7420 7430 7440 7450 7460 7470
7480 7490 7500
TAACCCTAGCCACAGGACCAATAACAACACTCTGGGAAGGATCACCTGGGAAGTTCTGGAACACCACGATAGCT-
GTTTCCATGGCGAACATCTTTAGAGG
LeuThrLeuAlaThrGlyProIleThrThrLeuTrpGluGlySerProGlyLysPheTrpAsnThrThrIleAl-
aValSerMetAlaAsnIlePheArgGly> 7510 7520 7530 7540 7550 7560 7570
7580 7590 7600
GAGCTATTTAGCAGGAGCTGGGCTTGCTTTTTCTATCATGAAATCAGTTGGAACAGGAAAGAGAGGGACAGGGT-
CACAGGGTGAAACCTTGGGAGAAAAG
SerTyrLeuAlaGlyAlaGlyLeuAlaPheSerIleMetLysSerValGlyThrGlyLysArgGlyThrGlySe-
rGlnGlyGluThrLeuGlyGluLys> 7610 7620 7630 7640 7650 7660 7670
7680 7690 7700
TGGAAAAAGAAATTGAATCAATTACCCCGGAAAGAGTTTGACCTTTACAAGAAATCCGGAATCACTGAAGTGGA-
TAGAACAGAAGCCAAAGAAGGGTTGA
TrpLysLysLysLeuAsnGlnLeuProArgLysGluPheAspLeuTyrLysLysSerGlyIleThrGluValAs-
pArgThrGluAlaLysGluGlyLeu> 7710 7720 7730 7740 7750 7760 7770
7780 7790 7800
AAAGAGGAGAAATAACACACCATGCCGTGTCCAGAGGCAGCGCAAAACTTCAATGGTTCGTGGAGAGAAACATG-
GTCATCCCCGAAGGAAGAGTCATAGA
LysArgGlyGluIleThrHisHisAlaValSerArgGlySerAlaLysLeuGlnTrpPheValGluArgAsnMe-
tValIleProGluGlyArgValIleAsp> 7810 7820 7830 7840 7850 7860 7870
7880 7890 7900
CTTAGGCTGTGGAAGAGGAGGCTGGTCATATTATTGTGCAGGACTGAAAAAAGTTACAGAAGTGCGAGGATACA-
CAAAAGGCGGCCCAGGACATGAAGAA
LeuGlyCysGlyArgGlyGlyTrpSerTyrTyrCysAlaGlyLeuLysLysValThrGluValArgGlyTyrTh-
rLysGlyGlyProGlyHisGluGlu> 7910 7920 7930 7940 7950 7960 7970
7980 7990 8000
CCAGTACCTATGTCTACATACGGATGGAACATAGTCAAGTTAATGAGTGGAAAGGATGTGTTTTATCTTCCACC-
TGAAAAGTGTGATACTCTATTGTGTG
ProValProMetSerThrTyrGlyTrpAsnIleValLysLeuMetSerGlyLysAspValPheTyrLeuProPr-
oGluLysCysAspThrLeuLeuCys> 8010 8020 8030 8040 8050 8060 8070
8080 8090 8100
ACATTGGAGAATCTTCACCAAGCCCAACAGTGGAAGAAAGCAGAACCATAAGAGTCTTGAAGATGGTTGAACCA-
TGGCTAAAAAATAACCAGTTTTGCAT
AspIleGlyGluSerSerProSerProThrValGluGluSerArgThrIleArgValLeuLysMetValGluPr-
oTrpLeuLysAsnAsnGlnPheCysIle> 8110 8120 8130 8140 8150 8160 8170
8180 8190 8200
TAAAGTATTGAACCCTTACATGCCAACTGTGATTGAGCACCTAGAAAGACTACAAAGGAAACATGGAGGAATGC-
TTGTGAGAAATCCACTCTCACGAAAC
LysValLeuAsnProTyrMetProThrValIleGluHisLeuGluArgLeuGlnArgLysHisGlyGlyMetLe-
uValArgAsnProLeuSerArgAsn> 8210 8220 8230 8240 8250 8260 8270
8280 8290 8300
TCCACGCACGAAATGTACTGGATATCTAATGGCACAGGCAATATCGTTTCTTCAGTCAACATGGTATCCAGATT-
GCTACTTAACAGATTCACAATGACAC
SerThrHisGLuMetTyrTrpIleSerAsnGlyThrGlyAsnIleValSerSerValAsnMetValSerArgLe-
uLeuLeuAsnArgPheThrMetThr>
8310 8320 8330 8340 8350 8360 8370 8380 8390 8400
ATAGGAGACCCACCATAGAGAAAGATGTGGATTTAGGAGCGGGGACCCGACATGTCAATGCGGAACCAGAAACA-
CCCAACATGGATGTCATTGGGGAAAG
HisArgArgProThrIleGluLysAspValAspLeuGlyAlaGlyThrArgHisValAsnAlaGluProGluTh-
rProAsnMetAspValIleGlyGluArg> 8410 8420 8430 8440 8450 8460 8470
8480 8490 8500
AATAAGAAGGATCAAGGAGGAGCATAGTTCAACATGGCACTATGATGATGAAAATCCTTATAAAACGTGGGCTT-
ACCATGGATCCTATGAAGTTAAGGCC
IleArgArgIleLysGluGluHisSerSerThrTrpHisTyrAspAspGluAsnProTyrLysThrTrpAlaTy-
rHisGlySerTyrGluValLysAla> 8510 8520 8530 8540 8550 8560 8570
8580 8590 8600
ACAGGCTCAGCCTCCTCCATGATAAATGGAGTCGTGAAACTCCTCACGAAACCATGGGATGTGGTGCCCATGGT-
GACACAGATGGCAATGACGGATACAA
ThrGlySerAlaSerSerMetIleAsnGlyValValLysLeuLeuThrLysProTrpAspValValProMetVa-
lThrGlnMetAlaMetThrAspThr> 8610 8620 8630 8640 8650 8660 8670
8680 8690 8700
CCCCATTCGGCCAGCAAAGGGTTTTTAAAGAGAAAGTGGACACCAGGACACCCAGACCTATGCCAGGAACAAGA-
AAGGTTATGGAGATCACAGCGGAATG
ThrProPheGlyGlnGlnArgValPheLysGluLysValAspThrArgThrProArgProMetProGlyThrAr-
gLysValMetGluIleThrAlaGluTrp> 8710 8720 8730 8740 8750 8760 8770
8780 8790 8800
GCTTTGGAGAACCCTGGGAAGGAACAAAAGACCCAGATTATGTACGAGAGAGGAGTTCACAAAAAAGGTCAGAA-
CCAACGCAGCTATGGGCGCCGTTTTT
LeuTrpArgThrLeuGlyArgAsnLysArgProArgLeuCysThrArgGluGluPheThrLysLysValArgTh-
rAsnAlaAlaMetGlyAlaValPhe> 8810 8820 8830 8840 8850 8860 8870
8880 8890 8900
ACAGAGGAGAACCAATGGGACAGTGCTAGAGCTGCTGTTGAGGATGAAGAATTCTGGAAACTCGTGGACAGAGA-
ACGTGAACTCCACAAATTGGGCAAGT
ThrGluGluAsnGlnTrpAspSerAlaArgAlaAlaValGluAspGluGluPheTrpLysLeuValAspArgGl-
uArgGluLeuHisLysLeuGlyLys 8910 8920 8930 8940 8950 8960 8970 8980
8990 9000
GTGGAAGCTGCGTTTACAACATGATGGGCAAGAGAGAGAAGAAACTTGGAGAGTTTGGCAAAGCAAAAGGCAGT-
AGAGCCATATGGTACATGTGGTTGGG
CysGlySerCysValTyrAsnMetMetGlyLysArgGluLysLysLeuGlyGluPheGlyLysAlaLysGlySe-
rArgAlaIleTrpTyrMetTrpLeuGly> 9010 9020 9030 9040 9050 9060 9070
9080 9090 9100
AGCCAGATACCTTGAGTTCGAAGCACTCGGATTCTTAAATGAAGACCATTGGTTCTCGCGTGAAAACTCTTACA-
GTGGAGTAGAAGGAGAAGGACTGCAC
AlaArgTyrLeuGluPheGluAlaLeuGlyPheLeuAsnGluAspHisTrpPheSerArgGluAsnSerTyrSe-
rGlyValGluGlyGluGlyLeuHis> 9110 9120 9130 9140 9150 9160 9170
9180 9190 9200
AAGCTGGGATACATCTTAAGAGACATTTCCAGATACCCGGAGGAGCTATGTATGCTGATGACACAGCTGGTTGG-
GACACAAGAATTAACAGAAGATGACC
LysLeuGlyTyrIleLeuArgAspIleSerLysIleProGlyGlyAlaMetTyrAlaAspAspThrAlaGlyTr-
pAspThrArgIleThrGluAspAsp> 9210 9220 9230 9240 9250 9260 9270
9280 9290 9300
TGCACAATGAGGAAAAAATCACACAGCAAATGGACCCTGAACACAGGCAGTTAGCAAACGCTATATTCAAGCTC-
ACATACCAAAACAAAGTGGTCAAAGT
LeuHisAsnGluGluLysIleThrGlnGlnMetAspProGluHisArgGlnLeuAlaAsnAlaIlePheLysLe-
uThrTyrGlnAsnLysValValLysVal> 9310 9320 9330 9340 9350 9360 9370
9380 9390 9400
TCAACGACCAACTCCAAAGGGCACGGTAATGGACATCATATCTAGGAAAGACCAAAGAGGCAGTGGACAGGTGG-
GAACTTATGGTCTGAATACATTCACC
GlnArgProThrProLysGlyThrValMetAspIleIleSerArgLysAspGlnArgGlySerGlyGlnValGl-
yThrTyrGlyLeuAsnThrPheThr> 9410 9420 9430 9440 9450 9460 9470
9480 9490 9500
AACATGGAAGCCCAGTTAATCAGACAAATGGAAGGAGAAGGTGTGTTGTCGAAGGCAGACCTCGAGAACCCTCA-
TCTGCTAGAGAAGAAAGTTACACAAT
AsnMetGluAlaGlnLeuIleArgGlnMetGluGlyGluGlyValLeuSerLysAlaAspLeuGluAsnProHi-
sLeuLeuGluLysLysValThrGln> 9510 9520 9530 9540 9550 9560 9570
9580 9590 9600
GGTTGGAAACAAAAGGAGTGGAGAGGTTAAAAAGAATGGCCATCAGCGGGGATGATTGCGTGGTGAAACCAATT-
GATGACAGGTTCGCCAATGCCCTGCT
TrpLeuGluThrLysGlyValGluArgLeuLysArgMetAlaIleSerGlyAspAspCysValValLysProIl-
eAspAspArgPheAlaAsnAlaLeuLeu> 9610 9620 9630 9640 9650 9660 9670
9680 9690 9700
TGCCCTGAATGACATGGGAAAAGTTAGGAAGGACATACCTCAATGGCAGCCATCAAAGGGATGGCATGATTGGC-
AACAGGTCCCTTTCTGCTCCCACCAC
AlaLeuAsnAspMetGlyLysValArgLysAspIleProGlnTrpGlnProSerLysGlyTrpHisAspTrpGL-
nGlnValProPheCysSerHisHis> 9710 9720 9730 9740 9750 9760 9770
9780 9790 9800
TTTCATGAATTGATCATGAAAGATGGAAGAAAGTTGGTAGTTCCCTGCAGACCTCAGGATGAATTAATCGGGAG-
AGCGAGAATCTCTCAAGGAGCAGGAT
PheHisGluLeuIleMetLysAspGlyArgLysLeuValValProCysArgProGlnAspGluLeuIleGlyAr-
gAlaArgIleSerGlnGlyAlaGly> 9810 9820 9830 9840 9850 9860 9870
9880 9890 9900
GGAGCCTTAGAGAAACTGCATGCCTAGGGAAAGCCTACGCCCAAATGTGGACTCTCATGTACTTTCACAGAAGA-
GATCTTAGACTAGCATCCAACGCCAT
TrpSerLeuArgGluThrAlaCysLeuGlyLysAlaTyrAlaGlnMetTrpThrLeuMetTyrPheHisArgAr-
gAspLeuArgLeuAlaSerAsnAlaIle> 9910 9920 9930 9940 9950 9960 9970
9980 9990 10000
ATGTTCAGCAGTACCAGTCCATTGGGTCCCCACAAGCAGAACGACGTGGTCTATTCATGCTCACCATCAGTGGA-
TGACTACAGAAGACATGCTTACTGTT
CysSerAlaValProValHisTrpValProThrSerArgThrThrTrpSerIleHisAlaHisHisGlnTrpMe-
tThrThrGluAspMetLeuThrVal> 10010 10020 10030 10040 10050 10060
10070 10080 10090 10100
TGGAACAGGGTGTGGATAGAGGATAATCCATGGATGGAAGACAAAACTCCAGTCAAAACCTGGGAAGATGTTCC-
ATATCTAGGGAAGAGAGAAGACCAAT
TrpAsnArgValTrpIleGluAspAsnProTrpMetGluAspLysThrProValLysThrTrpGluAspValPr-
oTyrLeuGlyLysArgGluAspGln> 10110 10120 10130 10140 10150 10160
10170 10180 10190 10200
GGTGCGGATCACTCATTGGTCTCACTTCCAGAGCAACCTGGGCCCAGAACATACTTACGGCAATCCAACAGGTG-
AGAAGCCTTATAGGCAATGAAGAGTT
TrpCysGlySerLeuIleGlyLeuThrSerArgAlaThrTrpAlaGlnAsnIleLeuThrAlaIleGlnGlnVa-
lArgSerLeuIleGlyAsnGluGluPhe> 10210 10220 10230 10240 10250
10260 10270 10280 10290 10300
TCTGGACTACATGCCTTCGATGAAGAGATTCAGGAAGGAGGAGGAGTCAGAGGGAGCCATTTGGTAAACGTAGG-
AAGTGAAAAAGAGGCAAACTGTCAGG
LeuAspTyrMetProSerMetLysArgPheArgLysGluGluGluSerGluGlyAlaIleTrp***>
10310 10320 10330 10340 10350 10360 10370 10380 10390 10400
CCACCTTAAGCCACAGTACGGAAGAAGCTGTGCAGCCTGTGAGCCCCGTCCAAGGACGTTAAAAGAAGAAGTCA-
GGCCCAAAAGCCACGGTTTGAGCAAA 10410 10420 10430 10440 10450 10460
10470 10480 10490 10500
CCGTGCTGCCTGTGGCTCCGTCGTGGGGACGTAAAACCTGGGAGGCTGCAAACTGTGGAAGCTGTACGCACGGT-
GTAGCAGACTAGCGGTTAGAGGAGAC 10510 10520 10530 10540 10550 10560
10570 10580 10590 10600
CCCTCCCATGACACAACGCAGCAGCGGGGCCCGAGCTCTGAGGGAAGCTGTACCTCCTTGCAAAGGACTAGAGG-
TTAGAGGAGACCCCCCGCAAATAAAA 10610 10620 10630 10640 10650 10660
10670 10680 10690 10700
ACAGCATATTGACGCTGGGAGAGACCAGAGATCCTGCTGTCTCCTCAGCATCATTCCAGGCACAGAACGCCAGA-
AAATGGAATGGTGCTGTTGAATCAAC 10710 10720 10730 10740 10750 10760
10770 10780 10790 10800
AGGTTCTGGTACCGGTAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAA-
CGATCAAGGCGAGTTACATGATCCCC 10810 10820 10830 10840 10850 10860
10870 10880 10890 10900
CATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTAT-
CACTCATGGTTATGGCAGCACTGCAT 10910 10920 10930 10940 10950 10960
10970 10980 10990 11000
AATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGA-
ATAGTGTATGCGGCGACCGAGTTGCT 11010 11020 11030 11040 11050 11060
11070 11080 11090 11100
CTTGCCCGGCGTCAACACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGT-
TCTTCGGGGCGAAAACTCTCAAGGAT 11110 11120 11130 11140 11150 11160
11170 11180 11190 11200
CTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCA-
CCAGCGTTTCTGGGTGAGCAAAAACA 11210 11220 11230 11240 11250 11260
11270 11280 11290 11300
GGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCA-
ATATTATTGAAGCATTTATCAGGGTT 11310 11320 11330 11340 11350 11360
11370 11380 11390 11400
ATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCC-
CGAAAAGTGCCACCTGACGTCTAAGA 11410 11420 11430 11440 11450 11460
11470 11480 11490 11500
AACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTCTTCAAGAATTCTCAT-
GTTTGACAGCTTATCATCGATAAGCT 11510 11520 11530 11540 11550 11560
11570 11580 11590 11600
TTAATGCGGTAGTTTATCACAGTTAAATTGCTAACGCAGTCAGGCACCGTGTATGAAATCTAACAATGCGCTCA-
TCGTCATCCTCGGCACCGTCACCCTG 11610 11620 11630 11640 11650 11660
11670 11680 11690 11700
GATGCTGTAGGCATAGGCTTGGTTATGCCGGTACTGCCGGGCCTCTTGCGGGATATCGTCCATTCCGACAGCAT-
CGCCAGTCACTATGGCGTGCTGCTGG 11710 11720 11730 11740 11750 11760
11770 11780 11790 11800
CGCTATATGCGTTGATGCAATTTCTATGCGCACCCGTTCTCGGAGCACTGTCCGACCGCTTTGGCCGCCGCCCA-
GTCCTGCTCGCTTCGCTACTTGGAGC 11810 11820 11830 11840 11850 11860
11870 11880 11890 11900
CACTATCGACTACGCGATCATGGCGACCACACCCGTCCTGTGGATCCTCTACGCCGGACGCATCGTGGCCGGCA-
TCACCGGCGCCACAGGTGCGGTTGCT 11910 11920 11930 11940 11950 11960
11970 11980 11990 12000
GGCGCCTATATCGCGACATCACCGATGGGGAAGATCGGGCTCGCCACTTCGGGCTCATGAGCGCTTGTTTCGGC-
GTGGGTATGGTTGGCAGGCCCCGTGG 12010 12020 12030 12040 12050 12060
12070 12080 12090 12100
CCGGGGGACTGTTGGGCGCCATCTCCTTGCATGCACCATTCCTTGCGGCGGCGGTGCTCAACGGCCTCAACCTA-
CTACTGGGCTGCTTCCTAATGCAGGA 12110 12120 12130 12140 12150 12160
12170 12180 12190 12200
GTCGCATAAGGGAGAGCGTCGACCGATGCCCTTGAGAGCCTTCAACCCAGTCAGCTCCTTCCGGTGGGCGCGGG-
GCATGACTATCGTCGCCGCACTTATG 12210 12220 12230 12240 12250 12260
12270 12280 12290 12300
ACTGTCTTCTTTATCATGCAACTCGTAGGACAGGTGCCGGCAGCGCTCTGGGTCATTTTCGGCGAGGACCGCTT-
TCGCTGGAGCGCGACGATGATCGGCC 12310 12320 12330 12340 12350 12360
12370 12380 12390 12400
TGTCGCTTGCGGTATTCGGAATCTTGCACGCCCTCGCTCAAGCCTTCGTCACTGGTCCCGCCACCAAACGTTCG-
GCGAGAAGCAGGCCATTATCGCCGG 12410 12420 12430 12440 12450 12460 12470
12480 12490 12500
CATGGCGGCCGACGCGCTGGGCTACGTCTTGCTGGCGTTCGCGACGCGAGGCTGGATGGCCTTCCCCATTATGA-
TTCTTCTCGCTTCCGGCGGCATCGGG 12510 12520 12530 12540 12550 12560
12570 12580 12590 12600
ATGCCCGCGTTGCAGGCCATGCTGTCCAGGCAGGTAGATGACGACCATCAGGGACAGCTTCAAGGATCGCTCGC-
GGCTCTTACCAGCCTAACTTCGATCA 12610 12620 12630 12640 12650 12660
12670 12680 12690 12700
CTGGACCGCTGATCGTCACGGCGATTTATGCCGCCTCGGCGAGCACATGGAACGGGTTGGCATGGATTGTAGGC-
GCCGCCCTATACCTTGTCTGCCTCCC 12710 12720 12730 12740 12750 12760
12770 12780 12790 12800
CGCGTTGCGTCGCGGTGCATGGAGCCGGGCCACCTCGACCTGAATGGAAGCCGGCGGCACCTCGCTAACGGATT-
CACCACTCCAAGAATTGGAGCCAATC 12810 12820 12830 12840 12850 12860
12870 12880 12890 12900
AATTCTTGCGGAGAACTGTGAATGCGCAAACCAACCCTTGGCAGAACATATCCATCGCGTCCGCCATCTCCAGC-
AGCCGCACGCGGCGCATCTCGGGCAG 12910 12920 12930 12940 12950 12960
12970 12980 12990 13000
CGTTGGGTCCTGGCCACGGGTGCGCATGATCGTGCTCCTGTCGTTGAGGACCCGGCTAGGCTGGCGGGGTTGCC-
TTACTGGTTAGCAGAATGAATCACCG 13010 13020 13030 13040 13050 13060
13070 13080 13090 13100
ATACGCGAGCGAACGTGAAGCGACTGCTGCTGCAAAACGTCTGCGACCTGAGCAACAACATGAATGGTCTTCGG-
TTTCCGTGTTTCGTAAAGTCTGGAAA 13110 13120 13130 13140 13150 13160
13170 13180 13190 13200
CGCGGAAGTCAGCGCCCTGCACCATTATGTTCCGGATCTGCATCGCAGGATGCTGCTGGCTACCCTGTGGAACA-
CCTACATCTGTATTAACGAAGCGCTG 13210 13220 13230 13240 13250 13260
13270 13280 13290 13300
GCATTGACCCTGAGTGATTTTTCTCTGGTCCCGCCGCATCCATACCGCCAGTTGTTTACCCTCACAACGTTCCA-
GTAACCGGGCATGTTCATCATCAGTA 13310 13320 13330 13340 13350 13360
13370 13380 13390 13400
ACCCGTATCGTGAGCATCCTCTCTCGTTTCATCGGTATCATTACCCCCATGAACAGAAATCCCCCTTACACGGA-
GGCATCAGTGACCAAACAGGAAAAAA 13410 13420 13430 13440 13450 13460
13470 13480 13490 13500
CCGCCCTTAACATGGCCCGCTTTATCAGAAGCCAGACATTAACGCTTCTGGAGAAACTCAACGAGCTGGACGCG-
GATGAACAGGCAGACATCTGTGAATC 13510 13520 13530 13540 13550 13560
13570 13580 13590 13600
GCTTCACGACCACGCTGATGAGCTTTACCGCAGCTGCCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGAC-
ACATGCAGCTCCCGGAGACGGTCACA 13610 13620 13630 13640 13650 13660
13670 13680 13690 13700
GCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGG-
CGCAGCCATGACCCAGTCACGTAGCG 13710 13720 13730 13740 13750 13760
13770 13780 13790 13800
ATAGCGGAGTGTATACTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATGCGGTGTG-
AAATACCGCACAGATGCGTAAGGAGA 13810 13820 13830 13840 13850 13860
13870 13880 13890 13900
AAATACCGCATCAGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGC-
GGTATCAGCTCACTCAAAGGCGGTAA 13910 13920 13930 13940 13950 13960
13970 13980 13990 14000
TACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAAC-
CGTAAAAAGGCCGCGTTGCTGGCGTT 14010 14020 14030 14040 14050 14060
14070 14080 14090 14100
TTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAG-
GACTATAAAGATACCAGGCGTTTCCC 14110 14120 14130 14140 14150 14160
14170 14180 14190 14200
CCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTC-
GGGAAGCGTGGCGCTTTCTCATAGCT 14210 14220 14230 14240 14250 14260
14270 14280 14290 14300
CACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAG-
CCCGACCGCTGCGCCTTATCCGGTAA 14310 14320 14330 14340 14350 14360
14370 14380 14390 14400
CTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCA-
GAGCGAGGTATGTAGGCGGTGCTACA 14410 14420 14430 14440 14450 14460
14470 14480 14490 14500
GAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCC-
AGTTACCTTCGGAAAAAGAGTTGGTA 14510 14520 14530 14540 14550 14560
14570 14580 14590 14600
GCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGA-
AAAAAAGGATCTCAAGAAGATCCTTT 14610 14620 14630 14640 14650 14660
14670 14680 14690 14700
GATCTTTTCTACGGGGTCTGACGCTCATTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAA-
AAAGGATCTTCACCTAGATCCTTTTA 14710 14720 14730 14740 14750 14760
14770 14780 14790 14800
AATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAAT-
CAGTGAGGCACCTATCTCAGCGATCT 14810 14820 14830 14840 14850 14860
14870 14880 14890 14900
GTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCT-
GGCCCCAGTGCTGCAATGATACCGCG 14910 14920 14930 14940 14950 14960
14970 14980 14990 15000
AGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTC-
CTGCAACTTTATCCGCCTCCATCCAG 15010 15020 15030 15040 15050 15060
15070 15080 15090 15100
TCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGC-
TGCAAGATCTGGCTAGCGATGACCCT 15110 15120 15130 15140 15150
GCTGATTGGTTCGCTGACCATTTCCGGGCGCGCCGATTTAGGTGACACTATAG Bases 1 to
10707: DEN3 virus genome cDNA Bases 95 to 10264: DEN3 polyprotein
ORF Bases 95 to 436: C protein ORF Bases 437 to 934: prM protein
ORF Bases 935 to 2413: E protein ORF Bases 2414 to 3469: NS1
protein ORF Bases 3470 to 4123: NS2A protein ORF Bases 4124 to
4513: NS2B protein ORF Bases 4514 to 6370: NS3 protein ORF Bases
6371 to 6751: NS4A protein ORF Bases 6752 to 6820: 2K protein ORF
Bases 6821 to 7564: NS4B protein ORF Bases 7575 to 10264 NS5
protein ORF
TABLE-US-00046 APPENDIX 3 Nucleotide and amino acid sequence of
DEN1 (Puerto Rico/94) CME chimeric region 10 20 30 40 50 60 70 80
90 100
AGTTGTTAGTCTGTGTGGACCGACAAGGACAGTTCCAAATCGGAAGCTTGCTTAACACAGTTCTAACAGTTTGT-
TTGAATAGAGAGCAGATCTCTGGAAA 110 120 130 140 150 160 170 180 190 200
AATGAACAACCAACGGAAAAAGACGGGTCGACCGTCTTTCAATATGCTGAAACGCGCGAGAAACCGCGTGTCAA-
CTGGTTCACAGTTGGCGAAGAGATTC
MetAsnAsnGlnArgLysLysThrGlyArgProSerPheAsnMetLeuLysArgAlaArgAsnArgValSerTh-
rGlySerGlnLeuAlaLysArgPhe> 210 220 230 240 250 260 270 280 290
300
TCAAAAGGATTGCTTTCAGGCCAAGGACCCATGAAATTGGTGATGGCTTTCATAGCATTTCTAAGATTTCTAGC-
CATACCCCCAACAGCAGGAATTTTGG
SerLysGlyLeuLeuSerGlyGlnGlyProMetLysLeuValMetAlaPheIleAlaPheLeuArgPheLeuAl-
aIleProProThrAlaGlyIleLeu> 310 320 330 340 350 360 370 380 390
400
CTAGATGGAGCTCATTCAAGAAGAATGGAGCGATCAAAGTGTTACGGGGTTTCAAAAAAGAGATCTCAAGCATG-
TTGAACATTATGAACAGGAGGAAAAA
AlaArgTrpSerSerPheLysLysAsnGlyAlaIleLysValLeuArgGlyPheLysLysGluIleSerSerMe-
tLeuAsnIleMetAsnArgArgLysLys> 410 420 430 440 450 460 470 480
490 500
ATCTGTGACCATGCTCCTCATGCTGCTGCCCACAGCCCTGGCGTTCCATTTGACCACACGAGGGGGAGAGCCAC-
ACATGATAGTTAGTAAGCAGGAAAGA
SerValThrMetLeuLeuMetLeuLeuProThrAlaLeuAlaPheHisLeuThrThrArgGlyGlyGluProHi-
sMetIleValSerLysGlnGluArg> 510 520 530 540 550 560 570 580 590
600
GGAAAGTCACTGTTGTTTAAGACCTCTGCAGGCATCAATATGTGCACTCTCATTGCGATGGATTTGGGAGAGTT-
ATGCGAGGACACAATGACCTACAAAT
GlyLysSerLeuLeuPheLysThrSerAlaGlyIleAsnMetCysThrLeuIleAlaMetAspLeuGlyGluLe-
uCysGluAspThrMetThrTyrLys> 610 620 630 640 650 660 670 680 690
700
GCCCCCGGATCACTGAGGCGGAACCAGATGACGTTGACTGCTGGTGCAATGCCACAGACACATGGGTGACCTAT-
GGGACGTGTTCTCAAACCGGCGAACA
CysProArgIleThrGluAlaGluProAspAspValAspCysTrpCysAsnAlaThrAspThrTrpValThrTy-
rGlyThrCysSerGlnThrGlyGluHis> 710 720 730 740 750 760 770 780
790 800
CCGACGAGACAAACGTTCCGTGGCACTGGCCCCACACGTGGGACTTGGTCTAGAAACAAGAACCGAAACATGGA-
TGTCCTCTGAAGGTGCCTGGAAACAA
ArgArgAspLysArgSerValAlaLeuAlaProHisValGlyLeuGlyLeuGluThrArgThrGluThrTrpMe-
tSerSerGluGlyAlaTrpLysGln> 810 820 830 840 850 860 870 880 890
900
GTACAAAAAGTGGAGACTTGGGCTTTGAGACACCCAGGATTCACGGTGACAGCCCTTTTTTTAGCACATGCCAT-
AGGAACATCCATTACTCAGAAAGGGA
ValGlnLysValGluThrTrpAlaLeuArgHisProGlyPheThrValThrAlaLeuPheLeuAlaHisAlaIl-
eGlyThrSerIleThrGlnLysGly> 910 920 930 940 950 960 970 980 990
1000
TCATTTTCATTCTGCTGATGCTAGTAACACCATCAATGGCCATGCGATGTGTGGGAATAGGCAACAGAGACTTC-
GTTGAAGGACTGTCAGGAGCAACGTG
IleIlePheIleLeuLeuMetLeuValThrProSerMetAlaMetArgCysValGlyIleGlyAsnArgAspPh-
eValGluGlyLeuSerGlyAlaThrTrp> 1010 1020 1030 1040 1050 1060 1070
1080 1090 1100
GGTGGACGTGGTATTGGAGCATGGAAGCTGCGTCACCACCATGGCAAAAGATAAACCAACATTGGACATTGAAC-
TCTTGAAGACGGAGGTCACAAACCCT
ValAspValValLeuGluHisGlySerCysValThrThrMetAlaLysAspLysProThrLeuAspIleGluLe-
uLeuLysThrGluValThrAsnPro> 1110 1120 1130 1140 1150 1160 1170
1180 1190 1200
GCCGTCTTGCGCAAACTGTGCATTGAAGCTAAAATATCAAACACCACCACCGATTCAAGGTGTCCAACACAAGG-
AGAGGCTACACTGGTGGAAGAACAGG
AlaValLeuArgLysLeuCysIleGluAlaLysIleSerAsnThrThrThrAspSerArgCysProThrGlnGl-
yGluAlaThrLeuValGluGluGln> 1210 1220 1230 1240 1250 1260 1270
1280 1290 1300
ACTCGAACTTTGTGTGTCGACGAACGTTTGTGGACAGAGGCTGGGGTAATGGCTGCGGACTATTTGGAAAAGGA-
AGCCTACTGACGTGTGCTAAGTTCAA
AspSerAsnPheValCysArgArgThrPheValAspArgGlyTrpGlyAsnGlyCysGlyLeuPheGlyLysGl-
ySerLeuLeuThrCysAlaLysPheLys> 1310 1320 1330 1340 1350 1360 1370
1380 1390 1400
GTGTGTGACAAAACTAGAAGGAAAGATAGTTCAATATGAAAACTTAAAATATTCAGTGATAGTCACTGTCCACA-
CTGGGGACCAGCACCAGGTGGGAAAC
CysValThrLysLeuGluGlyLysIleValGlnTyrGluAsnLeuLysTyrSerValIleValThrValHisTh-
rGlyAspGlnHisGlnValGlyAsn> 1410 1420 1430 1440 1450 1460 1470
1480 1490 1500
GAGACTACAGAACATGGAACAATTGCAACCATAACACCTCAAGCTCCTACGTCGGAAATACAGCTGACTGACTA-
CGGAGCCCTCACATTGGACTGCTCGC
GluThrThrGluHisGlyThrIleAlaThrIleThrProGlnAlaProThrSerGluIleGlnLeuThrAspTy-
rGlyAlaLeuThrLeuAspCysSer> 1510 1520 1530 1540 1550 1560 1570
1580 1590 1600
CTAGAACAGGGCTGGACTTTAATGAGATGGTTCTATTGACAATGAAAGAAAAATCATGGCTTGTCCACAAACAA-
TGGTTTCTAGACTTACCACTGCCTTG
ProArgThrGlyLeuAspPheAsnGluMetValLeuLeuThrMetLysGluLysSerTrpLeuValHisLysGl-
nTrpPheLeuAspLeuProLeuProTrp> 1610 1620 1630 1640 1650 1660 1670
1680 1690 1700
GACTTCAGGAGCTTCAACATCTCAAGAGACTTGGAACAGACAAGATTTGCTGGTCACATTCAAGACAGCTCATG-
CAAAGAAACAGGAAGTAGTCGTACTG
ThrSerGlyAlaSerThrSerGlnGluThrTrpAsnArgGlnAspLeuLeuValThrPheLysThrAlaHisAl-
aLysLysGlnGluValValValLeu> 1710 1720 1730 1740 1750 1760 1770
1780 1790 1800
GGATCACAGGAAGGAGCAATGCACACTGCGTTGACTGGGGCGACAGAAATCCAGACGTCAGGAACGACAACAAT-
CTTTGCAGGACACCTGAAATGCAGAC
GlySerGlnGluGlyAlaMetHisThrAlaLeuThrGlyAlaThrGluIleGlnThrSerGlyThrThrThrIl-
ePheAlaGlyHisLeuLysCysArg> 1810 1820 1830 1840 1850 1860 1870
1880 1890 1900
TAAAAATGGATAAACTGACTTTAAAAGGGAGTCATATGTAATGTGCACAGGCTCATTTAAGCTAGAGAAGGAAG-
TGGCTGAGACCCAGCATGGAACTGT
LeuLysMetAspLysLeuThrLeuLysGlyMetSerTyrValMetCysThrGlySerPheLysLeuGluLysGl-
uValAlaGluThrGlnHisGlyThrVal> 1910 1920 1930 1940 1950 1960 1970
1980 1990 2000
TTTAGTGCAGGTTAAATACGAAGGAACAGATGCGCCATGCAAGATCCCTTTTTCGGCCCAAGATGAGAAAGGAG-
TGACCCAGAATGGGAGATTGATAACA
LeuValGlnValLysTyrGluGlyThrAspAlaProCysLysIleProPheSerAlaGlnAspGluLysGlyVa-
lThrGlnAsnGlyArgLeuIleThr> 2010 2020 2030 2040 2050 2060 2070
2080 2090 2100
GCCAACCCCATAGTCACTGACAAAGAAAAACCAGTCAACATTGAGACAGAACCACCTTTTGGTGAGAGCTACAT-
CGTGGTAGGGGCAGGTGAAAAAGCTT
AlaAsnProIleValThrAspLysGluLysProValAsnIleGluThrGluProProPheGlyGluSerTyrIl-
eValValGlyAlaGlyGluLysAla> 2110 2120 2130 2140 2150 2160 2170
2180 2190 2200
TGAAACTGAGCTGGTTCAAGAAAGGGAGCAGCATAGGGAAAATGTTCGAAGCAACTGCCCGAGGAGCGCGAAGG-
ATGGCTATCCTGGGAGACACCGCATG
LeuLysLeuSerTrpPheLysLysGlySerSerIleGlyLysMetPheGluAlaThrAlaArgGlyAlaArgAr-
gMetAlaIleLeuGlyAspThrAlaTrp> 2210 2220 2230 2240 2250 2260 2270
2280 2290 2300
GGACTTTGGCTCTATAGGAGGAGTGTTCACATCAGTGGGAAAATTGGTACACCAGGTTTTTGGAGCCGCATATG-
GGGTTCTGTTCAGCGGTGTTTCTTGG
AspPheGlySerIleGlyGlyValPheThrSerValGlyLysLeuValHisGlnValPheGlyAlaAlaTyrGl-
yValLeuPheSerGlyValSerTyr> 2310 2320 2330 2340 2350 2360 2370
2380 2390 2400
ACCATGAAAATAGGAATAGGGATTCTGCTGACATGGCTAGGATTAAACTCGAGGAACACTTCAATGGCTATGAC-
GTGCATAGCTGTTGGAGGAATCACTC
ThrMetLysIleGlyIleGlyIleLeuLeuThrTrpLeuGlyLeuAsnSerArgAsnThrSerMetAlaMetTh-
rCysIleAlaValGlyGlyIleThr> 2410 2420 TGTTTCTGGGCTTCACAGTTCAAGCA
LeuPheLeuGlyPheThrValGlnAla> Bases 1 to 88 (BglII): DEN4 Bases
89 (BglII) to 2348 (XhoI): DEN1 Bases 2349 (XhoI) to 2426: DEN4
Bases 102 to 443: C protein ORF Bases 444 to 941: prM protein ORF
Bases 942 to 2426: E protein ORF
TABLE-US-00047 APPENDIX 4 Nucleotide and amino acid sequence of
DEN1 (Puerto Rico/94) ME chimeric region 10 20 30 40 50 60 70 80 90
100
AGTTGTTAGTCTGTGTGGACCGACAAGGACAGTTCCAAATCGGAAGCTTGCTTAACACAGTTCTAACAGTTTGT-
TTGAATAGAGAGCAGATCTCTGGAAA 110 120 130 140 150 160 170 180 190 200
AATGAACCAACGAAAAAAGGTGGTTAGACCACCTTTCAATATGCTGAAACGCGAGAGAAACCGCGTATCAACCC-
CTCAAGGGTTGGTGAAGAGATTCTCA
MetAsnGlnArgLysLysValValArgProProPheAsnMetLeuLysArgGluArgAsnArgValSerThrPr-
oGlnGlyLeuValLysArgPheSer> 210 220 230 240 250 260 270 280 290
300
ACCGGACTTTTTTCTGGGAAAGGACCCTTACGGATGGTGCTAGCATTCATCACGTTTTTGCGAGTCCTTTCCAT-
CCCACCAACAGCAGGGATTCTGAAGA
ThrGlyLeuPheSerGlyLysGlyProLeuArgMetValLeuAlaPheIleThrPheLeuArgValLeuSerIl-
eProProThrAlaGlyIleLeuLys> 310 320 330 340 350 360 370 380 390
400
GATGGGGACAGTTGAAGAAAAATAAGGCCATCAAGATACTGATTGGATTCAGGAAGGAGATAGGCCGCATGCTG-
AACATCTTGAACGGGAGAAAAAGGTC
ArgTrpGlyGlnLeuLysLysAsnLysAlaIleLysIleLeuIleGlyPheArgLysGluIleGlyArgMetLe-
uAsnIleLeuAsnGlyArgLysArgSer> 410 420 430 440 450 460 470 480
490 500
TGCAGCCATGCTCCTCATGCTGCTGCCCACAGCCCTGGCGTTCCATTTGACCACACGAGGGGGAGAGCCACACA-
TGATAGTTAGTAAGCAGGAAAGAGGA
AlaAlaMetLeuLeuMetLeuLeuProThrAlaLeuAlaPheHisLeuThrThrArgGlyGlyGluProHisMe-
tIleValSerLysGlnGluArgGly> 510 520 530 540 550 560 570 580 590
600
AAGTCACTGTTGTTTAAGACCTCTGCAGGCATCAATATGTGCACTCTCATTGCGATGGATTTGGGAGAGTTATG-
CGAGGACACAATGACCTACAAATGCC
LysSerLeuLeuPheLysThrSerAlaGlyIleAsnMetCysThrLeuIleAlaMetAspLeuGlyGluLeuCy-
sGluAspThrMetThrTyrLysCys> 610 620 630 640 650 660 670 680 690
700
CCCGGATCACTGAGGCGGAACCAGATGACGTTGACTGCTGGTGCAATGCCACAGACACATGGGTGACCTATGGG-
ACGTGTTCTCAAACCGGCGAACACCG
ProArgIleThrGluAlaGluProAspAspValAspCysTrpCysAsnAlaThrAspThrTrpValThrTyrGl-
yThrCysSerGlnThrGlyGluHisArg> 710 720 730 740 750 760 770 780
790 800
ACGAGACAAACGTTCCGTGGCACTGGCCCCACACGTGGGACTTGGTCTAGAAACAAGAACCGAAACATGGATGT-
CCTCTGAAGGTGCCTGGAAACAAGTA
ArgAspLysArgSerValAlaLeuAlaProHisValGlyLeuGlyLeuGluThrArgThrGluThrTrpMetSe-
rSerGluGlyAlaTrpLysGlnVal> 810 820 830 840 850 860 870 880 890
900
CAAAAAGTGGAGACTTGGGCTTTGAGACACCCAGGATTCACGGTGACAGCCCTTTTTTTAGCACATGCCATAGG-
AACATCCATTACTCAGAAAGGGATCA
GlnLysValGluThrTrpAlaLeuArgHisProGlyPheThrValThrAlaLeuPheLeuAlaHisAlaIleGl-
yThrSerIleThrGlnLysGlyIle> 910 920 930 940 950 960 970 980 990
1000
TTTTCATTCTGCTGATGCTAGTAACACCATCAATGGCCATGCGATGTGTGGGAATAGGCAACAGAGACTTCGTT-
GAAGGACTGTCAGGAGCAACGTGGGT
IlePheIleLeuLeuMetLeuValThrProSerMetAlaMetArgCysValGlyIleGlyAsnArgAspPheVa-
lGluGlyLeuSerGlyAlaThrTrpVal> 1010 1020 1030 1040 1050 1060 1070
1080 1090 1100
GGACGTGGTATTGGAGCATGGAAGCTGCGTCACCACCATGGCAAAAGATAAACCAACATTGGACATTGAACTCT-
TGAAGACGGAGGTCACAAACCCTGCC
AspValValLeuGluHisGlySerCysValThrThrMetAlaLysAspLysProThrLeuAspIleGluLeuLe-
uLysThrGluValThrAsnProAla> 1110 1120 1130 1140 1150 1160 1170
1180 1190 1200
GTCTTGCGCAAACTGTGCATTGAAGCTAAAATATCAAACACCACCACCGATTCAAGGTGTCCAACACAAGGAGA-
GGCTACACTGGTGGAAGAACAGGACT
ValLeuArgLysLeuCysIleGluAlaLysIleSerAsnThrThrThrAspSerArgCysProThrGlnGlyGl-
uAlaThrLeuValGluGluGlnAsp> 1210 1220 1230 1240 1250 1260 1270
1280 1290 1300
CGAACTTTGTGTGTCGACGAACGTTTGTGGACAGAGGCTGGGGTAATGGCTGCGGACTATTTGGAAAAGGAAGC-
CTACTGACGTGTGCTAAGTTCAAGTG
SerAsnPheValCysArgArgThrPheValAspArgGlyTrpGlyAsnGlyCysGlyLeuPheGlyLysGlySe-
rLeuLeuThrCysAlaLysPheLysCys> 1310 1320 1330 1340 1350 1360 1370
1380 1390 1400
TGTGACAAAACTAGAAGGAAAGATAGTTCAATATGAAAACTTAAAATATTCAGTGATAGTCACTGTCCACACTG-
GGGACCAGCACCAGGTGGGAAACGAG
ValThrLysLeuGluGlyLysIleValGlnTyrGluAsnLeuLysTyrSerValIleValThrValHisThrGl-
yAspGlnHisGlnValGlyAsnGlu> 1410 1420 1430 1440 1450 1460 1470
1480 1490 1500
ACTACAGAACATGGAACAATTGCAACCATAACACCTCAAGCTCCTACGTCGGAAATACAGCTGACTGACTACGG-
AGCCCTCACATTGGACTGCTCGCCTA
ThrThrGluHisGlyThrIleAlaThrIleThrProGlnAlaProThrSerGluIleGlnLeuThrAspTyrGl-
yAlaLeuThrLeuAspCysSerPro> 1510 1520 1530 1540 1550 1560 1570
1580 1590 1600
GAACAGGGCTGGACTTTAATGAGATGGTTCTATTGACAATGAAAGAAAAATCATGGCTTGTCCACAAACAATGG-
TTTCTAGACTTACCACTGCCTTGGAC
ArgThrGlyLeuAspPheAsnGluMetValLeuLeuThrMetLysGluLysSerTrpLeuValHisLysGlnTr-
pPheLeuAspLeuProLeuProTrpThr> 1610 1620 1630 1640 1650 1660 1670
1680 1690 1700
TTCAGGAGCTTCAACATCTCAAGAGACTTGGAACAGACAAGATTTGCTGGTCACATTCAAGACAGCTCATGCAA-
AGAAACAGGAAGTAGTCGTACTGGGA
SerGlyAlaSerThrSerGlnGluThrTrpAsnArgGlnAspLeuLeuValThrPheLysThrAlaHisAlaLy-
sLysGlnGluValValValLeuGly> 1710 1720 1730 1740 1750 1760 1770
1780 1790 1800
TCACAGGAAGGAGCAATGCACACTGCGTTGACTGGGGCGACAGAAATCCAGACGTCAGGAACGACAACAATCTT-
TGCAGGACACCTGAAATGCAGACTAA
SerGlnGluGlyAlaMetHisThrAlaLeuThrGlyAlaThrGluIleGlnThrSerGlyThrThrThrIlePh-
eAlaGlyHisLeuLysCysArgLeu> 1810 1820 1830 1840 1850 1860 1870
1880 1890 1900
AAATGGATAAACTGACTTTAAAAGGGATGTCATATGTAATGTGCACAGGCTCATTTAAGCTAGAGAAGGAAGTG-
GCTGAGACCCAGCATGGAACTGTTTT
LysMetAspLysLeuThrLeuLysGlyMetSerTyrValMetCysThrGlySerPheLysLeuGluLysGluVa-
lAlaGluThrGlnHisGlyThrValLeu> 1910 1920 1930 1940 1950 1960 1970
1980 1990 2000
AGTGCAGGTTAAATACGAAGGAACAGATGCGCCATGCAAGATCCCTTTTTCGGCCCAAGATGAGAAAGGAGTGA-
CCCAGAATGGGAGATTGATAACAGCC
ValGlnValLysTyrGluGlyThrAspAlaProCysLysIleProPheSerAlaGlnAspGluLysGlyValTh-
rGlnAsnGlyArgLeuIleThrAla> 2010 2020 2030 2040 2050 2060 2070
2080 2090 2100
AACCCCATAGTCACTGACAAAGAAAAACCAGTCAACATTGAGACAGAACCACCTTTTGGTGAGAGCTACATCGT-
GGTAGGGGCAGGTGAAAAAGCTTTGA
AsnProIleValThrAspLysGluLysProValAsnIleGluThrGluProProPheGlyGluSerTyrIleVa-
lValGlyAlaGlyGluLysAlaLeu> 2110 2120 2130 2140 2150 2160 2170
2180 2190 2200
AACTGAGCTGGTTCAAGAAAGGGAGCAGCATAGGGAAAATGTTCGAAGCAACTGCCCGAGGAGCGCGAAGGATG-
GCTATCCTGGGAGACACCGCATGGGA
LysLeuSerTrpPheLysLysGlySerSerIleGlyLysMetPheGluAlaThrAlaArgGlyAlaArgArgMe-
tAlaIleLeuGlyAspThrAlaTrpAsp> 2210 2220 2230 2240 2250 2260 2270
2280 2290 2300
CTTTGGCTCTATAGGAGGAGTGTTCACATCAGTGGGAAAATTGGTACACCAGGTTTTTGGAGCCGCATATGGGG-
TTCTGTTCAGCGGTGTTTCTTGGACC
PheGlySerIleGlyGlyValPheThrSerValGlyLysLeuValHisGlnValPheGlyAlaAlaTyrGlyVa-
lLeuPheSerGlyValSerTrpThr> 2310 2320 2330 2340 2350 2360 2370
2380 2390 2400
ATGAAAATAGGAATAGGGATTCTGCTGACATGGCTAGGATTAAACTCGAGGAACACTTCAATGGCTATGACGTG-
CATAGCTGTTGGAGGAATCACTCTGT
MetLysIleGlyIleGlyIleLeuLeuThrTrpLeuGlyLeuAsnSerArgAsnThrSerMetAlaMetThrCy-
sIleAlaValGlyGlyIleThrLeu> 2410 2420 TTCTGGGCTTCACAGTTCAAGCA
PheLeuGlyPheThrValGlnAla Bases 1 to 404 (PstI): DEN4 Bases 405
(PstI) to 2345 (XhoI): DEN1 Bases 2346 (XhoI) to 2423: DEN4 Bases
102 to 440: C protein ORF Bases 441 to 938: prM protein ORF Bases
939 to 2423: E protein ORF
While the present invention has been described in some detail for
purposes of clarity and understanding, one skilled in the art will
appreciate that various changes in form and detail can be made
without departing from the true scope of the invention. All
figures, tables, appendices, patents, patent applications and
publications, referred to above, are hereby incorporated by
reference.
SEQUENCE LISTINGS
1
53182RNADengue 1 virus 1gcagcagcgg ggcccaacac caggggaagc uguacccugg
ugguaaggac uagagguuag 60aggagacccc ccgcaacaac aa 82284RNADengue 2
virus 2agcaacaaug ggggcccaag gugagaugaa gcuguagucu cacuggaagg
acuagagguu 60agaggagacc cccccaaaac aaaa 84383RNADengue 3 virus
3gcagcagcgg ggcccgagcu cugagggaag cuguaccucc uugcaaagga cuagagguua
60gaggagaccc cccgcaaaua aaa 83483RNADengue 4 virus 4agcaaaaggg
ggcccgaagc caggaggaag cuguacuccu gguggaagga cuagagguua 60gaggagaccc
ccccaacaca aaa 83516RNAArtificial SequenceDengue 1 delta 30
5ggggcccaag acuaga 16616RNAArtificial SequenceDengue 2 delta 30
6ggggcccaag acuaga 16716RNAArtificial SequenceDengue 3 delta 30
7ggggcccaag acuaga 16816RNAArtificial SequenceDengue 4 delta 30
8ggggcccaag acuaga 16951DNAArtificial SequenceTL2 region of p2
plasmid 9tgggggccca aggtgagatg aagctgtagt ctcactggaa ggactagagg t
511021DNAArtificial SequenceTL2 region of p2 delta 30 10tgggggccca
agactagagg t 211151DNAArtificial SequenceTL2 region of p3 plasmid
11cggggcccga gctctgaggg aagctgtacc tccttgcaaa ggactagagg t
511220DNAArtificial SequenceTL2 region of p3 delta 30 12gggggcccaa
gactagaggt 201329DNAArtificial SequenceSpe1 linker in p3
13actagttaga ctaacttaag tcaactagt 291451DNAArtificial
SequencerDEN2/4 junction 1 14cagtttgttt gaatagagag cagatctctg
atgaataacc aacgaaaaaa g 51157PRTArtificial SequencerDEN2/4 junction
1 15Met Asn Asn Gln Arg Lys Lys 1 51651DNAArtificial
SequencerDEN2/4 junction 2 16attatcacat ggataggaat gaactcgagg
aacacttcaa tggctatgac g 511717PRTArtificial SequencerDEN2/4
junction 2 17Ile Ile Thr Trp Ile Gly Met Asn Ser Arg Asn Thr Ser
Met Ala Met 1 5 10 15Thr1851DNAArtificial SequencerDEN2/4 junction
3 18atcttgaacg ggagaaaaag gtctgcaggc atgatcatta tgctgattcc a
511917PRTArtificial SequencerDEN2/4 junction 3 19Ile Leu Asn Gly
Arg Lys Arg Ser Ala Gly Met Ile Ile Met Leu Ile 1 5 10
15Pro2050DNAArtificial SequencerDEN3/4 junction 1 20cagtttgttt
gaatagagag cagatctctg gaaaaatgaa caaccaacgg 50215PRTArtificial
SequencerDEN3/4 junction 1 21Met Asn Asn Gln Arg 1
52251DNAArtificial SequencerDEN3/4 junction 2 22cttttaacct
ggatagggtt gaactcgagg aacacttcaa tggctatgac g 512317PRTArtificial
SequencerDEN3/4 junction 2 23Leu Leu Thr Trp Ile Gly Leu Asn Ser
Arg Asn Thr Ser Met Ala Met 1 5 10 15Thr2451DNAArtificial
SequencerDEN3/4 junction 3 24atcttgaacg ggagaaaaag gtctgcagtc
tgtctcatga tgatgttacc a 512517PRTArtificial SequencerDEN3/4
junction 3 25Ile Leu Asn Gly Arg Lys Arg Ser Ala Val Cys Leu Met
Met Met Leu 1 5 10 15Pro2650DNAArtificial SequencerDEN1/4 junction
1 26cagtttgttt gaatagagag cagatctctg gaaaaatgaa caaccaacgg
50275PRTArtificial SequencerDEN1/4 junction 1 27Met Asn Asn Gln Arg
1 52851DNAArtificial SequencerDEN1/4 junction 2 28ctgctgacat
ggctaggatt aaactcgagg aacacttcaa tggctatgac g 512917PRTArtificial
SequencerDEN1/4 junction 2 29Leu Leu Thr Trp Leu Gly Leu Asn Ser
Arg Asn Thr Ser Met Ala Met 1 5 10 15Thr3051DNAArtificial
SequencerDEN1/4 junction 3 30atcttgaacg ggagaaaaag gtctgcagcc
atgctcctca tgctgctgcc c 513117PRTArtificial SequencerDEN1/4
junction 3 31Ile Leu Asn Gly Arg Lys Arg Ser Ala Ala Met Leu Leu
Met Leu Leu 1 5 10 15Pro3260RNADengue 4 virus 32ccaacaaccu
ugacagcauc cuuagucaug cuuuuagucc auuaugcaau aauaggccca
603320PRTDengue 4 virus 33Pro Thr Thr Leu Thr Ala Ser Leu Val Met
Leu Leu Val His Thr Ala 1 5 10 15Ile Ile Gly Pro 203460RNADengue 1
virus 34ccgcugacgc ugacagcggc gguauuuaug cuaguggcuc auuaugccau
aauuggaccc 603520PRTDengue 1 virus 35Pro Leu Thr Leu Thr Ala Ala
Val Pro Met Leu Val Ala His Thr Ala 1 5 10 15Ile Ile Gly Pro
203660RNADengue 2 virus 36ccuauaaccc ucacagcggc ucuucuuuua
uugguagcac auuaugccau cauaggaccg 603720PRTDengue 2 virus 37Pro Ile
Thr Leu Thr Ala Ala Leu Leu Leu Leu Val Ala His Thr Ala 1 5 10
15Ile Ile Gly Pro 203860RNADengue 3 virus 38ccacuaacuc ucacagcggc
aguucuccug cuagucacgc auuaugcuau uauaggucca 603920PRTDengue 3 virus
39Pro Leu Thr Leu Thr Ala Ala Val Leu Leu Leu Val Thr His Thr Ala 1
5 10 15Ile Ile Gly Pro 204013DNAArtificial Sequenceprimer
40ccacgggcgc cgt 134110DNAArtificial Sequenceprimer 41aaggcctgga
104212DNAArtificial Sequenceprimer 42tatccccggg ac
124311DNAArtificial Sequenceprimer 43agagctctct c
114415DNAArtificial Sequenceprimer 44gaatctccac ccgga
154510DNAArtificial Sequenceprimer 45ctgtcgaatc
104615159DNAArtificial SequenceDengue 2 plasmid p2 46agttgttagt
ctacgtggac cgacaaagac agattctttg agggagctaa gctcaacgta 60gttctaactg
ttttttgatt agagagcaga tctctgatga ataaccaacg gaaaaaggcg
120agaaacacgc ctttcaatat gctgaaacgc gagagaaacc gcgtgtcaac
tgtacaacag 180ttgacaaaga gattctcact tggaatgctg cagggacgag
gaccactaaa attgttcatg 240gccctggtgg cattccttcg tttcctaaca
atcccaccaa cagcagggat attaaaaaga 300tggggaacaa ttaaaaaatc
aaaggctatt aatgttctga gaggcttcag gaaagagatt 360ggaaggatgc
tgaatatctt aaacaggaga cgtagaactg taggcatgat catcatgctg
420actccaacag tgatggcgtt tcatctgacc acacgcaacg gagaaccaca
catgattgtc 480agtagacaag aaaaagggaa aagccttctg ttcaagacaa
aggatggcac gaacatgtgt 540accctcatgg ccatggacct tggtgagttg
tgtgaagaca caatcacgta taaatgtcct 600tttctcaagc agaacgaacc
agaagacata gattgttggt gcaactccac gtccacatgg 660gtaacttatg
ggacatgtac caccacagga gagcacagaa gagaaaaaag atcagtggcg
720cttgttccac acgtgggaat gggattggag acacgaactg aaacatggat
gtcatcagaa 780ggggcctgga aacatgccca gagaattgaa acttggattc
tgagacatcc aggctttacc 840ataatggccg caatcctggc atacaccata
gggacgacgc atttccaaag agtcctgata 900ttcatcctac tgacagccat
cgctccttca atgacaatgc gctgcatagg aatatcaaat 960agggactttg
tggaaggagt gtcaggaggg agttgggttg acatagtttt agaacatgga
1020agttgtgtga cgacgatggc aaaaaacaaa ccaacactgg actttgaact
gataaaaaca 1080gaagccaaac aacctgccac cttaaggaag tactgtatag
aggccaaact gaccaacacg 1140acaacagact cgcgctgccc aacacaaggg
gaacccaccc tgaatgaaga gcaggacaaa 1200aggtttgtct gcaaacattc
catggtagac agaggatggg gaaatggatg tggattgttt 1260ggaaaaggag
gcatcgtgac ctgtgctatg ttcacatgca aaaagaacat ggaaggaaaa
1320attgtgcagc cagaaaacct ggaatacact gtcgtgataa cacctcattc
aggggaagaa 1380catgcagtgg gaaatgacac aggaaaacat ggtaaagaag
tcaagataac accacagagc 1440tccatcacag aggcggaact gacaggctat
ggcactgtta cgatggagtg ctctccaaga 1500acgggcctcg acttcaatga
gatggtgttg ctgcaaatgg aagacaaagc ctggctggtg 1560cacagacaat
ggttcctaga cctaccgttg ccatggctgc ccggagcaga cacacaagga
1620tcaaattgga tacagaaaga aacactggtc accttcaaaa atccccatgc
gaaaaaacag 1680gatgttgttg tcttaggatc ccaagagggg gccatgcata
cagcactcac aggggctacg 1740gaaatccaga tgtcatcagg aaacctgctg
ttcacaggac atctcaagtg caggctgaga 1800atggacaaat tacaacttaa
agggatgtca tactccatgt gcacaggaaa gtttaaaatt 1860gtgaaggaaa
tagcagaaac acaacatgga acaatagtca ttagagtaca atatgaagga
1920gacggctctc catgcaagat cccctttgag ataatggatc tggaaaaaag
acatgttttg 1980ggccgcctga tcacagtcaa cccaattgta acagaaaagg
acagtccagt caacatagaa 2040gcagaacctc cattcggaga cagctacatc
atcataggag tggaaccagg acaattgaag 2100ctggactggt tcaagaaagg
aagttccatc ggccaaatgt ttgagacaac aatgagggga 2160gcgaaaagaa
tggccatttt gggtgacaca gcctgggatt ttggatctct gggaggagtg
2220ttcacatcaa taggaaaggc tctccaccag gtttttggag caatctacgg
ggctgctttc 2280agtggggtct catggactat gaagatcctc ataggagtta
tcatcacatg gataggaatg 2340aactcacgta gcactagtct gagcgtgtca
ctggtgttag tgggaatcgt gacactttac 2400ttgggagtta tggtgcaggc
cgatagtggt tgcgttgtga gctggaagaa caaagaacta 2460aaatgtggca
gtggaatatt cgtcacagat aacgtgcata catggacaga acaatacaag
2520ttccaaccag aatccccttc aaaactggcc tcagccatcc agaaagcgca
tgaagagggc 2580atctgtggaa tccgctcagt aacaagactg gaaaatctta
tgtggaaaca gataacatca 2640gaattgaatc atattctatc agaaaatgaa
gtgaaactga ccatcatgac aggagacatc 2700aaaggaatca tgcaggtagg
aaaacgatct ttgcggcctc aacccactga gttgaggtat 2760tcatggaaaa
catggggtaa agcgaaaatg ctctccacag aactccacaa tcagaccttc
2820ctcattgatg gtcccgaaac agcagaatgc cccaacacaa acagagcttg
gaattcactg 2880gaagttgagg actacggctt tggagtattc actaccaata
tatggctaag attgagagaa 2940aagcaggatg tattttgtga ctcaaaactc
atgtcagcgg ccataaagga caacagagcc 3000gtccatgctg atatgggtta
ttggatagaa agcgcactca atgatacatg gaagatagag 3060aaagcttctt
tcattgaagt caaaagttgc cactggccaa agtcacacac cctatggagt
3120aatggagtgc tagaaagcga gatggtcatt ccaaagaatt tcgctggacc
agtgtcacaa 3180cataataaca gaccaggcta ttacacacaa acagcaggac
cttggcatct aggcaagctt 3240gagatggact ttgatttctg cgaagggact
acagtggtgg taaccgagaa ctgtggaaac 3300agagggccct ctttaagaac
aaccactgcc tcaggaaaac tcataacgga atggtgttgt 3360cgatcttgca
cactaccacc actaagatac agaggtgagg atggatgttg gtacgggatg
3420gaaatcagac cattgaaaga gaaagaagaa aatctggtca gttctctggt
tacagccgga 3480catgggcaga ttgacaattt ctcattagga atcttgggaa
tggcactgtt ccttgaagaa 3540atgctcagga ctcgagtagg aacaaaacat
gcaatattac tcgtcgcagt ttctttcgtg 3600acgctaatca cagggaacat
gtcttttaga gacctgggaa gagtgatggt tatggtgggt 3660gccaccatga
cagatgacat aggcatgggt gtgacttatc tcgctctact agcagctttt
3720agagtcagac caacctttgc agctggactg ctcttgagaa aactgacctc
caaggaatta 3780atgatgacta ccataggaat cgttcttctc tcccagagta
gcataccaga gaccattctt 3840gaactgaccg acgcgttagc tctaggcatg
atggtcctca agatggtgag aaacatggaa 3900aaatatcagc tggcagtgac
catcatggct attttgtgcg tcccaaatgc tgtgatatta 3960cagaacgcat
ggaaagtgag ttgcacaata ttggcagtgg tgtctgtttc ccccctgctc
4020ttaacatcct cacaacagaa agcggactgg ataccattag cgttgacgat
caaaggtctt 4080aatccaacag ccatttttct aacaaccctc tcaagaacca
acaagaaaag gagctggcct 4140ttaaatgagg ccatcatggc ggttgggatg
gtgagtatct tggccagctc tctcttaaag 4200aatgacatcc ccatgacagg
accattagtg gctggagggc tccttactgt gtgctacgtg 4260ctaactgggc
ggtcagccga tctggaatta gagagagcta ccgatgtcaa atgggatgac
4320caggcagaga tatcaggtag cagtccaatc ctgtcaataa caatatcaga
agatggcagc 4380atgtcaataa agaatgaaga ggaagagcaa acactgacta
tactcattag aacaggattg 4440cttgtgatct caggactctt tccggtatca
ataccaatta cagcagcagc atggtatctg 4500tgggaagtaa agaaacaacg
ggctggagtg ctgtgggatg tcccctcacc accacccgtg 4560ggaaaagctg
aattggaaga tggagcctac agaatcaagc aaaaaggaat ccttggatat
4620tcccagatcg gagctggagt ttacaaagaa ggaacatttc acacaatgtg
gcacgtcaca 4680cgtggcgctg tcctaatgca taaggggaag aggattgaac
catcatgggc ggacgtcaag 4740aaagacttaa tatcatatgg aggaggttgg
aagctagaag gagaatggaa agaaggagaa 4800gaagtccagg tcttggcatt
ggagccaggg aaaaatccaa gagccgtcca aacaaagcct 4860ggccttttta
gaaccaacac tggaaccata ggtgccgtat ctctggactt ttcccctggg
4920acgtcaggat ctccaatcgt cgacaaaaaa ggaaaagttg taggtctcta
tggcaatggt 4980gtcgttacaa ggagtggagc atatgtgagt gccatagctc
agactgaaaa aagcattgaa 5040gacaatccag agattgaaga tgacatcttt
cgaaagagaa gattgactat catggatctc 5100cacccaggag caggaaagac
aaagagatac ctcccggcca tagtcagaga ggccataaaa 5160agaggcttga
gaacactaat cctagccccc actagagtcg tggcagctga aatggaggaa
5220gcccttagag gacttccaat aagataccaa actccagcta tcagggctga
gcacaccggg 5280cgggagattg tagacttaat gtgtcatgcc acatttacca
tgaggctgct atcaccaatc 5340agggtgccaa attacaacct gatcatcatg
gacgaagccc attttacaga tccagcaagc 5400atagcagcta ggggatacat
ctcaactcga gtggagatgg gggaggcagc tggaattttt 5460atgacagcca
ctcctccggg tagtagagat ccatttcctc agagcaatgc accaattatg
5520gacgaagaaa gagaaattcc ggaacgttca tggaactctg ggcacgagtg
ggtcacggat 5580tttaaaggaa agactgtctg gtttgttcca agcataaaaa
ccggaaatga catagcagcc 5640tgcctgagaa agaatggaaa gagggtgata
caactcagta ggaagacctt tgattctgaa 5700tatgtcaaga ctagaaccaa
tgactgggat ttcgtggtta caactgacat ctcggaaatg 5760ggcgccaact
ttaaagctga gagggtcata gaccccagac gctgcatgaa accagttata
5820ttgacagacg gcgaagagcg ggtgattctg gcaggaccca tgccagtgac
ccactctagt 5880gcagcacaaa gaagagggag aataggaagg aatccaagga
atgaaaatga tcaatatata 5940tatatggggg aaccactgga aaatgatgaa
gactgtgcgc actggaagga agctaagatg 6000ctcctagata atatcaacac
acctgaagga atcattccca gcttgttcga gccagagcgt 6060gaaaaggtgg
atgccattga cggtgaatat cgcttgagag gagaagcacg gaaaactttt
6120gtggacctaa tgagaagagg agacctacca gtctggttgg cttataaagt
ggcagctgaa 6180ggtatcaact acgcagacag aagatggtgt tttgacggaa
ccagaaacaa tcaaatcttg 6240gaagaaaatg tggaagtgga aatctggaca
aaggaagggg aaaggaaaaa attgaaacct 6300agatggttag atgctaggat
ctactccgac ccactggcgc taaaagagtt caaggaattt 6360gcagccggaa
gaaagtccct aaccctgaac ctaattacag agatgggcag actcccaact
6420tttatgactc agaaggccag agatgcacta gacaacttgg cggtgctgca
cacggctgaa 6480gcgggtggaa aggcatacaa tcatgctctc agtgaattac
cggagaccct ggagacattg 6540cttttgctga cactgttggc cacagtcacg
ggaggaatct tcctattcct gatgagcgga 6600aggggtatgg ggaagatgac
cctgggaatg tgctgcataa tcacggccag catcctctta 6660tggtatgcac
aaatacagcc acattggata gcagcctcaa taatattgga gttctttctc
6720atagtcttgc tcattccaga accagaaaag cagaggacac ctcaggataa
tcaattgact 6780tatgtcatca tagccatcct cacagtggtg gccgcaacca
tggcaaacga aatgggtttt 6840ctggaaaaaa caaagaaaga cctcggactg
ggaaacattg caactcagca acctgagagc 6900aacattctgg acatagatct
acgtcctgca tcagcatgga cgttgtatgc cgtggctaca 6960acatttatca
caccaatgtt gagacatagc attgaaaatt cctcagtaaa tgtgtcccta
7020acagccatag ctaaccaagc cacagtgcta atgggtctcg gaaaaggatg
gccattgtca 7080aagatggaca ttggagttcc cctccttgct attgggtgtt
actcacaagt caaccctata 7140accctcacag cggctcttct tttattggta
gcacattatg ccatcatagg accgggactt 7200caagccaaag caactagaga
agctcagaaa agagcagcag cgggcatcat gaaaaaccca 7260actgtggatg
gaataacagt gatagatcta gatccaatac cctatgatcc aaagtttgaa
7320aagcagttgg gacaagtaat gctcctagtc ctctgcgtga cccaagtgct
gatgatgagg 7380actacgtggg ctttgtgtga agccttaact ctagcaactg
gacccgtgtc cacattgtgg 7440gaaggaaatc cagggagatt ctggaacaca
accattgcag tgtcaatggc aaacatcttt 7500agagggagtt acctggctgg
agctggactt ctcttttcta tcatgaagaa cacaaccagc 7560acgagaagag
gaactggcaa tataggagaa acgttaggag agaaatggaa aagcagactg
7620aacgcattgg ggaaaagtga attccagatc tacaaaaaaa gtggaattca
agaagtggac 7680agaaccttag caaaagaagg cattaaaaga ggagaaacgg
atcatcacgc tgtgtcgcga 7740ggctcagcaa aactgagatg gttcgttgaa
aggaatttgg tcacaccaga agggaaagta 7800gtggaccttg gttgtggcag
agggggctgg tcatactatt gtggaggatt aaagaatgta 7860agagaagtta
aaggcttaac aaaaggagga ccaggacacg aagaacctat ccctatgtca
7920acatatgggt ggaatctagt acgcttacag agcggagttg atgttttttt
tgttccacca 7980gagaagtgtg acacattgtt gtgtgacata ggggaatcat
caccaaatcc cacggtagaa 8040gcgggacgaa cactcagagt cctcaaccta
gtggaaaatt ggctgaacaa taacacccaa 8100ttttgcgtaa aggttcttaa
cccgtacatg ccctcagtca ttgaaagaat ggaaacctta 8160caacggaaat
acggaggagc cttggtgaga aatccactct cacggaattc cacacatgag
8220atgtactggg tgtccaatgc ttccgggaac atagtgtcat cagtgaacat
gatttcaaga 8280atgctgatca acagattcac tatgagacac aagaaggcca
cctatgagcc agatgtcgac 8340ctcggaagcg gaacccgcaa tattggaatt
gaaagtgaga caccgaacct agacataatt 8400gggaaaagaa tagaaaaaat
aaaacaagag catgaaacgt catggcacta tgatcaagac 8460cacccataca
aaacatgggc ttaccatggc agctatgaaa caaaacagac tggatcagca
8520tcatccatgg tgaacggagt agtcagattg ctgacaaaac cctgggacgt
tgttccaatg 8580gtgacacaga tggcaatgac agacacaact ccttttggac
aacagcgcgt cttcaaagag 8640aaggtggata cgagaaccca agaaccaaaa
gaaggcacaa aaaaactaat gaaaatcacg 8700gcagagtggc tctggaaaga
actaggaaag aaaaagacac ctagaatgtg taccagagaa 8760gaattcacaa
aaaaggtgag aagcaatgca gccttggggg ccatattcac cgatgagaac
8820aagtggaaat cggcgcgtga agccgttgaa gatagtaggt tttgggagct
ggttgacaag 8880gaaaggaacc tccatcttga agggaaatgt gaaacatgtg
tatacaacat gatggggaaa 8940agagagaaaa aactaggaga gtttggtaaa
gcaaaaggca gcagagccat atggtacatg 9000tggctcggag cacgcttctt
agagtttgaa gccctaggat ttttgaatga agaccattgg 9060ttctccagag
agaactccct gagtggagtg gaaggagaag ggctgcataa gctaggttac
9120atcttaagag aggtgagcaa gaaagaagga ggagcaatgt atgccgatga
caccgcaggc 9180tgggacacaa gaatcacaat agaggatttg aaaaatgaag
aaatgataac gaaccacatg 9240gcaggagaac acaagaaact tgccgaggcc
atttttaaat tgacgtacca aaacaaggtg 9300gtgcgtgtgc aaagaccaac
accaagaggc acagtaatgg acatcatatc gagaagagac 9360caaaggggta
gtggacaagt tggcacctat ggcctcaaca ctttcaccaa catggaagca
9420caactaatta ggcaaatgga gggggaagga atcttcaaaa gcatccagca
cttgacagcc 9480tcagaagaaa tcgctgtgca agattggcta gtaagagtag
ggcgtgaaag gttgtcaaga 9540atggccatca gtggagatga ttgtgttgtg
aaacctttag atgatagatt tgcaagagct 9600ctaacagctc taaatgacat
gggaaaggtt aggaaggaca tacagcaatg ggagccctca 9660agaggatgga
acgactggac gcaggtgccc ttctgttcac accattttca cgagttaatt
9720atgaaagatg gtcgcacact cgtagttcca tgcagaaacc aagatgaatt
gatcggcaga 9780gcccgaattt cccagggagc tgggtggtct ttacgggaga
cggcctgttt ggggaagtct 9840tacgcccaaa tgtggagctt gatgtacttc
cacagacgtg atctcaggct agcggcaaat 9900gccatctgct cggcagtccc
atcacactgg attccaacaa gccggacaac ctggtccata 9960cacgccagcc
atgaatggat gacgacggaa gacatgttga cagtttggaa cagagtgtgg
10020atcctagaaa atccatggat ggaagacaaa actccagtgg aatcatggga
ggaaatccca 10080tacctgggaa aaagagaaga ccaatggtgc ggctcgctga
ttgggctgac aagcagagcc 10140acctgggcga agaatatcca gacagcaata
aaccaagtca gatccctcat tggcaatgag 10200gaatacacag attacatgcc
atccatgaaa agattcagaa gagaagagga agaggcagga 10260gttttgtggt
agaaaaacat gaaacaaaac agaagtcagg tcggattaag ccatagtacg
10320ggaaaaacta tgctacctgt gagccccgtc caaggacgtt aaaagaagtc
aggccatttt 10380gatgccatag cttgagcaaa ctgtgcagcc tgtagctcca
cctgagaagg tgtaaaaaat 10440ccgggaggcc acaaaccatg gaagctgtac
gcatggcgta gtggactagc ggttagagga 10500gacccctccc ttacagatcg
cagcaacaat gggggcccaa ggtgagatga agctgtagtc 10560tcactggaag
gactagaggt tagaggagac ccccccaaaa caaaaaacag catattgacg
10620ctgggaaaga ccagagatcc tgctgtctcc tcagcatcat tccaggcaca
ggacgccaga 10680aaatggaatg gtgctgttga atcaacaggt tctggtaccg
gtaggcatcg tggtgtcacg 10740ctcgtcgttt ggtatggctt cattcagctc
cggttcccaa cgatcaaggc gagttacatg 10800atcccccatg ttgtgcaaaa
aagcggttag ctccttcggt cctccgatcg ttgtcagaag 10860taagttggcc
gcagtgttat cactcatggt tatggcagca ctgcataatt ctcttactgt
10920catgccatcc gtaagatgct tttctgtgac tggtgagtac tcaaccaagt
cattctgaga 10980atagtgtatg cggcgaccga gttgctcttg cccggcgtca
acacgggata ataccgcgcc 11040acatagcaga actttaaaag tgctcatcat
tggaaaacgt tcttcggggc gaaaactctc 11100aaggatctta ccgctgttga
gatccagttc gatgtaaccc actcgtgcac ccaactgatc 11160ttcagcatct
tttactttca ccagcgtttc tgggtgagca aaaacaggaa ggcaaaatgc
11220cgcaaaaaag ggaataaggg cgacacggaa atgttgaata ctcatactct
tcctttttca 11280atattattga agcatttatc agggttattg tctcatgagc
ggatacatat ttgaatgtat 11340ttagaaaaat aaacaaatag gggttccgcg
cacatttccc cgaaaagtgc cacctgacgt 11400ctaagaaacc attattatca
tgacattaac ctataaaaat aggcgtatca cgaggccctt 11460tcgtcttcaa
gaattctcat gtttgacagc ttatcatcga taagctttaa tgcggtagtt
11520tatcacagtt aaattgctaa cgcagtcagg caccgtgtat gaaatctaac
aatgcgctca 11580tcgtcatcct cggcaccgtc accctggatg ctgtaggcat
aggcttggtt atgccggtac 11640tgccgggcct cttgcgggat atcgtccatt
ccgacagcat cgccagtcac tatggcgtgc 11700tgctggcgct atatgcgttg
atgcaatttc tatgcgcacc cgttctcgga gcactgtccg 11760accgctttgg
ccgccgccca gtcctgctcg cttcgctact tggagccact atcgactacg
11820cgatcatggc gaccacaccc gtcctgtgga tcctctacgc cggacgcatc
gtggccggca 11880tcaccggcgc cacaggtgcg gttgctggcg cctatatcgc
cgacatcacc gatggggaag 11940atcgggctcg ccacttcggg ctcatgagcg
cttgtttcgg cgtgggtatg gtggcaggcc 12000ccgtggccgg gggactgttg
ggcgccatct ccttgcatgc accattcctt gcggcggcgg 12060tgctcaacgg
cctcaaccta ctactgggct gcttcctaat gcaggagtcg cataagggag
12120agcgtcgacc gatgcccttg agagccttca acccagtcag ctccttccgg
tgggcgcggg 12180gcatgactat cgtcgccgca cttatgactg tcttctttat
catgcaactc gtaggacagg 12240tgccggcagc gctctgggtc attttcggcg
aggaccgctt tcgctggagc gcgacgatga 12300tcggcctgtc gcttgcggta
ttcggaatct tgcacgccct cgctcaagcc ttcgtcactg 12360gtcccgccac
caaacgtttc ggcgagaagc aggccattat cgccggcatg gcggccgacg
12420cgctgggcta cgtcttgctg gcgttcgcga cgcgaggctg gatggccttc
cccattatga 12480ttcttctcgc ttccggcggc atcgggatgc ccgcgttgca
ggccatgctg tccaggcagg 12540tagatgacga ccatcaggga cagcttcaag
gatcgctcgc ggctcttacc agcctaactt 12600cgatcactgg accgctgatc
gtcacggcga tttatgccgc ctcggcgagc acatggaacg 12660ggttggcatg
gattgtaggc gccgccctat accttgtctg cctccccgcg ttgcgtcgcg
12720gtgcatggag ccgggccacc tcgacctgaa tggaagccgg cggcacctcg
ctaacggatt 12780caccactcca agaattggag ccaatcaatt cttgcggaga
actgtgaatg cgcaaaccaa 12840cccttggcag aacatatcca tcgcgtccgc
catctccagc agccgcacgc ggcgcatctc 12900gggcagcgtt gggtcctggc
cacgggtgcg catgatcgtg ctcctgtcgt tgaggacccg 12960gctaggctgg
cggggttgcc ttactggtta gcagaatgaa tcaccgatac gcgagcgaac
13020gtgaagcgac tgctgctgca aaacgtctgc gacctgagca acaacatgaa
tggtcttcgg 13080tttccgtgtt tcgtaaagtc tggaaacgcg gaagtcagcg
ccctgcacca ttatgttccg 13140gatctgcatc gcaggatgct gctggctacc
ctgtggaaca cctacatctg tattaacgaa 13200gcgctggcat tgaccctgag
tgatttttct ctggtcccgc cgcatccata ccgccagttg 13260tttaccctca
caacgttcca gtaaccgggc atgttcatca tcagtaaccc gtatcgtgag
13320catcctctct cgtttcatcg gtatcattac ccccatgaac agaaatcccc
cttacacgga 13380ggcatcagtg accaaacagg aaaaaaccgc ccttaacatg
gcccgcttta tcagaagcca 13440gacattaacg cttctggaga aactcaacga
gctggacgcg gatgaacagg cagacatctg 13500tgaatcgctt cacgaccacg
ctgatgagct ttaccgcagc tgcctcgcgc gtttcggtga 13560tgacggtgaa
aacctctgac acatgcagct cccggagacg gtcacagctt gtctgtaagc
13620ggatgccggg agcagacaag cccgtcaggg cgcgtcagcg ggtgttggcg
ggtgtcgggg 13680cgcagccatg acccagtcac gtagcgatag cggagtgtat
actggcttaa ctatgcggca 13740tcagagcaga ttgtactgag agtgcaccat
atgcggtgtg aaataccgca cagatgcgta 13800aggagaaaat accgcatcag
gcgctcttcc gcttcctcgc tcactgactc gctgcgctcg 13860gtcgttcggc
tgcggcgagc ggtatcagct cactcaaagg cggtaatacg gttatccaca
13920gaatcagggg ataacgcagg aaagaacatg tgagcaaaag gccagcaaaa
ggccaggaac 13980cgtaaaaagg ccgcgttgct ggcgtttttc cataggctcc
gcccccctga cgagcatcac 14040aaaaatcgac gctcaagtca gaggtggcga
aacccgacag gactataaag ataccaggcg 14100tttccccctg gaagctccct
cgtgcgctct cctgttccga ccctgccgct taccggatac 14160ctgtccgcct
ttctcccttc gggaagcgtg gcgctttctc atagctcacg ctgtaggtat
14220ctcagttcgg tgtaggtcgt tcgctccaag ctgggctgtg tgcacgaacc
ccccgttcag 14280cccgaccgct gcgccttatc cggtaactat cgtcttgagt
ccaacccggt aagacacgac 14340ttatcgccac tggcagcagc cactggtaac
aggattagca gagcgaggta tgtaggcggt 14400gctacagagt tcttgaagtg
gtggcctaac tacggctaca ctagaaggac agtatttggt 14460atctgcgctc
tgctgaagcc agttaccttc ggaaaaagag ttggtagctc ttgatccggc
14520aaacaaacca ccgctggtag cggtggtttt tttgtttgca agcagcagat
tacgcgcaga 14580aaaaaaggat ctcaagaaga tcctttgatc ttttctacgg
ggtctgacgc tcagtggaac 14640gaaaactcac gttaagggat tttggtcatg
agattatcaa aaaggatctt cacctagatc 14700cttttaaatt aaaaatgaag
ttttaaatca atctaaagta tatatgagta aacttggtct 14760gacagttacc
aatgcttaat cagtgaggca cctatctcag cgatctgtct atttcgttca
14820tccatagttg cctgactccc cgtcgtgtag ataactacga tacgggaggg
cttaccatct 14880ggccccagtg ctgcaatgat accgcgagac ccacgctcac
cggctccaga tttatcagca 14940ataaaccagc cagccggaag ggccgagcgc
agaagtggtc ctgcaacttt atccgcctcc 15000atccagtcta ttaattgttg
ccgggaagct agagtaagta gttcgccagt taatagtttg 15060cgcaacgttg
ttgccattgc tgcaagatct ggctagcgat gaccctgctg attggttcgc
15120tgaccatttc cgggcgcgcc gatttaggtg acactatag
15159473391PRTDengue 2 virus (Tonga/74) 47Met Asn Asn Gln Arg Lys
Lys Ala Arg Asn Thr Pro Phe Asn Met Leu 1 5 10 15Lys Arg Glu Arg
Asn Arg Val Ser Thr Val Gln Gln Leu Thr Lys Arg 20 25 30Phe Ser Leu
Gly Met Leu Gln Gly Arg Gly Pro Leu Lys Leu Phe Met 35 40 45Ala Leu
Val Ala Phe Leu Arg Phe Leu Thr Ile Pro Pro Thr Ala Gly 50 55 60Ile
Leu Lys Arg Trp Gly Thr Ile Lys Lys Ser Lys Ala Ile Asn Val65 70 75
80Leu Arg Gly Phe Arg Lys Glu Ile Gly Arg Met Leu Asn Ile Leu Asn
85 90 95Arg Arg Arg Arg Thr Val Gly Met Ile Ile Met Leu Thr Pro Thr
Val 100 105 110Met Ala Phe His Leu Thr Thr Arg Asn Gly Glu Pro His
Met Ile Val 115 120 125Ser Arg Gln Glu Lys Gly Lys Ser Leu Leu Phe
Lys Thr Lys Asp Gly 130 135 140Thr Asn Met Cys Thr Leu Met Ala Met
Asp Leu Gly Glu Leu Cys Glu145 150 155 160Asp Thr Ile Thr Tyr Lys
Cys Pro Phe Leu Lys Gln Asn Glu Pro Glu 165 170 175Asp Ile Asp Cys
Trp Cys Asn Ser Thr Ser Thr Trp Val Thr Tyr Gly 180 185 190Thr Cys
Thr Thr Thr Gly Glu His Arg Arg Glu Lys Arg Ser Val Ala 195 200
205Leu Val Pro His Val Gly Met Gly Leu Glu Thr Arg Thr Glu Thr Trp
210 215 220Met Ser Ser Glu Gly Ala Trp Lys His Ala Gln Arg Ile Glu
Thr Trp225 230 235 240Ile Leu Arg His Pro Gly Phe Thr Ile Met Ala
Ala Ile Leu Ala Tyr 245 250 255Thr Ile Gly Thr Thr His Phe Gln Arg
Val Leu Ile Phe Ile Leu Leu 260 265 270Thr Ala Ile Ala Pro Ser Met
Thr Met Arg Cys Ile Gly Ile Ser Asn 275 280 285Arg Asp Phe Val Glu
Gly Val Ser Gly Gly Ser Trp Val Asp Ile Val 290 295 300Leu Glu His
Gly Ser Cys Val Thr Thr Met Ala Lys Asn Lys Pro Thr305 310 315
320Leu Asp Phe Glu Leu Ile Lys Thr Glu Ala Lys Gln Pro Ala Thr Leu
325 330 335Arg Lys Tyr Cys Ile Glu Ala Lys Leu Thr Asn Thr Thr Thr
Asp Ser 340 345 350Arg Cys Pro Thr Gln Gly Glu Pro Thr Leu Asn Glu
Glu Gln Asp Lys 355 360 365Arg Phe Val Cys Lys His Ser Met Val Asp
Arg Gly Trp Gly Asn Gly 370 375 380Cys Gly Leu Phe Gly Lys Gly Gly
Ile Val Thr Cys Ala Met Phe Thr385 390 395 400Cys Lys Lys Asn Met
Glu Gly Lys Ile Val Gln Pro Glu Asn Leu Glu 405 410 415Tyr Thr Val
Val Ile Thr Pro His Ser Gly Glu Glu His Ala Val Gly 420 425 430Asn
Asp Thr Gly Lys His Gly Lys Glu Val Lys Ile Thr Pro Gln Ser 435 440
445Ser Ile Thr Glu Ala Glu Leu Thr Gly Tyr Gly Thr Val Thr Met Glu
450 455 460Cys Ser Pro Arg Thr Gly Leu Asp Phe Asn Glu Met Val Leu
Leu Gln465 470 475 480Met Glu Asp Lys Ala Trp Leu Val His Arg Gln
Trp Phe Leu Asp Leu 485 490 495Pro Leu Pro Trp Leu Pro Gly Ala Asp
Thr Gln Gly Ser Asn Trp Ile 500 505 510Gln Lys Glu Thr Leu Val Thr
Phe Lys Asn Pro His Ala Lys Lys Gln 515 520 525Asp Val Val Val Leu
Gly Ser Gln Glu Gly Ala Met His Thr Ala Leu 530 535 540Thr Gly Ala
Thr Glu Ile Gln Met Ser Ser Gly Asn Leu Leu Phe Thr545 550 555
560Gly His Leu Lys Cys Arg Leu Arg Met Asp Lys Leu Gln Leu Lys Gly
565 570 575Met Ser Tyr Ser Met Cys Thr Gly Lys Phe Lys Ile Val Lys
Glu Ile 580 585 590Ala Glu Thr Gln His Gly Thr Ile Val Ile Arg Val
Gln Tyr Glu Gly 595 600 605Asp Gly Ser Pro Cys Lys Ile Pro Phe Glu
Ile Met Asp Leu Glu Lys 610 615 620Arg His Val Leu Gly Arg Leu Ile
Thr Val Asn Pro Ile Val Thr Glu625 630 635 640Lys Asp Ser Pro Val
Asn Ile Glu Ala Glu Pro Pro Phe Gly Asp Ser 645 650 655Tyr Ile Ile
Ile Gly Val Glu Pro Gly Gln Leu Lys Leu Asp Trp Phe 660 665 670Lys
Lys Gly Ser Ser Ile Gly Gln Met Phe Glu Thr Thr Met Arg Gly 675 680
685Ala Lys Arg Met Ala Ile Leu Gly Asp Thr Ala Trp Asp Phe Gly Ser
690 695 700Leu Gly Gly Val Phe Thr Ser Ile Gly Lys Ala Leu His Gln
Val Phe705 710 715 720Gly Ala Ile Tyr Gly Ala Ala Phe Ser Gly Val
Ser Trp Thr Met Lys 725 730 735Ile Leu Ile Gly Val Ile Ile Thr Trp
Ile Gly Met Asn Ser Arg Ser 740 745 750Thr Ser Leu Ser Val Ser Leu
Val Leu Val Gly Ile Val Thr Leu Tyr 755 760 765Leu Gly Val Met Val
Gln Ala Asp Ser Gly Cys Val Val Ser Trp Lys 770 775 780Asn Lys Glu
Leu Lys Cys Gly Ser Gly Ile Phe Val Thr Asp Asn Val785 790 795
800His Thr Trp Thr Glu Gln Tyr Lys Phe Gln Pro Glu Ser Pro Ser Lys
805 810 815Leu Ala Ser Ala Ile Gln Lys Ala His Glu Glu Gly Ile Cys
Gly Ile 820 825 830Arg Ser Val Thr Arg Leu Glu Asn Leu Met Trp Lys
Gln Ile Thr Ser 835 840 845Glu Leu Asn His Ile Leu Ser Glu Asn Glu
Val Lys Leu Thr Ile Met 850 855 860Thr Gly Asp Ile Lys Gly Ile Met
Gln Val Gly Lys Arg Ser Leu Arg865 870 875 880Pro Gln Pro Thr Glu
Leu Arg Tyr Ser Trp Lys Thr Trp Gly Lys Ala 885 890 895Lys Met Leu
Ser Thr Glu Leu His Asn Gln Thr Phe Leu Ile Asp Gly 900 905 910Pro
Glu Thr Ala Glu Cys Pro Asn Thr Asn Arg Ala Trp Asn Ser Leu 915 920
925Glu Val Glu Asp Tyr Gly Phe Gly Val Phe Thr Thr Asn Ile Trp Leu
930 935 940Arg Leu Arg Glu Lys Gln Asp Val Phe Cys Asp Ser Lys Leu
Met Ser945 950 955 960Ala Ala Ile Lys Asp Asn Arg Ala Val His Ala
Asp Met Gly Tyr Trp 965 970 975Ile Glu Ser Ala Leu Asn Asp Thr Trp
Lys Ile Glu Lys Ala Ser Phe 980 985 990Ile Glu Val Lys Ser Cys His
Trp Pro Lys Ser His Thr Leu Trp Ser 995 1000 1005Asn Gly Val Leu
Glu Ser Glu Met Val Ile Pro Lys Asn Phe Ala Gly 1010 1015 1020Pro
Val Ser Gln His Asn Asn Arg Pro Gly Tyr Tyr Thr Gln Thr Ala1025
1030 1035 1040Gly Pro Trp His Leu Gly Lys Leu Glu Met Asp Phe Asp
Phe Cys Glu 1045 1050 1055Gly Thr Thr Val Val Val Thr Glu Asn Cys
Gly Asn Arg Gly Pro Ser 1060 1065 1070Leu Arg Thr Thr Thr Ala Ser
Gly Lys Leu Ile Thr Glu Trp Cys Cys 1075 1080 1085Arg Ser Cys Thr
Leu Pro Pro Leu Arg Tyr Arg Gly Glu Asp Gly Cys 1090 1095 1100Trp
Tyr Gly Met Glu Ile Arg Pro Leu Lys Glu Lys Glu Glu Asn Leu1105
1110 1115 1120Val Ser Ser Leu Val Thr Ala Gly His Gly Gln Ile Asp
Asn Phe Ser 1125 1130 1135Leu Gly Ile Leu Gly Met Ala Leu Phe Leu
Glu Glu Met Leu Arg Thr 1140 1145 1150Arg Val Gly Thr Lys His Ala
Ile Leu Leu Val Ala Val Ser Phe Val 1155 1160 1165Thr Leu Ile Thr
Gly Asn Met Ser Phe Arg Asp Leu Gly Arg Val Met 1170 1175 1180Val
Met Val Gly Ala Thr Met Thr Asp Asp Ile Gly Met Gly Val Thr1185
1190 1195 1200Tyr Leu Ala Leu Leu Ala Ala Phe Arg Val Arg Pro Thr
Phe Ala Ala 1205 1210 1215Gly Leu Leu Leu Arg Lys Leu Thr Ser Lys
Glu Leu Met Met Thr Thr 1220 1225 1230Ile Gly Ile Val Leu Leu Ser
Gln Ser Ser Ile Pro Glu Thr Ile Leu 1235 1240 1245Glu Leu Thr Asp
Ala Leu Ala Leu Gly Met Met Val Leu Lys Met Val 1250 1255 1260Arg
Asn Met Glu Lys Tyr Gln Leu Ala Val Thr Ile Met Ala Ile Leu1265
1270 1275 1280Cys Val Pro Asn Ala Val Ile Leu Gln Asn Ala Trp Lys
Val Ser Cys 1285 1290 1295Thr Ile Leu Ala Val Val Ser Val Ser Pro
Leu Leu Leu Thr Ser Ser 1300 1305 1310Gln Gln Lys Ala Asp Trp Ile
Pro Leu Ala Leu Thr Ile Lys Gly Leu 1315 1320 1325Asn Pro Thr Ala
Ile Phe Leu Thr Thr Leu Ser Arg Thr Asn Lys Lys 1330 1335 1340Arg
Ser Trp Pro Leu Asn Glu Ala Ile Met Ala Val Gly Met Val Ser1345
1350 1355 1360Ile Leu Ala Ser Ser Leu Leu Lys Asn Asp Ile Pro Met
Thr Gly Pro 1365 1370 1375Leu Val Ala Gly Gly Leu Leu Thr Val Cys
Tyr Val Leu Thr Gly Arg 1380 1385 1390Ser Ala Asp Leu Glu Leu Glu
Arg Ala Thr Asp Val Lys Trp Asp Asp 1395 1400 1405Gln Ala Glu Ile
Ser Gly Ser Ser Pro Ile Leu Ser Ile Thr Ile Ser 1410 1415 1420Glu
Asp Gly Ser Met Ser Ile Lys Asn Glu Glu Glu Glu Gln Thr Leu1425
1430 1435 1440Thr Ile Leu Ile Arg Thr Gly Leu Leu Val Ile Ser Gly
Leu Phe Pro 1445 1450 1455Val Ser Ile Pro Ile Thr Ala Ala Ala Trp
Tyr Leu Trp Glu Val Lys 1460 1465 1470Lys Gln Arg Ala Gly Val Leu
Trp Asp Val Pro Ser Pro Pro Pro Val 1475 1480 1485Gly Lys Ala Glu
Leu Glu Asp Gly Ala Tyr Arg Ile Lys Gln Lys Gly 1490 1495 1500Ile
Leu Gly Tyr Ser Gln Ile Gly Ala Gly Val Tyr Lys Glu Gly Thr1505
1510 1515 1520Phe His Thr Met Trp His Val Thr Arg Gly Ala Val Leu
Met His Lys 1525 1530 1535Gly Lys Arg Ile Glu Pro Ser Trp Ala Asp
Val Lys Lys Asp Leu Ile 1540 1545 1550Ser Tyr Gly Gly Gly Trp Lys
Leu Glu Gly Glu Trp Lys Glu Gly Glu 1555 1560 1565Glu Val Gln Val
Leu Ala Leu Glu Pro Gly Lys Asn Pro Arg Ala Val 1570 1575 1580Gln
Thr Lys Pro Gly Leu Phe Arg Thr Asn Thr Gly Thr Ile Gly Ala1585
1590 1595 1600Val Ser Leu Asp Phe Ser Pro Gly Thr Ser Gly Ser Pro
Ile Val Asp 1605 1610 1615Lys Lys Gly Lys Val Val Gly Leu Tyr Gly
Asn Gly Val Val Thr
Arg 1620 1625 1630Ser Gly Ala Tyr Val Ser Ala Ile Ala Gln Thr Glu
Lys Ser Ile Glu 1635 1640 1645Asp Asn Pro Glu Ile Glu Asp Asp Ile
Phe Arg Lys Arg Arg Leu Thr 1650 1655 1660Ile Met Asp Leu His Pro
Gly Ala Gly Lys Thr Lys Arg Tyr Leu Pro1665 1670 1675 1680Ala Ile
Val Arg Glu Ala Ile Lys Arg Gly Leu Arg Thr Leu Ile Leu 1685 1690
1695Ala Pro Thr Arg Val Val Ala Ala Glu Met Glu Glu Ala Leu Arg Gly
1700 1705 1710Leu Pro Ile Arg Tyr Gln Thr Pro Ala Ile Arg Ala Glu
His Thr Gly 1715 1720 1725Arg Glu Ile Val Asp Leu Met Cys His Ala
Thr Phe Thr Met Arg Leu 1730 1735 1740Leu Ser Pro Ile Arg Val Pro
Asn Tyr Asn Leu Ile Ile Met Asp Glu1745 1750 1755 1760Ala His Phe
Thr Asp Pro Ala Ser Ile Ala Ala Arg Gly Tyr Ile Ser 1765 1770
1775Thr Arg Val Glu Met Gly Glu Ala Ala Gly Ile Phe Met Thr Ala Thr
1780 1785 1790Pro Pro Gly Ser Arg Asp Pro Phe Pro Gln Ser Asn Ala
Pro Ile Met 1795 1800 1805Asp Glu Glu Arg Glu Ile Pro Glu Arg Ser
Trp Asn Ser Gly His Glu 1810 1815 1820Trp Val Thr Asp Phe Lys Gly
Lys Thr Val Trp Phe Val Pro Ser Ile1825 1830 1835 1840Lys Thr Gly
Asn Asp Ile Ala Ala Cys Leu Arg Lys Asn Gly Lys Arg 1845 1850
1855Val Ile Gln Leu Ser Arg Lys Thr Phe Asp Ser Glu Tyr Val Lys Thr
1860 1865 1870Arg Thr Asn Asp Trp Asp Phe Val Val Thr Thr Asp Ile
Ser Glu Met 1875 1880 1885Gly Ala Asn Phe Lys Ala Glu Arg Val Ile
Asp Pro Arg Arg Cys Met 1890 1895 1900Lys Pro Val Ile Leu Thr Asp
Gly Glu Glu Arg Val Ile Leu Ala Gly1905 1910 1915 1920Pro Met Pro
Val Thr His Ser Ser Ala Ala Gln Arg Arg Gly Arg Ile 1925 1930
1935Gly Arg Asn Pro Arg Asn Glu Asn Asp Gln Tyr Ile Tyr Met Gly Glu
1940 1945 1950Pro Leu Glu Asn Asp Glu Asp Cys Ala His Trp Lys Glu
Ala Lys Met 1955 1960 1965Leu Leu Asp Asn Ile Asn Thr Pro Glu Gly
Ile Ile Pro Ser Leu Phe 1970 1975 1980Glu Pro Glu Arg Glu Lys Val
Asp Ala Ile Asp Gly Glu Tyr Arg Leu1985 1990 1995 2000Arg Gly Glu
Ala Arg Lys Thr Phe Val Asp Leu Met Arg Arg Gly Asp 2005 2010
2015Leu Pro Val Trp Leu Ala Tyr Lys Val Ala Ala Glu Gly Ile Asn Tyr
2020 2025 2030Ala Asp Arg Arg Trp Cys Phe Asp Gly Thr Arg Asn Asn
Gln Ile Leu 2035 2040 2045Glu Glu Asn Val Glu Val Glu Ile Trp Thr
Lys Glu Gly Glu Arg Lys 2050 2055 2060Lys Leu Lys Pro Arg Trp Leu
Asp Ala Arg Ile Tyr Ser Asp Pro Leu2065 2070 2075 2080Ala Leu Lys
Glu Phe Lys Glu Phe Ala Ala Gly Arg Lys Ser Leu Thr 2085 2090
2095Leu Asn Leu Ile Thr Glu Met Gly Arg Leu Pro Thr Phe Met Thr Gln
2100 2105 2110Lys Ala Arg Asp Ala Leu Asp Asn Leu Ala Val Leu His
Thr Ala Glu 2115 2120 2125Ala Gly Gly Lys Ala Tyr Asn His Ala Leu
Ser Glu Leu Pro Glu Thr 2130 2135 2140Leu Glu Thr Leu Leu Leu Leu
Thr Leu Leu Ala Thr Val Thr Gly Gly2145 2150 2155 2160Ile Phe Leu
Phe Leu Met Ser Gly Arg Gly Met Gly Lys Met Thr Leu 2165 2170
2175Gly Met Cys Cys Ile Ile Thr Ala Ser Ile Leu Leu Trp Tyr Ala Gln
2180 2185 2190Ile Gln Pro His Trp Ile Ala Ala Ser Ile Ile Leu Glu
Phe Phe Leu 2195 2200 2205Ile Val Leu Leu Ile Pro Glu Pro Glu Lys
Gln Arg Thr Pro Gln Asp 2210 2215 2220Asn Gln Leu Thr Tyr Val Ile
Ile Ala Ile Leu Thr Val Val Ala Ala2225 2230 2235 2240Thr Met Ala
Asn Glu Met Gly Phe Leu Glu Lys Thr Lys Lys Asp Leu 2245 2250
2255Gly Leu Gly Asn Ile Ala Thr Gln Gln Pro Glu Ser Asn Ile Leu Asp
2260 2265 2270Ile Asp Leu Arg Pro Ala Ser Ala Trp Thr Leu Tyr Ala
Val Ala Thr 2275 2280 2285Thr Phe Ile Thr Pro Met Leu Arg His Ser
Ile Glu Asn Ser Ser Val 2290 2295 2300Asn Val Ser Leu Thr Ala Ile
Ala Asn Gln Ala Thr Val Leu Met Gly2305 2310 2315 2320Leu Gly Lys
Gly Trp Pro Leu Ser Lys Met Asp Ile Gly Val Pro Leu 2325 2330
2335Leu Ala Ile Gly Cys Tyr Ser Gln Val Asn Pro Ile Thr Leu Thr Ala
2340 2345 2350Ala Leu Leu Leu Leu Val Ala His Tyr Ala Ile Ile Gly
Pro Gly Leu 2355 2360 2365Gln Ala Lys Ala Thr Arg Glu Ala Gln Lys
Arg Ala Ala Ala Gly Ile 2370 2375 2380Met Lys Asn Pro Thr Val Asp
Gly Ile Thr Val Ile Asp Leu Asp Pro2385 2390 2395 2400Ile Pro Tyr
Asp Pro Lys Phe Glu Lys Gln Leu Gly Gln Val Met Leu 2405 2410
2415Leu Val Leu Cys Val Thr Gln Val Leu Met Met Arg Thr Thr Trp Ala
2420 2425 2430Leu Cys Glu Ala Leu Thr Leu Ala Thr Gly Pro Val Ser
Thr Leu Trp 2435 2440 2445Glu Gly Asn Pro Gly Arg Phe Trp Asn Thr
Thr Ile Ala Val Ser Met 2450 2455 2460Ala Asn Ile Phe Arg Gly Ser
Tyr Leu Ala Gly Ala Gly Leu Leu Phe2465 2470 2475 2480Ser Ile Met
Lys Asn Thr Thr Ser Thr Arg Arg Gly Thr Gly Asn Ile 2485 2490
2495Gly Glu Thr Leu Gly Glu Lys Trp Lys Ser Arg Leu Asn Ala Leu Gly
2500 2505 2510Lys Ser Glu Phe Gln Ile Tyr Lys Lys Ser Gly Ile Gln
Glu Val Asp 2515 2520 2525Arg Thr Leu Ala Lys Glu Gly Ile Lys Arg
Gly Glu Thr Asp His His 2530 2535 2540Ala Val Ser Arg Gly Ser Ala
Lys Leu Arg Trp Phe Val Glu Arg Asn2545 2550 2555 2560Leu Val Thr
Pro Glu Gly Lys Val Val Asp Leu Gly Cys Gly Arg Gly 2565 2570
2575Gly Trp Ser Tyr Tyr Cys Gly Gly Leu Lys Asn Val Arg Glu Val Lys
2580 2585 2590Gly Leu Thr Lys Gly Gly Pro Gly His Glu Glu Pro Ile
Pro Met Ser 2595 2600 2605Thr Tyr Gly Trp Asn Leu Val Arg Leu Gln
Ser Gly Val Asp Val Phe 2610 2615 2620Phe Val Pro Pro Glu Lys Cys
Asp Thr Leu Leu Cys Asp Ile Gly Glu2625 2630 2635 2640Ser Ser Pro
Asn Pro Thr Val Glu Ala Gly Arg Thr Leu Arg Val Leu 2645 2650
2655Asn Leu Val Glu Asn Trp Leu Asn Asn Asn Thr Gln Phe Cys Val Lys
2660 2665 2670Val Leu Asn Pro Tyr Met Pro Ser Val Ile Glu Arg Met
Glu Thr Leu 2675 2680 2685Gln Arg Lys Tyr Gly Gly Ala Leu Val Arg
Asn Pro Leu Ser Arg Asn 2690 2695 2700Ser Thr His Glu Met Tyr Trp
Val Ser Asn Ala Ser Gly Asn Ile Val2705 2710 2715 2720Ser Ser Val
Asn Met Ile Ser Arg Met Leu Ile Asn Arg Phe Thr Met 2725 2730
2735Arg His Lys Lys Ala Thr Tyr Glu Pro Asp Val Asp Leu Gly Ser Gly
2740 2745 2750Thr Arg Asn Ile Gly Ile Glu Ser Glu Thr Pro Asn Leu
Asp Ile Ile 2755 2760 2765Gly Lys Arg Ile Glu Lys Ile Lys Gln Glu
His Glu Thr Ser Trp His 2770 2775 2780Tyr Asp Gln Asp His Pro Tyr
Lys Thr Trp Ala Tyr His Gly Ser Tyr2785 2790 2795 2800Glu Thr Lys
Gln Thr Gly Ser Ala Ser Ser Met Val Asn Gly Val Val 2805 2810
2815Arg Leu Leu Thr Lys Pro Trp Asp Val Val Pro Met Val Thr Gln Met
2820 2825 2830Ala Met Thr Asp Thr Thr Pro Phe Gly Gln Gln Arg Val
Phe Lys Glu 2835 2840 2845Lys Val Asp Thr Arg Thr Gln Glu Pro Lys
Glu Gly Thr Lys Lys Leu 2850 2855 2860Met Lys Ile Thr Ala Glu Trp
Leu Trp Lys Glu Leu Gly Lys Lys Lys2865 2870 2875 2880Thr Pro Arg
Met Cys Thr Arg Glu Glu Phe Thr Lys Lys Val Arg Ser 2885 2890
2895Asn Ala Ala Leu Gly Ala Ile Phe Thr Asp Glu Asn Lys Trp Lys Ser
2900 2905 2910Ala Arg Glu Ala Val Glu Asp Ser Arg Phe Trp Glu Leu
Val Asp Lys 2915 2920 2925Glu Arg Asn Leu His Leu Glu Gly Lys Cys
Glu Thr Cys Val Tyr Asn 2930 2935 2940Met Met Gly Lys Arg Glu Lys
Lys Leu Gly Glu Phe Gly Lys Ala Lys2945 2950 2955 2960Gly Ser Arg
Ala Ile Trp Tyr Met Trp Leu Gly Ala Arg Phe Leu Glu 2965 2970
2975Phe Glu Ala Leu Gly Phe Leu Asn Glu Asp His Trp Phe Ser Arg Glu
2980 2985 2990Asn Ser Leu Ser Gly Val Glu Gly Glu Gly Leu His Lys
Leu Gly Tyr 2995 3000 3005Ile Leu Arg Glu Val Ser Lys Lys Glu Gly
Gly Ala Met Tyr Ala Asp 3010 3015 3020Asp Thr Ala Gly Trp Asp Thr
Arg Ile Thr Ile Glu Asp Leu Lys Asn3025 3030 3035 3040Glu Glu Met
Ile Thr Asn His Met Ala Gly Glu His Lys Lys Leu Ala 3045 3050
3055Glu Ala Ile Phe Lys Leu Thr Tyr Gln Asn Lys Val Val Arg Val Gln
3060 3065 3070Arg Pro Thr Pro Arg Gly Thr Val Met Asp Ile Ile Ser
Arg Arg Asp 3075 3080 3085Gln Arg Gly Ser Gly Gln Val Gly Thr Tyr
Gly Leu Asn Thr Phe Thr 3090 3095 3100Asn Met Glu Ala Gln Leu Ile
Arg Gln Met Glu Gly Glu Gly Ile Phe3105 3110 3115 3120Lys Ser Ile
Gln His Leu Thr Ala Ser Glu Glu Ile Ala Val Gln Asp 3125 3130
3135Trp Leu Val Arg Val Gly Arg Glu Arg Leu Ser Arg Met Ala Ile Ser
3140 3145 3150Gly Asp Asp Cys Val Val Lys Pro Leu Asp Asp Arg Phe
Ala Arg Ala 3155 3160 3165Leu Thr Ala Leu Asn Asp Met Gly Lys Val
Arg Lys Asp Ile Gln Gln 3170 3175 3180Trp Glu Pro Ser Arg Gly Trp
Asn Asp Trp Thr Gln Val Pro Phe Cys3185 3190 3195 3200Ser His His
Phe His Glu Leu Ile Met Lys Asp Gly Arg Thr Leu Val 3205 3210
3215Val Pro Cys Arg Asn Gln Asp Glu Leu Ile Gly Arg Ala Arg Ile Ser
3220 3225 3230Gln Gly Ala Gly Trp Ser Leu Arg Glu Thr Ala Cys Leu
Gly Lys Ser 3235 3240 3245Tyr Ala Gln Met Trp Ser Leu Met Tyr Phe
His Arg Arg Asp Leu Arg 3250 3255 3260Leu Ala Ala Asn Ala Ile Cys
Ser Ala Val Pro Ser His Trp Ile Pro3265 3270 3275 3280Thr Ser Arg
Thr Thr Trp Ser Ile His Ala Ser His Glu Trp Met Thr 3285 3290
3295Thr Glu Asp Met Leu Thr Val Trp Asn Arg Val Trp Ile Leu Glu Asn
3300 3305 3310Pro Trp Met Glu Asp Lys Thr Pro Val Glu Ser Trp Glu
Glu Ile Pro 3315 3320 3325Tyr Leu Gly Lys Arg Glu Asp Gln Trp Cys
Gly Ser Leu Ile Gly Leu 3330 3335 3340Thr Ser Arg Ala Thr Trp Ala
Lys Asn Ile Gln Thr Ala Ile Asn Gln3345 3350 3355 3360Val Arg Ser
Leu Ile Gly Asn Glu Glu Tyr Thr Asp Tyr Met Pro Ser 3365 3370
3375Met Lys Arg Phe Arg Arg Glu Glu Glu Glu Ala Gly Val Leu Trp
3380 3385 33904815153DNAArtificial SequenceDengue 3 plasmid p3
48agttgttagt ctacgtggac cgacaagaac agtttcgact cggaagcttg cttaacgtag
60tactgacagt tttttattag agagcagatc tctgatgaac aaccaacgga aaaagacggg
120aaaaccgtct atcaatatgc tgaaacgcgt gagaaaccgt gtgtcaactg
gatcacagtt 180ggcgaagaga ttctcaagag gactgctgaa cggccaagga
ccaatgaaat tggttatggc 240gttcatagct ttcctcagat ttctagccat
tccaccgaca gcaggagtct tggctagatg 300gggaaccttt aagaagtcgg
gggctattaa ggtcctgaga ggcttcaaga aggagatctc 360aaacatgctg
agcattatca acagacggaa aaagacatcg ctctgtctca tgatgatgtt
420accagcaaca cttgctttcc acttgacttc acgagatgga gagccgcgca
tgattgtggg 480gaagaatgaa agaggaaaat ccctactttt taagacagcc
tctggaatca acatgtgcac 540actcatagcc atggatttgg gagagatgtg
tgatgacacg gtcacctaca aatgccccct 600cattactgaa gtggagcctg
aagacattga ctgctggtgc aaccttacat cgacatgggt 660gacctacgga
acgtgcaatc aagctggaga gcacagacgc gacaaaagat cggtggcgtt
720agctccccat gtcggcatgg gactggacac acgcacccaa acctggatgt
cggctgaagg 780agcttggaga caggtcgaga aggtagagac atgggccttt
aggcacccag ggttcacaat 840actagcccta tttcttgccc attacatagg
cacttccttg acccagaaag tggttatttt 900catactacta atgctggtca
ccccatccat gacaatgaga tgcgtgggag taggaaacag 960agattttgtg
gaaggcctat caggagctac gtgggttgac gtggtgctcg agcacggtgg
1020gtgtgtgact accatggcta agaacaagcc cacgctggat atagagctcc
agaagaccga 1080ggccacccaa ctggcgaccc taaggaaact atgtattgag
ggaaaaatta ccaacgtaac 1140aaccgactca aggtgcccca cccaagggga
agcgatttta cctgaggagc aggaccagaa 1200ccacgtgtgc aagcacacat
acgtggacag aggctgggga aacggttgtg gtttgtttgg 1260caagggaagc
ctggtaacat gcgcgaaatt tcaatgtttg gaatcaatag agggaaaagt
1320ggtgcagcat gagaacctca aatacaccgt catcatcaca gtgcacacag
gagatcaaca 1380ccaggtggga aatgaaacgc agggagtcac ggctgagata
acaccccagg catcaaccgt 1440tgaagccatc ttacctgaat atggaaccct
tgggctagaa tgctcaccac ggacaggttt 1500agatttcaat gaaatgattt
tgttgacaat gaagaacaaa gcatggatgg tacatagaca 1560atggtttttt
gacctacctt taccatggac atcaggagct acaacagaaa caccaacctg
1620gaataagaaa gagcttcttg tgacattcaa aaacgcacat gcaaaaaagc
aagaagtagt 1680agtccttgga tcgcaagagg gagcaatgca cacagcactg
acaggagcta cagagatcca 1740aacctcagga ggcacaagta tttttgcggg
gcacttaaaa tgtagactca agatggacaa 1800attggaactc aaggggatga
gctatgcaat gtgcttgaat gcctttgtgt tgaagaaaga 1860agtctccgaa
acgcaacatg ggacaatact catcaaggtt gagtacaaag gggaagatgc
1920accttgcaag attcctttct ccacggagga tggacaaggg aaagcccaca
atggcagact 1980gatcacagct aacccagtgg tgaccaagaa ggaggagcct
gtcaatattg aggcagaacc 2040tccttttggg gaaagcaata tagtaattgg
aattggagac aaagccttga aaatcaactg 2100gtacaagaag ggaagctcga
ttgggaagat gttcgaggcc actgccagag gtgcaaggcg 2160catggccatc
ttgggagaca cagcctggga ctttggatca gtaggtggtg ttttaaattc
2220attaggaaaa atggtgcacc aaatatttgg aagtgcttac acagccctat
ttagtggagt 2280ctcctggata atgaaaattg gaataggtgt ccttttaacc
tggatagggt tgaattcaaa 2340aaacactagt atgagcttta gctgcattgt
gataggaatc attacactct atctgggagc 2400cgtggtgcaa gctgacatgg
ggtgtgtcat aaactggaaa ggcaaagaac tcaaatgtgg 2460aagtggaatt
ttcgtcacta atgaggtcca cacctggaca gagcaataca aatttcaagc
2520agactccccc aaaagactgg cgacagccat tgcaggcgct tgggagaatg
gagtgtgcgg 2580aatcaggtcg acaaccagaa tggagaacct cttgtggaag
caaatagcca atgaactgaa 2640ctacatatta tgggaaaaca acatcaaatt
aacggtagtt gtgggtgata taattggggt 2700cttagagcaa gggaaaagaa
cactaacacc acaacccatg gaactaaaat attcatggaa 2760aacatgggga
aaggcgaaga tagtgacagc tgaaacacaa aattcctctt tcataataga
2820tgggccaaac acaccagagt gtccaagtgc ctcaagagca tggaatgtgt
gggaggtgga 2880agattacggg ttcggagtct tcacaactaa catatggctg
aaactccgag agatgtacac 2940ccaactatgt gaccacaggc taatgtcggc
agccgttaag gatgagaggg ccgtacacgc 3000cgacatgggc tattggatag
aaagccaaaa gaatggaagt tggaagctag aaaaggcatc 3060cctcatagag
gtaaaaacct gcacatggcc aaaatcacac actctttgga gcaatggtgt
3120gctagagagt gacatgatca tcccaaagag tctggctggt cccatttcgc
aacacaacta 3180caggcccgga taccacaccc aaacggcagg accctggcac
ttaggaaaat tggagctgga 3240cttcaactat tgtgaaggaa caacagttgt
catcacagaa aattgtggga caagaggccc 3300atcactgaga acaacaacag
tgtcagggaa gttgatacac gaatggtgtt gccgctcgtg 3360tacacttcct
cccctgcgat acatgggaga agacggctgc tggtatggca tggaaattag
3420acccattaat gagaaagaag agaacatggt aaagtcttta gtctcagcag
ggagtggaaa 3480ggtggataac ttcacaatgg gtgtcttgtg tttggcaatc
ctttttgaag aggtgatgag 3540aggaaaattt gggaaaaagc acatgattgc
aggggttctc ttcacgtttg tactccttct 3600ctcagggcaa ataacatgga
gagacatggc gcacacactc ataatgattg ggtccaacgc 3660ctctgacaga
atgggaatgg gcgtcactta cctagcattg attgcaacat ttaaaattca
3720gccatttttg gctttgggat tcttcctgag gaaactgaca tctagagaaa
atttattgtt 3780gggagttggg ttggccatgg caacaacgtt acaactgcca
gaggacattg aacaaatggc 3840gaatggaata gctttagggc tcatggctct
taaattaata acacaatttg aaacatacca 3900actatggacg gcattagtct
ccctaatgtg ttcaaataca attttcacgt tgactgttgc 3960ctggagaaca
gccaccctga ttttggccgg aatttctctt ttgccagtgt gccagtcttc
4020gagcatgagg aaaacagatt ggctcccaat ggctgtggca gctatgggag
ttccacccct 4080accacttttt attttcagtt tgaaagatac gctcaaaagg
agaagctggc cactgaatga 4140gggggtgatg gctgttggac ttgtgagtat
tctagctagt tctctcctta
ggaatgacgt 4200gcccatggct ggaccattag tggctggggg cttgctgata
gcgtgctacg tcataactgg 4260cacgtcagca gacctcactg tagaaaaagc
agcagatgtg acatgggagg aagaggctga 4320gcaaacagga gtgtcccaca
atttaatgat cacagttgat gacgatggaa caatgagaat 4380aaaagatgat
gagactgaga acatcttaac agtgcttttg aaaacagcat tactaatagt
4440gtcaggcatt tttccatact ccatacccgc aacactgttg gtctggcaca
cttggcaaaa 4500gcaaacccaa agatccggtg tcctatggga cgttcccagc
cccccagaga cacagaaagc 4560agaactggaa gaaggggttt ataggatcaa
gcagcaagga atttttggga aaacccaagt 4620gggggttgga gtacaaaaag
aaggagtttt ccacaccatg tggcacgtca caagaggagc 4680agtgttgaca
cacaatggga aaagactgga accaaactgg gctagcgtga aaaaagatct
4740gatttcatac ggaggaggat ggaaattgag tgcacaatgg caaaaaggag
aggaggtgca 4800ggttattgcc gtagagcctg ggaagaaccc aaagaacttt
caaaccatgc caggcatttt 4860ccagacaaca acaggggaga taggagcgat
tgcactggac ttcaagcctg gaacttcagg 4920atctcccatc ataaacagag
agggaaaggt actgggattg tatggcaatg gagtggtcac 4980aaagaatggt
ggctatgtca gtggaatagc acaaacaaat gcagaaccag acggaccgac
5040accagagttg gaagaagaga tgttcaaaaa gcgaaatcta accataatgg
atctccatcc 5100cgggtcagga aagacgcgga aatatcttcc agctattgtt
agagaggcaa tcaagagacg 5160cttaaggact ctaattttgg caccaacaag
ggtagttgca gctgagatgg aagaagcatt 5220gaaagggctc ccaataaggt
atcaaacaac tgcaacaaaa tctgaacaca cagggagaga 5280gattgttgat
ctaatgtgcc acgcaacgtt cacaatgcgt ttgctgtcac cagtcagggt
5340tccaaactac aacttgataa taatggatga ggctcatttc acagacccag
ccagtatagc 5400ggctagaggg tacatatcaa ctcgtgtagg aatgggagag
gcagccgcaa ttttcatgac 5460agccacaccc cctggaacag ctgatgcctt
tcctcagagc aacgctccaa ttcaagatga 5520agaaagagac ataccagaac
gctcatggaa ttcaggcaat gaatggatta ccgactttgc 5580cgggaagacg
gtgtggtttg tccctagcat caaagctgga aatgacatag caaactgctt
5640gcggaaaaat ggaaaaaagg tcattcaact tagtaggaag acttttgaca
cagaatatca 5700aaagactaaa ctaaatgatt gggactttgt ggtgacaaca
gacatttcag aaatgggagc 5760caatttcaaa gcagacagag tgatcgaccc
aagaagatgt ctcaagccag tgattttgac 5820agacggaccc gagcgcgtga
tcctggcggg accaatgcca gtcaccgtag cgagcgctgc 5880gcaaaggaga
gggagagttg gcaggaaccc acaaaaagaa aatgaccaat acatattcat
5940gggccagccc ctcaataatg atgaagacca tgctcactgg acagaagcaa
aaatgctgct 6000agacaacatc aacacaccag aagggatcat accagctctc
tttgaaccag aaagggagaa 6060gtcagccgcc atagacggcg aataccgcct
gaagggtgag tccaggaaga ccttcgtgga 6120actcatgagg aggggtgacc
tcccagtttg gctagcccat aaagtagcat cagaagggat 6180caaatataca
gatagaaagt ggtgttttga tggagaacgc aacaatcaaa ttttagagga
6240gaatatggat gtggaaatct ggacaaagga aggagaaaag aaaaaattga
gacctaggtg 6300gcttgatgcc cgcacttatt cagatccctt agcgctcaag
gaattcaagg actttgcggc 6360tggtagaaag tcaattgccc ttgatcttgt
gacagaaata ggaagagtgc cttcacactt 6420agctcacaga acgagaaacg
ccctggacaa tctggtgatg ttgcacacgt cagaacatgg 6480cgggagggcc
tacaggcatg cagtggagga actaccagaa acaatggaaa cactcttact
6540cctgggactc atgatcctgt taacaggtgg agcaatgctt ttcttgatat
caggtaaagg 6600gattggaaag acttcaatag gactcatttg tgtagctgct
tccagcggta tgttatggat 6660ggctgatgtc ccactccaat ggatcgcgtc
tgccatagtc ctggagtttt ttatgatggt 6720gttacttata ccagaaccag
aaaagcagag aactccccaa gacaatcaac tcgcatatgt 6780cgtgataggc
atactcacac tggctgcaat agtagcagcc aatgaaatgg gactgttgga
6840aaccacaaag agagatttag gaatgtccaa agaaccaggt gttgtttctc
caaccagcta 6900tttggatgtg gacttgcacc cagcatcagc ctggacattg
tacgctgtgg ccacaacagt 6960aataacacca atgttgagac ataccataga
gaattccaca gcaaatgtgt ccctggcagc 7020tatagccaac caggcagtgg
tcctgatggg tttagacaaa ggatggccga tatcgaaaat 7080ggacttaggc
gtgccactat tggcactggg ttgttattca caagtgaacc cactaactct
7140cacagcggca gttctcctgc tagtcacgca ttatgctatt ataggtccag
gattgcaggc 7200aaaagccact cgtgaagctc aaaaaaggac agctgctgga
ataatgaaga atccaacggt 7260ggatgggata atgacaatag acctagatcc
tgtaatatac gattcaaaat ttgaaaagca 7320actaggacag gttatgctcc
tggttctgtg tgcagttcaa cttttgttaa tgagaacatc 7380atgggctttt
tgtgaagctc taaccctagc cacaggacca ataacaacac tctgggaagg
7440atcacctggg aagttctgga acaccacgat agctgtttcc atggcgaaca
tctttagagg 7500gagctattta gcaggagctg ggcttgcttt ttctatcatg
aaatcagttg gaacaggaaa 7560gagagggaca gggtcacagg gtgaaacctt
gggagaaaag tggaaaaaga aattgaatca 7620attaccccgg aaagagtttg
acctttacaa gaaatccgga atcactgaag tggatagaac 7680agaagccaaa
gaagggttga aaagaggaga aataacacac catgccgtgt ccagaggcag
7740cgcaaaactt caatggttcg tggagagaaa catggtcatc cccgaaggaa
gagtcataga 7800cttaggctgt ggaagaggag gctggtcata ttattgtgca
ggactgaaaa aagttacaga 7860agtgcgagga tacacaaaag gcggcccagg
acatgaagaa ccagtaccta tgtctacata 7920cggatggaac atagtcaagt
taatgagtgg aaaggatgtg ttttatcttc cacctgaaaa 7980gtgtgatact
ctattgtgtg acattggaga atcttcacca agcccaacag tggaagaaag
8040cagaaccata agagtcttga agatggttga accatggcta aaaaataacc
agttttgcat 8100taaagtattg aacccttaca tgccaactgt gattgagcac
ctagaaagac tacaaaggaa 8160acatggagga atgcttgtga gaaatccact
ctcacgaaac tccacgcacg aaatgtactg 8220gatatctaat ggcacaggca
atatcgtttc ttcagtcaac atggtatcca gattgctact 8280taacagattc
acaatgacac ataggagacc caccatagag aaagatgtgg atttaggagc
8340ggggacccga catgtcaatg cggaaccaga aacacccaac atggatgtca
ttggggaaag 8400aataagaagg atcaaggagg agcatagttc aacatggcac
tatgatgatg aaaatcctta 8460taaaacgtgg gcttaccatg gatcctatga
agttaaggcc acaggctcag cctcctccat 8520gataaatgga gtcgtgaaac
tcctcacgaa accatgggat gtggtgccca tggtgacaca 8580gatggcaatg
acggatacaa ccccattcgg ccagcaaagg gtttttaaag agaaagtgga
8640caccaggaca cccagaccta tgccaggaac aagaaaggtt atggagatca
cagcggaatg 8700gctttggaga accctgggaa ggaacaaaag acccagatta
tgtacgagag aggagttcac 8760aaaaaaggtc agaaccaacg cagctatggg
cgccgttttt acagaggaga accaatggga 8820cagtgctaga gctgctgttg
aggatgaaga attctggaaa ctcgtggaca gagaacgtga 8880actccacaaa
ttgggcaagt gtggaagctg cgtttacaac atgatgggca agagagagaa
8940gaaacttgga gagtttggca aagcaaaagg cagtagagcc atatggtaca
tgtggttggg 9000agccagatac cttgagttcg aagcactcgg attcttaaat
gaagaccatt ggttctcgcg 9060tgaaaactct tacagtggag tagaaggaga
aggactgcac aagctgggat acatcttaag 9120agacatttcc aagatacccg
gaggagctat gtatgctgat gacacagctg gttgggacac 9180aagaataaca
gaagatgacc tgcacaatga ggaaaaaatc acacagcaaa tggaccctga
9240acacaggcag ttagcaaacg ctatattcaa gctcacatac caaaacaaag
tggtcaaagt 9300tcaacgacca actccaaagg gcacggtaat ggacatcata
tctaggaaag accaaagagg 9360cagtggacag gtgggaactt atggtctgaa
tacattcacc aacatggaag cccagttaat 9420cagacaaatg gaaggagaag
gtgtgttgtc gaaggcagac ctcgagaacc ctcatctgct 9480agagaagaaa
gttacacaat ggttggaaac aaaaggagtg gagaggttaa aaagaatggc
9540catcagcggg gatgattgcg tggtgaaacc aattgatgac aggttcgcca
atgccctgct 9600tgccctgaat gacatgggaa aagttaggaa ggacatacct
caatggcagc catcaaaggg 9660atggcatgat tggcaacagg tccctttctg
ctcccaccac tttcatgaat tgatcatgaa 9720agatggaaga aagttggtag
ttccctgcag acctcaggat gaattaatcg ggagagcgag 9780aatctctcaa
ggagcaggat ggagccttag agaaactgca tgcctaggga aagcctacgc
9840ccaaatgtgg actctcatgt actttcacag aagagatctt agactagcat
ccaacgccat 9900atgttcagca gtaccagtcc attgggtccc cacaagcaga
acgacgtggt ctattcatgc 9960tcaccatcag tggatgacta cagaagacat
gcttactgtt tggaacaggg tgtggataga 10020ggataatcca tggatggaag
acaaaactcc agtcaaaacc tgggaagatg ttccatatct 10080agggaagaga
gaagaccaat ggtgcggatc actcattggt ctcacttcca gagcaacctg
10140ggcccagaac atacttacgg caatccaaca ggtgagaagc cttataggca
atgaagagtt 10200tctggactac atgccttcga tgaagagatt caggaaggag
gaggagtcag agggagccat 10260ttggtaaacg taggaagtga aaaagaggca
aactgtcagg ccaccttaag ccacagtacg 10320gaagaagctg tgcagcctgt
gagccccgtc caaggacgtt aaaagaagaa gtcaggccca 10380aaagccacgg
tttgagcaaa ccgtgctgcc tgtggctccg tcgtggggac gtaaaacctg
10440ggaggctgca aactgtggaa gctgtacgca cggtgtagca gactagcggt
tagaggagac 10500ccctcccatg acacaacgca gcagcggggc ccgagctctg
agggaagctg tacctccttg 10560caaaggacta gaggttagag gagacccccc
gcaaataaaa acagcatatt gacgctggga 10620gagaccagag atcctgctgt
ctcctcagca tcattccagg cacagaacgc cagaaaatgg 10680aatggtgctg
ttgaatcaac aggttctggt accggtaggc atcgtggtgt cacgctcgtc
10740gtttggtatg gcttcattca gctccggttc ccaacgatca aggcgagtta
catgatcccc 10800catgttgtgc aaaaaagcgg ttagctcctt cggtcctccg
atcgttgtca gaagtaagtt 10860ggccgcagtg ttatcactca tggttatggc
agcactgcat aattctctta ctgtcatgcc 10920atccgtaaga tgcttttctg
tgactggtga gtactcaacc aagtcattct gagaatagtg 10980tatgcggcga
ccgagttgct cttgcccggc gtcaacacgg gataataccg cgccacatag
11040cagaacttta aaagtgctca tcattggaaa acgttcttcg gggcgaaaac
tctcaaggat 11100cttaccgctg ttgagatcca gttcgatgta acccactcgt
gcacccaact gatcttcagc 11160atcttttact ttcaccagcg tttctgggtg
agcaaaaaca ggaaggcaaa atgccgcaaa 11220aaagggaata agggcgacac
ggaaatgttg aatactcata ctcttccttt ttcaatatta 11280ttgaagcatt
tatcagggtt attgtctcat gagcggatac atatttgaat gtatttagaa
11340aaataaacaa ataggggttc cgcgcacatt tccccgaaaa gtgccacctg
acgtctaaga 11400aaccattatt atcatgacat taacctataa aaataggcgt
atcacgaggc cctttcgtct 11460tcaagaattc tcatgtttga cagcttatca
tcgataagct ttaatgcggt agtttatcac 11520agttaaattg ctaacgcagt
caggcaccgt gtatgaaatc taacaatgcg ctcatcgtca 11580tcctcggcac
cgtcaccctg gatgctgtag gcataggctt ggttatgccg gtactgccgg
11640gcctcttgcg ggatatcgtc cattccgaca gcatcgccag tcactatggc
gtgctgctgg 11700cgctatatgc gttgatgcaa tttctatgcg cacccgttct
cggagcactg tccgaccgct 11760ttggccgccg cccagtcctg ctcgcttcgc
tacttggagc cactatcgac tacgcgatca 11820tggcgaccac acccgtcctg
tggatcctct acgccggacg catcgtggcc ggcatcaccg 11880gcgccacagg
tgcggttgct ggcgcctata tcgccgacat caccgatggg gaagatcggg
11940ctcgccactt cgggctcatg agcgcttgtt tcggcgtggg tatggtggca
ggccccgtgg 12000ccgggggact gttgggcgcc atctccttgc atgcaccatt
ccttgcggcg gcggtgctca 12060acggcctcaa cctactactg ggctgcttcc
taatgcagga gtcgcataag ggagagcgtc 12120gaccgatgcc cttgagagcc
ttcaacccag tcagctcctt ccggtgggcg cggggcatga 12180ctatcgtcgc
cgcacttatg actgtcttct ttatcatgca actcgtagga caggtgccgg
12240cagcgctctg ggtcattttc ggcgaggacc gctttcgctg gagcgcgacg
atgatcggcc 12300tgtcgcttgc ggtattcgga atcttgcacg ccctcgctca
agccttcgtc actggtcccg 12360ccaccaaacg tttcggcgag aagcaggcca
ttatcgccgg catggcggcc gacgcgctgg 12420gctacgtctt gctggcgttc
gcgacgcgag gctggatggc cttccccatt atgattcttc 12480tcgcttccgg
cggcatcggg atgcccgcgt tgcaggccat gctgtccagg caggtagatg
12540acgaccatca gggacagctt caaggatcgc tcgcggctct taccagccta
acttcgatca 12600ctggaccgct gatcgtcacg gcgatttatg ccgcctcggc
gagcacatgg aacgggttgg 12660catggattgt aggcgccgcc ctataccttg
tctgcctccc cgcgttgcgt cgcggtgcat 12720ggagccgggc cacctcgacc
tgaatggaag ccggcggcac ctcgctaacg gattcaccac 12780tccaagaatt
ggagccaatc aattcttgcg gagaactgtg aatgcgcaaa ccaacccttg
12840gcagaacata tccatcgcgt ccgccatctc cagcagccgc acgcggcgca
tctcgggcag 12900cgttgggtcc tggccacggg tgcgcatgat cgtgctcctg
tcgttgagga cccggctagg 12960ctggcggggt tgccttactg gttagcagaa
tgaatcaccg atacgcgagc gaacgtgaag 13020cgactgctgc tgcaaaacgt
ctgcgacctg agcaacaaca tgaatggtct tcggtttccg 13080tgtttcgtaa
agtctggaaa cgcggaagtc agcgccctgc accattatgt tccggatctg
13140catcgcagga tgctgctggc taccctgtgg aacacctaca tctgtattaa
cgaagcgctg 13200gcattgaccc tgagtgattt ttctctggtc ccgccgcatc
cataccgcca gttgtttacc 13260ctcacaacgt tccagtaacc gggcatgttc
atcatcagta acccgtatcg tgagcatcct 13320ctctcgtttc atcggtatca
ttacccccat gaacagaaat cccccttaca cggaggcatc 13380agtgaccaaa
caggaaaaaa ccgcccttaa catggcccgc tttatcagaa gccagacatt
13440aacgcttctg gagaaactca acgagctgga cgcggatgaa caggcagaca
tctgtgaatc 13500gcttcacgac cacgctgatg agctttaccg cagctgcctc
gcgcgtttcg gtgatgacgg 13560tgaaaacctc tgacacatgc agctcccgga
gacggtcaca gcttgtctgt aagcggatgc 13620cgggagcaga caagcccgtc
agggcgcgtc agcgggtgtt ggcgggtgtc ggggcgcagc 13680catgacccag
tcacgtagcg atagcggagt gtatactggc ttaactatgc ggcatcagag
13740cagattgtac tgagagtgca ccatatgcgg tgtgaaatac cgcacagatg
cgtaaggaga 13800aaataccgca tcaggcgctc ttccgcttcc tcgctcactg
actcgctgcg ctcggtcgtt 13860cggctgcggc gagcggtatc agctcactca
aaggcggtaa tacggttatc cacagaatca 13920ggggataacg caggaaagaa
catgtgagca aaaggccagc aaaaggccag gaaccgtaaa 13980aaggccgcgt
tgctggcgtt tttccatagg ctccgccccc ctgacgagca tcacaaaaat
14040cgacgctcaa gtcagaggtg gcgaaacccg acaggactat aaagatacca
ggcgtttccc 14100cctggaagct ccctcgtgcg ctctcctgtt ccgaccctgc
cgcttaccgg atacctgtcc 14160gcctttctcc cttcgggaag cgtggcgctt
tctcatagct cacgctgtag gtatctcagt 14220tcggtgtagg tcgttcgctc
caagctgggc tgtgtgcacg aaccccccgt tcagcccgac 14280cgctgcgcct
tatccggtaa ctatcgtctt gagtccaacc cggtaagaca cgacttatcg
14340ccactggcag cagccactgg taacaggatt agcagagcga ggtatgtagg
cggtgctaca 14400gagttcttga agtggtggcc taactacggc tacactagaa
ggacagtatt tggtatctgc 14460gctctgctga agccagttac cttcggaaaa
agagttggta gctcttgatc cggcaaacaa 14520accaccgctg gtagcggtgg
tttttttgtt tgcaagcagc agattacgcg cagaaaaaaa 14580ggatctcaag
aagatccttt gatcttttct acggggtctg acgctcagtg gaacgaaaac
14640tcacgttaag ggattttggt catgagatta tcaaaaagga tcttcaccta
gatcctttta 14700aattaaaaat gaagttttaa atcaatctaa agtatatatg
agtaaacttg gtctgacagt 14760taccaatgct taatcagtga ggcacctatc
tcagcgatct gtctatttcg ttcatccata 14820gttgcctgac tccccgtcgt
gtagataact acgatacggg agggcttacc atctggcccc 14880agtgctgcaa
tgataccgcg agacccacgc tcaccggctc cagatttatc agcaataaac
14940cagccagccg gaagggccga gcgcagaagt ggtcctgcaa ctttatccgc
ctccatccag 15000tctattaatt gttgccggga agctagagta agtagttcgc
cagttaatag tttgcgcaac 15060gttgttgcca ttgctgcaag atctggctag
cgatgaccct gctgattggt tcgctgacca 15120tttccgggcg cgccgattta
ggtgacacta tag 15153493390PRTDengue 3 (Sleman/78) virus 49Met Asn
Asn Gln Arg Lys Lys Thr Gly Lys Pro Ser Ile Asn Met Leu 1 5 10
15Lys Arg Val Arg Asn Arg Val Ser Thr Gly Ser Gln Leu Ala Lys Arg
20 25 30Phe Ser Arg Gly Leu Leu Asn Gly Gln Gly Pro Met Lys Leu Val
Met 35 40 45Ala Phe Ile Ala Phe Leu Arg Phe Leu Ala Ile Pro Pro Thr
Ala Gly 50 55 60Val Leu Ala Arg Trp Gly Thr Phe Lys Lys Ser Gly Ala
Ile Lys Val65 70 75 80Leu Arg Gly Phe Lys Lys Glu Ile Ser Asn Met
Leu Ser Ile Ile Asn 85 90 95Arg Arg Lys Lys Thr Ser Leu Cys Leu Met
Met Met Leu Pro Ala Thr 100 105 110Leu Ala Phe His Leu Thr Ser Arg
Asp Gly Glu Pro Arg Met Ile Val 115 120 125Gly Lys Asn Glu Arg Gly
Lys Ser Leu Leu Phe Lys Thr Ala Ser Gly 130 135 140Ile Asn Met Cys
Thr Leu Ile Ala Met Asp Leu Gly Glu Met Cys Asp145 150 155 160Asp
Thr Val Thr Tyr Lys Cys Pro Leu Ile Thr Glu Val Glu Pro Glu 165 170
175Asp Ile Asp Cys Trp Cys Asn Leu Thr Ser Thr Trp Val Thr Tyr Gly
180 185 190Thr Cys Asn Gln Ala Gly Glu His Arg Arg Asp Lys Arg Ser
Val Ala 195 200 205Leu Ala Pro His Val Gly Met Gly Leu Asp Thr Arg
Thr Gln Thr Trp 210 215 220Met Ser Ala Glu Gly Ala Trp Arg Gln Val
Glu Lys Val Glu Thr Trp225 230 235 240Ala Phe Arg His Pro Gly Phe
Thr Ile Leu Ala Leu Phe Leu Ala His 245 250 255Tyr Ile Gly Thr Ser
Leu Thr Gln Lys Val Val Ile Phe Ile Leu Leu 260 265 270Met Leu Val
Thr Pro Ser Met Thr Met Arg Cys Val Gly Val Gly Asn 275 280 285Arg
Asp Phe Val Glu Gly Leu Ser Gly Ala Thr Trp Val Asp Val Val 290 295
300Leu Glu His Gly Gly Cys Val Thr Thr Met Ala Lys Asn Lys Pro
Thr305 310 315 320Leu Asp Ile Glu Leu Gln Lys Thr Glu Ala Thr Gln
Leu Ala Thr Leu 325 330 335Arg Lys Leu Cys Ile Glu Gly Lys Ile Thr
Asn Val Thr Thr Asp Ser 340 345 350Arg Cys Pro Thr Gln Gly Glu Ala
Ile Leu Pro Glu Glu Gln Asp Gln 355 360 365Asn His Val Cys Lys His
Thr Tyr Val Asp Arg Gly Trp Gly Asn Gly 370 375 380Cys Gly Leu Phe
Gly Lys Gly Ser Leu Val Thr Cys Ala Lys Phe Gln385 390 395 400Cys
Leu Glu Ser Ile Glu Gly Lys Val Val Gln His Glu Asn Leu Lys 405 410
415Tyr Thr Val Ile Ile Thr Val His Thr Gly Asp Gln His Gln Val Gly
420 425 430Asn Glu Thr Gln Gly Val Thr Ala Glu Ile Thr Pro Gln Ala
Ser Thr 435 440 445Val Glu Ala Ile Leu Pro Glu Tyr Gly Thr Leu Gly
Leu Glu Cys Ser 450 455 460Pro Arg Thr Gly Leu Asp Phe Asn Glu Met
Ile Leu Leu Thr Met Lys465 470 475 480Asn Lys Ala Trp Met Val His
Arg Gln Trp Phe Phe Asp Leu Pro Leu 485 490 495Pro Trp Thr Ser Gly
Ala Thr Thr Glu Thr Pro Thr Trp Asn Lys Lys 500 505 510Glu Leu Leu
Val Thr Phe Lys Asn Ala His Ala Lys Lys Gln Glu Val 515 520 525Val
Val Leu Gly Ser Gln Glu Gly Ala Met His Thr Ala Leu Thr Gly 530 535
540Ala Thr Glu Ile Gln Thr Ser Gly Gly Thr Ser Ile Phe Ala Gly
His545 550 555 560Leu Lys Cys Arg Leu Lys Met Asp Lys Leu Glu Leu
Lys Gly Met Ser 565 570 575Tyr Ala Met Cys Leu Asn Ala Phe Val Leu
Lys Lys Glu Val Ser Glu 580 585 590Thr Gln His Gly Thr Ile Leu Ile
Lys Val Glu Tyr Lys Gly Glu Asp 595 600 605Ala Pro Cys Lys Ile Pro
Phe Ser Thr Glu Asp Gly Gln Gly Lys Ala 610 615 620His Asn Gly Arg
Leu Ile Thr Ala Asn Pro Val Val Thr Lys Lys Glu625 630 635 640Glu
Pro Val Asn Ile Glu Ala Glu Pro Pro Phe Gly Glu Ser Asn Ile 645 650
655Val Ile Gly Ile Gly Asp Lys Ala Leu Lys Ile Asn
Trp Tyr Lys Lys 660 665 670Gly Ser Ser Ile Gly Lys Met Phe Glu Ala
Thr Ala Arg Gly Ala Arg 675 680 685Arg Met Ala Ile Leu Gly Asp Thr
Ala Trp Asp Phe Gly Ser Val Gly 690 695 700Gly Val Leu Asn Ser Leu
Gly Lys Met Val His Gln Ile Phe Gly Ser705 710 715 720Ala Tyr Thr
Ala Leu Phe Ser Gly Val Ser Trp Ile Met Lys Ile Gly 725 730 735Ile
Gly Val Leu Leu Thr Trp Ile Gly Leu Asn Ser Lys Asn Thr Ser 740 745
750Met Ser Phe Ser Cys Ile Val Ile Gly Ile Ile Thr Leu Tyr Leu Gly
755 760 765Ala Val Val Gln Ala Asp Met Gly Cys Val Ile Asn Trp Lys
Gly Lys 770 775 780Glu Leu Lys Cys Gly Ser Gly Ile Phe Val Thr Asn
Glu Val His Thr785 790 795 800Trp Thr Glu Gln Tyr Lys Phe Gln Ala
Asp Ser Pro Lys Arg Leu Ala 805 810 815Thr Ala Ile Ala Gly Ala Trp
Glu Asn Gly Val Cys Gly Ile Arg Ser 820 825 830Thr Thr Arg Met Glu
Asn Leu Leu Trp Lys Gln Ile Ala Asn Glu Leu 835 840 845Asn Tyr Ile
Leu Trp Glu Asn Asn Ile Lys Leu Thr Val Val Val Gly 850 855 860Asp
Ile Ile Gly Val Leu Glu Gln Gly Lys Arg Thr Leu Thr Pro Gln865 870
875 880Pro Met Glu Leu Lys Tyr Ser Trp Lys Thr Trp Gly Lys Ala Lys
Ile 885 890 895Val Thr Ala Glu Thr Gln Asn Ser Ser Phe Ile Ile Asp
Gly Pro Asn 900 905 910Thr Pro Glu Cys Pro Ser Ala Ser Arg Ala Trp
Asn Val Trp Glu Val 915 920 925Glu Asp Tyr Gly Phe Gly Val Phe Thr
Thr Asn Ile Trp Leu Lys Leu 930 935 940Arg Glu Met Tyr Thr Gln Leu
Cys Asp His Arg Leu Met Ser Ala Ala945 950 955 960Val Lys Asp Glu
Arg Ala Val His Ala Asp Met Gly Tyr Trp Ile Glu 965 970 975Ser Gln
Lys Asn Gly Ser Trp Lys Leu Glu Lys Ala Ser Leu Ile Glu 980 985
990Val Lys Thr Cys Thr Trp Pro Lys Ser His Thr Leu Trp Ser Asn Gly
995 1000 1005Val Leu Glu Ser Asp Met Ile Ile Pro Lys Ser Leu Ala
Gly Pro Ile 1010 1015 1020Ser Gln His Asn Tyr Arg Pro Gly Tyr His
Thr Gln Thr Ala Gly Pro1025 1030 1035 1040Trp His Leu Gly Lys Leu
Glu Leu Asp Phe Asn Tyr Cys Glu Gly Thr 1045 1050 1055Thr Val Val
Ile Thr Glu Asn Cys Gly Thr Arg Gly Pro Ser Leu Arg 1060 1065
1070Thr Thr Thr Val Ser Gly Lys Leu Ile His Glu Trp Cys Cys Arg Ser
1075 1080 1085Cys Thr Leu Pro Pro Leu Arg Tyr Met Gly Glu Asp Gly
Cys Trp Tyr 1090 1095 1100Gly Met Glu Ile Arg Pro Ile Asn Glu Lys
Glu Glu Asn Met Val Lys1105 1110 1115 1120Ser Leu Val Ser Ala Gly
Ser Gly Lys Val Asp Asn Phe Thr Met Gly 1125 1130 1135Val Leu Cys
Leu Ala Ile Leu Phe Glu Glu Val Met Arg Gly Lys Phe 1140 1145
1150Gly Lys Lys His Met Ile Ala Gly Val Leu Phe Thr Phe Val Leu Leu
1155 1160 1165Leu Ser Gly Gln Ile Thr Trp Arg Asp Met Ala His Thr
Leu Ile Met 1170 1175 1180Ile Gly Ser Asn Ala Ser Asp Arg Met Gly
Met Gly Val Thr Tyr Leu1185 1190 1195 1200Ala Leu Ile Ala Thr Phe
Lys Ile Gln Pro Phe Leu Ala Leu Gly Phe 1205 1210 1215Phe Leu Arg
Lys Leu Thr Ser Arg Glu Asn Leu Leu Leu Gly Val Gly 1220 1225
1230Leu Ala Met Ala Thr Thr Leu Gln Leu Pro Glu Asp Ile Glu Gln Met
1235 1240 1245Ala Asn Gly Ile Ala Leu Gly Leu Met Ala Leu Lys Leu
Ile Thr Gln 1250 1255 1260Phe Glu Thr Tyr Gln Leu Trp Thr Ala Leu
Val Ser Leu Met Cys Ser1265 1270 1275 1280Asn Thr Ile Phe Thr Leu
Thr Val Ala Trp Arg Thr Ala Thr Leu Ile 1285 1290 1295Leu Ala Gly
Ile Ser Leu Leu Pro Val Cys Gln Ser Ser Ser Met Arg 1300 1305
1310Lys Thr Asp Trp Leu Pro Met Ala Val Ala Ala Met Gly Val Pro Pro
1315 1320 1325Leu Pro Leu Phe Ile Phe Ser Leu Lys Asp Thr Leu Lys
Arg Arg Ser 1330 1335 1340Trp Pro Leu Asn Glu Gly Val Met Ala Val
Gly Leu Val Ser Ile Leu1345 1350 1355 1360Ala Ser Ser Leu Leu Arg
Asn Asp Val Pro Met Ala Gly Pro Leu Val 1365 1370 1375Ala Gly Gly
Leu Leu Ile Ala Cys Tyr Val Ile Thr Gly Thr Ser Ala 1380 1385
1390Asp Leu Thr Val Glu Lys Ala Ala Asp Val Thr Trp Glu Glu Glu Ala
1395 1400 1405Glu Gln Thr Gly Val Ser His Asn Leu Met Ile Thr Val
Asp Asp Asp 1410 1415 1420Gly Thr Met Arg Ile Lys Asp Asp Glu Thr
Glu Asn Ile Leu Thr Val1425 1430 1435 1440Leu Leu Lys Thr Ala Leu
Leu Ile Val Ser Gly Ile Phe Pro Tyr Ser 1445 1450 1455Ile Pro Ala
Thr Leu Leu Val Trp His Thr Trp Gln Lys Gln Thr Gln 1460 1465
1470Arg Ser Gly Val Leu Trp Asp Val Pro Ser Pro Pro Glu Thr Gln Lys
1475 1480 1485Ala Glu Leu Glu Glu Gly Val Tyr Arg Ile Lys Gln Gln
Gly Ile Phe 1490 1495 1500Gly Lys Thr Gln Val Gly Val Gly Val Gln
Lys Glu Gly Val Phe His1505 1510 1515 1520Thr Met Trp His Val Thr
Arg Gly Ala Val Leu Thr His Asn Gly Lys 1525 1530 1535Arg Leu Glu
Pro Asn Trp Ala Ser Val Lys Lys Asp Leu Ile Ser Tyr 1540 1545
1550Gly Gly Gly Trp Lys Leu Ser Ala Gln Trp Gln Lys Gly Glu Glu Val
1555 1560 1565Gln Val Ile Ala Val Glu Pro Gly Lys Asn Pro Lys Asn
Phe Gln Thr 1570 1575 1580Met Pro Gly Ile Phe Gln Thr Thr Thr Gly
Glu Ile Gly Ala Ile Ala1585 1590 1595 1600Leu Asp Phe Lys Pro Gly
Thr Ser Gly Ser Pro Ile Ile Asn Arg Glu 1605 1610 1615Gly Lys Val
Leu Gly Leu Tyr Gly Asn Gly Val Val Thr Lys Asn Gly 1620 1625
1630Gly Tyr Val Ser Gly Ile Ala Gln Thr Asn Ala Glu Pro Asp Gly Pro
1635 1640 1645Thr Pro Glu Leu Glu Glu Glu Met Phe Lys Lys Arg Asn
Leu Thr Ile 1650 1655 1660Met Asp Leu His Pro Gly Ser Gly Lys Thr
Arg Lys Tyr Leu Pro Ala1665 1670 1675 1680Ile Val Arg Glu Ala Ile
Lys Arg Arg Leu Arg Thr Leu Ile Leu Ala 1685 1690 1695Pro Thr Arg
Val Val Ala Ala Glu Met Glu Glu Ala Leu Lys Gly Leu 1700 1705
1710Pro Ile Arg Tyr Gln Thr Thr Ala Thr Lys Ser Glu His Thr Gly Arg
1715 1720 1725Glu Ile Val Asp Leu Met Cys His Ala Thr Phe Thr Met
Arg Leu Leu 1730 1735 1740Ser Pro Val Arg Val Pro Asn Tyr Asn Leu
Ile Ile Met Asp Glu Ala1745 1750 1755 1760His Phe Thr Asp Pro Ala
Ser Ile Ala Ala Arg Gly Tyr Ile Ser Thr 1765 1770 1775Arg Val Gly
Met Gly Glu Ala Ala Ala Ile Phe Met Thr Ala Thr Pro 1780 1785
1790Pro Gly Thr Ala Asp Ala Phe Pro Gln Ser Asn Ala Pro Ile Gln Asp
1795 1800 1805Glu Glu Arg Asp Ile Pro Glu Arg Ser Trp Asn Ser Gly
Asn Glu Trp 1810 1815 1820Ile Thr Asp Phe Ala Gly Lys Thr Val Trp
Phe Val Pro Ser Ile Lys1825 1830 1835 1840Ala Gly Asn Asp Ile Ala
Asn Cys Leu Arg Lys Asn Gly Lys Lys Val 1845 1850 1855Ile Gln Leu
Ser Arg Lys Thr Phe Asp Thr Glu Tyr Gln Lys Thr Lys 1860 1865
1870Leu Asn Asp Trp Asp Phe Val Val Thr Thr Asp Ile Ser Glu Met Gly
1875 1880 1885Ala Asn Phe Lys Ala Asp Arg Val Ile Asp Pro Arg Arg
Cys Leu Lys 1890 1895 1900Pro Val Ile Leu Thr Asp Gly Pro Glu Arg
Val Ile Leu Ala Gly Pro1905 1910 1915 1920Met Pro Val Thr Val Ala
Ser Ala Ala Gln Arg Arg Gly Arg Val Gly 1925 1930 1935Arg Asn Pro
Gln Lys Glu Asn Asp Gln Tyr Ile Phe Met Gly Gln Pro 1940 1945
1950Leu Asn Asn Asp Glu Asp His Ala His Trp Thr Glu Ala Lys Met Leu
1955 1960 1965Leu Asp Asn Ile Asn Thr Pro Glu Gly Ile Ile Pro Ala
Leu Phe Glu 1970 1975 1980Pro Glu Arg Glu Lys Ser Ala Ala Ile Asp
Gly Glu Tyr Arg Leu Lys1985 1990 1995 2000Gly Glu Ser Arg Lys Thr
Phe Val Glu Leu Met Arg Arg Gly Asp Leu 2005 2010 2015Pro Val Trp
Leu Ala His Lys Val Ala Ser Glu Gly Ile Lys Tyr Thr 2020 2025
2030Asp Arg Lys Trp Cys Phe Asp Gly Glu Arg Asn Asn Gln Ile Leu Glu
2035 2040 2045Glu Asn Met Asp Val Glu Ile Trp Thr Lys Glu Gly Glu
Lys Lys Lys 2050 2055 2060Leu Arg Pro Arg Trp Leu Asp Ala Arg Thr
Tyr Ser Asp Pro Leu Ala2065 2070 2075 2080Leu Lys Glu Phe Lys Asp
Phe Ala Ala Gly Arg Lys Ser Ile Ala Leu 2085 2090 2095Asp Leu Val
Thr Glu Ile Gly Arg Val Pro Ser His Leu Ala His Arg 2100 2105
2110Thr Arg Asn Ala Leu Asp Asn Leu Val Met Leu His Thr Ser Glu His
2115 2120 2125Gly Gly Arg Ala Tyr Arg His Ala Val Glu Glu Leu Pro
Glu Thr Met 2130 2135 2140Glu Thr Leu Leu Leu Leu Gly Leu Met Ile
Leu Leu Thr Gly Gly Ala2145 2150 2155 2160Met Leu Phe Leu Ile Ser
Gly Lys Gly Ile Gly Lys Thr Ser Ile Gly 2165 2170 2175Leu Ile Cys
Val Ala Ala Ser Ser Gly Met Leu Trp Met Ala Asp Val 2180 2185
2190Pro Leu Gln Trp Ile Ala Ser Ala Ile Val Leu Glu Phe Phe Met Met
2195 2200 2205Val Leu Leu Ile Pro Glu Pro Glu Lys Gln Arg Thr Pro
Gln Asp Asn 2210 2215 2220Gln Leu Ala Tyr Val Val Ile Gly Ile Leu
Thr Leu Ala Ala Ile Val2225 2230 2235 2240Ala Ala Asn Glu Met Gly
Leu Leu Glu Thr Thr Lys Arg Asp Leu Gly 2245 2250 2255Met Ser Lys
Glu Pro Gly Val Val Ser Pro Thr Ser Tyr Leu Asp Val 2260 2265
2270Asp Leu His Pro Ala Ser Ala Trp Thr Leu Tyr Ala Val Ala Thr Thr
2275 2280 2285Val Ile Thr Pro Met Leu Arg His Thr Ile Glu Asn Ser
Thr Ala Asn 2290 2295 2300Val Ser Leu Ala Ala Ile Ala Asn Gln Ala
Val Val Leu Met Gly Leu2305 2310 2315 2320Asp Lys Gly Trp Pro Ile
Ser Lys Met Asp Leu Gly Val Pro Leu Leu 2325 2330 2335Ala Leu Gly
Cys Tyr Ser Gln Val Asn Pro Leu Thr Leu Thr Ala Ala 2340 2345
2350Val Leu Leu Leu Val Thr His Tyr Ala Ile Ile Gly Pro Gly Leu Gln
2355 2360 2365Ala Lys Ala Thr Arg Glu Ala Gln Lys Arg Thr Ala Ala
Gly Ile Met 2370 2375 2380Lys Asn Pro Thr Val Asp Gly Ile Met Thr
Ile Asp Leu Asp Pro Val2385 2390 2395 2400Ile Tyr Asp Ser Lys Phe
Glu Lys Gln Leu Gly Gln Val Met Leu Leu 2405 2410 2415Val Leu Cys
Ala Val Gln Leu Leu Leu Met Arg Thr Ser Trp Ala Phe 2420 2425
2430Cys Glu Ala Leu Thr Leu Ala Thr Gly Pro Ile Thr Thr Leu Trp Glu
2435 2440 2445Gly Ser Pro Gly Lys Phe Trp Asn Thr Thr Ile Ala Val
Ser Met Ala 2450 2455 2460Asn Ile Phe Arg Gly Ser Tyr Leu Ala Gly
Ala Gly Leu Ala Phe Ser2465 2470 2475 2480Ile Met Lys Ser Val Gly
Thr Gly Lys Arg Gly Thr Gly Ser Gln Gly 2485 2490 2495Glu Thr Leu
Gly Glu Lys Trp Lys Lys Lys Leu Asn Gln Leu Pro Arg 2500 2505
2510Lys Glu Phe Asp Leu Tyr Lys Lys Ser Gly Ile Thr Glu Val Asp Arg
2515 2520 2525Thr Glu Ala Lys Glu Gly Leu Lys Arg Gly Glu Ile Thr
His His Ala 2530 2535 2540Val Ser Arg Gly Ser Ala Lys Leu Gln Trp
Phe Val Glu Arg Asn Met2545 2550 2555 2560Val Ile Pro Glu Gly Arg
Val Ile Asp Leu Gly Cys Gly Arg Gly Gly 2565 2570 2575Trp Ser Tyr
Tyr Cys Ala Gly Leu Lys Lys Val Thr Glu Val Arg Gly 2580 2585
2590Tyr Thr Lys Gly Gly Pro Gly His Glu Glu Pro Val Pro Met Ser Thr
2595 2600 2605Tyr Gly Trp Asn Ile Val Lys Leu Met Ser Gly Lys Asp
Val Phe Tyr 2610 2615 2620Leu Pro Pro Glu Lys Cys Asp Thr Leu Leu
Cys Asp Ile Gly Glu Ser2625 2630 2635 2640Ser Pro Ser Pro Thr Val
Glu Glu Ser Arg Thr Ile Arg Val Leu Lys 2645 2650 2655Met Val Glu
Pro Trp Leu Lys Asn Asn Gln Phe Cys Ile Lys Val Leu 2660 2665
2670Asn Pro Tyr Met Pro Thr Val Ile Glu His Leu Glu Arg Leu Gln Arg
2675 2680 2685Lys His Gly Gly Met Leu Val Arg Asn Pro Leu Ser Arg
Asn Ser Thr 2690 2695 2700His Glu Met Tyr Trp Ile Ser Asn Gly Thr
Gly Asn Ile Val Ser Ser2705 2710 2715 2720Val Asn Met Val Ser Arg
Leu Leu Leu Asn Arg Phe Thr Met Thr His 2725 2730 2735Arg Arg Pro
Thr Ile Glu Lys Asp Val Asp Leu Gly Ala Gly Thr Arg 2740 2745
2750His Val Asn Ala Glu Pro Glu Thr Pro Asn Met Asp Val Ile Gly Glu
2755 2760 2765Arg Ile Arg Arg Ile Lys Glu Glu His Ser Ser Thr Trp
His Tyr Asp 2770 2775 2780Asp Glu Asn Pro Tyr Lys Thr Trp Ala Tyr
His Gly Ser Tyr Glu Val2785 2790 2795 2800Lys Ala Thr Gly Ser Ala
Ser Ser Met Ile Asn Gly Val Val Lys Leu 2805 2810 2815Leu Thr Lys
Pro Trp Asp Val Val Pro Met Val Thr Gln Met Ala Met 2820 2825
2830Thr Asp Thr Thr Pro Phe Gly Gln Gln Arg Val Phe Lys Glu Lys Val
2835 2840 2845Asp Thr Arg Thr Pro Arg Pro Met Pro Gly Thr Arg Lys
Val Met Glu 2850 2855 2860Ile Thr Ala Glu Trp Leu Trp Arg Thr Leu
Gly Arg Asn Lys Arg Pro2865 2870 2875 2880Arg Leu Cys Thr Arg Glu
Glu Phe Thr Lys Lys Val Arg Thr Asn Ala 2885 2890 2895Ala Met Gly
Ala Val Phe Thr Glu Glu Asn Gln Trp Asp Ser Ala Arg 2900 2905
2910Ala Ala Val Glu Asp Glu Glu Phe Trp Lys Leu Val Asp Arg Glu Arg
2915 2920 2925Glu Leu His Lys Leu Gly Lys Cys Gly Ser Cys Val Tyr
Asn Met Met 2930 2935 2940Gly Lys Arg Glu Lys Lys Leu Gly Glu Phe
Gly Lys Ala Lys Gly Ser2945 2950 2955 2960Arg Ala Ile Trp Tyr Met
Trp Leu Gly Ala Arg Tyr Leu Glu Phe Glu 2965 2970 2975Ala Leu Gly
Phe Leu Asn Glu Asp His Trp Phe Ser Arg Glu Asn Ser 2980 2985
2990Tyr Ser Gly Val Glu Gly Glu Gly Leu His Lys Leu Gly Tyr Ile Leu
2995 3000 3005Arg Asp Ile Ser Lys Ile Pro Gly Gly Ala Met Tyr Ala
Asp Asp Thr 3010 3015 3020Ala Gly Trp Asp Thr Arg Ile Thr Glu Asp
Asp Leu His Asn Glu Glu3025 3030 3035 3040Lys Ile Thr Gln Gln Met
Asp Pro Glu His Arg Gln Leu Ala Asn Ala 3045 3050 3055Ile Phe Lys
Leu Thr Tyr Gln Asn Lys Val Val Lys Val Gln Arg Pro 3060 3065
3070Thr Pro Lys Gly Thr Val Met Asp Ile Ile Ser Arg Lys Asp Gln Arg
3075 3080 3085Gly Ser Gly Gln Val Gly Thr Tyr Gly Leu Asn Thr Phe
Thr Asn Met 3090 3095 3100Glu Ala Gln Leu Ile Arg Gln Met Glu Gly
Glu Gly Val Leu Ser Lys3105 3110 3115 3120Ala Asp Leu Glu Asn
Pro
His Leu Leu Glu Lys Lys Val Thr Gln Trp 3125 3130 3135Leu Glu Thr
Lys Gly Val Glu Arg Leu Lys Arg Met Ala Ile Ser Gly 3140 3145
3150Asp Asp Cys Val Val Lys Pro Ile Asp Asp Arg Phe Ala Asn Ala Leu
3155 3160 3165Leu Ala Leu Asn Asp Met Gly Lys Val Arg Lys Asp Ile
Pro Gln Trp 3170 3175 3180Gln Pro Ser Lys Gly Trp His Asp Trp Gln
Gln Val Pro Phe Cys Ser3185 3190 3195 3200His His Phe His Glu Leu
Ile Met Lys Asp Gly Arg Lys Leu Val Val 3205 3210 3215Pro Cys Arg
Pro Gln Asp Glu Leu Ile Gly Arg Ala Arg Ile Ser Gln 3220 3225
3230Gly Ala Gly Trp Ser Leu Arg Glu Thr Ala Cys Leu Gly Lys Ala Tyr
3235 3240 3245Ala Gln Met Trp Thr Leu Met Tyr Phe His Arg Arg Asp
Leu Arg Leu 3250 3255 3260Ala Ser Asn Ala Ile Cys Ser Ala Val Pro
Val His Trp Val Pro Thr3265 3270 3275 3280Ser Arg Thr Thr Trp Ser
Ile His Ala His His Gln Trp Met Thr Thr 3285 3290 3295Glu Asp Met
Leu Thr Val Trp Asn Arg Val Trp Ile Glu Asp Asn Pro 3300 3305
3310Trp Met Glu Asp Lys Thr Pro Val Lys Thr Trp Glu Asp Val Pro Tyr
3315 3320 3325Leu Gly Lys Arg Glu Asp Gln Trp Cys Gly Ser Leu Ile
Gly Leu Thr 3330 3335 3340Ser Arg Ala Thr Trp Ala Gln Asn Ile Leu
Thr Ala Ile Gln Gln Val3345 3350 3355 3360Arg Ser Leu Ile Gly Asn
Glu Glu Phe Leu Asp Tyr Met Pro Ser Met 3365 3370 3375Lys Arg Phe
Arg Lys Glu Glu Glu Ser Glu Gly Ala Ile Trp 3380 3385
3390502426DNAArtificial SequenceDengue 1 CME chimeric region
50agttgttagt ctgtgtggac cgacaaggac agttccaaat cggaagcttg cttaacacag
60ttctaacagt ttgtttgaat agagagcaga tctctggaaa aatgaacaac caacggaaaa
120agacgggtcg accgtctttc aatatgctga aacgcgcgag aaaccgcgtg
tcaactggtt 180cacagttggc gaagagattc tcaaaaggat tgctttcagg
ccaaggaccc atgaaattgg 240tgatggcttt catagcattt ctaagatttc
tagccatacc cccaacagca ggaattttgg 300ctagatggag ctcattcaag
aagaatggag cgatcaaagt gttacggggt ttcaaaaaag 360agatctcaag
catgttgaac attatgaaca ggaggaaaaa atctgtgacc atgctcctca
420tgctgctgcc cacagccctg gcgttccatt tgaccacacg agggggagag
ccacacatga 480tagttagtaa gcaggaaaga ggaaagtcac tgttgtttaa
gacctctgca ggcatcaata 540tgtgcactct cattgcgatg gatttgggag
agttatgcga ggacacaatg acctacaaat 600gcccccggat cactgaggcg
gaaccagatg acgttgactg ctggtgcaat gccacagaca 660catgggtgac
ctatgggacg tgttctcaaa ccggcgaaca ccgacgagac aaacgttccg
720tggcactggc cccacacgtg ggacttggtc tagaaacaag aaccgaaaca
tggatgtcct 780ctgaaggtgc ctggaaacaa gtacaaaaag tggagacttg
ggctttgaga cacccaggat 840tcacggtgac agcccttttt ttagcacatg
ccataggaac atccattact cagaaaggga 900tcattttcat tctgctgatg
ctagtaacac catcaatggc catgcgatgt gtgggaatag 960gcaacagaga
cttcgttgaa ggactgtcag gagcaacgtg ggtggacgtg gtattggagc
1020atggaagctg cgtcaccacc atggcaaaag ataaaccaac attggacatt
gaactcttga 1080agacggaggt cacaaaccct gccgtcttgc gcaaactgtg
cattgaagct aaaatatcaa 1140acaccaccac cgattcaagg tgtccaacac
aaggagaggc tacactggtg gaagaacagg 1200actcgaactt tgtgtgtcga
cgaacgtttg tggacagagg ctggggtaat ggctgcggac 1260tatttggaaa
aggaagccta ctgacgtgtg ctaagttcaa gtgtgtgaca aaactagaag
1320gaaagatagt tcaatatgaa aacttaaaat attcagtgat agtcactgtc
cacactgggg 1380accagcacca ggtgggaaac gagactacag aacatggaac
aattgcaacc ataacacctc 1440aagctcctac gtcggaaata cagctgactg
actacggagc cctcacattg gactgctcgc 1500ctagaacagg gctggacttt
aatgagatgg ttctattgac aatgaaagaa aaatcatggc 1560ttgtccacaa
acaatggttt ctagacttac cactgccttg gacttcagga gcttcaacat
1620ctcaagagac ttggaacaga caagatttgc tggtcacatt caagacagct
catgcaaaga 1680aacaggaagt agtcgtactg ggatcacagg aaggagcaat
gcacactgcg ttgactgggg 1740cgacagaaat ccagacgtca ggaacgacaa
caatctttgc aggacacctg aaatgcagac 1800taaaaatgga taaactgact
ttaaaaggga tgtcatatgt aatgtgcaca ggctcattta 1860agctagagaa
ggaagtggct gagacccagc atggaactgt tttagtgcag gttaaatacg
1920aaggaacaga tgcgccatgc aagatccctt tttcggccca agatgagaaa
ggagtgaccc 1980agaatgggag attgataaca gccaacccca tagtcactga
caaagaaaaa ccagtcaaca 2040ttgagacaga accacctttt ggtgagagct
acatcgtggt aggggcaggt gaaaaagctt 2100tgaaactgag ctggttcaag
aaagggagca gcatagggaa aatgttcgaa gcaactgccc 2160gaggagcgcg
aaggatggct atcctgggag acaccgcatg ggactttggc tctataggag
2220gagtgttcac atcagtggga aaattggtac accaggtttt tggagccgca
tatggggttc 2280tgttcagcgg tgtttcttgg accatgaaaa taggaatagg
gattctgctg acatggctag 2340gattaaactc gaggaacact tcaatggcta
tgacgtgcat agctgttgga ggaatcactc 2400tgtttctggg cttcacagtt caagca
242651775PRTArtificial SequenceDengue 1 CME chimeric region 51Met
Asn Asn Gln Arg Lys Lys Thr Gly Arg Pro Ser Phe Asn Met Leu 1 5 10
15Lys Arg Ala Arg Asn Arg Val Ser Thr Gly Ser Gln Leu Ala Lys Arg
20 25 30Phe Ser Lys Gly Leu Leu Ser Gly Gln Gly Pro Met Lys Leu Val
Met 35 40 45Ala Phe Ile Ala Phe Leu Arg Phe Leu Ala Ile Pro Pro Thr
Ala Gly 50 55 60Ile Leu Ala Arg Trp Ser Ser Phe Lys Lys Asn Gly Ala
Ile Lys Val65 70 75 80Leu Arg Gly Phe Lys Lys Glu Ile Ser Ser Met
Leu Asn Ile Met Asn 85 90 95Arg Arg Lys Lys Ser Val Thr Met Leu Leu
Met Leu Leu Pro Thr Ala 100 105 110Leu Ala Phe His Leu Thr Thr Arg
Gly Gly Glu Pro His Met Ile Val 115 120 125Ser Lys Gln Glu Arg Gly
Lys Ser Leu Leu Phe Lys Thr Ser Ala Gly 130 135 140Ile Asn Met Cys
Thr Leu Ile Ala Met Asp Leu Gly Glu Leu Cys Glu145 150 155 160Asp
Thr Met Thr Tyr Lys Cys Pro Arg Ile Thr Glu Ala Glu Pro Asp 165 170
175Asp Val Asp Cys Trp Cys Asn Ala Thr Asp Thr Trp Val Thr Tyr Gly
180 185 190Thr Cys Ser Gln Thr Gly Glu His Arg Arg Asp Lys Arg Ser
Val Ala 195 200 205Leu Ala Pro His Val Gly Leu Gly Leu Glu Thr Arg
Thr Glu Thr Trp 210 215 220Met Ser Ser Glu Gly Ala Trp Lys Gln Val
Gln Lys Val Glu Thr Trp225 230 235 240Ala Leu Arg His Pro Gly Phe
Thr Val Thr Ala Leu Phe Leu Ala His 245 250 255Ala Ile Gly Thr Ser
Ile Thr Gln Lys Gly Ile Ile Phe Ile Leu Leu 260 265 270Met Leu Val
Thr Pro Ser Met Ala Met Arg Cys Val Gly Ile Gly Asn 275 280 285Arg
Asp Phe Val Glu Gly Leu Ser Gly Ala Thr Trp Val Asp Val Val 290 295
300Leu Glu His Gly Ser Cys Val Thr Thr Met Ala Lys Asp Lys Pro
Thr305 310 315 320Leu Asp Ile Glu Leu Leu Lys Thr Glu Val Thr Asn
Pro Ala Val Leu 325 330 335Arg Lys Leu Cys Ile Glu Ala Lys Ile Ser
Asn Thr Thr Thr Asp Ser 340 345 350Arg Cys Pro Thr Gln Gly Glu Ala
Thr Leu Val Glu Glu Gln Asp Ser 355 360 365Asn Phe Val Cys Arg Arg
Thr Phe Val Asp Arg Gly Trp Gly Asn Gly 370 375 380Cys Gly Leu Phe
Gly Lys Gly Ser Leu Leu Thr Cys Ala Lys Phe Lys385 390 395 400Cys
Val Thr Lys Leu Glu Gly Lys Ile Val Gln Tyr Glu Asn Leu Lys 405 410
415Tyr Ser Val Ile Val Thr Val His Thr Gly Asp Gln His Gln Val Gly
420 425 430Asn Glu Thr Thr Glu His Gly Thr Ile Ala Thr Ile Thr Pro
Gln Ala 435 440 445Pro Thr Ser Glu Ile Gln Leu Thr Asp Tyr Gly Ala
Leu Thr Leu Asp 450 455 460Cys Ser Pro Arg Thr Gly Leu Asp Phe Asn
Glu Met Val Leu Leu Thr465 470 475 480Met Lys Glu Lys Ser Trp Leu
Val His Lys Gln Trp Phe Leu Asp Leu 485 490 495Pro Leu Pro Trp Thr
Ser Gly Ala Ser Thr Ser Gln Glu Thr Trp Asn 500 505 510Arg Gln Asp
Leu Leu Val Thr Phe Lys Thr Ala His Ala Lys Lys Gln 515 520 525Glu
Val Val Val Leu Gly Ser Gln Glu Gly Ala Met His Thr Ala Leu 530 535
540Thr Gly Ala Thr Glu Ile Gln Thr Ser Gly Thr Thr Thr Ile Phe
Ala545 550 555 560Gly His Leu Lys Cys Arg Leu Lys Met Asp Lys Leu
Thr Leu Lys Gly 565 570 575Met Ser Tyr Val Met Cys Thr Gly Ser Phe
Lys Leu Glu Lys Glu Val 580 585 590Ala Glu Thr Gln His Gly Thr Val
Leu Val Gln Val Lys Tyr Glu Gly 595 600 605Thr Asp Ala Pro Cys Lys
Ile Pro Phe Ser Ala Gln Asp Glu Lys Gly 610 615 620Val Thr Gln Asn
Gly Arg Leu Ile Thr Ala Asn Pro Ile Val Thr Asp625 630 635 640Lys
Glu Lys Pro Val Asn Ile Glu Thr Glu Pro Pro Phe Gly Glu Ser 645 650
655Tyr Ile Val Val Gly Ala Gly Glu Lys Ala Leu Lys Leu Ser Trp Phe
660 665 670Lys Lys Gly Ser Ser Ile Gly Lys Met Phe Glu Ala Thr Ala
Arg Gly 675 680 685Ala Arg Arg Met Ala Ile Leu Gly Asp Thr Ala Trp
Asp Phe Gly Ser 690 695 700Ile Gly Gly Val Phe Thr Ser Val Gly Lys
Leu Val His Gln Val Phe705 710 715 720Gly Ala Ala Tyr Gly Val Leu
Phe Ser Gly Val Ser Trp Thr Met Lys 725 730 735Ile Gly Ile Gly Ile
Leu Leu Thr Trp Leu Gly Leu Asn Ser Arg Asn 740 745 750Thr Ser Met
Ala Met Thr Cys Ile Ala Val Gly Gly Ile Thr Leu Phe 755 760 765Leu
Gly Phe Thr Val Gln Ala 770 775522423DNAArtificial SequenceDengue 1
ME chimeric region 52agttgttagt ctgtgtggac cgacaaggac agttccaaat
cggaagcttg cttaacacag 60ttctaacagt ttgtttgaat agagagcaga tctctggaaa
aatgaaccaa cgaaaaaagg 120tggttagacc acctttcaat atgctgaaac
gcgagagaaa ccgcgtatca acccctcaag 180ggttggtgaa gagattctca
accggacttt tttctgggaa aggaccctta cggatggtgc 240tagcattcat
cacgtttttg cgagtccttt ccatcccacc aacagcaggg attctgaaga
300gatggggaca gttgaagaaa aataaggcca tcaagatact gattggattc
aggaaggaga 360taggccgcat gctgaacatc ttgaacggga gaaaaaggtc
tgcagccatg ctcctcatgc 420tgctgcccac agccctggcg ttccatttga
ccacacgagg gggagagcca cacatgatag 480ttagtaagca ggaaagagga
aagtcactgt tgtttaagac ctctgcaggc atcaatatgt 540gcactctcat
tgcgatggat ttgggagagt tatgcgagga cacaatgacc tacaaatgcc
600cccggatcac tgaggcggaa ccagatgacg ttgactgctg gtgcaatgcc
acagacacat 660gggtgaccta tgggacgtgt tctcaaaccg gcgaacaccg
acgagacaaa cgttccgtgg 720cactggcccc acacgtggga cttggtctag
aaacaagaac cgaaacatgg atgtcctctg 780aaggtgcctg gaaacaagta
caaaaagtgg agacttgggc tttgagacac ccaggattca 840cggtgacagc
ccttttttta gcacatgcca taggaacatc cattactcag aaagggatca
900ttttcattct gctgatgcta gtaacaccat caatggccat gcgatgtgtg
ggaataggca 960acagagactt cgttgaagga ctgtcaggag caacgtgggt
ggacgtggta ttggagcatg 1020gaagctgcgt caccaccatg gcaaaagata
aaccaacatt ggacattgaa ctcttgaaga 1080cggaggtcac aaaccctgcc
gtcttgcgca aactgtgcat tgaagctaaa atatcaaaca 1140ccaccaccga
ttcaaggtgt ccaacacaag gagaggctac actggtggaa gaacaggact
1200cgaactttgt gtgtcgacga acgtttgtgg acagaggctg gggtaatggc
tgcggactat 1260ttggaaaagg aagcctactg acgtgtgcta agttcaagtg
tgtgacaaaa ctagaaggaa 1320agatagttca atatgaaaac ttaaaatatt
cagtgatagt cactgtccac actggggacc 1380agcaccaggt gggaaacgag
actacagaac atggaacaat tgcaaccata acacctcaag 1440ctcctacgtc
ggaaatacag ctgactgact acggagccct cacattggac tgctcgccta
1500gaacagggct ggactttaat gagatggttc tattgacaat gaaagaaaaa
tcatggcttg 1560tccacaaaca atggtttcta gacttaccac tgccttggac
ttcaggagct tcaacatctc 1620aagagacttg gaacagacaa gatttgctgg
tcacattcaa gacagctcat gcaaagaaac 1680aggaagtagt cgtactggga
tcacaggaag gagcaatgca cactgcgttg actggggcga 1740cagaaatcca
gacgtcagga acgacaacaa tctttgcagg acacctgaaa tgcagactaa
1800aaatggataa actgacttta aaagggatgt catatgtaat gtgcacaggc
tcatttaagc 1860tagagaagga agtggctgag acccagcatg gaactgtttt
agtgcaggtt aaatacgaag 1920gaacagatgc gccatgcaag atcccttttt
cggcccaaga tgagaaagga gtgacccaga 1980atgggagatt gataacagcc
aaccccatag tcactgacaa agaaaaacca gtcaacattg 2040agacagaacc
accttttggt gagagctaca tcgtggtagg ggcaggtgaa aaagctttga
2100aactgagctg gttcaagaaa gggagcagca tagggaaaat gttcgaagca
actgcccgag 2160gagcgcgaag gatggctatc ctgggagaca ccgcatggga
ctttggctct ataggaggag 2220tgttcacatc agtgggaaaa ttggtacacc
aggtttttgg agccgcatat ggggttctgt 2280tcagcggtgt ttcttggacc
atgaaaatag gaatagggat tctgctgaca tggctaggat 2340taaactcgag
gaacacttca atggctatga cgtgcatagc tgttggagga atcactctgt
2400ttctgggctt cacagttcaa gca 242353774PRTArtificial SequenceDengue
1 ME chimeric region 53Met Asn Gln Arg Lys Lys Val Val Arg Pro Pro
Phe Asn Met Leu Lys 1 5 10 15Arg Glu Arg Asn Arg Val Ser Thr Pro
Gln Gly Leu Val Lys Arg Phe 20 25 30Ser Thr Gly Leu Phe Ser Gly Lys
Gly Pro Leu Arg Met Val Leu Ala 35 40 45Phe Ile Thr Phe Leu Arg Val
Leu Ser Ile Pro Pro Thr Ala Gly Ile 50 55 60Leu Lys Arg Trp Gly Gln
Leu Lys Lys Asn Lys Ala Ile Lys Ile Leu65 70 75 80Ile Gly Phe Arg
Lys Glu Ile Gly Arg Met Leu Asn Ile Leu Asn Gly 85 90 95Arg Lys Arg
Ser Ala Ala Met Leu Leu Met Leu Leu Pro Thr Ala Leu 100 105 110Ala
Phe His Leu Thr Thr Arg Gly Gly Glu Pro His Met Ile Val Ser 115 120
125Lys Gln Glu Arg Gly Lys Ser Leu Leu Phe Lys Thr Ser Ala Gly Ile
130 135 140Asn Met Cys Thr Leu Ile Ala Met Asp Leu Gly Glu Leu Cys
Glu Asp145 150 155 160Thr Met Thr Tyr Lys Cys Pro Arg Ile Thr Glu
Ala Glu Pro Asp Asp 165 170 175Val Asp Cys Trp Cys Asn Ala Thr Asp
Thr Trp Val Thr Tyr Gly Thr 180 185 190Cys Ser Gln Thr Gly Glu His
Arg Arg Asp Lys Arg Ser Val Ala Leu 195 200 205Ala Pro His Val Gly
Leu Gly Leu Glu Thr Arg Thr Glu Thr Trp Met 210 215 220Ser Ser Glu
Gly Ala Trp Lys Gln Val Gln Lys Val Glu Thr Trp Ala225 230 235
240Leu Arg His Pro Gly Phe Thr Val Thr Ala Leu Phe Leu Ala His Ala
245 250 255Ile Gly Thr Ser Ile Thr Gln Lys Gly Ile Ile Phe Ile Leu
Leu Met 260 265 270Leu Val Thr Pro Ser Met Ala Met Arg Cys Val Gly
Ile Gly Asn Arg 275 280 285Asp Phe Val Glu Gly Leu Ser Gly Ala Thr
Trp Val Asp Val Val Leu 290 295 300Glu His Gly Ser Cys Val Thr Thr
Met Ala Lys Asp Lys Pro Thr Leu305 310 315 320Asp Ile Glu Leu Leu
Lys Thr Glu Val Thr Asn Pro Ala Val Leu Arg 325 330 335Lys Leu Cys
Ile Glu Ala Lys Ile Ser Asn Thr Thr Thr Asp Ser Arg 340 345 350Cys
Pro Thr Gln Gly Glu Ala Thr Leu Val Glu Glu Gln Asp Ser Asn 355 360
365Phe Val Cys Arg Arg Thr Phe Val Asp Arg Gly Trp Gly Asn Gly Cys
370 375 380Gly Leu Phe Gly Lys Gly Ser Leu Leu Thr Cys Ala Lys Phe
Lys Cys385 390 395 400Val Thr Lys Leu Glu Gly Lys Ile Val Gln Tyr
Glu Asn Leu Lys Tyr 405 410 415Ser Val Ile Val Thr Val His Thr Gly
Asp Gln His Gln Val Gly Asn 420 425 430Glu Thr Thr Glu His Gly Thr
Ile Ala Thr Ile Thr Pro Gln Ala Pro 435 440 445Thr Ser Glu Ile Gln
Leu Thr Asp Tyr Gly Ala Leu Thr Leu Asp Cys 450 455 460Ser Pro Arg
Thr Gly Leu Asp Phe Asn Glu Met Val Leu Leu Thr Met465 470 475
480Lys Glu Lys Ser Trp Leu Val His Lys Gln Trp Phe Leu Asp Leu Pro
485 490 495Leu Pro Trp Thr Ser Gly Ala Ser Thr Ser Gln Glu Thr Trp
Asn Arg 500 505 510Gln Asp Leu Leu Val Thr Phe Lys Thr Ala His Ala
Lys Lys Gln Glu 515 520 525Val Val Val Leu Gly Ser Gln Glu Gly Ala
Met His Thr Ala Leu Thr 530 535 540Gly Ala Thr Glu Ile Gln Thr Ser
Gly Thr Thr Thr Ile Phe Ala Gly545 550 555 560His Leu Lys Cys Arg
Leu Lys Met Asp Lys Leu Thr Leu Lys Gly Met 565 570 575Ser Tyr Val
Met Cys Thr Gly Ser Phe Lys Leu Glu Lys Glu Val Ala 580
585 590Glu Thr Gln His Gly Thr Val Leu Val Gln Val Lys Tyr Glu Gly
Thr 595 600 605Asp Ala Pro Cys Lys Ile Pro Phe Ser Ala Gln Asp Glu
Lys Gly Val 610 615 620Thr Gln Asn Gly Arg Leu Ile Thr Ala Asn Pro
Ile Val Thr Asp Lys625 630 635 640Glu Lys Pro Val Asn Ile Glu Thr
Glu Pro Pro Phe Gly Glu Ser Tyr 645 650 655Ile Val Val Gly Ala Gly
Glu Lys Ala Leu Lys Leu Ser Trp Phe Lys 660 665 670Lys Gly Ser Ser
Ile Gly Lys Met Phe Glu Ala Thr Ala Arg Gly Ala 675 680 685Arg Arg
Met Ala Ile Leu Gly Asp Thr Ala Trp Asp Phe Gly Ser Ile 690 695
700Gly Gly Val Phe Thr Ser Val Gly Lys Leu Val His Gln Val Phe
Gly705 710 715 720Ala Ala Tyr Gly Val Leu Phe Ser Gly Val Ser Trp
Thr Met Lys Ile 725 730 735Gly Ile Gly Ile Leu Leu Thr Trp Leu Gly
Leu Asn Ser Arg Asn Thr 740 745 750Ser Met Ala Met Thr Cys Ile Ala
Val Gly Gly Ile Thr Leu Phe Leu 755 760 765Gly Phe Thr Val Gln Ala
770
* * * * *